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 With the avalanche of biological sequences generated in the postgenomic age, molecular 
science is facing an unprecedented challenge, i.e., how to timely utilize the huge amount of 
data to benefit human beings. Stimulated by such a challenge, a rapid development has taken 
place in molecular science, particularly in the areas associated with drug development and 
biomedicine, both experimental and theoretical. The current thematic book was launched with 
the focus on the topic of “Molecular Science for Drug Development and Biomedicine”, in 
hopes to further stimulate more useful techniques and findings from various approaches of 
molecular science for drug development and biomedicine. 
 
 The papers collected in this monograph can be categorized into the following four topics: 
1) Pseudo Amino Acid Composition/Pseudo Oligonucleotide Composition; 2) Structure-
Based Drug Design; 3) In Vitro/In Vivo Pharmacological Models; 4) Computational Model 
for Drug Development 
 
1. Pseudo Amino Acid Composition and Pseudo Oligonucleotide Composition 
 
 One of the most challenging problems in computational biology and biomedicine is how 
to formulate a biological sequence with a discrete model or a vector, yet still keep 
considerable sequence order information. To avoid completely losing the sequence-order 
information for proteins, particularly for their long-range or global sequence-order effects, the 
pseudo amino acid composition [1,2] or Chou’s PseAAC [3] was proposed. Ever since the 
concept of PseAAC was proposed in 2001, it has rapidly penetrated into almost all the areas 
of computational proteomics. Because it has been widely and increasingly used, in the paper 
entitled “PseAAC-General: Fast Building Various Modes of General Form of Chou’s Pseudo-
Amino Acid Composition for Large-Scale Protein Datasets”, Professor Dr. Pufeng Du and his 
coworkers proposed a powerful software called “PseAAC-General” that can be used for fast 
building various modes of general form of Chou’s PseAAC for large-scale protein datasets, 
including the GO (Gene Ontology) mode, FunD (Functional Domain) mode, PSSM (Position-
Specific Scoring Matrix) mode and many others as defined by the users according to their 
own desires and needs. 
 
 SNO (S-nitrosylation) is one of the most important and universal PTMs (posttranslational 
modifications) responsible for sensing and transducing signals to regulate various cellular 
functions and signaling events. In the article entitled “PSNO: Predicting Cysteine S-
Nitrosylation Sites by Incorporating Various Sequence-Derived Features into the General 





tool to identify SNO sites in protein sequences by incorporating various sequence-derived 
features into the general form of Chou’s PseAAC, and achieved very promising results. 
  
 Encouraged by the successes of using PseAAC to deal with protein/peptide sequences, a 
question has naturally and logically occurred: how to use the similar approach to deal with 
DNA/RNA sequences?  To address this problem, recently the pseudo oligonucleotide 
composition or PseKNC [4] and PseKNC-General [5] were developed. In the article with the 
title of “iRSpot-TNCPseAAC: Identify Recombination Spots with Trinucleotide Composition 
and Pseudo Amino Acid Components”, Dr. Wang-Ren Qiu and coauthors proposed a 
different approach to deal with this problem. They first convert a DNA sequence into a 
protein sequence by using the 3®1 rule from a 3-nucleotide codon to an amino acid, 
followed by using the Chou’s PseAAC to predict the recombination spots of DNA. 
Meanwhile, a publically accessible web-server for the prediction method has been established. 
Furthermore, for the convenience of the vast majority of experimental scientists, a step-by-
step guide is also given on how to use the web server to obtain the desired result. 
 
2. Structure-Based Drug Design 
 
 The article entitled with “Structure of N-Terminal Sequence Asp-Ala-Glu-Phe-Arg-His-
Asp-Ser of Aβ-Peptide with Phospholipase A2 from Venom of Andaman Cobra Sub-Species 
Naja naja sagittifera at 2.0 Å Resolution” authored by Professor Dr. Zeenat Mirza, and 
coauthors reported the structure from Alzheimer's Aβ-peptide in complex with phospholipase 
A2, which was determined by X-ray crystallography at 2.0 Å resolution.  Their findings 
suggest the possibility of interactions between N-terminus residues (DAEFRHDS) and 
phospholipase A2.  Their study is a key step towards understanding the mechanism behind the 
Aβ and PLA2 interaction that may facilitate the development of novel therapeutic strategies 
against the inflammatory responses to retard many diseases. 
 
Mostafa M. Ghorab and colleagues, in the article “Synthesis, Characterization and Anti-
Breast Cancer Activity of New 4-Aminoantipyrine-Based Heterocycles”, reported that a new 
series of heterocycles synthesized by incorporating antipyrine moiety. They observed that 
these molecules have anticancer activity against human tumor breast cell line (MCF7). In 
their study, the authors utilized 4-Aminoantipyrine as key intermediate for the synthesis of 
pyrazolone derivatives bearing biologically active moieties. As claimed by the authors, these 
findings might be of use for developing more potent and selective anti-breast cancer agents. 
 
In their article “The Discovery of Potentially Selective Human Neuronal Nitric Oxide 
Synthase (nNOS) Inhibitors: A Combination of Pharmacophore Modelling, CoMFA, Virtual 
Screening and Molecular Docking Studies”, Dr. Guanhong Xu et al. presented a workflow for 
the identification and prioritization of compounds as potentially selective human nNOS 




hit compounds were structurally different from available inhibitors and may serve as potential 
leads or starting points for structural optimization to identify novel nNOS inhibitors. 
 
As described in the paper entitled “Synthesis, Preliminary Bioevaluation and 
Computational Analysis of Caffeic Acid Analogues”, Dr. Weidong Zhang and coworkers 
designed, synthesized and evaluated a series of caffeic acid amides for the anti-inflammatory 
activity. They developed a 3D pharmacophore model on the basis of biological results for 
further structural optimization and also performed the predication of the potential targets 
using the PharmMapper server.  Results from their study suggest that these amide analogues 
represent a promising class of anti-inflammatory scaffold for further exploration and target 
identification. 
 
As reported in the article “Synthesis and Antioxidant Activity Evaluation of New 
Compounds from Hydrazinecarbothioamide and 1,2,4-Triazole Class Containing 
Diarylsulfone and 2,4-Difluorophenyl Moieties”, Dr. Stefania-Felicia Barbuceanu and 
coauthors synthesized the new hydrazinecarbothioamides, 1,2,4-triazole-3-thiones and S-





and mass spectral data. The results obtained by them with the preliminary screening of 
antioxidant activity suggest that the molecules from hydrazinecarbothioamide class might 
serve as interesting compounds for the development of new antioxidant agents by synthesis of 
some new derivatives with this structure. 
 
3. In Vitro/In Vivo Pharmacological Models 
 
According to the report by Dr. Hong Jiang and coworkers in “Perineural 
Dexmedetomidine Attenuates Inflammation in Rat Sciatic Nerve via the NF-κB Pathway”, 
they have established a rat model that simulates a clinical surgical procedure to investigate the 
anti-inflammatory effect of perineural administration of dexmedetomidine and the underlying 
mechanism.  Results from their studies suggest that dexmedetomidine inhibits the nuclear 
translocation and binding activity of activated NF-κB, thus reducing inflammatory cytokines.  
It may hold high potential for applying the dexmedetomidine as an adjuvant in peripheral 
nerve anesthesia.  
 
Dr. Jin Yeul Ma and colleagues evaluated the inhibitory effects of Palmultang (PM) on the 
production of inflammatory factors and on the activation of mechanisms in murine 
macrophages. They found that PM suppressed the expression of nitric oxide, inflammatory 
cytokines and inflammatory proteins by inhibiting nuclear factor (NF)-κB and mitogen-
activated protein kinase (MAPK) signaling pathways and by inducing heme oxygenase (HO)-
1 expression. Their results as detailed in the research article “Inhibitory Effects of Palmultang 
on Inflammatory Mediator Production Related to Suppression of NF-κB and MAPK 
Pathways and Induction of HO-1 Expression in Macrophages” suggest that PM could be 




In the review paper entitled “Colonization and Infection of the Skin by S. aureus: Immune 
System Evasion and the Response to Cationic Antimicrobial Peptides”, Professor Dr. 
Yoonkyung Park and coworkers discussed the peptides (defensins, cathelicidins, RNase7, 
dermcidin) and other mediators (toll-like receptor, IL-1 and IL-17) that comprise the host 
defense against S. aureus skin infection, as well as the various mechanisms by which S. 
aureus evades host defenses. They anticipate that targeted drug development around highly 
conserved bacterial resistance mechanisms against host cationic antimicrobial peptides will be 
a promising pharmacologic approach in this era of highly virulent and drug-resistant strains of 
S. aureus. 
 
Diallyl disulfide (DADS) is a natural organosulfur compound isolated from garlic. The 
anticancer mechanisms of DADS in human esophageal carcinoma have not been elucidated, 
especially in vivo. In the research article entitled “DADS Suppresses Human Esophageal 
Xenograft Tumors through RAF/MEK/ERK and Mitochondria-Dependent Pathways” 
contributed by Dr. Hongbing Ma and his colleagues, the authors reported that the DADS 
suppresses esophageal tumors without any apparent signs of toxicity, which is in agreement 
with a strong increase of apoptosis both in vitro and in vivo. They claimed that DADS might 
be a potentially effective and safe anti-cancer agent for esophageal carcinoma treatment. 
 
In the article “4-Hydroxyphenylacetic Acid Attenuated Inflammation and Edema via 
Suppressing HIF-1α in Seawater Aspiration-Induced Lung Injury in Rats”, Drs. Xiaobo Wang 
and Faguang Jin, and coworkers conducted an investigation in the effect of 4-
Hydroxyphenylacetic acid (4-HPA) on seawater aspiration-induced lung injury using a 
seawater drowning rat model in vivo and the hypoxia-inducible factor-1α (HIF-1α) siRNA 
and permeability assay in vitro. Their results indicated that 4-HPA attenuated inflammation 
and edema through suppressing hypertonic and hypoxic induction of HIF-1α in seawater 
aspiration-induced lung injury in rats, and hence may be considered as a potential agent in the 
treatment of seawater aspiration-induced lung injury. 
 
 Wound healing plays an important role in protecting the human body from external 
infection. Cell migration and proliferation of keratinocytes and dermal fibroblasts are 
essential for proper wound healing. In the research article entitled “Effects of the Novel 
Compound DK223 ([1E,2E-1,2-Bis(6-methoxy-2H-chromen-3-yl)methylene]hydrazine) on 
Migration and Proliferation of Human Keratinocytes and Primary Dermal Fibroblasts”, Dr. 
Moonjae Cho and colleagues identified a novel compound DK223 ([1E,2E-1,2-bis(6-
methoxy-2H-chromen-3-yl)methylene]hydrazine) that concomitantly induced human 
keratinocyte migration and dermal fibroblast proliferation. They also found that DK223 
simultaneously induced both keratinocyte migration via reactive oxygen species production 







4. Computational Model for Drug Development 
 
 With the huge amount uncharacterized proteins entering into the protein database, it is 
time-consuming and expensive to identify the protein-protein interactions (PPIs) by 
experiments alone. Therefore, it is highly demanding to develop computational methods for 
predicting PPIs. In the research article entitled “Prediction of Protein–Protein Interaction with 
Pairwise Kernel Support Vector Machine”, Professor Dr. Shaowu Zhang and his colleagues 
offered a novel method along with its web-server PPI-PKSVM developed by using the two 
feature extraction approaches (DFPCA and AAID) to represent the protein sequence samples, 
followed by using the pairwise kernel function support vector machine model. They conclude 
that the predicted results are very encouraging and promising for predicting PPIs according to 
the sequence information alone. 
 
 Nuclear receptors (NRs) are closely associated with various major diseases such as cancer, 
diabetes, inflammatory disease, and osteoporosis. Therefore, NRs have become a frequent 
target for drug development. During the process of developing drugs against these diseases by 
targeting NRs, we are often facing a problem: Given a NR and chemical compound, can we 
identify whether they are really in interaction with each other in a cell? To address this 
problem, in the article “iNR-Drug: Predicting the Interaction of Drugs with Nuclear Receptors 
in Cellular Networking”, Dr. Xuan Xiao et al. proposed a predictor called “iNR-Drug” in 
which the drug compound concerned was formulated by a 256-D (dimensional) vector 
derived from its molecular fingerprint, and the NR a 500-D vector formed by incorporating its 
sequential evolution information and physicochemical features into the general form of 
Chou’s PseAAC. Compared with the existing prediction methods in this regard, iNR-Drug not 
only can yield a higher success rate, but is also featured by a user-friendly web-server, which 
is particularly useful for most experimental scientists to obtain their desired data in a timely 
manner.  
 
Inherently chiral calix[4]arenes can be theoretically regarded as a type of complex planar 
chiral molecule when bridging carbons are treated as achiral and each phenyl ring and its six 
substituents treated as coplanar. Based on one approximation and one hypothesis, Drs. Shao-
Yong Li, Wei Qiao and Jun-Min Liu, and their colleagues have derived a expression for 
qualitatively analyzing the microhelical electronic energy, as elaborated in the article 
“Qualitative Analysis of the Helical Electronic Energy of Inherently Chiral Calix[4]arenes: 
An Approach to Effectively Assign Their Absolute Configuration”.  According to their report, 
the scientificity and effectiveness in absolute configuration assignments of inherently chiral 
calix[4]arenes were almost entirely confirmed for all of the entities whose absolute 
configurations and optical rotation signs have been ascertained. 
 
 




It is a great challenge to elucidate the polypharmacological mechanisms of polyphenols. 
In the research article “Elucidating Polypharmacological Mechanisms of Polyphenols by 
Gene Module Profile Analysis”, Dr. Hong-Yu Zhang and coworkers have developed a 
method for identifying the multiple targets of chemical agents through analyzing the module 
profiles of gene expression upon chemical treatments. By using this method, they have 
identified 148 targets for 20 polyphenols derived from cMap. As claimed by these authors, a 
large part of the targets were validated by experimental observations, implying that the 
medicinal effects of polyphenols are far beyond their well-known antioxidant activities. 
 
In the last decade or so, it has been observed that many molecular biosystems and 
biomedical systems belong to the multi-label systems where each of their constituent 
molecules may possess two or more attributes, functions or features, and hence need multiple-
label or multi-target method to analyze them [6]. In the paper entitled “Prediction of Multi-
Target Networks of Neuroprotective Compounds with Entropy Indices and Synthesis, Assay, 
and Theoretical Study of New Asymmetric 1,2-Rasagiline Carbamates”, Professor Drs. 
Humberto González-Díaz and Xerardo García-Mera and their colleagues used Shannon 
entropy measures to develop predictive models for multi-target networks of 
neuroprotective/neurotoxic compounds. Their method has been demonstrated to be a useful 
complementary tool in the organic synthesis and evaluation of the multi-target biological 
activity of new compounds with potential neuroprotective activity, as well as in the prediction 
of complex networks of drug-target interactions. 
 
As one can see from the aforementioned nineteen papers collected in this book they are all 
featured by either developing powerful tools or reporting important findings, which will be 
very useful for both the basic research in molecular sciences and drug design in 
pharmaceutical industry.  
 
It is our hope that publication of this thematic book can stimulate more powerful tools in 
computational biomedicine as well as more profound findings in treating diseases so as to 
benefit human beings. 
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1. Pseudo Amino Acid Composition and 
Pseudo Oligonucleotide Composition 
 
PseAAC-General: Fast Building Various Modes of General 
Form of Chou’s Pseudo-Amino Acid Composition for  
Large-Scale Protein Datasets 
Pufeng Du, Shuwang Gu and Yasen Jiao 
Abstract: The general form pseudo-amino acid composition (PseAAC) has been widely used to 
represent protein sequences in predicting protein structural and functional attributes. We developed 
the program PseAAC-General to generate various different modes of Chou’s general PseAAC, 
such as the gene ontology mode, the functional domain mode, and the sequential evolution mode. 
This program allows the users to define their own desired modes. In every mode, 544 
physicochemical properties of the amino acids are available for choosing. The computing 
efficiency is at least 100 times that of existing programs, which makes it able to facilitate the 
extensive studies on proteins and peptides. The PseAAC-General is freely available via SourceForge. 
It runs on both Linux and Windows. 
Reprinted from Int. J. Mol. Sci. Cite as: Du, P.; Gu, S.; Krail, K.; Jiao, Y. PseAAC-General: Fast 
Building Various Modes of General Form of Chou’s Pseudo-Amino Acid Composition for  
Large-Scale Protein Datasets. Int. J. Mol. Sci. 2014, 15, 3495-3506. 
1. Introduction 
Over the last few years, machine learning has been introduced to predict protein structures and 
functions. In these studies, one of the keys is to formulate the protein sequences with a 
mathematical form that can reflect the intrinsic correlation with their structures and functions. To 
be more specific, this mathematical form should keep representing a protein sequence with a 
discrete form yet without completely losing its sequence-order information. The pseudo-amino acid 
compositions (PseAAC), which was originally introduced to predict protein attributes [1], is a 
typical mathematical form in this regard.  
Ever since its first appearance, the PseAAC formulation has been widely applied for studying 
various problems in protein science, such as predicting eukaryotes and prokaryotes protein 
subcellular locations [2–11], protein sub-subcellular locations [12–22], membrane protein subcellular 
locations [23–26], viral protein subcellular locations [27,28], protein structural classes [29–35], 
secondary structures [36], super-secondary structures [37], quaternary structural attributes [38,39], 
GPCR classes [40–42], enzyme families [43,44], membrane protein types [45–47], metalloproteinase 
families [48], risk types of human papillomavirus [49], cell-wall lytic enzymes [50], cyclic  
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proteins [51], allergenic proteins [52], bioluminescent proteins [53], DNA-binding proteins [54], 
GABA(A) receptor proteins [55], bacterial virulent proteins [56], essential proteins [57], anti-cancer 
peptides [58], anti-bacterial peptides [59], protein-protein interactions [60], protein solubility [61], 
drug-target network [62], and many more [63–76]. Recently, it was applied to represent DNA 
sequences in identifying the recombination spot [77]. 
Many different types of information, such as gene ontology annotations, functional domain 
compositions, and sequential evolution information, have been integrated skillfully with the 
concept of PseAAC to represent protein samples in order to enhance the prediction quality of their 
attributes. In essence, the protein sample thus formulated were actually various modes of Chou’s 
general form PseAAC, as clearly indicated by Equations 9–14 in a comprehensive review [78]. On 
the contrary, the Type I PseAAC [1] and Type II PseAAC [79] belong to Chou’s special form 
PseAAC. The modes of Chou’s special form PseAAC can be calculated by several programs, such 
as PseAAC server [80], PseAAC-Builder [81] and the propy package [82]. 
However, so far no publicly accessible program could calculate Chou’s general PseAAC.  
The current PseAAC-General is a universal software platform for users to generate various modes 
of general form PseAAC, including several widely used modes, such as the gene ontology mode [3], 
functional domain mode [83], and sequential evolution mode [18]. It is anticipated that  
PseAAC-General will become a very useful tool in bioinformatics, computational proteomics, and 
system biology. 
2. Results and Discussion 
The current PseAAC-General can generate 13 different modes of general form PseAAC, 
including conventional amino acid composition, di-peptide composition, tri-peptide composition, 
Type I PseAAC, Type II PseAAC, the gene ontology mode, the functional domain mode, the 
sequential evolution mode, the normalized Moreau-Broto autocorrelation coefficients, the Moran 
autocorrelation coefficients, the Geary autocorrelation coefficients, the composition-transition-
distribution (CTD) descriptors and the quasi-sequence order descriptors. In every mode, 544 types 
of physicochemical properties are available for choosing. Over 20,000 different descriptor values can 
be calculated. 
We list several commonly used modes of general form PseAAC as well as some program 
features in PseAAC-General program in Table 1. Several modes are uniquely available in 
PseAAC-General, which include the gene ontology mode, the functional domain mode and the 
sequential evolution mode. These modes have been mentioned in existing programs [81,82]. 
However, no program implemented these modes. 
PseAAC-General provided two methods for the users to create their own desired modes. The 
first method is called the Binary Extension Module (BEM). The gene ontology mode and 
functional domain mode were actually implemented by this method. A set of tools was provided 
along with the PseAAC-General, so that the users can create their own BEM to represent all kinds 
of descriptive information, which includes but not limited to the gene ontology annotations and the 
functional domain compositions. 
The other method is the Lua script module. Lua script language is a very simple programming 
language that has been considered in analyzing sequence annotations [90]. We provided a 
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programming interface that allows the user to use Lua script to access the internal data structures 
and functions of PseAAC-General. Furthermore, the algorithm modules of PseAAC-General can be 
replaced by the user-defined Lua script modules. This provides the maximal flexibility for the  
user-defined mode. Actually, the sequential evolution mode was implemented in this way.  
Because of these extension modules, the input to the PseAAC-General is not only the protein 
sequences. These extension modules should also be loaded if they are needed. We illustrate the 
data flow of PseAAC-General in Figure 1. 
 
Table 1. Comparison of program features. 
Program Functions 
a
 PseAAC-General PseAAC-Builder Propy PseAAC Server 
Physicochemical Properties 544 544 8 6 
Output Features 
Type I PseAAC [1] Y Y Y Y 
Type II PseAAC [79] Y Y Y Y 
Amino acid composition Y Y Y Y 
di-Peptide composition Y Y Y Y 
tri-Peptide composition Y N Y N 
Normalized Moreau-Broto  
autocorrelation [84,85] 
Y N Y N 
Moran autocorrelation [86] Y N Y N 
Geary autocorrelation [87] Y N Y N 
Composition-Transition-Distribution  
(CTD) [88] 
Y N Y N 
Quasi-sequence order [89] Y N Y N 
Gene ontology mode [83] Y N N N 
Functional domain mode [83] Y N N N 
Sequential evolution mode [18] Y N N N 
Other functions     
User defined Y N N N 
Online updates Y N N N 
Graphical User Interface (GUI) Y Y N Y 
Execution efficiency b ~17,000 seqs/s ~170 seqs/s N.A. ~15 seqs/s 
a The program functions that were compared. There are three groups of functions, including the 
physicochemical properties, the sequence features that can be generated and the other function properties 
of the software. Y = YES; N = NO; b the execution time for PseAAC-General and PseAAC-Builder was  
tested on a dataset containing over 510,000 sequences by the wall-clock time. The execution time for  
PseAAC-Server was tested on a dataset containing 500 sequences due to the limitation of the service and 
the internet connection conditions. The execution time for Propy was not tested due the limitation of 
testing environments. Seqs/s means sequences per second. 
The usefulness of PseAAC-General is undisputed. In the early days of general form PseAAC,  
every study had to implement the PseAAC independently. This may bring a number of problems, 
including but not limited to inconsistent results, different computation efficiency and different basis 
in comparing predictive performance. PseAAC-General can serve as a standard program that saves 
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time for all these studies. Furthermore, our program eliminates those unforeseen problems that 
were brought by the different implementations of PseAAC. 
PseAAC-General is much faster than existing programs. We tested PseAAC-General by using  
it to calculate Type I PseAAC with default parameters. On the same machine that we tested  
PseAAC-Builder [81], it can process about 17,000 sequences per second. This is about 100 times 
faster than PseAAC-Builder. In other words, PseAAC-General can convert the entire Swiss-Prot 
database to Type I PseAAC within 30 s, while PseAAC-Builder needs about 40 min. 
 
Figure 1. The data flow of pseudo-amino acid composition (PseAAC)-General. The 
input data is FASTA format sequences. The output data is general form PseAAC. The 
mode of the general form PseAAC is chosen by the users. For the modes, which are 
implemented by Binary Extension Modules or Lua script modules, the corresponding 
modules should be loaded as well. 
 
3. Implementations 
PseAAC-General is released under GNU GPL (GNU General Public License). It can be 
integrated with other programs in the source code level. We have ported PseAAC-General to both 
Linux and Windows platforms. A GUI (Graphical User Interface) module was provided for both 
platforms. The users, who do not familiar with the command line, can use PseAAC-General 
through GUI. However, it should be noted that the most efficient way is the command line, which 
was designed to follow the GNU command line standard. 
PseAAC-General was designed to be a stand-alone program running on the local machine 
without internet connection requirements. Therefore, we did not include the online sequence 
retrieving function within the program. On the other hand, the propy package has perfectly 
implemented the retrieving function. The best choice for the users is to let PseAAC-General work 
side by side with the propy package. For example, the users can use Propy to retrieve protein 
sequences and call PseAAC-General to calculate the PseAAC, as python environment has the built-in 
ability to call external programs, like PseAAC-General. In future versions of PseAAC-General, a 
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similar function will be implemented. PseAAC-General and all its extension modules can be 
downloaded from its website [91]. To facilitate further studies, all source code of PseAAC-General, 
including the main program, GUI module and all extension modules, can be freely downloaded 
from the SourceForge website [92]. We also provided detailed documents within the software 
package, so that the users can learn not only how to use the existing modes, but also how to create 
their own modes by building their own extension modules. For the users’ convenience to test their 
own modes, we provided four different testing dataset with different size. These testing datasets 
can also be downloaded from the website. Along with the testing datasets, we provided simple 
testing scripts to demonstrate the usage of PseAAC-General in a common case. The users can 
simply try the testing scripts to learn how to use the program. 
Because the gene ontology mode and the functional domain mode should be upgraded along 
with the Swiss-Prot database, we deployed a cloud-computation based server in Amazon EC2 
(Elastic Cloud 2, Amazon.com Inc., Seattle, WA, USA) to automatically upgrade the relevant 
extension modules on monthly basis. 
4. Conclusions 
As PseAAC-General is a very powerful and very flexible computation tool, we believe that 
PseAAC-General will facilitate all studies that apply the general form PseAAC, including those 
existing modes and those modes in development. 
However, as a final reminder, we would like to remind the users to read the manual of  
PseAAC-General and those literatures describing the algorithm of general form PseAAC carefully 
before using it. Because of the powerful function and the flexibility of PseAAC-General, using it in 
your study without knowing the algorithms and technics behind the program and the source code 
could be very risky. 
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PSNO: Predicting Cysteine S-Nitrosylation Sites by  
Incorporating Various Sequence-Derived Features  
into the General Form of Chou’s PseAAC 
Jian Zhang, Xiaowei Zhao, Pingping Sun and Zhiqiang Ma 
Abstract: S-nitrosylation (SNO) is one of the most universal reversible post-translational 
modifications involved in many biological processes. Malfunction or dysregulation of SNO leads 
to a series of severe diseases, such as developmental abnormalities and various diseases. Therefore, 
the identification of SNO sites (SNOs) provides insights into disease progression and drug 
development. In this paper, a new bioinformatics tool, named PSNO, is proposed to identify SNOs 
from protein sequences. Firstly, we explore various promising sequence-derived discriminative 
features, including the evolutionary profile, the predicted secondary structure and the physicochemical 
properties. Secondly, rather than simply combining the features, which may bring about information 
redundancy and unwanted noise, we use the relative entropy selection and incremental feature 
selection approach to select the optimal feature subsets. Thirdly, we train our model by the 
technique of the k-nearest neighbor algorithm. Using both informative features and an elaborate 
feature selection scheme, our method, PSNO, achieves good prediction performance with a mean 
Mathews correlation coefficient (MCC) value of about 0.5119 on the training dataset using 10-fold 
cross-validation. These results indicate that PSNO can be used as a competitive predictor among 
the state-of-the-art SNOs prediction tools. A web-server, named PSNO, which implements the 
proposed method, is freely available at http://59.73.198.144:8088/PSNO/. 
Reprinted from Int. J. Mol. Sci. Cite as: Zhang, J.; Zhao, X.; Sun, P.; Ma, Z. PSNO: Predicting 
Cysteine S-Nitrosylation Sites by Incorporating Various Sequence-Derived Features into the 
General Form of Chou’s PseAAC. Int. J. Mol. Sci. 2014, 15, 11204-11219. 
1. Introduction 
S-nitrosylation (SNO) is one of the most ubiquitous post-translational modifications (PTMs) 
involving the covalent interaction of nitric oxide with the thiol group of cysteine residues [1]. Many 
lines of evidence have suggested that S-nitrosylation sites (SNOs) play key roles in providing 
proteins with structural and functional diversity, as well as in regulating cellular plasticity and 
dynamics. Malfunction or dysregulation of SNOs leads to a series of severe diseases [2], including 
developmental abnormalities and various diseases, such as cancer [3], Parkinson’s [4],  
Alzheimer’s [5] and amyotrophic lateral sclerosis [6]. Therefore, detecting possible SNO substrates 
and their corresponding exact sites is crucial for understanding the mechanisms of the biological 
processes of these diseases and promising great possibilities as effective therapeutic targets or 
diagnostic markers. 
Several biochemical methodologies, including absorbance detection [7], colorimetric assays [8] 
and fluorescent assays [8,9], have been developed to identify SNOs. Compared with expensive and 
time-consuming biochemical experiments, computational methods are attracting more and more 
attention, due to their convenience and efficiency. 
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In 2001, Jaffrey made the first attempt to develop a biotin-switch technique (BST) for the  
large-scale detection of SNO substrates [10]. The BST includes three principal steps: (i) the 
methylthiolation of free protein thiols; (ii) the reduction of SNO bonds on Cys residues with 
ascorbate; and (iii) the ligation of thiols using N-[6-(Biotinamido)hexyl]-3'-(2'-pyridyldithio) 
propionamide (biotin-HPDP). Soon after that, Gross developed a predictor, named SNOSID [11]. 
This is a proteomic method, which identified endogenous and chemically-induced SNOs in proteins 
from tissues or cells. In 2009, Forrester explored a protein microarray-based approach using resin-
assisted capture (RAC) to screen SNOs [12]. Compared with BST using a human embryonic 
kidney cell dataset, SNO-RAC outperformed it with higher sensitivity for proteins larger than ~100 
kDa. Although these methods did make contributions to the development of the prediction of SNOs 
from different aspects, they were labor intensive and had a relatively low throughput. 
Recent years have witnessed several computational methods that have been proposed in this 
field. Xue adopted a group-based prediction system for the prediction of kinase-specific SNOs and 
developed software named GPS-SNO (Group-based Prediction System) [13]. Li used a coupling 
pattern-based encoding scheme (CPR) and built a web server named CPR-SNO [14]. Xu 
introduced a position-specific amino acid propensity matrix to construct the predictor and built a 
free website, iSNO-pseudo-amino acid composition (PseAAC) [15]. As the iSNO-PseAAC treated 
all the proteins independently without taking into account any of their correlations, the following 
iSNO-AAPair incorporated some sequence correlation effects into the feature vector [16]. 
Each of the aforementioned methods has its own merit and does facilitate the development of 
this field. Although these computational models have been developed to predict SNOs, their 
accuracy is unsatisfactory, and they lack a detailed analysis of the features. Therefore, it is 
important to develop an efficient method for the site-specific detection of SNOs. 
In this paper, we focus on the challenging problem of predicting SNOs based on primary 
sequence information. A novel method, PSNO, is proposed for differentiating SNOs from non-
SNOs. Firstly, various informative sequence-derived features that effectively reflect the intrinsic 
characters of a given peptide are combined to construct informative features; Secondly, relative 
entropy selection and incremental feature selection are adopted to select the optimal feature 
subsets; Thirdly, we use k-nearest neighbor to identify SNOs based on the selected optimal  
feature subsets. In order to evaluate the proposed method with previous works fairly, 10-fold  
cross-validation is implemented on the widely-used low-similarity training dataset. The experimental 
results show that the proposed PSNO is a powerful computational tool for SNOs prediction. A  
web-server, named PSNO, that implements the proposed method is freely available at 
http://59.73.198.144:8088/PSNO/. 
2. Results and Discussion 
2.1. The Feature Selection Results 
The output of the relative entropy selector was two lists: one was called the feature list, which 
sorted the features according to their importance to the class of samples; the other was called the 
coefficient list, which sorted the coefficient values in descending order (Table S1). In the 
coefficient value list, a feature with a larger index implied that it tended to play a more important 
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role in identifying SNOs. Such a list of ranked features would be used in the following IFS 
procedure for searching the optimal feature subset. 
Based on the results of the relative entropy selector, 458 individual classifiers were built by  
adding features one by one from the top of the feature list to the bottom (Table S2). As shown  
in Figure 1, the mean MCC values reached the maximum when 57 features were provided. 
Figure 1. The IFS curve of 458 features for the training dataset. The x-axis and y-axis 
indicates the mean Mathews correlation coefficient (MCC) and number of features, 
respectively. When the number of selected features is 57, the mean MCC reaches the 
maximum, 0.51194. 
 
In this paper, 10-fold cross-validation was performed on the training dataset (731 SNOs and  
810 non-SNOs). We obtained a mean accuracy of 68.85% using all the features with a sensitivity 
of 67.99%, a specificity of 69.63% and an MCC of 0.3759. Using 57 optimal features, our model 
produced 75.67% accuracy with 74.15% sensitivity, 77.04% specificity and an MCC of 0.5119. 
The results suggested that our feature selection approach successfully chose “good” features, as 
well as eliminated “bad” features. 
2.2. Analysis of the Optimal Feature Set 
To discover the different contributions of various types of features, we further investigated the 
distribution of each kind of feature in the final optimal feature subset. The results are shown in  
Figure 2. Of the 57 optimal features, 48 belonged to the evolutionary conservation score, three to 
the predicted secondary structure, six to the physicochemical properties, which indicated that all 
three types of features contribute to the prediction of protein SNOs. The detailed descriptions of  
the 57 optimal features are shown in the Table S3. In addition, evolutionary conservation scores 




Figure 2. The distribution of each feature type in the final optimal feature subset. The 
x-axis and y-axis indicate the feature type and the number of selected features, 
respectively. Of the 57 optimal features, 48 belong to the evolutionary conservation 
score, three to the predicted secondary structure and six to the physicochemical properties. 
 
As is well known, all biological species were developed starting from a very limited number  
of ancestral species. Evolution was an eternal process that impenetrated the whole history of life. 
The evolution of protein sequences involved the changes, insertions and deletions of single residues or 
peptides along with the entire development of proteins [17]. Although some similarities may be 
eliminated after a long time of evolution, the corresponding protein zones may still share some 
common attributes, because the functional sites of a protein always locate in the conservation  
zone [18]. This explains why evolutionary conservation scores occupy the biggest part of the 
optimal subset. In addition, the features within the top 10 features in the final optimal feature 
subsets contained seven evolutional profile features. 
We also calculated different kinds of features accounting for the various proportions of the 
optimal feature subset (Figure 3). The blue blocks represented the percentage of the selected 
features accounting for the whole optimal feature subsets, and the red ones represented the percentage 
of the selected features accounting for the corresponding feature type. Although, within the final 
optimal feature subset, a few secondary structure features are selected, we cannot say that the 
secondary structure features are not tightly related to SNOs. Among all nine secondary structure 




Figure 3. The proportion of each type of feature in the optimal feature subset. The  
x-axis and y-axis indicate the feature type and the proportion of the selected features, 
respectively. The blue blocks represent the percentage of the selected features accounting 
for the whole optimal feature subsets, and the red ones represent the percentage of the 
selected features accounting for the corresponding feature type. 
 
2.3. Comparison of PSNO with Other Methods 
In this section, we compare PSNO with GPS-SNO [13], iSNO-PseAAC [15] and  
iSNO-AAPair [16], which were all sequence-based prediction methods. As the iSNO-AAPair was built 
on a different dataset (1530 human and mouse proteins), we adopted the independent dataset to 
compare our PSNO with iSNO-AAPair. In order to reach a consensus assessment with GPS-SNO 
and iSNO-PseAAC, a 10-fold cross-validation was adopted here to examine the prediction quality. 
Listed in Table 1 are the corresponding results obtained by the aforementioned two methods on the 
same training dataset. As can be seen, the SN, ACC and MCC rates achieved by PSNO were 
obviously higher than those by GPS-SNO with different thresholds and iSNO-PseAAC. Although 
the GPS-SNO 1 achieved the highest SP value, the SN and MCC value was relatively low. It may 
be that when the threshold parameter was set at “high”, more non-SNOs tended to be correctly 
classified, while some SNOs were mistakenly identified as non-SNOs. 
Listed in the Table S4 are the predicted results by PSNO for Xue’s independent dataset. As we 
can see from Table S4, of the 2302 SNOs, 2188 were successfully identified. The overall success 
rate was about 95.05%. 
In order to assess the ability of the proposed PSNO for practical applications, we adopted Xu’s 
independent dataset containing 81 SNO and 100 non-SNO experimentally-verified peptides. 
Among the existing models for the prediction of the SNOs, the web server for the model proposed 
in [14] did not work, and the method in [19] had no web server at all. Therefore, the comparison 
was made among the following four methods: GPS-SNO, iSNO-PseAAC, iSNO-AAPair and ours, 
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PSNO. Table 2 summarizes the results of PSNO with the existing prediction methods for the four 
different metrics. Using the optimal 57 features, the SN, SP, ACC and MCC values produced by PSNO 
are 87.7%, 85.0%, 86.2% and 0.72, respectively, which are about 8.1%~43.2%, 0.9%~9.8%, 
5.5%~24.6% and 0.09~0.44 higher than previous studies. 
Table 1. The performance comparison of PSNO with other existing prediction methods  
on the training dataset. GPS, group-based prediction system. 
Predictor SN (%) SP (%) ACC (%) MCC 
GPS-SNO 1 18.88 89.63 56.07 0.1210 
GPS-SNO 2 28.04 81.98 56.39 0.1193 
GPS-SNO 3 45.01 73.33 59.90 0.1915 
iSNO-PseAAC 67.01 68.15 67.62 0.3515 
PSNO 74.15 77.04 75.67 0.5119 
1 The method proposed in [13] where the threshold parameter was set at “high”; 2 the method proposed  
in [13] where the threshold parameter was set at “medium”; 3 the method proposed in [13] where the 
threshold was set at “low”. SN, SP, ACC and MCC represented the sensitivity, specificity, accuracy and the 
Mathews correlation coefficient, respectively. 
Table 2. Comparison of PSNO with the existing prediction methods via Xu’s independent dataset. 
Predictor SN (%) SP (%) ACC (%) MCC 
GPS-SNO 1 44.5 81.0 64.7 0.28 
iSNO-PseAAC 50.2 75.2 62.8 0.30 
iSNO-AAPair 79.6 84.1 81.7 0.63 
PSNO 87.7 85.0 86.2 0.72 
1 The method proposed in [13] where the threshold parameter was set at “medium”. SN, SP, ACC and 
MCC represented the sensitivity, specificity, accuracy and the Mathews correlation coefficient, 
respectively. 
In practical applications, the input should be entire protein sequences. To test the state-of-the-art  
web servers used for practical applications, our independent dataset (see Section 3.1) was used 
here. The predicted results are shown in Table 3. Our PSNO produced an MCC of 0.4475, which 
was about 14.22%~32.29% higher than previous studies. 
Table 3. Comparison of PSNO with the existing prediction methods using our independent 
dataset. PseAAC, pseudo-amino acid composition. 
Predictor SN (%) SP (%) ACC (%) MCC 
GPS-SNO 1 41.51 70.87 60.90 0.1244 
iSNO-PseAAC 60.38 67.96 65.38 0.2722 
iSNO-AAPair 66.04 66.02 66.03 0.3053 
PSNO 79.25 67.96 71.79 0.4475 
1 The method proposed in [13] where the threshold parameter was set at “medium”. SN, SP, ACC and 




2.4. Implementation of PSNO Server 
For the convenience of biology scientists, PSNO has been implemented as a free web server 
located at http://59.73.198.144:8088/PSNO/. Here, a step-by-step brief guide is given below to 
describe how to use it. 
Step 1. Access the web server, and the home page is the default interface displayed (Figure 4). 
Click on the “Introduction” link to see a detailed description about the server, which includes the 
User’s Guide, “Input”, “Output”, “Limitation” and “Requirement”. 
Step 2. You can either type or paste the query sequence into the text box in Figure 4. The query 
sequence should be in the FASTA format. The FASTA format sequence consists of a single initial 
line beginning with a symbol (“>”), followed by lines of sequence data. You can click on the 
“Example” link to see the example sequences. You are also required to provide a valid email 
address in the text box. 
Step 3. Click on the “Query” button to submit the computation request. PSNO begins processing 
and the predicted probabilities of a site being an SNOs or non-SNOs will be sent to you through the  
email provided. 
Figure 4. The home page of the PSNO web server. 
 
3. Materials and Methods 
3.1. Benchmark Datasets 
In order to reach a consensus assessment with previous studies [13,15,16], four datasets were 
used in this paper. The training dataset used in this paper was derived from dbSNO 
(http://dbsno.mbc.nctu.edu.tw), which integrated the experimentally verified cysteine SNOs from 
different species [20]. The training dataset contained 731 experimentally-verified SNOs and 810 




than 40% similarity to any other. The peptide segments for SNOs and non-SNOs could be 
formulated by:  
 (1) 
where R−ξ and Rξ represented the ξ-th downstream and upstream residues from cysteine (C), 
respectively. P represented the peptide being either an SNO peptide or a non-SNO peptide. To test 
our method, as well as to reach a consensus assessment with previous investigators [13,15,16], ξ 
was set as 10 to compile the training dataset. If the upstream or downstream for a cysteine was less 
than 10, the lacking residues would be filled with dummy code X. 
Xue’s independent dataset [13,15] consisted of 461 experimentally-verified nitrosylated proteins 
from published literature or the UniProt database (http://www.uniprot.org/). All of these proteins 
are clustered with a threshold of less than 40% identity by CD-HIT (Cluster Database at High 
Identity with Tolerance) [21]. After using the same technique mentioned above, 2302 SNOs are 
compiled from the 461 nitrosylated proteins. None of these 2302 SNOs occurred in the training 
dataset. In [16], Xu developed a public independent dataset (81 SNOs and 100 non-SNOs). The 
corresponding nitrosylated proteins and sequences were taken from dbSNO and UniProt, respectively. 
In practical applications, the input should be entire protein sequences. To test the state-of-the-art 
web servers used for practical applications, we collected a new independent dataset by extracting 
the experimental-verified 20 nitrosylated proteins from dbSNO. None of them occurred in the 
training dataset. After compiling based on the same technique, 53 SNOs and 103 non-SNOs are 
obtained from the 20 nitrosylated proteins. The sequences of these 20 proteins, as well as SNOs 
(red) and non-SNOs (blue) are freely available at our PSNO web server. Table 4 summarizes the 
detailed compositions of above-mentioned four datasets. 
Table 4. Detailed compositions of the four datasets. 
Dataset Proteins Peptides SNOs Non-SNOs 
Training dataset 438 1541 731 810 
Xue’s independent dataset 461 2302 2302 0 
Xu’s independent dataset - 181 81 100 
Our independent dataset 20 156 53 103 
“-” The paper [16] makes no mention. 
3.2. Sample Formulation and Feature Construction 
In order to build a powerful protein system, the first thing was to represent the sequences with 
proper and effective mathematical expressions, which can reflect the intrinsic correction with the 
target to be predicted. In this study, we incorporated sequence-derived features into pseudo-amino 
acid composition (PseAAC) to represent the sample of a target protein. The PseAAC method had 
been widely used in bioinformatics, such as identifying proteins attributes [22,23], predicting 
protein structures [24,25] and predicting protein classes [26,27]. According to a recent review [28], 
the general form of PseAAC for a protein could be formulated as:  
 (2) 
( 1) 2 1 1 2 ( 1)... ...P R R R R CR R R R            
1 2[ , ... , , ... , ]
T
uP    
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where T was a transpose operator and the ψ1, ψ2 … depended on how to extract the desired  
information from the protein sequence of P. Here, several sequence-derived features were explored  
to distinguish the SNOs and non-SNOs. These features included evolutionary conservation scores, the 
predicted secondary structure and physicochemical properties. 
3.2.1. Features of Evolutionary Conservation Scores 
Evolutionary conservation scores had been widely used by the investigators to predict various 
attributes of proteins, such as predicting the protein subcellular location [29], identifying the subnuclear 
protein location [30] and identifying the protease family [31]. To incorporate evolutionary conservation 
scores, PSSM (Position-specific Scoring Matrix) was generated by the program “blastpgp”  
(PSIBLAST) [32], which was used to search the Swiss-Prot database (released on 15 May 2011; 
http://www.ebi.ac.uk/swissprot/) through 3 iterations (−j 3) and an e-value threshold of 0.0001  
(−h 0.0001) for multiple sequence alignment against the protein, P. According to [33], the sequence 
evolution information of protein P with L amino acid residues could be expressed by a 20 × L 
matrix, as given by:  
 (3) 
where Ei,j represented the score of the amino acid in the i-th position of the sequence that was being 
changed to amino acid type j (j = 1, 2, …, 20) during the evolutionary process. 
PSSM scores were generally displayed as positive or negative integers. Positive scores  
(ratio > 0) indicated that the given amino acid substitution exceeded the expected frequency, 
suggesting that this substitution was surprisingly favored in the alignment than expected by chance, 
while negative scores (ratio < 0) indicated the opposite; that the frequency occurred less than the 
expected frequency, suggesting that the substitution was not favored. 
The preference of evolutionary conservation in SNOs and non-SNOs were calculated and 
displayed in a heat map (Figure 5). In this figure, amino acids were sorted in both the x-axis and  
y-axis. The color palette from black to yellow indicated a growing preference for evolutionary 
conservation in SNOs and non-SNOs. The yellow color indicated the higher probability of the 
appearance of evolutionary conservation, while the black color meant less appearance. For 
instance, the substitution of C/H (x-axis/y-axis) was black, while the H/C (x-axis/y-axis) was 
yellow in SNOs, which suggested that the mean probabilities (or tendency) for His being 
substituted by Cys was higher than that for Cys being substituted by His in the SNOs. In addition, 
the H/C of non-SNOs was red. This determined the mean probabilities (or tendency) for His being 
substituted by Cys in SNOs being higher than those in non-SNOs. Generally speaking, compared with 
non-SNOs, evolutionary-conserved sets were preferred to aggregate in SNOs, which indicated critical 
active sites or functional residues that may be required for other intermolecular interactions being 






















Figure 5. The heat maps of the preference of evolutionary conservation in S-nitrosylation 
sites (SNOs) and non-SNOs. The yellow color indicates the higher probability of 
appearance of evolutionary conservation, while the black color indicates less appearance. 
 
In order to make the descriptor uniformly cover the peptide, we used the elements in the above 
equation for PSSM (Equation (3)) to define a new matrix, MPSSM, as formulated by: 
 
(4) 
where the value of equaled the sum of amino acid type i being changed to amino acid type j  
in above-mentioned matrix PPSSM. In summary, 400 features were obtained to construct features of 
evolutionary conservation scores. 
3.2.2. Features of Predicted Secondary Structure 
Consider the fact that proteins with low sequence similarity, but in the same structural class, are 
likely to share high similarity in their corresponding secondary structural elements. Therefore, it 
would be useful to encode the protein sequences by taking into account the secondary structure 
information. In this study, several predicted secondary structure-based features were introduced to 
further improve low-similarity protein prediction accuracy. In this work, PSIPRED [34] was 
adopted to explore the secondary structure of a query protein sequence. The outputs of PSIPRED 
were encoded in terms of “C” for coil, “H” for helix and “E” for strand. The total number, average 
length and composition percent of C, H and E segments were calculated and constructed for the 


























































































where α = {H,E,C}, is the sum of the secondary structure of type α in the peptide.
is the sum of segments of type α in the peptide. As a result, 3 + 3 + 3 = 9 features were 
obtained to construct the predicted secondary structure features. 
3.2.3. Features of Physicochemical Properties 
Forty nine selected physical chemical, energetic and conformational properties, which have 
been observed to be widely used in pre-works [29,35,36], were used here. More detailed 
descriptions can be found at http://www.cbrc.jp/~gromiha/fold_rate/property.html. For each sequence, 
49 properties values were firstly calculated by taking the sum of each property value over the whole 
residues and then divided by the length of the sequence. In this encoding scheme, a peptide was 
encoded by a 49-dimensional vector. 
3.3. The Relative Entropy Selection 
Commonly, the combination of various features would bring more informative features  
to the classifier. Nevertheless, some “bad” features were also added and became the unwanted 
noise. This noise, which was redundant with other features, may deteriorate the performance of 
learning algorithms and decrease the generalization power of the learned classifiers [37]. In order to get 
rid of the related or noisy feature, the feature selection approach for the optimal subset of features from  
a high-dimensional feature space was a critical job in machine learning. Relative entropy selection  
(i.e., Kullback–Leibler divergence) [38] was proven to be a powerful method to identify those 
features that were the most useful in describing the essential differences among the possible classes. In 
this algorithm, relative entropy can be defined the as: 
DKL(P||Q) + DKL(Q||P) (8) 
where P and Q are the conditional probability density function of a feature under two different classes; 
DKL(P||Q) is the K–L divergence of Q from P and DKL(Q||P) was the K–L divergence of P from Q. 
After the calculation, we got a feature list, L:  
L = {f1, f2, f3,…, fi, …}and i = {1,2,3…N} (9) 




















3.4. Incremental Feature Selection 
Through the relative entropy selection, we obtained the ranked feature list. In order to determine 
which features should be selected for the optimal feature set for our model, the incremental feature 
selection (IFS) procedure [19] was adopted here to search for a good feature subset involving 
finding those features that were highly correlated with the decision features, but that are 
uncorrelated with each other. 
During the IFS procedure, we added the feature in the ranked feature list one by one from  
the top to the bottom. After a feature had been added, a new feature subset was composed. For  
each new feature subset, a classifier was built based on the new feature subset using 10-fold  
cross-validation on the training dataset. As a result, 458 individual classifiers were constructed for 
the 458 feature subsets. By doing so, a table named IFS, with one column for the feature index and 
the other column for the prediction performance of each individual classifier, was obtained. An IFS 
curve was drawn to identify the best prediction performance, as well as the corresponding optimal 
feature subsets. 
3.5. K-Nearest Neighbor Algorithm 
The k-nearest neighbor algorithm (KNN) is quite popular in pattern recognition and machine 
learning. According to the KNN algorithm [39], the query sample would be assigned to the subset 
represented by its k-nearest neighbors. In this study, if the majority of the k-nearest neighbors of 
the query sample is a positive sample, this means that it is an SNO site. Otherwise, the query sample is 
regarded as a negative one. There are many different distances to measure the nearest neighbors for the 
KNN algorithm, such as the Hamming distance [40], Euclidean distance [40] and the Mahalanobis 
distance [41]. In order to build a KNN model, we tested different k-values from 3 to 19, as well  
as various different definitions. The best performance was achieved with K = 9 using the  
Euclidean distance.  
3.6. Assessment of Prediction Accuracy 
Four routinely used evaluation indexes were adopted in this paper, i.e., sensitivity (SN), 






where TP, TN, FP and FN were the abbreviations of true positives, true negatives, false positives 
and false negatives. In this paper, MCC was used as the major evaluation criteria to evaluate the 
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performance of the proposed approach as the positive and negative samples in the training dataset 
were imbalanced. 
3.7. Cross-Validation Test 
In statistical prediction, the independent dataset, sub-sampling (k-fold cross-validation) and jackknife 
analysis (leave-one-out) are the three cross-validation methods that are often used to assess a 
prediction tool for its effectiveness in practical application. In order to reach a consensus assessment 
with previous studies [13,15,16], we used the same 10-fold cross-validation to examine the 
prediction performance as done by many studies for SNOs prediction. Firstly, the dataset was 
randomly divided into ten equal subsets; then, nine subsets were used for training and the 
remaining one for testing. The procedure was repeated 10 times, and the final performance was 
calculated by averaging over 10 testing sets. The system architecture of the proposed model is 
illustrated in Figure 6. 
Figure 6. The system architecture of the proposed model. Three different types of  
sequence-derived features, i.e., evolutionary conservation, secondary structure and 
physicochemical properties, are generated and constructed as the feature space. Relative 
entropy selection and the incremental feature selection (IFS) procedure are adopted to 
select the optimal feature subset. The final results are obtained by using 10-fold  




In this paper, we present a novel method named PSNO based on sequence-derived features and 
effective feature selection techniques to identify SNOs. The PSNO model achieves a promising 
performance and outperforms many other prediction tools. We ascribe the excellent performance of 
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our predictor PSNO to two aspects. The first aspect is the informativeness of the feature vector in 
our model in representing proteins. The feature vector in this study includes an evolutionary 
profile, a secondary structure and physicochemical properties. However, rich information also 
brings the enlargement of the dimension and worsening of the predictor, which needs a proper 
feature selection strategy. Therefore, the second aspect is the effectiveness of relative entropy 
selection, followed by the IFS procedure. By means of powerful feature selection, an optimal set of 
57 features, which contribute significantly to the prediction of SNOs, are selected. With the 57 optimal 
features selected, our predictor achieves an overall accuracy of 75.67% and an MCC of 0.5119 on a 
training dataset using 10-fold cross-validation. Theoretically, the protein structures can bring  
rich information to construct powerful prediction models compared to simple sequences. However,  
the sequence-based prediction is an alternative to the structure-based prediction in the absence  
of structures. As a result of the completion of whole-genome sequencing projects, the  
sequence-structure gap is rapidly increasing. Thus, it would be a powerful prediction tool to 
identify SNOs for newfound proteins without structure information. For the convenience of biology 
scientists, the proposed PSNO has been implemented as a web server and is freely available. 
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iRSpot-TNCPseAAC: Identify Recombination Spots  
with Trinucleotide Composition and Pseudo Amino  
Acid Components 
Wang-Ren Qiu, Xuan Xiao and Kuo-Chen Chou 
Abstract: Meiosis and recombination are the two opposite aspects that coexist in a DNA system. 
As a driving force for evolution by generating natural genetic variations, meiotic recombination 
plays a very important role in the formation of eggs and sperm. Interestingly, the recombination 
does not occur randomly across a genome, but with higher probability in some genomic regions 
called “hotspots”, while with lower probability in so-called “coldspots”. With the ever-increasing 
amount of genome sequence data in the postgenomic era, computational methods for effectively 
identifying the hotspots and coldspots have become urgent as they can timely provide us with 
useful insights into the mechanism of meiotic recombination and the process of genome evolution 
as well. To meet the need, we developed a new predictor called “iRSpot-TNCPseAAC”, in which a 
DNA sample was formulated by combining its trinucleotide composition (TNC) and the pseudo 
amino acid components (PseAAC) of the protein translated from the DNA sample according to its 
genetic codes. The former was used to incorporate its local or short-rage sequence order 
information; while the latter, its global and long-range one. Compared with the best existing 
predictor in this area, iRSpot-TNCPseAAC achieved higher rates in accuracy, Mathew’s 
correlation coefficient, and sensitivity, indicating that the new predictor may become a useful tool 
for identifying the recombination hotspots and coldspots, or, at least, become a complementary tool 
to the existing methods. It has not escaped our notice that the aforementioned novel approach to 
incorporate the DNA sequence order information into a discrete model may also be used for many 
other genome analysis problems. The web-server for iRSpot-TNCPseAAC is available at 
http://www.jci-bioinfo.cn/iRSpot-TNCPseAAC. Furthermore, for the convenience of the vast majority 
of experimental scientists, a step-by-step guide is provided on how to use the current web server to 
obtain their desired result without the need to follow the complicated mathematical equations. 
Reprinted from Int. J. Mol. Sci. Cite as: Qiu, W.-R.; Xiao, X.; Chou, K.-C. iRSpot-TNCPseAAC: 
Identify Recombination Spots with Trinucleotide Composition and Pseudo Amino Acid Components. 
Int. J. Mol. Sci. 2014, 15, 1746-1766. 
1. Introduction 
Meiosis and recombination are two indispensible aspects for cell reproduction and growth  
(Figure 1). The former is a special type of cell division by which the genome is divided in half to 
generate daughter cells for participating in sexual reproduction, while the latter is to produce 




Figure 1. An illustration to show the process of meiosis and recombination in a DNA 
system. Adapted from [2]. 
 
Recombination is initiated by double-strand breaks (or broken DNA ends); defecting in meiosis 
may lead to male infertility [3–5]. Meiotic recombination ensures accurate chromosome 
segregation during the first meiotic division and provides a mechanism to increase genetic 
heterogeneity among the meiotic products. Accordingly, identification of recombination spots may 
provide very useful information for in-depth understanding the reproduction and growth of cells. 
In the past decades, a lot of global mapping studies have been performed to map double-strand 
break sites on chromosomes [6–13]. The following findings were observed through these studies 
for the meiotic recombination events. (i) They generally concentrate in 1:2.5 kilobase regions; (ii) 
They do not occur randomly across the entire genome but with a higher rate in some regions and 
lower in others; the former is a so-called “hotspot” while the latter, “coldspot”; (iii) They do not 
share a consensus sequence pattern. 
With the rapid increasing number of genome sequences, it is important to address the following 
problem. Given a genome sequence, how can we predict which part of it is the hotspot for 
recombination, and which part is not? 
Based on the nucleotide sequence contents, Liu et al. [14] proposed a computational method to 
deal with this problem. However, in their method no sequence-order effect whatsoever was taken 
into account, and, hence, its prediction power might be limited.  
Actually, one of the most important, but also most difficult, problems in computational biology 
is how to formulate a biological sequence with a discrete model or a vector, yet still keep considerable 
sequence order information. This is as all the existing operation engines, such as covariance 
discriminant (CD) [15–20], neural network [21–23], support vector machine (SVM) [24–26], 
random forest [27,28], conditional random field [29], nearest neighbor (NN) [30,31], K-nearest 
neighbor (KNN) [32–34], OET-KNN (optimized evidence-theoretic k-nearest neighbors) [35–38], 
and Fuzzy K-nearest neighbor [39–43], can only handle vector, but not sequence,  
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5’end resection 






samples. However, a vector defined in a discrete model may completely lose all the  
sequence-order information. 
To avoid completely losing the sequence-order information for proteins, the pseudo amino acid 
composition [44,45] or Chou’s pseudo amino acid components (PseAAC) [46] was proposed. Ever 
since the concept of PseAAC was proposed in 2001 [44], it has penetrated into almost all the areas 
of computational proteomics, such as identifying cysteine S-nitrosylation sites in proteins [29], 
predicting bacterial virulent proteins [47], predicting antibacterial peptides [48], identifying 
bacterial secreted proteins [49], predicting supersecondary structure [50], predicting protein 
subcellular location [51–59], predicting membrane protein types [60,61], discriminating outer 
membrane proteins [62], identifying antibacterial peptides [48], identifying allergenic proteins [63], 
predicting metalloproteinase family [64], predicting protein structural class [65], identifying GPCRs 
(G protein-coupled receptors) and their types [66,67], identifying protein quaternary structural 
attributes [68,69], predicting protein submitochondria locations [70–73], identifying risk type of 
human papillomaviruses [74], identifying cyclin proteins [75], predicting GABA(A) receptor 
proteins [76], classifying amino acids [77], predicting the cofactors of oxidoreductases [78], 
predicting enzyme subfamily classes [79], detecting remote homologous proteins [80], analyzing 
genetic sequences [81], predicting anticancer peptides [82], among many others (see a long list of 
papers cited in the References section of [83]). Recently, the concept of PseAAC was further 
extended to represent the feature vectors of nucleotides [15], as well as other biological  
samples [84–86]. As it has been widely and increasingly used, recently two powerful soft-wares, called 
“PseAAC-Builder” [87] and “propy” [88], were established for generating various special Chou’s 
pseudo-amino acid compositions, in addition to the web-server “PseAAC” [89], built in 2008. 
Encouraged by the success of introducing PseAAC for proteins, recently, Chen et al. [25] 
proposed the pseudo dinucleotide composition or PseDNC to represent DNA sequences for 
identifying the recombination spots by counting some sequence effects, remarkably improving the 
prediction results in comparison with those by Liu et al. [14], without including any sequence 
information. However, in PseDNC, only the correlations of dinucleotides along a DNA sequence 
were considered, and, hence, some important sequence order effects might be missed. 
The present study was initiated in an attempt to incorporate the long-range or global correlations 
of trinucleotides along a DNA sequences in hope to further improve the prediction quality in 
indentifying the recombination spots. 
As demonstrated in a series of recent publications [24,42,90–92] and summarized in a 
comprehensive review [83], to establish a really useful statistical predictor for a biological system, 
one needs to consider the following procedures: (i) construct or select a valid benchmark dataset to 
train and test the predictor; (ii) formulate the biological samples with an effective mathematical 
expression that can truly reflect their intrinsic correlation with the target to be predicted;  
(iii) introduce or develop a powerful algorithm (or engine) to operate the prediction; (iv) properly 
perform cross-validation tests to objectively evaluate the anticipated accuracy of the predictor; and 
(v) establish a user-friendly web-server for the predictor that is accessible to the public. Below, let 




2. Results and Discussion 
2.1. Benchmark Dataset 
The benchmark dataset S used in this study was taken from Liu et al. [14], which contains 490 
recombination hotspots and 591 recombination coldspots, as can be formulated by:  
 (1) 
where subset S+ and S− are respectively for the hot and cold spots, while  represents the symbol 
for “union” in the set theory. For reader’s convenience, the 490 DNA sequences in S+ and 591 
sequences in S− are given in the Supplementary Information S1. 
2.2. Formulate DNA Samples by Combining Trinucleotide Composition and Pseudo Amino  
Acid Components 
Suppose a DNA sequence D with L nucleotides; i.e., 
D = N1N2N3N4N5N6N7 NL  (2) 
where  
 A (adenine), C (cytosine) G (guanine) T (thymine)iN   (3) 
denotes the i-th (i = 1, 2, …, L) nucleotide in the DNA sequence. If the feature vector of the DNA 
sequence is formulated by its mononucleotide composition (MNC), we have: 
















           
 (4) 
where f1
(1) = f (A) , f2
(1) = f (C) , f3
(1) = f (G) , and f4
(1) = f (T)  are the normalized occurrence 
frequencies of adenine (A), cytosine (C), guanine (G), and thymine (T), respectively, in the DNA 
sequence; and the symbol T is the transpose operator. As we can see from Equation (4), all the 
sequence order information is missed if using MNC to represent a DNA sequence. If using the 
dinucleotide composition (DNC) to represent the DNA sequence, instead of the four components as 
shown in Equation (4), the corresponding feature vector will contain 4 × 4 = 16 components, as  
given below: 
















                        
 (5) 
where f1
(2) = f (AA)  is the normalized occurrence frequency of AA in the DNA sequence; 
f2
(2) = f (AC), that of AC; f3




trinucleotide composition (TNC), the corresponding feature vector will contain 34 4 4 4 64     
components, as given below:  
















                                  
 (6) 
where f1
(3) = f (AAA) is the normalized occurrence frequency of AAA in the DNA sequence; 
f2
(3) = f (AAC), that of AAC; and so forth. Generally speaking, if a DNA sequence is represented 
by the K-tuple nucleotide composition, the corresponding vector D for the DNA sequence will 













        (7) 
As we can see from Equations (5–7), with increasing the tuple number, although the base  
sequence-order information within a local or very short range could be gradually included, none of 
the global or long-range sequence-order information would be reflected by the formulation. 
Actually, in computational proteomics, we have also faced exactly the same situation; i.e., 
although the dipeptide composition, tripeptide composition, and K-tuple peptide composition were 
used by many investigators to represent protein sequences by incorporating their local sequence 
order information [93–97], their global or long-range sequence order information still could not be 
reflected. As mentioned above, to deal with this kind of problems in proteomics, the concept of 
PseAAC [44,45] was introduced.  
Stimulated by the PseAAC approach [44,45] in computational proteomics, below let us propose 
a novel feature vector to represent the DNA sequence (cf. Equation (2)) by combining its TNC  
(see Equation (2)) and the pseudo amino acid components of its translated protein chain.  
As is well known, three nucleotides encode an amino acid (see Figure 2). Thus, according the 
conversion table from DNA codons to amino acids (Table 1), the DNA sequence in Equation (2) 
can be translated into a protein sequence expressed by: 
P= A1A2A3 AL* (8) 
with  
Ai  20 native amino acids{ }






where the symbol “Int” is an integer truncation operator meaning to take the integer part for the 




Figure 2. A graph to show how a DNA codon of three nucleotides is converted to an 
amino acid. The characters in the first three rings from the center represent four bases 
in DNA, while those in the fourth ring represent the single-letter codes of the 20 native 
amino acids in protein. The symbol * means the “Stop” sign. 
 
Table 1. The conversion code of the 64 trinucleotides in DNA to the 20 amino acids in protein. 
Trinucleotide Amino acid Trinucleotide Amino acid 
AAA Lys (K) GAA Glu (E) 
AAC Asn (N) GAC Asp (D) 
AAG Lys (K) GAG Glu (E) 








AGA Arg (R) GGA 
Gly (G) 
AGC Ser (S) GGC 
AGG Arg (R)  GGG 






ATG Met (M) GTG 
ATT Ile (I) GTT 
CAA Gln (Q) TAA Stop! 
CAC His (H) TAC Tyr (Y) 
CAG Gln (Q) TAG Stop! 











Table 1. Cont. 




CGC TGC Cys (C) 
CGG TGG Trp (W) 
CGT TGT Cys (C) 
CTA 
Leu (L) 
TTA Leu (L) 
CTC TTC Phe (F) 
CTG TTG Leu (L) 
CTT TTT Phe (F) 
Now, according to the formulation of Chou’s PseAAC approach [44,45], for the protein chain of 
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where  ( 1,2,3, , )k k   is called the k-th tier correlation factor that reflects the sequence order 
correlation between all the k-th most contiguous residues along a protein chain. In this study, the 
correlation function in Equation 10 is given by: 
6 2
1
1( , ) ( ) ( )
6i j n j n in
A A H A H A

	 
     (11) 
where Hn(Aj ) (n=1,2, ,6) is the six physicochemical properties of amino acid Aj ; they are, 
respectively, hydrophobicity, hydrophilicity, side-chain mass, pK1 (α-COOH), pK2 (NH3), and PI. 
Note that before substituting these physicochemical values into Equation (11), they were all 













  (12) 
where Hn(Ai ) (n=1,2, ,6)is the n-thoriginal physicochemical property value for the amino acid 
A i  as given in Table 2, the symbol < and > means taking the average of the quantity therein over 
20 native amino acids, and SD means the corresponding standard deviation. Listed in Table 3 are 
the converted values obtained by Equation (12) that will have a zero mean value over the 20 native 
amino acids, and will remain unchanged if going through the same conversion procedure again. 
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Table 2. List of the original values of the six physical-chemical properties for each of 
the 20 native amino acids. 































A 0.62 −0.5 15 2.35 9.87 6.11 
C 0.29 −1.00 47 1.71 10.78 5.02 
D −0.90 3.00 59 1.88 9.60 2.98 
E −0.74 3.00 73 2.19 9.67 3.08 
F 1.19 −2.50 91 2.58 9.24 5.91 
G 0.48 0.00 1 2.34 9.60 6.06 
H −0.40 −0.50 82 1.78 8.97 7.64 
I 1.38 −1.80 57 2.32 9.76 6.04 
K −1.50 3.00 73 2.20 8.90 9.47 
L 1.06 −1.80 57 2.36 9.60 6.04 
M 0.64 −1.30 75 2.28 9.21 5.74 
N −0.78 0.20 58 2.18 9.09 10.76 
P 0.12 0.00 42 1.99 10.60 6.30 
Q −0.85 0.20 72 2.17 9.13 5.65 
R −2.53 3.00 101 2.18 9.09 10.76 
S −0.18 0.30 31 2.21 9.15 5.68 
T −0.05 −0.40 45 2.15 9.12 5.60 
V 1.08 −1.50 43 2.29 9.74 6.02 
W 0.81 −3.40 130 2.38 9.39 5.88 
Y 0.26 −2.30 107 2.20 9.11 5.63 
a Taken from [98]; b Taken from [99]; c Taken from any biochemistry text book; d Taken from [100] for 
C -COOH; e Taken from [100] for NH3; f Taken from [101]. 
By combining the   correlation factors with the 64 components in TNC (see Equation (6)), the 
DNA sequence is formulated by: 
 1 2 64 64 1 64d d d d d  
T
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where w  is the weight factor which is determined by optimizing the outcome as will be mentioned 
later. The rationale of using Equation (13) to represent the DNA sequence is that the local or  
short-range sequence order effect can be directly reflected via the occurrence frequencies of its  
64 trinucleotides, while the global or long-range sequence order effect can be indirectly reflected 
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via the   pseudo amino acid components of its translated protein chain. As three nucleotides 
encode an amino acid, the above approach is both quite rational and natural. 
Table 3. The corresponding values obtained by the standard conversion of Equation12 
on the original values in Table 2.  
Amino acid H1  H2  H3  H4  H5  H6  
A 0.62 −0.15 −1.55 0.78 0.77 −0.10 
C 0.29 −0.41 −0.52 −2.27 2.57 −0.64 
D −0.90 1.67 −0.13 −1.46 0.24 −1.65 
E −0.74 1.67 0.33 0.01 0.37 −1.61 
F 1.19 −1.19 0.91 1.87 −0.48 −0.20 
G 0.48 0.11 −2.00 0.73 0.24 −0.13 
H −0.40 −0.15 0.62 −1.94 −1.01 0.65 
I 1.38 −0.82 −0.19 0.63 0.55 −0.14 
K −1.50 1.67 0.33 0.06 −1.15 1.56 
L 1.06 −0.82 −0.19 0.82 0.24 −0.14 
M 0.64 −0.56 0.39 0.44 −0.54 −0.29 
N −0.78 0.22 −0.16 −0.03 −0.77 2.20 
P 0.12 0.11 −0.68 −0.94 2.21 −0.01 
Q −0.85 0.22 0.29 −0.08 −0.69 −0.33 
R −2.53 1.67 1.23 −0.03 −0.77 2.20 
S −0.18 0.27 −1.03 0.11 −0.65 −0.32 
T −0.05 −0.10 −0.58 −0.18 −0.71 −0.36 
V 1.08 −0.67 −0.65 0.49 0.51 −0.15 
W 0.81 −1.65 2.17 0.92 −0.18 −0.22 
Y 0.26 −1.08 1.43 0.06 −0.73 −0.34 
2.3. Use Support Vector Machine as an Operation Engine  
Support vector machine (SVM) has been widely to make classification prediction (see,  
e.g., [24,102–105]. The basic idea of SVM is to transform the input data into a high dimensional 
feature space and then determine the optimal separating hyperplane. A brief introduction about the 
formulation of SVM was given in [103,106]. Here, the DNA samples as formulated by Equation (13) 
were used as inputs for the SVM. Its software was downloaded from the LIBSVM  
package [107,108], which provided a simple interface. Due to this advantages, the users can easily 
perform classification prediction by properly selecting the built-in parameters C and  . In order  
to maximize the performance of the SVM algorithm, the two parameters in the RBF kernel  
were preliminarily optimized through a grid search strategy in this study. To obtain the  
optimized parameters, the search function “SVMcgForClass” was downloaded from 
http://www.matlabsky.com. 
The predictor obtained via the aforementioned procedures is called iRSpot-TNCPseAAC, where 
“i” means “identify”, “RSpot” means “Recombination Spots”, while TNCPseAAC means a 
combination of “Tri-Nucleotide Composition” and “Pseudo Amino Acid Components.”  
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To objectively evaluate the quality of a new predictor, one should use proper metrics [109] and 
rigorous cross-validation [83] to test it. Below, let us address these problems. 
2.4. Four Different Metrics for Measuring the Prediction Quality 
In literature, the following metrics are often used for examining the performance quality of  
a predictor:  
Sn = TP
TP+ FN
                                                           
Sp = TN
TN + FP
                                                          
Acc = TP+TN
TP+TN + FP+ FN
                                        
MCC = (TPTN) (FP FN)















where TP represents the number of the true positive; TN, the number of the true negative; FP,  
the number of the false positive; FN, the number of the false negative; Sn, the sensitivity; Sp,  
the specificity; Acc, the accuracy; MCC, the Mathew’s correlation coefficient. To most  
biologists, however, the four metrics as formulated in Equation (15) are not quite intuitive and  
easier-to-understand, particularly for the Mathew’s correlation coefficient. Here let us adopt the 
formulation proposed recently [25,29] based on the Chou’s symbol and definition [110]; i.e., 
1                                           
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where N   is the total number of the hotspot samples investigated while N   the number of  
the hotspot samples incorrectly predicted as coldspots; N  the total number of the coldspot  
samples investigated while N   the number of the coldspot samples incorrectly predicted as the 
hotspots [111]. 
Now, it can be clearly seen from Equation (16) that when N
+ = 0 meaning none of the hotspots 
was incorrectly predicted to be a coldspot, we have the sensitivity Sn=1 . When N N    
meaning that all the hotspots were incorrectly predicted to be the coldspots, we have the sensitivity 
Sn= 0. Likewise, when 0N    meaning none of the coldspots was incorrectly predicted to be the 
hotspot, we have the specificity 1Sp  ; whereas N N    meaning all the coldspots were 
incorrectly predicted as the hotspots, we have the specificity Sp= 0. When 0N N     meaning 
that none of hotspots in the positive dataset and none of the coldspots in the negative dataset was 
incorrectly predicted, we have the overall accuracy Acc=1 and MCC =1; when N N   and 
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N N    meaning that all the hotspots in the positive dataset and all the coldspots in the negative 
dataset were incorrectly predicted, we have the overall accuracy Acc= 0  and 1MCC   ; whereas 
when / 2N N    and / 2N N
 
   we have Acc= 0.5  and MCC = 0  meaning no better than 
random guess. As we can see from the above discussion based on Equation (16), the meanings of 
sensitivity, specificity, overall accuracy, and Mathew’s correlation coefficient have become much 
more intuitive and easier-to-understand. 
It should be pointed out that the metrics as given in Equation (15) and Equation (16) are valid 
only for the single-label systems as in the current case. For the multi-label systems in which 
emergence has become increasingly frequent in cell’s molecular systems [112–118] and biomedical 
systems [43,119], a completely different set of metrics as defined in [109] is needed. 
2.5. Evaluate the Anticipated Success Rates by Jackknife Tests 
The following three cross-validation methods are often used in statistical prediction to  
evaluate the anticipated accuracy of a predictor: independent dataset test, subsampling (K-fold 
cross-validation) test, and jackknife test [120]. However, as elucidated by a review article [83], 
among the three methods, the jackknife test is deemed the least arbitrary and most objective  
as it can always yield a unique outcome for a given benchmark dataset, and hence has been 
increasingly used and widely recognized by investigators to examine the accuracy of various 
predictor [48,60,63,65,69,76,121,122]. Accordingly, in this study we also used the results obtained 
by jackknife tests to optimizing the uncertain parameters and to compare with the other predictors 
in this area. 
3. Experimental Section 
The results obtained with iRSpot-TNCPseAAC on the benchmark dataset S of Supplementary 
Information S1 by the jackknife test are given in Table 4, where for facilitating comparison the 
corresponding results by the iRSpot-PseDNC [25] on the same benchmark dataset are also given.  
Table 4. A comparison of iRSpot-TNCPseAAC with the best existing method. 
Predictor Test method Sn (%) Sp (%) Acc (%) MCC 
iRSpot-PseDNC a Jackknife 73.06 89.49 82.04 0.638 
iRSpot-KNCPseAAC b Jackknife 87.14 79.59 83.72 0.671 
a From [25]; b This paper with 5  , w=1.1, C = 32 and 0.5   for the LIBSVM operation engine [107,108]. 
As we can clearly see from the table, the iRSpot-TNCPseAAC predictor is superior to  
iRSpot-PseDNC [25] in three of the four metrics as defined by Equation (16); i.e., it can yield 
higher accuracy Acc, higher Mathew’s correlation coefficient MCC, and higher sensitivity Sn. 
Therefore, it is anticipated that the new predictor will become a useful tool for identifying the 
recombination spots in DNA, or at the very least become a complementary tool to iRSpot-PseDNC, 





The above fact has also proved that it is indeed a feasible and promising approach to extend  
the concept of pseudo amino acid composition [44,45,123] developed in computational proteomics 
to the area of computational genomics. As shown by Equation (13) and the related equations  
in defining its 64   components, each of the DNA samples investigated in this study was 
formulated by a combination of its trinucleotide composition (TNC) with the pseudo amino  
acid components (PseAAC) that were derived from the protein translated from the DNA  
sample according to its genetic codes. The former can better incorporate its local or short-rage 
sequence order information in comparison with the dinucleotide composition (DNC) used in 
iRSpot-PseDNC [25]; while the latter can incorporate its global or long-range sequence order 
effects in a more natural or logical manner. Accordingly, it is anticipated that the idea or approach 
by extending the Chou’s pseudo amino acid composition [44,45,123] for protein sequences to the 
pseudo oligonucleotide composition for DNA or RNA sequences may also be used to deal with 
many other genome analysis problems. 
5. Web Server and User Guide 
To enhance the value of its practical applications, a web-server for the iRSpot-TNCPseAAC 
predictor was established. Moreover, for the convenience of the vast majority of experimental 
scientists, here a step-to-step guide is provided for how to use the web server to get the desired 
results without the need to follow the mathematic equations that were presented just for the 
integrity in developing the predictor. 
Step 1. Open the web server at http://www.jci-bioinfo.cn/iRSpot-TNCPseAAC and you will see 
the top page of the predictor on your computer screen, as shown in Figure 3. Click on the Read Me 
button to see a brief introduction about the iRSpot-TNCPseAAC predictor and the caveat when 
using it. 
Figure 3. A semi-screenshot for the top page of the web-server iRSpot-TNCPseAAC at 
http://www.jci-bioinfo.cn/iRSpot-TNCPseAAC. 
 
iRSpot-TNCPseAAC: identify recombination spots with trinucleotide  
     composition and pseudo amino acid components  
| Read Me | Supporting Information | Citation |  
Enter the sequence of query DNA sequences in FASTA format (Example): the 
number of DNA sequences is limited at 100 or less for each submission. It will 
usually take about 10 seconds for each query DNA sequence. 
Submit Clear 
Or, enter your e-mail address and upload the batch input file (Batch-
example).  The predicted results will be sent to you by e-mail once 
completed. 
Upload file: 





Step 2. Either type or copy/paste the query DNA sequences into the input box at the center of 
Figure 3. The input sequence should be in the FASTA format. For the examples of sequences in 
FASTA format, click the Example button right above the input box. 
Step 3. Click on the Submit button to see the predicted result. For example, if you use the three 
query DNA sequences in the Example window as the input, after clicking the Submit button, you 
will see the following message shown on the screen of your computer: the outcome for the 1st 
query sample is “recombination hotspot”; the outcome for the 2nd query sample is “recombination 
coldspot”. All these results are fully consistent with the experimental observations as 
summarized in the Supplementary Information S1. However, no result was given for the 3rd 
query sample as it contains some invalid characters as warned in the output screen. It takes 
about a few seconds for the above computation before the predicted result appears on your 
computer screen; the more number of query sequences and longer of each sequence, the more time 
it is usually needed. 
Step 4. As shown on the lower panel of Figure 3, you may also choose the batch prediction by 
entering your e-mail address and your desired batch input file (in FASTA format) via the 
‘‘Browse’’ button. To see the sample of batch input file, click on the button Batch-example. After 
clicking the button Batch-submit, you will see “Your batch job is under computation; once the 
results are available, you will be notified by e-mail.”  
Step 5. Click the Supporting Information button to download the benchmark dataset used to 
train and test the iRSpot-TNCPseAAC predictor. 
Step 6. Click the Citation button to find the relevant papers that document the detailed 
development and algorithm of iRSpot-TNCPseAAC. 
Supplementary Information 
Supplementary Information S1. The benchmark dataset S consists of a positive dataset S+  
and a negative dataset S  . The positive dataset contains 490 recombination hot spots, while the 
negative dataset contains 591 recombination cold spots. 
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2. Structure-Based Drug Design 
 
Structure of N-Terminal Sequence Asp-Ala-Glu-Phe-Arg-His-
Asp-Ser of Aβ-Peptide with Phospholipase A2 from Venom of 
Andaman Cobra Sub-Species Naja naja sagittifera at  
2.0 Å Resolution 
Zeenat Mirza, Vikram Gopalakrishna Pillai and Wei-Zhu Zhong 
Abstract: Alzheimer’s disease (AD) is one of the most significant social and health burdens of the 
present century. Plaques formed by extracellular deposits of amyloid β (Aβ) are the prime player of 
AD’s neuropathology. Studies have implicated the varied role of phospholipase A2 (PLA2) in brain 
where it contributes to neuronal growth and inflammatory response. Overall contour and chemical 
nature of the substrate-binding channel in the low molecular weight PLA2s are similar. This study 
involves the reductionist fragment-based approach to understand the structure adopted by N-terminal 
fragment of Alzheimer’s Aβ peptide in its complex with PLA2. In the current communication, we 
report the structure determined by X-ray crystallography of N-terminal sequence Asp-Ala-Glu-Phe-
Arg-His-Asp-Ser (DAEFRHDS) of Aβ-peptide with a Group I PLA2 purified from venom of 
Andaman Cobra sub-species Naja naja sagittifera at 2.0 Å resolution (Protein Data Bank (PDB) 
Code: 3JQ5). This is probably the first attempt to structurally establish interaction between 
amyloid-β peptide fragment and hydrophobic substrate binding site of PLA2 involving H bond and 
van der Waals interactions. We speculate that higher affinity between Aβ and PLA2 has the 
therapeutic potential of decreasing the Aβ–Aβ interaction, thereby reducing the amyloid 
aggregation and plaque formation in AD. 
Reprinted from Int. J. Mol. Sci. Cite as: Mirza, Z.; Pillai, V.G.; Zhong, W.-Z. Structure of  
N-Terminal Sequence Asp-Ala-Glu-Phe-Arg-His-Asp-Ser of Aβ-Peptide with Phospholipase A2 
from Venom of Andaman Cobra Sub-Species Naja naja sagittifera at 2.0 Å Resolution. Int. J.  
Mol. Sci. 2014, 15, 4221-4236. 
1. Introduction 
An estimated 36 million people globally are suffering from Alzheimer’s disease (AD), which 
causes irreversible neurodegeneration and usually strikes in the later years of life. According to the 
World Health Organization, this figure is anticipated to rise to 65.7 million by 2030 and may 
increase to 115.4 million by 2050 [1]. Dementia is the most frequent type of neurodegenerative 
disease and it is rarely detected before symptoms develop; no drugs presently exist for its  
therapy [2,3]. The characteristic disease landmarks include neurofibrillary tangles [4] and amyloid 
plaques, surrounded by reactive astrocytes, activated microglial cells causing neuroinflammatory 
responses and dystrophic neuritis. Although the neuroinflammation mechanism in AD brain is not 
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apparent, there is ample data suggesting a role for specific forms of amyloid beta peptide (Aβ) in 
inducing release of pro-inflammatory cytokines by microglia and astrocytes. Hence, identifying the 
modulating mechanisms of neuroinflammatory responses and neuronal degeneration will unravel 
vital aspects to develop new therapeutic strategies [5,6]. Developing chemical interventions for AD 
is exigent and has proceeded in a virtual vacuum due to lack of tertiary structural information of 
amyloid-β peptide [7], which is cleaved via the β/γ-secretase pathway from the membrane-bound 
amyloid precursor protein (APP) [8]. β-secretase generates the N-terminus of Aβ by cleaving β-
APP within the Glu-Val-Lys-Met-↓-Asp-Ala sequence or by cleaving the Swedish mutant β-APPSW 
within the Glu-Val-Asn-Leu-↓-Asp-Ala sequence. In addition, cleavage has been reported to occur 
within the Aβ sequence Asp-Ser-Gly-Tyr10-Glu11-Val, generating Aβ11–40/42 [9]. Solubility may be 
modulated in a pH-dependent manner by the charged N-terminal sequence [10]. 
The phospholipase A2 (PLA2) is a lipolytic enzyme commonly expressed in several types of 
mammalian cells [11]. Two most notable forms of PLA2 are the secretory PLA2 (sPLA2) and the 
calcium-dependent cytosolic PLA2 (cPLA2). In healthy brain cells, equilibrium between 
arachidonic acid conversion into proinflammatory mediators and arachidonic acid reincorporation 
into the membrane is maintained by PLA2 regulation. Unregulated PLA2 activity causes production 
of an inconsistent amount of proinflammatory mediators, leading to oxidative stress and 
neuroinflammation as seen in neurological diseases such as AD, epilepsy, and multiple sclerosis. 
The most common and extensively studied PLA2s belong to group I and II. sPLA2-IIA mRNA is 
up-regulated in AD brains as compared to non-demented elderly brains, and a higher percentage of 
sPLA2-IIA-immunoreactive astrocytes associated with Aβ plaques have been reported in the AD 
hippocampus and inferior temporal gyrus [12]. Increased sPLA2 activity is observed in the 
cerebrospinal fluid of humans with AD and multiple sclerosis, and can perhaps be a marker of 
permeability increases of the blood–cerebrospinal fluid barrier [13]. Also, other types of sPLA2 
bearing a similar structure—e.g., groups 1B, IIE, V and X—are present in distinct brain  
regions [14]. A feature identified for the design of tight PLA2 inhibitors is the presence of the OH 
group on the aromatic framework, which may be extended in the opposite direction with the 
hydrophobic moiety [15]. 
A series of recent studies have indicated that much useful information for drug development can 
be obtained in a timely manner by conducting various studies, either experimentally or theoretically. 
However, different targets would need different approaches. For instance, to reveal the molecular 
mechanism of Alzheimer’s disease [16–18] and find useful clues for developing drugs against 
Alzheimer’s disease [19,20], the structural bioinformatics tools [21] were adopted. On the other 
hand, as is well known, X-ray crystallography and high-resolusion NMR (see, e.g., [22–24]) are 
two very powerful tools for structure-based drug design. Although it is time-consuming and 
expensive to use these facilities, the results thus acquired are usually more reliable and dependable. 
Our primary goal is to determine the possibility of a direct interaction between Aβ peptide and 
PLA2 and the structure adopted by the peptide that may in the future pave the way for novel 





2.1. Quality of the Final Model 
The final model consists of 909 protein atoms, 68 atoms of peptide molecule, one calcium ion 
and 99 water molecules. The final |2Fo − Fc| electron density map is continuous and well defined 
for both the backbone and the side chains of the protein. The final model has a good overall 
geometry with the r.m.s. deviations in bond lengths and angles are 0.009 Å and 1.1', respectively. 
The Ramachandran plot calculated using PROCHECK [25], indicates that 89.1% of the residues 
are present in the most favourable regions, 10.0% were observed in the additionally allowed 
regions, while the remaining 0.9% residues were observed in the generously allowed regions of the 
Ramachandran plot [26] (Figure 1). The results of data collection and processing are given in Table 
1 and the refinement statistics are given in Table 2. 
2.2. Overall Structure 
The general structure of PLA2 contains an N-terminal helix, H1 (residues: 2–12), a  
calcium-binding loop (residues: 25–35), a second α-helix, H2 (residues: 40–55), a short  
two-stranded antiparallel (-sheet (residues: 75–78 and 81–84), referred to as the (-wing and a third 
α-helix, H3 (residues: 90–108). There are two helical short turns involving residues 19–22 (SH4) 
and 113–115 (SH5) (Figure 2). The two antiparallel helices H2 and H3 form the core of the protein 
structure. The hydrophobic residues on the inner surface of the helix H1 are highly conserved and 
form one wall of the hydrophobic channel, which provides access to the catalytic site (Figure 3). 
Additional contributions to the hydrophobic channel include amino acid 19, which is located in the 
short turn following the helix H1, amino acid 30, 31 and 32 located within the calcium-binding 
loop and amino acid 69 located before the first strand of the β-wing. The structure is in accordance 















Figure 1. A Ramachandran plot of the main chain torsion angles (φ,ψ) for the final 
refined model. The plot was calculated with the program PROCHECK [25]; non-

















Table 1. Data collection statistics. 
Space Group P41 
System Tetragonal 
Unit-cell parameters (Ǻ)  




Solvent Content (%) 46.7 
Resolution range (Ǻ) 20.0–2.0 
No. of observed reflections 33,510 
No. of unique reflections 7735 
Overall completeness (%) 98.7 
Completeness in the highest shell (2.06–2.03 Ǻ) (%) 87.7 
Overall Rsym (%) 7.0 
Rsym in the highest shell (2.06–2.03 Ǻ) (%) 18.8 
Overall I/)(I) 11.1 
I/)(I) in the highest shell (2.06–2.03 Ǻ) 2.3 
Table 2. Refinement statistics. 
PDB code 3JQ5 
Resolution range (Ǻ) 20.0–2.0 
Number of reflections 7735 
RCryst (for all data) (%) 18.1 
RFree (5% data) (%) 22.0 
Number of protein atoms 909 
Number of peptide atoms 68 
Number of Water Molecules 99 
Number of calcium atoms 1 
R.m.s. deviations 
Bond length (Ǻ2) 0.009 
Bond angles (o) 1.1 
Dihedral angles (') 14.4 
Overall G factor 0.05 
Mean B factor (Ǻ2) 
Main chain atoms 22.0 
Side chains and water molecules 27.3 
Overall 24.8 
Ramachandran plot statistics 
Residues in the most allowed region (%) 89.1 
Residues in the additionally allowed region (%) 10.0 




Figure 2. A ribbon diagram showing the overall structure of PLA2: helical segment is 
shown in red, β strands colored yellow and disulfide links shown in ball and stick, 
colored green and yellow. The three main helices are indicated as H1, H2 and H3, while 
two short helices are designated as SH4 and SH5. β wing, calcium-binding loop and 
disulfide linkages are also indicated. 
 
Figure 3. The |Fo − Fc| electron density map contoured at 2.0 σ showing the electron 
density for the peptide Asp-Ala-Glu-Phe-Arg-His-Asp-Ser. 
 
The overall folding of PLA2 observed in the complex with peptide is essentially similar to that 
of native PLA2 (1MF4) with an r.m.s. shift of 0.2 Å for the Cα positions. One milli molar CaCl2 
was added in the protein drops that were used for crystallization and the structure revealed the 
presence of Ca2+ ion in the so-called calcium-binding loop. The Ca2+ ion is considered generally 
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essential for catalytic activities of secretory PLA2s [28,29]. In the present structure, the Ca2+ ion 
stabilizes the conformation of the calcium-binding loop (Figure 4). 
Figure 4. Difference |Fo − Fc| electron density for the calcium ion drawn at 2σ. Calcium 
coordinated interactions are indicated by dotted lines. Ser8 of peptide is shown  
in green. 
 
2.3. Structure of Peptide 
The structure of PLA2 in the complex remains unchanged from its native structure. All the eight 
residues of the peptide can be traced from their electron densities (Figure 3). The interaction of the 
peptide with the protein is depicted in Figure 5. Half of the peptide residue’s torsional angles are in 
the most favoured region of the Ramachandran plot, although none were observed in the 
disallowed region. The structure of the peptide is given in Figure 6. 
Figure 5. Interactions between PLA2 and the peptide Asp-Ala-Glu-Phe-Arg-His-Asp-
Ser. The peptide residues are colored yellow. The critical interactions between peptide 








We have attempted the fragment assembly approach to elucidate the structure of Aβ. The 
fragment assembly and global optimization method has been established and extensively used in 
computational biology [30,31]. This work may be the first design of experiments following this 
approach. However, reductionist methods are common in protein crystallography. There are vast 
numbers of entries in PDB that are exclusively the domains, or even a small fragment of proteins. 
Most of the time, the intact protein is not amenable to crystallization, such as the beta-amyloid 
precursor protein. The co-crystallization method is another useful method of crystallography. 
Hundreds of Fab–Ag complexes are available to corroborate this fact. Co-crystallization of 
complete Aβ with mitochondrial alcohol dehydrogenase has been attempted [32]. The presence of 
Aβ in the crystal has been established by SDS-PAGE and N-terminal sequencing of the washed 
crystal in this study. However, no electron density corresponding to Aβ could be observed in the 
determined structure. This suggests the Aβ in this complex is flexible. The only instance where the 
Aβ molecule is seen in the crystal is the structure of the complex between Aβ and insulin-
degrading enzyme (IDE). The Aβ is seen as a cleaved substrate. The complete molecule is not 
observed—only residues 1–3 and 17–22 are same [33].  
There are many NMR studies describing the structures of partial and complete abeta molecule 
(3BAE, 1BA6, 1BA4, 2BEG). The results are generally combined with molecular modelling 
calculations. From all these studies, the following structural properties for the aggregating abeta is 
proposed—the central region Aβ16–21 and C-terminal region Aβ33–40(42) are in β-strand 
conformation; Aβ25–29 is in loop conformation, and the rest of the molecule is in random 
conformation. This is also corroborated by X-ray fiber—diffraction of the fibrils while the attempts 
to crystallize or co-crystallize the Aβ17–21 and Aβ35–40/Aβ37–42 have been described and the peptides 
are observed in β-conformation. Apparently, the nature of binding sites of the protein influences 
the conformation of the Aβ peptide. The large space available in IDE accommodated the intact Aβ 
molecule. In 2OTK, [34], Aβ17–36 is seen in β-sheet conformation with residues 25–29 forming the 
loop. In their studies, Lustbader et al. could not view the Aβ molecule even though it was in the 
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crystal. One conclusive aspect of crystal structures are that the peptides, Aβ17–21, Aβ35–42 and  
Aβ17–36 are in β conformation. This is in contrast to the solution studies that report all 
conformational possibilities. The same peptide has been observed in different conformations in 
different studies. Most of the studies report helical or coil conformation [35–38]. These results may 
be due to the variable solvent conditions used in these studies. Solvent conditions vary from 
completely polar to non-polar. The conformation of Aβ is highly dependent on the environmental 
conditions. Solvent polarity, temperature, pH and additives influence the solubility and aggregation 
behaviour of Aβ [39,40]. 
Figure 7. Surface diagram representation of the binding cavity and the hydrophobic 
channel with the peptide DAEFRHDS going inside the pocket. 
 
An electron density was observed in the difference Fourier |Fo − Fc| map in the complex 
structure (Figure 3), which allowed the interpretation of one molecule of the octa-peptide, as well 
as the detailed description of its interactions with PLA2. The peptide was positioned well in the 
hydrophobic channel (Figure 7) and was fitted well in the substrate binding site of enzyme. Peptide 
interacts with active site residues through a series of hydrogen bonds and hydrophobic interactions. 
The N-terminal part of the peptide lies towards the opening of the hydrophobic channel at the 
protein surface. The C-terminal serine residue is involved in hydrogen bonding with the active site 
residues. The rest of the peptide aligned in the hydrophobic channel makes a series of van der 
Waals contacts with protein atoms. The oxygen atom Oγ of Ser8 of peptide is hydrogen bonded 
with active site residue Asp49 Oδ1 and also with backbone atoms of Gly30 of the calcium-binding 
loop. The backbone oxygen atom of Ser8 is directly hydrogen bonded to His48 Nδ1. Thus the 
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peptide interacts with the active site residues through direct hydrogen bonds (Table 3). The peptide 
also interacts with important residues of the hydrophobic channel like Asp1 residue of peptide 
interacts with Lys6 and Trp19 residue of protein and His6 residue of peptide interacts with Gly30 
and Tyr64. Additionally the peptide is involved in van der Waals interaction with most of the 
residues lining the substrate-binding hydrophobic channel (Table 4). 
Table 3. Hydrogen bonds between PLA2 and peptide DAEFRHDS. 
Atoms of peptide Protein atoms Distance (Å) 
Asp1 Oδ2 
Lys6 Nζ 3.35 
Trp19 Nε1 2.64 
His6 Nδ1 
Gly30 O 3.43 
Tyr64 OH 2.78 
Ser8 Oγ 
Gly30 N 3.22 
Gly30 O 2.62 
 Tyr28 O 3.35 
 Asp49 Oδ1 2.95 
Ser8 O His48 Nδ1 2.80 
Table 4. Van der Waal interactions between PLA2 and peptide DAEFRHDS. 
Atoms of peptide Protein atoms Distance (Å) 
Asp1 Cγ Trp19 Cε2 3.79 
 Trp19 Cζ2 3.48 
Ala2 Cβ Trp19 CH2 3.73 
 Trp19 Cζ2 3.97 
Phe4 Cδ1 Ala23 Cβ 3.91 
Arg5 Cζ Leu2 Cδ2 3.53 
His6 Cα Leu2 Cδ2 3.69 
His6 Cβ Gly30 Cα 3.63 
 Gly30 C 3.68 
His6 Cε1 Tyr64 Cζ 3.75 
Asp7 Cα Ala23 Cα 3.75 
Asp7 Cβ Ile9 Cδ1 3.78 
 Phe5 Cε2 3.97 
Asp7 C Phe5 Cε2 3.92 
Ser8 Cβ Tyr28 C 3.90 
 Cys29 Cα 3.51 
 Cys29 C 3.64 
 Gly30 Cα 3.76 
Ser8 C Phe101 Cζ 3.92 
 His48 Cγ 3.98 
 Cys45 Cβ 3.81 
In our studies, the binding site of the peptides on the protein is very hydrophobic. The binding 
cavity of PLA2 is lined with residues such as tryptophan, histidine, aspartic acid, and glycine. The  
non-polar surface extends from the molecule to the catalytic residues Aspartate and histidine at the 
other end. We expect that the non-polar nature of the binding site could have influenced the folding 
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of the Aβ peptide fragment. This is possible given the fact that the folding of the Aβ molecule is 
mediated and stabilized by non-polar interactions. Moreover, the co-crystallization experiments 
were carried at 35% ethanol concentrations. Organic solvents (mostly alcohols have been studied), 
generally induce a random conformation in Aβ molecule as seen from the experiments. The peptide 
in our co-crystallization experiment strongly interacted with the non-polar binding-cavity residues 
of PLA2. The only interaction arginine displays in DAEFRHDS is non-polar (Table 3). Even 
though this peptide is polar it has more non-polar interactions than polar interactions (Tables 3  
and 4). The observed conformation of the peptide in our result must have been dictated by the 
protein–ligand interactions. Though our aim of fragment assembly has not been achieved, the 
observations made by us are nevertheless interesting in their own right, exemplifying the strength 
of the interactions of the protein and ligand on one hand, and their effect on the conformation of the 
ligand on the other. 
4. Experimental Section 
4.1. Purification of Monomeric PLA2 
The lyophilized samples of crude cobra venom of Naja naja sagittifera were obtained from Irula 
Snake Catchers Industrial Cooperative Society, Chennai, India. The crude venom was dissolved in  
50 mM Tris-HCl, 100 mM NaCl, pH 7.0 at 100 mg/mL concentration and centrifuged at 12,000× g 
for 10 min to remove insoluble material. The collected supernatant was size fractionated on 
Sephadex G-100 column (100 × 2 cm) pre-equilibrated with 50 mM Tris-HCl, 100 mM NaCl, pH 
7.0. The column was eluted with the same buffer at a flow rate of 6 mL/h. The peak corresponding 
to molecular weight of 14 kDa on SDS-PAGE and showing PLA2 activity was pooled for further 
purification. The pooled fractions were desalted and dialysed against 50 mM Tris-HCl, pH 7.0 and 
loaded on CM Sephadex C-50 column (Pharmacia, Uppsala, Sweden). The column was washed 
with the above buffer. The unbound fractions were pooled and dialysed against ammonium acetate 
buffer, pH 6.0. The diluted sample was loaded on a pre-equilibrated column with same buffer 
containing Affi-gel Cibacron blue F3GA. The column was washed with 50 mM ammonium acetate 
buffer pH 6.0 to remove unbound fractions. The column was eluted with 50 mM ammonium 
bicarbonate buffer pH 8.0. These fractions showed PLA2 activity and indicated a molecular weight 
of 14 kDa on SDS-PAGE. The samples were pooled, desalted by ultrafiltration using a 3 kDa 
cutoff membrane and lyophilized, and their purity was checked by matrix-assisted laser desorption-
ionization–time of flight (MALDI-TOF) (Kratos, Shimadzu, Kyoto, Japan) and by activity 
measurements. On MALDI-TOF it showed a molecular weight of 13,401.99 Da. The protein 
samples were blotted on a polyvinyl difluoride (PVDF) membrane (Sigma-Aldrich, St. Louis, MO, 
USA) and were subjected to the N-terminal sequencing using an automated protein sequencer 
PPSQ-21A (Shimadzu, Japan). The N-terminal sequence of the first 15 residues was determined. It 




4.2. Enzymatic Assay and Inhibition Studies  
The purified enzyme was used for kinetic studies done using a PLA2 Assay Kit (Cayman 
Chemical Company, Ann Arbor, MI, USA). The enzymatic chromogenic assay utilized the 
conversion of arachidonoyl thio-phosphocholine into sulfahydryl molecule by PLA2. Arachidonoyl 
thio-PC is a synthetic substrate used to detect phospholipase activity [42]. Hydrolysis of the 
arachidonoyl thioester bound at the sn-2 position by PLA2 releases free thiol, colorimetrically 
detected by Ellman’s reagent [5,5ꞌ -dithiobis (2-nitrobenzoic acid) (DTNB)], which results in 
yellow colour along with the released sulfahydryl product. Stock concentration at 1.5 mM of PC-
substrate and 0.1 mM of PLA2 were used for the assay. Ten μL of colouring agent (DTNB) was 
added in each assay reaction. Peptide inhibitors (GenScript Corporation, Piscataway, NJ, USA) 
were dissolved in dimethyl sulfoxide and only 5 μL added to the assay. Peptide concentrations of 
0.10, 0.20, 0.30 and 0.40 mM were taken for studying PLA2 inhibition reactions. Bee venom PLA2 
was taken as positive control. The assay included a 30 min pre-incubation of enzyme with peptide 
and a further incubation of 60 min at room temperature after the addition of 200 μL substrate 
solution. The absorbance was measured at 414 nm wavelength on a plate reader and measurements 
were repeated thrice. Two wells were designated as non-enzyme controls and their absorbance was 
subtracted from the absorbance measured in the sample wells. Significant decrease in enzyme 
activity was seen in the presence of an inhibitor. 
4.3. Crystallization 
The purified samples of PLA2 were dissolved in 10 mM sodium phosphate buffer pH 6.0 
containing 1 mM CaCl2 to a final concentration of 2.5 mg/mL. Peptide was dissolved in the above 
buffer, containing 10% acetonitrile and added to the protein solution at 10-fold high molar 
concentration. The solution was incubated for 3 h, mixed well, centrifuged and kept for 
crystallization trials using hanging drop vapor diffusion method. The 10 μL drops of the above 
mixture were equilibrated against the same buffer containing 30% ethanol in the reservoir. The 
crystals grew to a size of 0.4  0.2  0.2 mm3 after two weeks.  
4.4. Data Collection and Data Processing 
The crystals of the complex formed between PLA2 and the N-terminus fragment DAEFRHDS 
were used for data collection at low temperature. A single crystal was mounted in a nylon loop and  
flash-frozen in a stream of nitrogen gas at 100 K. The data were collected on a 345 mm diameter 
MAR research scanner with 1.54 Å radiation generated by a Rigaku RU-300 rotating anode X-ray 
Generator filled with Osmic mirrors (Rigaku USA, Woodlands, TX, USA). The data were 
processed with DENZO and SCALEPACK from HKL package [43]. The final data set was 
complete to 87.7% up to 2.0 Å resolution. The crystals belong to the tetragonal space group P41 
with unit cell dimensions a = b = 42.7 Å, c = 65.8 Å. The presence of one molecule per asymmetric 
unit gave a crystal volume per protein mass (Vm) of 2.3 Å3Da−1 corresponding to a solvent content 
of 46.7%. The final data show an overall completeness of 98.7% with a Rsym of 7.0% to 2.0 Å 
resolution (Tables 1 and 2). 
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4.5. Structure Determination and Refinement 
The crystal structure was determined with molecular replacement method using auto-AMoRe [44] 
from the CCP4 software suit (Collaborative Computational Project, Number 4, 1994). The 
coordinates of a native PLA2 structure (PDB code: 1MF4) were used as a search model. The 
rotation and translation functions calculated with data in the resolution range, 12.0–3.5 Å yielded a 
unique solution with the first peak being very distinct. The stacking arrangement of the molecules 
in the unit cell for this solution yielded no unfavourable intermolecular contacts in space group P41, 
thus confirming it as the correct space group. The coordinates were transformed using AMoRe and 
were then subjected to 20 cycles of rigid-body refinement with REFMAC5 [45]. This reduced the 
Rcryst and Rfree factors to 18.1% and 22.0%, respectively. Of the reflections, 2% were used for the 
calculation of Rfree, and were not included in the refinement. The manual model building of the 
protein using Fourier |2Fo − Fc| and difference Fourier |Fo − Fc| maps was carried out with the 
Graphics Program “O” [46] on a Silicon Graphics O2 Workstation (Figure 2). A continuous non-
protein electron density at 2.0 σ cut off was observed in the proximity of the active site that 
extended in a direction parallel to helix H2. The ligand was only included because it was well 
defined by unbiased difference Fourier (i.e., before inclusion of any ligand) |Fo − Fc| map. The 
coordinates of the peptide structure were fitted into the characteristic electron density (Figure 3). 
Water molecules were then added using ARP/WARP [45]. The presence of calcium ions was 
detected from the difference Fourier |Fo − Fc| maps (Figure 4). Further refinement was carried out 
after adding the coordinates of the peptide molecule, one calcium ion and 99 water molecules. The 
final Rcryst and Rfree factors for the complete data in the resolution range of 20.0–2.03 Å were 0.188 
and 0.202, respectively (Table 2). A portion of the electron density indicating the quality of the 
structure at 2.03 Å resolution is shown in Figure 3. The atomic coordinates of this structure have 
been deposited to protein data bank (PDB) with an accession code of 3JQ5. 
5. Conclusions 
This is likely the first attempt to structurally establish the interaction between the amyloid-β 
peptide fragment and PLA2 peptide to the hydrophobic substrate binding site of PLA2 involving at 
least nine H bond and several van der Waals interactions. Higher affinity between Aβ and PLA2 
decreases the Aβ–Aβ interaction probability, thereby reducing the aggregation and subsequent 
plaque formation. In conclusion, this study is a step towards understanding the mechanism behind 
the Aβ and PLA2 interaction that may facilitate the development of novel therapeutic strategies to 
inhibit inflammatory responses to retard many diseases. 
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Synthesis, Characterization and Anti-Breast Cancer Activity 
of New 4-Aminoantipyrine-Based Heterocycles 
Mostafa M. Ghorab, Marwa G. El-Gazzar and Mansour S. Alsaid 
Abstract: 4-Aminoantipyrine was utilized as key intermediate for the synthesis of pyrazolone 
derivatives bearing biologically active moieties. The newly synthesized compounds were characterized 
by IR, 1H- and 13C-NMR spectral and microanalytical studies. The compounds were screened as 










tetrahydropyrimidine-5-carbonitrile 18, and (Z)-4-(3-amino-6-hydrazono-7-phenyl-6,7-
dihydropyrazolo[3,4-d]pyrimidin-5-yl)-1,5-dimethyl-2-phenyl-1,2-dihydropyrazol-3-one 19 were the 
most active compounds with IC50 values ranging from 30.68 to 60.72 μM compared with 
Doxorubicin as positive control with the IC50 value 71.8 μM. 
Reprinted from Int. J. Mol. Sci. Cite as: Ghorab, M.M.; El-Gazzar, M.G.; Alsaid, M.S. Synthesis, 
Characterization and Anti-Breast Cancer Activity of New 4-Aminoantipyrine-Based Heterocycles. 
Int. J. Mol. Sci. 2014, 15, 7539-7553. 
1. Introduction 
Pyrazolone derivatives such as antipyrine, aminopyrine, and dipyrone are well known 
compounds used mainly as analgesic and antipyretic drugs and their pharmacological molecular 
mechanism has been widely surveyed [1,2]. One of the best known antipyrine derivatives is  
4-aminoantipyrine which is used for the protection against oxidative stress as well as prophylactic 
of some diseases including cancer, and these are important directions in medical applications [3]. 
Several derivatives of antipyrine were also biologically evaluated, and analgesic [4],  
anti-inflammatory [5], antimicrobial [6], and anticancer activity [7–9] have been reported. 
Antipyrine derivatives are strong inhibitors of cycloxygenase isoenzymes, platelet tromboxane 
synthesis, and prostanoids synthesis [10], which catalyze the rate-limiting step of prostaglandin 
synthesis. Pyrazolones are also a well-known elicitor of hypersensitivity [11]. Recently,  
Al-Haiza et al. [12] synthesized a new compound with pyrazolone moiety with antimicrobial and 
antifungal activities. In the last decade, several pyrazole derivatives proved to have potent 
anticancer action by the inhibition of the cyclindependent kinases (CDKs) which are members of 
the large family of protein kinases and are responsible for the eukaryotic cell cycle regulation; they 
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are intensively studied for their cancer implication [13]. Based on the above information and due to 
our interest in pyrazole as a biologically active pharmacophore [14–18], we synthesized a new 
series of heterocycles incorporating antipyrine moiety starting from 4-aminoantipyrine to be 
evaluated for their anticancer activity against human tumor breast cell line (MCF7). 
2. Results and Discussion 
2.1. Chemistry 
The starting key reagent 4-aminoantipyrine was purchased from Sigma-Aldrich chemical  
company (St. Louis, MO, USA). In this work, the reactivity of 4-aminoantipyrine with active 
methylene containing compounds (malononitrile, 2-(ethoxymethylene)malononitrile, 
ethylcyanoacetate, (ethoxymethylene)ethylcyanoacetate and acetylacetone) was studied and the 
reaction proceeded in the presence of triethylorthoformate in methanol containing catalytic 
amounts of acetic acid following the reported reaction condition [19]. The obtained pyrazolone 
derivatives 2–4, respectively, were identified by elemental and spectral data. Due to the biological 
importance of pyrazole, pyrrole and pyrimidine rings as anticancer agents [20–22], the pyrazolone 
derivative 2 was reacted with different nucleophiles in order to obtain biologically active pyrazole 
5, pyrrole 6–8 and pyrimidine 9–16 derivatives bearing pyrazolone moieties. Thus, interaction of 
compound 2 with phenyl hydrazine yielded the corresponding pyrazole derivative 5. On the other 
hand, interaction of compound 2 with 2-chloroacetonitrile, ethylbromoacetate or 2-chloroacetamide 
in dioxane containing a catalytic amount of triethylamine yielded the corresponding pyrrole 
derivatives 6–8, respectively. Reaction of compound 2 with thiourea in refluxing ethanol 
containing sodium ethoxide gave the corresponding pyrimidine derivative 9 (Scheme 1). The 
reactivity of compound 2 towards different aryl isothiocyanates/NaOH was studied and the reaction 
proceeded via an addition reaction onto the isothiocyanato group followed by intramolecular 
cyclization to produce the pyrimidine ring as in compounds 10–15. Similarly, the bis-compound 16 
was obtained expectedly via the reaction of one mole of 1-(4-isothiocyanatophenylsulfonyl)-4-
isothiocyanatobenzene with two moles of compound 2 in ethanol containing sodium ethoxide 
(Scheme 2). The hydrazono pyrimidine derivatives 17, 18 were synthesized from compound 10 
through reaction with either hydrazine hydrate or phenyl hydrazine, respectively, and the reaction 
proceeded via elimination of H2S which was detected by a lead acetate paper. On the other hand, 
double cyclization took place when one mole of compound 10 was reacted with two moles of 
hydrazine hydrate to yield the corresponding pyrazolo[3,4-d]pyrimidine 19 (Scheme 3). Finally, 
treatment of 4-aminoantipyrine 1 with either triethylorthoformate or acetate in acetic anhydride 
resulted in the formation of compounds 20, 21, respectively (Scheme 4). The structures of 










Scheme 2. Synthetic pathways for compounds 10–16. 
 





Scheme 4. Synthetic pathways for compounds 20, 21. 
 
2.2. In-Vitro Anticancer Screening 
Doxorubicin, the positive control used in this study, is an anticancer drug used to treat several 
cancer diseases including breast cancer. The relationship between surviving fraction and drug 
concentration was plotted; the response parameters calculated was IC50 value, which corresponds to 
the compound concentration causing 50% mortality in net cells (Table 1). The present work 
describes the synthesis of novel derivatives starting from 4-aminoantipyrine 1 by incorporating 
biologically active moieties, pyrazole, pyrrole, pyrimidine and pyrazolopyrimidine. From Table 1, 
we can observe that some of the tested compounds were found to be equipotent or even more 
potent than Doxorubicin on MCF7 cell line with IC50 values ranging from 30.68 to 70.65 μM 
compared to the reference drug (71.8 μM). The most potent compounds in this study were found to 
be those belonging to the pyrimidine derivatives of antipyrine especially the halogenated ones, 
where, the iodophenyl 14 (IC50 = 30.68 μM) and the bromophenyl 13 (IC50 = 43.41 μM) 
derivatives showed significant activities, also, the biscompound 16 (IC50 = 37.22 μM). In addition, 
pyrazole 5, pyrimidines 17, 18, pyrazolopyrimidine 19 with IC50 values 60.72, 54.23, 44.99, and 
44.49 μM exhibited a higher activity when compared with the Doxorubicin as positive control. The 
phenyl and 4-nitro phenyl derivatives 10 and 12 (IC50 = 72.04 and 70.65 μM) are nearly as active 
as Doxorubicin. On the other hand, reaction of one mole of hydrazine hydrate or phenyl hydrazine 
with compound 10 yielded the pyrimidine derivatives 17 and 18 with significant activities  
(IC50 = 54.23 and 44.99 μM), while, addition of two moles of hydrazine hydrate yielded the 
pyrazolopyrimidine 19 (IC50 = 44.49 μM) which is nearly as potent as compounds 17 and 18. 
Moreover, the reaction of phenylhydrazine with compound 2 was also successful as it yielded the 
pyrazole derivative 5 which showed high activity (IC50 = 60.72 μM). All these compounds are 
more active than the reference drug. Considering the pyrrole derivatives 6, 7 and 8, they were 
found to exhibit lower activity compared to the reference drug (IC50 = 128.61, 104.11 and 85.12 
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μM, respectively). Compounds 2–4, 9, 11, 15, 20 and 21 are the least potent in this study with IC50 
ranging from 109.58 to 173.83 μM. 
Table 1. In-vitro anticancer screening of compounds 2–21 against human breast cell line (MCF7). 
Compound No. IC50 (μg/mL) IC50 (μM) 
2 48.2 173.83 
3 38.0 116.56 
4 34.9 111.50 
5 23.5 60.72 
6 40.9 128.61 
7 38.0 104.11 
8 28.6 85.12 
9 38.9 109.58 
10 29.9 72.04 
11 NA NA 
12 32.5 70.65 
13 21.4 43.41 
14 16.6 30.68 
15 NA NA 
16 33.2 37.22 
17 22.4 54.23 
18 22.0 44.99 
19 19.0 44.49 
20 35.8 138.22 
21 NA NA 
Doxorubicin 39.0 71.8 
NA: Compound having IC50 value > 100 μg/mL. 
Generally, incorporation of pyrimidine ring yielded the most potent compounds and these results 
point to the possible use of pyrimidine derivatives of antipyrine for treatment of breast tumors. 
3. Experimental Section 
3.1. General 
Reagents were obtained from commercial suppliers and were used without purification. Melting 
points were determined in open capillary tubes using Thermo system FP800 Mettler FP80 central 
processor supplied with FP81 MBC cell apparatus (Stuart Scientific, Redhill, UK), and were 
uncorrected. Elemental analyses (C, H, N) were performed on a Perkin-Elmer 2400 Instrument 
(Perkin-Elmer, Norwalk, CT, USA). All compounds were within ±0.4% of the theoretical values. 
Infrared (IR) spectra (KBr disc) were recorded on FT-IR spectrophotometer (Perkin Elmer, 
Norwalk, CT, USA) at the Research Center, College of Pharmacy, King Saud University, Saudi 
Arabia.1H and 13C NMR spectra were recorded on a Ultra Shield Plus 500 MHz (Bruker, Munich, 
Germany) spectrometer operating at 500 MHz for proton and 125 MHz for carbon, respectively. 
The chemical shift values are reported in δ (ppm) relative to the residual solvent peak, the coupling 






A mixture of 4-aminoantipyrine (0.01 mol), malononitrile (0.01 mol), triethylorthoformate  
(0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction mixture 
was cooled, filtered, the filtered solid was crystallized from ethanol to give 2. Yield%: 90,  
m.p. = 254.7 °C, IR, cm−1: 3210 (NH), 3055 (CH arom.), 2941, 2818 (CH aliph.), 2200 (CN),  
1658 (C=N). 1H (DMSO-d6, ppm): 2.2 [s, 3H, CH3], 3.2 [s, 3H, N–CH3], 7.3–7.9 [m, 5H, Ar–H], 
8.1 [s, 1H, CH], 10.5 [s, 1H, NH, D2O-exchangeable]. 13C (DMSO-d6, ppm): 10.3 (CH3), 29.1 (N–
CH3), 50.3, 104.6, 114.1(2), 116.4(2), 117.2, 127.2(2), 129.1, 134.5, 160.1 (C=O), 165.5. Anal. 
Calcd. for C15H13N5O (279): C, 64.51; H, 4.69; N, 25.07. Found: C, 64.91; H, 4.80; N, 25.34. 
3.2.2. (Z)-Ethyl-2-cyano-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-
ylamino)acrylate 3 
A mixture of 4-aminoantipyrine (0.01 mol), ethylcyanoacetate (0.01 mol), triethylorthoformate 
(0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction mixture 
was filtered, the filtered solid was crystallized from ethanol to give 3. Yield%: 83, m.p. = 154.8 °C,  
IR, cm−1: 3192 (NH), 3065 (CH arom.), 2965, 2841 (CH aliph.), 2214 (CN), 1710, 1658 (2C=O).  
1H (DMSO-d6, ppm): 1.2 [t, 3H, CH3, J = 7.9 Hz], 2.3 [s, 3H, CH3], 3.2 [s, 3H, N–CH3], 4.2 [q, 
2H, CH2, J = 8.1 Hz], 7.3–8.0 [m, 5H, Ar–H], 8.2 [d, 1H, CH, J = 7.12 Hz], 10.0 [d, 1H, NH,  
D2O-exchangeable, J = 7.3 Hz]. 13C (DMSO-d6, ppm): 10.3, 14.3, 39.0, 60.2, 72.6, 109.7, 115.7(2), 
116.0, 118,1, 129.0(2), 129.1, 134.3, 156.8, 161.0, 166.3. Anal. Calcd. for C17H18N4O3 (326):  
C, 62.57; H, 5.56; N, 17.17. Found: C, 62.90; H, 5.89; N, 17.25. 
3.2.3. 3-((1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylamino)methylene)-pentane- 
2,4-dione 4 
A mixture of 4-aminoantipyrine (0.01 mol), acetylacetone (0.01 mol), triethylorthoformate  
(0.01 mol), and acetic acid (1 mL) in methanol (30 mL) was refluxed for 5 h, the reaction mixture 
was filtered, the filtered solid was crystallized from ethanol to give 4. Yield%: 90, m.p. = 201.8 °C,  
IR, cm−1: 3209 (NH), 3100 (CH arom.), 2971, 2848 (CH aliph.), 1716, 1692, 1661 (3C=O),  
1612 (C=N). 1H (DMSO-d6, ppm): 1.9 [s, 3H, CH3], 2.1 [s, 6H, 2COCH3], 3.0 [s, 3H, N–CH3],  
7.3–7.5 [m, 6H, Ar–H + CH], 9.0 [s, 1H, NH, D2O-exchangeable]. 13C (DMSO-d6, ppm): 11.1, 
22.4(2), 39.1, 104.4, 107.8(2), 108.4, 121.8, 128.8(2), 129.0, 135.0, 151.0, 161.8, 195.1(2). Anal. 
Calcd. for C17H19N3O3 (313): C, 65.16; H, 6.11; N, 13.41. Found: C, 65.87; H, 6.37; N, 13.21. 
3.2.4. (Z)-4-((3-Amino-5-imino-1-phenyl-1H-pyrazol-4(5H)-ylidene)methylamino)-1,5-dimethyl-
2-phenyl-1,2-dihydropyrazol-3-one 5 
Compound 2 (0.01 mol) was mixed with phenyl hydrazine (0.01 mol) in dioxane (20 mL) and 
refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid 
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products were filtered and crystallized from methanol to give compound 5. Yield%: 76,  
m.p. = 172.7 °C, IR, cm−1: 3386, 3348, 3276 (NH, NH2), 3026 (CH arom.), 2981, 2872 (CH aliph.), 
1660 (C=O), 1595 (C=N). 1H (DMSO-d6, ppm): 2.2 [s, 3H, CH3], 3.2 [s, 3H, N–CH3], 7.2–7.9 [m, 
10H, Ar–H], 8.3 [s, 1H, CH], 8.7 [s, 1H, NH, D2O-exchangeable], 13.2 [s, 1H, NH-imino, D2O-
exchangeable]. 13C (DMSO-d6, ppm): 11.5, 39.5, 106.2, 108.0, 112.4(2), 116.1(2), 117.6, 124.1, 
127.7(2), 128.9, 129.5(2), 137.9, 141.2, 148.4, 156.5, 163.1, 166.2. Anal. Calcd. for C21H21N7 
(387): C, 65.10; H, 5.46; N, 25.31. Found: C, 65.32; H, 5.09; N, 25.55. 
3.2.5. 3-Amino-1-(1.5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1H-pyrrole-2,4-
dicarbonitrile 6 
Compound 2 (0.01 mol) was mixed with 2-chloroacetonitrile (0.01 mol) in dioxane (20 mL) 
containing 3 drops of triethylamine and refluxed for 5 h, the reaction mixture was cooled, poured 
onto ice water. The precipitated solid products were filtered and crystallized from methanol to give 
compound 6. Yield%: 70, m.p. > 350 °C, IR, cm−1: 3344, 3291 (NH2), 3100 (CH arom.), 2966, 
2881 (CH aliph.), 2200 (CN), 1699 (C=O). 1H (DMSO-d6, ppm): 1.6 [s, 3H, CH3], 2.4 [s, 3H,  
N–CH3], 6.5 [s, 2H, NH2, D2O-exchangeable], 7.0–8.0 [m, 6H, Ar–H + CH-pyrrole]. 13C (DMSO-d6, 
ppm): 13.9, 39.1, 101.2(2), 107.4, 110.4, 113.9(2), 116.2, 117.6(2), 119.1, 129.3(2), 138.1, 139.4, 




Compound 2 (0.01 mol) was mixed with ethyl bromoacetate (0.01 mol) in dioxane (20 mL) 
containing 3 drops of triethylamine and refluxed for 5 h, the reaction mixture was cooled, poured 
onto ice water. The precipitated solid products were filtered and crystallized from methanol to give 
compound 7. Yield%: 89, m.p. = 143.4 °C, IR, cm−1: 3411, 3396 (NH2), 3100 (CH arom.), 2976,  
2882 (CH aliph.), 2186 (CN), 1718, 1696 (2C=O). 1H (DMSO-d6, ppm): 1.2 [t, 3H, CH3–ester],  
2.0 [s, 3H, CH3], 2.4 [s, 3H, N–CH3], 4.1 [q, 2H, CH2–ester], 7.3–8.0 [m, 7H, Ar–H + NH2], 8.7  
[s, 1H, CH–pyrrole]. 13C (DMSO-d6, ppm): 12.6, 13.4, 39.0, 59.8, 98.7, 112.0, 114.3(2), 115.6, 
118.4, 122.7, 126.3, 129.1(2), 138.1, 139.6, 141.2, 160.0, 161.2. Anal. Calcd. for C19H19N5O3 
(365): C, 62.46; H, 5.24; N, 19.17. Found: C, 62.79; H, 5.57; N, 19.34. 
3.2.7. 3-Amino-4-cyano-1-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1H-
pyrrole-2-carboxamide 8 
Compound 2 (0.01 mol) was mixed with 2-chloroacetamide (0.01 mol) in dioxane (20 mL) 
containing 3 drops of triethylamine and refluxed for 5 h, the reaction mixture was cooled, poured 
onto ice water. The precipitated solid products were filtered and crystallized from methanol to give 
compound 8. Yield%: 76, m.p. > 350 °C, IR, cm−1: 3404, 3385, 3236 (NH2), 3066 (CH arom.), 
2961, 2836 (CH aliph.), 2196 (CN), 1700, 1680 (2C=O). 1H (DMSO-d6, ppm): 1.6 [s, 3H, CH3], 
2.3 [s, 3H, N–CH3], 7.2–8.0 [m, 9H, Ar–H + CONH2 + NH2], 8.5 [s, 1H, CH–pyrrole].  
13C (DMSO-d6, ppm): 11.9, 39.1, 99.2, 111.8, 114.3(2), 115.6, 118.2, 124.4, 129.0(2), 131.8, 135.7, 
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138.2, 153.2, 162.4, 166.0. Anal. Calcd. for C17H16N6O3 (336): C, 60.71; H, 4.79; N, 24.99. Found: 
C, 60.99; H, 4.49; N, 24.70. 
3.2.8. 4-((4,6-Diamino-2-thioxopyrimidin-5(2H)-ylidene)methylamino)-1,5-dimethyl-1,2-phenyl-
1,2-dihydropyrazol-3-one 9 
A mixture of 2 (0.01 mol) and thiourea (0.01 mol) was refluxed for 5 h in ethanol containing 
sodium ethoxide (0.01 mol). The reaction mixture was cooled, poured onto ice water, acidified 
with dil. HCl, the precipitated solid product was filtered and crystallized from methanol to give 9. 
Yield%: 90, m.p. = 219.6 °C, IR, cm−1: 3410, 3362, 3350 (NH2), 3054 (CH arom.), 2922, 2860 
(CH aliph.), 1675 (C=O), 1624 (C=N), 1317 (C=S). 1H (DMSO-d6, ppm): 2.2 [s, 3H, CH3],  
3.1 [s, 3H, N–CH3], 7.3 [s, 4H, 2NH2, D2O-exchangeable], 7.5–7.9 [m, 5H, Ar–H], 9.4 [s, 1H, CH], 
13.0 [s, 1H, NH, D2O-exchangeable]. 13C (DMSO-d6, ppm): 10.3, 39.3, 84.2, 109.1, 116.4(2), 
124.2, 127.2(2), 129.1, 134.4(2), 160.2, 170.8(2), 211.3 (C=S). Anal. Calcd. for C16H17N7OS (355): 
C, 54.07; H, 4.82; N, 27.59. Found: C, 54.34; H, 4.65; N, 27.25. 
3.3. General Procedure for Preparation of Compounds 10–15 
A mixture of 2 (0.01 mol) and the appropriate aryl isothiocyanate (0.01 mol) was refluxed for  
10 h in ethanol containing sodium ethoxide (0.01 mol). The reaction mixture was cooled, poured 
onto ice water, acidified with dil. HCl, the precipitated solid product was filtered and crystallized 
from methanol to give 10–15, respectively. 
3.3.1. 1-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-4-oxo-3-phenyl-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carbonitrile 10 
Yield%: 81, m.p. = 132.9 °C, IR, cm−1: 3100 (CH arom.), 2966, 2871 (CH aliph.), 2201 (CN), 
1672, 1659 (2C=O), 1292 (C=S). 1H (DMSO-d6, ppm): 2.2 [s, 3H, CH3], 3.2 [s, 3H, N–CH3],  
7.3 [s, 1H, CH–pyrimidine], 7.5–8.1 [m, 10H, Ar–H]. 13C (DMSO-d6, ppm): 14.4, 39.1, 104.6, 
109.3, 114.1(2), 116.5, 118.1, 122.0(2), 126.3, 128.6(2), 129.1(2), 129.3, 134.5, 137.8, 139.1, 
159.9, 160.5, 187.2 (C=S). Anal. Calcd. for C22H17N5O2S (415): C, 63.60; H, 4.12; N, 16.86. 
Found: C, 63.34; H, 4.32; N, 16.60. 
3.3.2. 1-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-3-(4-methoxyphenyl)-4-oxo-
2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 11 
Yield%: 71, m.p. = 90.6 °C, IR, cm−1: 3046 (CH arom.), 2991, 2875 (CH aliph.), 2208 (CN), 
1684, 1654 (2C=O), 1257 (C=S). 1H (DMSO-d6, ppm): 2.4 [s, 3H, CH3], 3.3 [s, 3H, N–CH3],  
3.7 [s, 3H, OCH3], 6.8–7.5 [m, 10H, Ar–H + CH–pyrimidine]. 13C (DMSO-d6, ppm): 13.9, 39.1, 
55.1, 95.2, 107.5, 113.5(2), 113.8(3), 123.3, 124.2(2), 124.9, 129.1(2), 130.8, 131.4, 143.6, 156.2, 
156.6, 164.7, 188.0. Anal. Calcd. for C23H19N5O3S (445): C, 62.01; H, 4.30; N, 15.72. Found: C, 






Yield%: 79, m.p. = 190.9 °C, IR, cm−1: 3076 (CH arom.), 2991, 2908 (CH aliph.), 2188 (CN), 
1700, 1689 (2C=O), 1597, 1380 (NO2), 1308 (C=S). 1H (DMSO-d6, ppm): 2.5 [s, 3H, CH3], 3.3 [s, 
3H, N–CH3], 7.8–8.2 [m, 10H, Ar–H + CH–pyrimidine]. 13C (DMSO-d6, ppm): 14.8, 39.3, 89.6, 
108.2, 112.3(3), 117.5, 120.9, 124.5(2), 124.9(2), 126.3(2), 129.0, 137.4(2), 142.8, 144.0, 155.6, 
162.4, 187.6 (C=S). Anal. Calcd. for C22H16N6O4S (460): C, 57.38; H, 3.50; N, 18.25. Found: C, 
57.69; H, 3.20; N, 18.56. 
3.3.4. 3-(4-Bromophenyl)-1-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-4-oxo-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 13 
Yield%: 69, m.p. = 76.0 °C, IR, cm−1: 3100 (CH arom.), 2986, 2861 (CH aliph.), 2218 (CN), 
1684, 1653 (2C=O), 1216 (C=S). 1H (DMSO-d6, ppm): 2.2 [s, 3H, CH3], 3.1 [s, 3H, N–CH3],  
7.0–7.6 [m, 10H, Ar–H + CH–pyrimidine]. 13C (DMSO-d6, ppm): 13.9, 39.5, 92.4, 104.6, 113.8(2), 
114.1, 116.6, 119.9, 121.0(2), 127.2(2), 129.0, 132.6, 133.4(2), 137.7, 138.6, 159.9, 160.1, 186.6 




Yield%: 90, m.p. = 114.1 °C, IR, cm−1: 3092 (CH arom.), 2980, 2861 (CH aliph.), 2187 (CN), 
1684, 1654 (2C=O), 1276 (C=S). 1H (DMSO-d6, ppm): 2.5 [s, 3H, CH3], 3.1 [s, 3H, N–CH3],  
7.6–7.9 [m, 10H, Ar–H + CH–pyrimidine]. 13C (DMSO-d6, ppm): 13.9, 39.5, 88.8(2), 107.3, 
114.6(2), 116.2, 120.2, 123.6(2), 129.0(3), 130.6, 137.2, 137.9(2), 139.1, 162.7, 166.1, 187.3. Anal. 
Calcd. for C22H16N5O2S (541): C, 48.81; H, 2.98; N, 12.94. Found: C, 48.69; H, 2.69; N, 12.72. 
3.3.6. 4-(5-Cyano-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-6-oxo-2-thioxo-
2,3-tetrahydropyrimidin-1(6H)-yl)benzensulfonamide 15 
Yield%: 90, m.p. = 164.8 °C, IR, cm−1: 3041 (CH arom.), 2934, 2881 (CH aliph.), 2217 (CN), 
1714, 1662 (2C=O), 1296 (C=S). 1H (DMSO-d6, ppm): 2.2 [s, 3H, CH3], 3.0 [s, 3H, N–CH3],  
7.3–8.0 [m, 11H, Ar–H + SO2NH2], 8.1 [s, 1H, CH–pyrimidine]. 13C (DMSO-d6, ppm): 13.9, 39.4, 
96.2, 104.6, 114.2(2), 116.4, 117.2, 121.6(2), 125.1(2), 127.3(2), 129.1, 134.2, 134.5, 139.6, 140.9, 
160.2, 160.5, 187.6 (C=S). Anal. Calcd. for C22H18N6O4S2 (494): C, 53.43; H, 3.67; N, 16.99.  
Found: C, 53.69; H, 3.90; N, 16.34. 
3.3.7. 3,3'-(4,4'-Sulfonylbis(4,1-phenylene))bis(1-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-
pyrazol-4-yl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile) 16 
A mixture of 2 (0.01 mol) and 1-(4-isothiocyanatophenylsulfonyl)-4-isothiocyanatobenzene  
(0.02 mol) was refluxed for 10 h in ethanol containing sodium ethoxide (0.01 mol). The reaction 
mixture was cooled, poured onto ice water, acidified with dil. HCl, the precipitated solid product  
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was filtered and crystallized from methanol to give 16. Yield%: 81, m.p. = 140.6 °C, IR, cm−1: 
3076 (CH arom.), 2981, 2861 (CH aliph.), 2219 (CN), 1661, 1643 (4C=O), 1322 (2C=S). 1H 
(DMSO-d6, ppm): 2.2 [s, 6H, 2CH3], 3.1 [s, 6H, 2N–CH3], 7.3–8.0 [m, 18H, Ar–H], 8.6 [s, 2H, 
2CH–pyrimidine]. 13C (DMSO-d6, ppm): 13.8(2), 39.0(2), 92.6(2), 108.6(2), 113.5(4), 114.1(2), 
118.4(2), 121.7(4), 127.0(4), 128.2(4), 129.1(2), 134.5(2), 136.2(2), 136.7(2), 142.4(2), 159.4(2), 
160.2(2), 187.6(2). Anal. Calcd. for C44H32N10O6S3 (892): C, 59.18; H, 3.61; N, 15.69. Found: C, 
59.40; H, 3.80; N, 15.48. 
3.4. General Procedure for Preparation of Compounds 17 and 18 
Compound 10 (0.01 mol) was mixed with either hydrazine hydrate or phenyl hydrazine (0.01 
mol) in dioxane (20 mL) and refluxed for 5 h, the reaction mixture was cooled, poured onto ice 
water. The precipitated solid products were filtered and crystallized from methanol to give 
compounds 17 and 18, respectively. 
3.4.1. (Z)-1-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-2-hydrazono-4-oxo-3-
phenyl-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 17 
Yield%: 68, m.p. = 78.0 °C, IR, cm−1: 3213, 3191 (NH2), 3047 (CH arom.), 2961, 2876 (CH 
aliph.), 2191 (CN). 1H (DMSO-d6, ppm): 2.5 [s, 3H, CH3], 3.2 [s, 3H, N–CH3], 4.5 [s, 2H, NH2,  
D2O-exchangeable], 7.1–7.5 [m, 11H, Ar–H + CH–pyrimidine]. 13C (DMSO-d6, ppm): 13.1, 39.0, 
94.6, 106.2, 114.5(2), 116.7, 118.2, 120.6(2), 122.1, 127.6(2), 128.4(2), 129.7, 134.2, 137.7, 138.5, 
156.2, 162.8, 168.9. Anal. Calcd. for C22H19N7O2 (413): C, 63.91; H, 4.63; N, 23.72. Found: C, 
63.70; H, 4.91; N, 23.55. 
3.4.2. (Z)-1-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-4-oxo-3-phenyl-2-(2-
phenylhydrazono)-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 18 
Yield%: 65, m.p. = 90.6 °C, IR, cm−1: 3381 (NH), 3074 (CH arom.), 2966, 2836 (CH aliph.),  
2220 (CN), 1700, 1653 (2C=O). 1H (DMSO-d6, ppm): 2.4 [s, 3H, CH3], 3.2 [s, 3H, N–CH3],  
7.0–8.0 [m, 15H, Ar–H], 8.4 [s, 1H, CH–pyrimidine], 9.5 [s, 1H, NH, D2O-exchangeable].  
13C (DMSO-d6, ppm): 14.1, 39.6, 95.3, 108.3, 113.8(2), 114.6, 115.8, 116.4(2), 118.9, 119.5(2), 
122.2, 128.6(2), 129.0(2), 129.6, 129.8(2), 130.2, 139.2, 141.5, 144.6, 153.5, 155.7, 165.6. Anal. 
Calcd. for C28H23N7O2 (489): C, 68.70; H, 4.74; N, 20.03. Found: C, 68.92; H, 4.99; N, 20.33. 
3.4.3. (Z)-4-(3-Amino-6-hydrazono-7-phenyl-6,7-dihydropyrazolo[3,4-d]pyrimidin-5-yl)-1,5-
dimethyl-2-phenyl-1,2-dihydropyrazol-3-one 19 
Compound 10 (0.01 mol) was mixed with hydrazine hydrate (0.02 mol) in dioxane (20 mL) and 
refluxed for 5 h, the reaction mixture was cooled, poured onto ice water. The precipitated solid 
products were filtered and crystallized from methanol to give compounds 19. Yield%: 73,  
m.p. = 222.6 °C, IR, cm−1: 3420, 3362 (NH2), 3050 (CH arom.), 2971, 2861 (CH aliph.),  
1654 (C=O), 1617 (C=N). 1H (DMSO-d6, ppm): 2.2 [s, 3H, CH3], 3.2 [s, 3H, N–CH3], 5.4 [s, 2H, 
N–NH2, D2O-exchangeable], 6.5 [s, 2H, NH2, D2O-exchangeable], 7.0–8.1 [m, 11H, Ar–H + CH–
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pyrimidine]. 13C (DMSO-d6, ppm): 11.4, 39.0, 97.6, 107.3, 112.6(2), 114.3(2), 116.7, 118.6, 123.7, 
128.6(2), 129.1, 129.4(2), 134.1, 139.8, 155.7, 162.3, 166.0(2). Anal. Calcd. for C22H21N9O (427): 
C, 61.81; H, 4.95; N, 29.49. Found: C, 62.03; H, 5.12; N, 29.67. 
3.5. General Procedure for Preparation of Compounds 20 and 21 
A solution of 4-aminoantipyrine 1 (0.001 mol) in either triethylorthoformate or 
triethylorthoacetate (0.001 mol) containing three drops of acetic anhydride was refluxed for 8 h, the 
reaction mixture was cooled and then poured onto cold water, the obtained solid was recrystallized 
from methanol to give compounds 20 and 21, respectively. 
3.5.1. (E)-Ethyl-N-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl-formimidate 20 
Yield%: 90, m.p. = 196.9 °C, IR, cm−1: 3078 (CH arom.), 2976, 2912 (CH aliph.), 1661 (C=O), 
1612 (C=N). 1H (DMSO-d6, ppm): 1.0 [t, 3H, CH3], 2.3 [s, 3H, CH3], 3.1 [s, 3H, N–CH3],  
3.5 [q, 2H, CH2], 7.2–7.5 [m, 5H, Ar–H], 8.1 [s, 1H, CH]. 13C (DMSO-d6, ppm): 11.3, 18.5, 39.3, 
56.0, 106.3, 107.0(2), 120.0, 129.0(2), 135.1, 151.6, 160.1, 164.7. Anal. Calcd. for C14H17N3O2 
(259): C, 64.85; H, 6.61; N, 16.34. Found: C, 64.66; H, 6.34; N, 16.67. 
3.5.2. (E)-Ethyl-N-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl-acetimidate 21 
Yield%: 88, m.p. = 81.6 °C, IR, cm−1: 3086 (CH arom.), 2936, 2817 (CH aliph.), 1658 (C=O), 
1598 (C=N). 1H (DMSO-d6, ppm): 1.2 [t, 3H, CH3], 1.9 [s, 3H, N=C–CH3], 2.1 [s, 3H, CH3],  
3.3 [s, 3H, N–CH3], 4.1 [q, 2H, CH2], 7.2–7.5 [m, 5H, Ar–H]. 13C (DMSO-d6, ppm):  
10.1 (CH3–pyrazole), 14.0 (CH3–ethyl), 17.4 (N=C–CH3), 39.1 (N–CH3), 61.0 (CH2–ethyl), 112.6, 
118.7(2), 122.8, 128.9(2), 135.4, 146.1, 160.0, 164.0 (C=O). Anal. Calcd. for C15H19N3O2 (273): C, 
65.91; H, 7.01; N, 15.37. Found: C, 66.13; H, 7.34; N, 15.48. 
3.6. In-Vitro Anticancer Screening 
The human tumor cell line (MCF7) was available from the National Cancer Institute, Cairo, 
Egypt. The antitumor activity of the newly synthesized compounds against the MCF7 cells was 
measured using the Sulforhodamine B (SRB) assay by the method of Skehan et al. (1990) [23,24]. 
The cell lines were grown in RPMI 1640 medium containing 10% fetal bovine serum and  
2 mM L-glutamine. Cells were plated in 96-multi-well plates (104 cells/well) and were incubated at 
37 °C, 5% CO2 in a humidified atmosphere for 24 h to allow attachment prior to addition of 
compounds. The test compounds 3–14 were dissolved in DMSO and diluted with saline to the 
appropriate volume and maintained in RPMI 1640 medium. Different concentrations of the 
compounds under test were made: 5, 12.5, 25, 30 and 50 μM and were added to the cells. Triplicate 
wells were prepared for each individual dose. Cells were incubated with the compounds for 48 h at 
37 °C, 5% CO2. After 48 h, cells were fixed in situ by the gentle addition of 50 μL of cold  
30% (w/v) trichloroacetic acid (TCA) (final concentration, 10%) and incubated for 60 min at 4 °C. 
The supernatant was discarded and the plates were washed five times with tap water and air dried. 
Sulforhodamine B (SRB) solution (50 μL) at 0.4% (w/v) in 1% acetic acid was added to each well 
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and plates were incubated for 20 min at room temperature. After staining, unbounded dye was 
removed by four washes with 1% acetic acid, and attached stain was recovered with Tris-EDTA 
buffer. Color intensity was measured at wave length 564 nm in an ELISA reader (Gmbh, 
Viesbaden, Germany). The relation between surviving fraction and drug concentration was plotted 
to get the survival curve from each compound after the specified time. The concentration required 
for 50% inhibition of cell viability (IC50) was calculated and compared with the reference drug 
doxorubicin and the results are given in Table 1. 
4. Conclusions 
The objective of the present study was to synthesize and investigate the anticancer activity of 
some novel pyrazole carrying a biologically active sulfonamide moieties. It was found that 
compounds 5, 13, 14, and 16–19 showed promising anticancer activity, higher than that of 
doxorubicin as reference drug against human breast cancer cell line (MCF7), while compounds 10, 
12 are nearly as active as doxorubicin as positive control. Compound 8 exhibited a moderate 
activity and compounds 2–4, 6, 7, 9, and 20 showed a weak activity, while compounds 11, 15 and 21 
revealed no activity. Further investigations on different probable mechanisms of action and dose-
response studies should be helpful in identifying the specific site(s) of action and optimum doses of 
the synthesized antipyrine derivatives. These investigations would be crucial in discovering more 
potent and more selective anti-breast cancer agents. 
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The Discovery of Potentially Selective Human Neuronal Nitric 
Oxide Synthase (nNOS) Inhibitors: A Combination of 
Pharmacophore Modelling, CoMFA, Virtual Screening and 
Molecular Docking Studies 
Guanhong Xu, Yue Chen, Kun Shen, Xiuzhen Wang, Fei Li and Yan He 
Abstract: Neuronal nitric oxide synthase (nNOS) plays an important role in neurotransmission and 
smooth muscle relaxation. Selective inhibition of nNOS over its other isozymes is highly desirable 
for the treatment of neurodegenerative diseases to avoid undesirable effects. In this study, we 
present a workflow for the identification and prioritization of compounds as potentially selective 
human nNOS inhibitors. Three-dimensional pharmacophore models were constructed based on a 
set of known nNOS inhibitors. The pharmacophore models were evaluated by Pareto surface and 
CoMFA (Comparative Molecular Field Analysis) analyses. The best pharmacophore model, which 
included 7 pharmacophore features, was used as a search query in the SPECS database (SPECS®, 
Delft, The Netherlands). The hit compounds were further filtered by scoring and docking. Ten hits 
were identified as potential selective nNOS inhibitors. 
Reprinted from Int. J. Mol. Sci. Cite as: Xu, G.; Chen, Y.; Shen, K.; Wang, X.; Li, F.; He, Y. The 
Discovery of Potentially Selective Human Neuronal Nitric Oxide Synthase (nNOS) Inhibitors: A 
Combination of Pharmacophore Modelling, CoMFA, Virtual Screening and Molecular Docking 
Studies. Int. J. Mol. Sci. 2014, 15, 8553-8569. 
1. Introduction 
Nitric oxide (NO) is one of the most studied biological signaling molecules and is produced by 
catalysis from nitric oxide synthase (NOS), which converts L-arginine to L-citrulline, and produces 
this tiny, short-lived molecule. To date, there are three distinct isoforms of NOS: neuronal NOS 
(nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). nNOS and eNOS are constitutively 
expressed and depend on increases in external calcium and binding of a calcium/calmodulin 
complex for activation. nNOS and eNOS play an important role in neurotransmission and smooth 
muscle relaxation, respectively, and iNOS is expressed during bacterial infection, tumor cell 
cytolysis and inflammation [1–3]. 
As an inorganic reactive free radical gas, NO is believed to be involved in a number of 
physiological processes such as inflammation, neurotransmission, blood pressure regulation, 
platelet aggregation and pain [4–6]. However, overproduction of NO has been implicated in 
numerous disease states [7]. In particular, excess NO in the central nervous system from nNOS 
activity can lead to many neurological disease states including neurodegeneration during Alzheimer’s 
and Parkinson’s diseases [8], altered spinal transmission of neuropathic pain [9,10], and progression 
of migraine and chronic tension-type headaches [11]. Consequently, an inhibitor of nNOS has the 
potential to be therapeutic in these diseases; however, the functions of eNOS in blood pressure 
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regulation and iNOS in immune responses must be preserved, and the selective inhibition of nNOS 
has been the challenge of many researchers in the past decade [12–15]. 
Recently, several categories of selective inhibitors of nNOS have been designed and developed 
for the treatment of central nervous system (CNS) disorders [3,15–22]. Some showed significant 
efficacy in the rat Chung model of neuropathic pain [22] and in a rodent model of dural 
inflammation relevant to migraine pain [22]. X-ray structures of nNOS co-crystallized with various 
ligands [23–25] provided insights into the essential structural elements and motifs central to its 
catalytic mechanism and mode of binding. These findings provide useful information about the 
interaction between the ligands and the residues near the binding site and can be utilized to design 
even more selective and potent drug-like NOS inhibitors. 
Virtual screening based on a pharmacophore model as a 3D search query has been successfully 
employed as an efficient alternative to high throughput screening approaches for the development 
of new compounds with the desired biological properties [26]. Pharmacophore modeling can be 
used to analyze the common functional groups responsible for specific drug receptor interactions or as 
a prelude to three dimensional quantitative structure activity relationship (3D-QSAR) analyses that 
are aligned accordingly with a set of known active compounds in 3D space. 3D-QSAR has been 
successfully applied in drug discovery and design. As a popular QSAR method, Comparative 
Molecular Field Analysis (CoMFA) [27] studies incorporate 3D information of the ligands by 
searching for the sites on molecules that are capable of being modified into more specific ligands. 
As a useful methodology for studying interaction mechanisms, receptor based molecular docking 
analysis can be used as a complementary tool to prioritize the hits from the pharmacophore-based 
virtual screening [28]. 
In the present study, a 3D pharmacophore model for nNOS inhibitors was assembled and  
the generated model was used as a search query in the SPECS database containing 197,000 
compounds. The virtual screening approach, in combination with pharmacophore modeling and 
molecular docking can be used to identify and design novel nNOS inhibitors with high selectivity. 
These molecules may be potential lead compounds for future drug development. 
2. Results and Discussion 
2.1. Pharmacophore Results 
Twenty pharmacophore models were generated using SYBYL X 1.3 (Tripos Associates Inc.,  
St. Louis, MO, USA). Table 1 lists the parameters of each model. Specificity is a logarithmic 
indicator of the expected discrimination for each query and is based on the number of features it 
contains, their allotment across partial match constraints, and the degree to which the features are 
separated in space. Strong models should have a high Specificity value. Generally, the Specificity 
value should be at least 5 in a pharmacophore model used as the query for a UNITY flex search [29]. 
For this study, MODEL 012, MODEL 019, and MODEL 003 had the high Specificity values of 
5.138, 5.128 and 4.8580, respectively. These models yielded reasonable pharmacophore models. 
The N_HITS column shows the actual number of ligands hit by the model query, with the majority 
of the models matching at least 5 ligands. The value in the FEATS column indicates the total 
number of features possessed by each model. All of the models had six or more features except for 
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MODEL 011. The retained models had a PARETO rank value of 0, indicating that a single model 
is not superior to any other. The HBOND term is a measure of the overall pharmacophoric 
similarity among the ligand conformers. The STERIC term is a measure of the overall steric 
similarity among the ligand conformers; this term is basically the same as the HBOND term. The 
ENERGY term indicates the total energy (using the Tripos force field) of all molecules in the 
training set. 
Table 1. Parameters of the pharmacophore model a. 
No. SPECIFICITY N_HITS FEATS PARETO ENERGY STERICS HBOND 
MOEDL_001 4.180 4 6 0 15.60 666.7 173.3 
MOEDL_002 3.881 8 7 0 15.44 703.1 161.8 
MOEDL_003 4.858 6 8 0 18.53 750.4 155.1 
MOEDL_004 4.108 6 6 0 18.62 712.0 166.6 
MOEDL_005 3.823 9 7 0 20.15 852.7 162.7 
MOEDL_006 3.735 6 7 0 17.54 714.7 160.5 
MOEDL_007 3.902 9 7 0 58.38 705.2 179.2 
MOEDL_008 4.051 6 6 0 19.3 784.6 171.4 
MOEDL_009 4.036 3 6 0 40.81 845.3 159.5 
MOEDL_010 3.393 5 9 0 35.12 612.2 178.2 
MOEDL_011 3.158 6 5 0 22.40 635.3 178.9 
MOEDL_012 b 5.138 5 7 0 41.13 870.1 166.1 
MOEDL_013 4.048 6 6 0 17.75 732.8 157.0 
MOEDL_014 4.124 6 6 0 19.25 861.2 160.2 
MOEDL_015 3.867 8 7 0 19.99 567.7 175.3 
MOEDL_016 4.050 5 6 0 23.76 834.0 165.7 
MOEDL_017 4.053 5 6 0 14.97 658.9 150.8 
MOEDL_018 4.058 5 6 0 55.07 859.6 162.8 
MOEDL_019 5.128 4 7 0 23.06 654.1 168.0 
MOEDL_020 4.050 5 6 0 16.91 748.1 158.3 
a SPECIFICITY is a logarithmic indicator of the expected discrimination for each query; N_HITS is the 
actual number of ligands hit by the model query; FEATS is the total number of features in the model 
query; PARETO indicates the Pareto rank of the each model; ENERGY is the total energy of the model; 
STERICS is the steric overlap for the model; HBOND is the pharmacophoric concordance; b The 
selected model (MODEL_012) is indicated in boldface. 
The most significant pharmacophore hypothesis was characterized by the conflicting demands 
of maximizing pharmacophore consensus, maximizing steric consensus, and minimizing conformer 
potential energy [30]. We constructed a 3D plot to visualize the Pareto surface and select the best 
pharmacophore model (Figure 1). Considering only the ENERGY and STERICS criteria, the best 
model is shown in the upper left-hand corner of the graph in Figure 1b, where the ENERGY is low 
and the STERICS score is high. In terms of ENERGY and HBOND criteria, the best model is 
shown in the lower part of the graph in Figure 1c, where the ENERGY is low and the HBOND 
score is high. Finally, in terms of ENERGY and HBOND, the best model is shown in the upper 
part of the graph, where both scores are high (Figure 1d). Among the considered models, 
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MODEL_012 (represented with a red cross in Figure 1) has the optimal position because it fulfills 
the three criteria and it has the highest Specificity value [31]. 
The best GALAHAD MODEL 012 is displayed in Figure 2. All of the aligned conformers  
represent low-energy conformations of the molecules, and the final alignment shows a satisfactory 
superimposition of the pharmacophoric points. Cyan, magenta, green and red spheres indicate 
hydrophobes, donor atoms, acceptor atoms and positive nitrogens, respectively. Model 012 
includes 7 pharmacophore features: three hydrophobes (HY_1, HY_2 and HY_3), one donor atom 
(DA_4), one acceptor atom (AA_5) and two positive nitrogens (NP_6 and NP_7). The magenta 
sphere is covered by a green sphere because the donor atom and the acceptor atom are in the same 
position in this molecule. 
Figure 1. Plot of the STERICS, ENERGY and HBOND values for the models with the top 
ten Specificity values. (a) 3D plot; (b) plot of STERICS vs. ENERGY; (c) plot of 






Figure 2. Selected pharmacophore MODEL_012 and the molecular alignment of the 
compounds used to elaborate the model. 
 
2.2. CoMFA (Comparative Molecular Field Analysis) Statistical Results 
We used MODEL 012 as a template to align all molecules. The generated steric and electrostatic 
fields were scaled by the CoMFA-Standard scaling method in SYBYL with the default energy 
cutoff value. The CoMFA model yielded a good cross-validated correlation coefficient (q2) of 
0.513 with an optimized component value of 4, which suggests that the model should be a useful 
tool for predicting the IC50 values. A high non-cross-validated correlation coefficient (r2ncv) of 
0.933 with a low standard error estimate (SEE) of 0.134 and an f value of 149.950 were obtained. 
The steric and electrostatic contributions were 45.1% and 54.9%, respectively. The predicted 
activities for the inhibitors are listed in Table 2 and the correlation between the predicted activities 
and the experimental activities is depicted in Figure 3. The predictive correlation coefficient (r2pred) 
was 0.742 for the test set. The statistical results indicate that the CoMFA model is a reliable predictor. 











 series 1 [22] 
- X Y - - 
1 H N(CH3)2 6.237 6.089 




















6 F N(CH3)2 5.474 5.770 











RX  series 2 [15,22] 
- X R - - 
9 * H -CH2CH2CH2N(CH3)2 6.569 6.588 
10 H -CH2CH2NCH3 6.754 6.741 
11 * H -CH2CH2N CH2CH3 6.857 6.694 
12 H -CH2CH2NCH(CH3)2 6.573 6.585 
13 H -CH2CH2N(CH3) (C2H5) 7.013 6.987 
14 * H -CH2CH2N(CH3)2 6.367 6.510 
15 H -CH2CH2N(C2H5)2 6.585 6.642 
16 F -CH2CH2N(C2H5)2 7.032 6.757 
17 H -(CH2)3NCH3 6.629 6.736 
18 H -CH2CH2N(CH3) (CH2)2OH 6.876 6.960 
19 H -(CH2)2NH(CH2)2OH 6.939 6.964 




































R  series 3 [21] 




















R  series 4 [17] 
- X R - - 
33 S N-(1-(3-(dimethylamino)propyl)- 6.328 6.419 
34 * S N-(1-(3-(cyclopropylamino)propyl)- 6.585 6.366 
35 S N-(1-(3-morpholinopropyl)- 6.181 6.120 
36 S N-(1-(3-((1-ethylpyrrolidin-2-yl)methylamino)propyl)- 6.886 6.700 
37 S N-(1-(3-adamantanaminopropyl)- 6.444 6.388 
38 S N-(1-(2-(dimethylamino)ethyl)- 6.770 6.736 
39 S N-(1-(2-(piperidin-1-yl)ethyl)- 6.770 6.930 
40 S N-(1-(2-(1-methylpiperidin-2-yl)ethyl)- 7.046 7.131 
41 S (S) N-(1-(2-(1-methylpyrrolidin-2-yl)ethyl)- 7.700 7.564 
42 O N-(1-(2-(1-methylpyrrolidin-2-yl)ethyl)- 6.602 6.824 
43 S N-(1-(1-methylazepan-4-yl)- 6.921 6.893 
44 O N-(1-(1-methylazepan-4-yl)- 6.367 6.443 
45 * S N-(1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)- 6.120 6.168 
46 S N-(1-(quinuclidin-3-yl)- 6.444 6.417 
















 Substituted R   
48 5 2-(Pyridin-2-yl)ethyl 5.959 6.025 
49 5 2-Morpholinoethyl 5.886 5.976 
50 * 5 1-Benzylpiperidin-4-yl 6.398 6.281 
51 5 1-(4-Fluorobenzyl)piperidin-4-yl 6.097 5.986 
52 5 (±)-2-(1-Methylpyrrolidin-2-yl)ethyl 7.523 7.582 
53 6 2-(Pyridin-2-yl)ethyl 5.886 5.83 
54 6 2-Morpholinoethyl 5.699 5.676 
55 6 1-Benzylpiperidin-4-yl 6.301 6.216 
56 6 1-(4-Fluorobenzyl)piperidin-4-yl 6.699 5.779 
57 * 6 2-(1H-Imidazol-5-yl)ethyl 6.523 6.789 
58 6 4-Bromophenethyl 5.357 5.188 
59 6 Tetrahydro-2H-pyran-4-yl 5.699 5.736 
* Compounds taken for the test set. 
Figure 3. Correlation between the experimental and CoMFA (Comparative Molecular 
Field Analysis) predicted activities of compounds. 
 
The CoMFA steric and electrostatic contour maps are shown in Figure 4 using compound 41 as 
a reference structure. In Figure 4a, the blue contour indicates regions in which an increase of 
positive charge enhances the activity, and the red contour indicates regions in which more negative 
charges are favorable for activity. The two large blue contours around the red sphere indicate that 
the substituent in this region should be electron deficient for increased binding affinity with a 
protein. Another small blue contour is found around the guanidine isosteric group indicating that a 
negatively charged substituent in this area is unfavorable. The CoMFA model showed the same 
result as the pharmacophore hypothesis. In Figure 4b, the steric field is represented by green and 
yellow contours, in which the green contours indicate regions where a bulky group is favorable and 
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the yellow regions represent regions where a bulky group will decrease activity. In this case, the 
green contours around the substituent R demonstrated that bulky groups enhance the binding 
affinity of the nNOS. Most compounds with high activities in this dataset have the same such 
properties. The CoMFA contour maps and the predicted result further indicated that MODEL 012 
can be used as a theoretical screening tool that is able to discriminate between active and inactive 
molecules [31]. 
Figure 4. (a) CoMFA steric contour maps and (b) CoMFA electrostatic contour maps. 
 
2.3. Virtual Screening 
The pharmacophore based virtual screening was conducted to find potential nNOS inhibitors.  
A stepwise virtual screening procedure was applied, wherein the pharmacophore based virtual 
screening was followed by drug-likeness evaluation, screening of the pharmacophore query, QFIT 
(The QFIT score is a value between 0 and 100, where 100 is best and represents how close the 
ligand atoms match the query target coordinates within the range of a spatial constraint tolerance) 
scoring filtration, and a molecular docking study. The sequential virtual screening flowchart we 
employed is depicted in Figure 5, in which the reduction in the number of hits for each screening 
step is shown. 
2.3.1. Database Searching  
Flexible 3D screening was performed using the UNITY tool to screen the SPECS database [32], 
which contains approximately 197,000 compounds. The database query was generated based on the 
pharmacophore MODEL 012. The database was restricted with Lipinski's rule. In general, this rule 
describes molecules that have drug-like properties. Drug-likeness is a property that is most often 
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used to characterize compound libraries such as combinatorial or screening libraries that are 
screened to find novel lead chemical compounds [33]. According to this rule, we used simple 
molecular descriptors, such as molecular weight (≤500), hydrophobicity (MLogP ≤ 4.15) and the 
number of H-bond donor (≤5) and acceptor atoms (≤10), as the first filter to select the molecules 
with good absorption or permeation [34]. The remaining 223 compounds were further screened on 
the basis of QFIT to reduce the dataset, where QFIT is the pharmacophore match between the 
query and hit [35]. 
Figure 5. Virtual screening flowchart. 
 
2.3.2. Molecular Docking 
To predict the appropriate binding conformation for nNOS inhibitors and the reported hit 
compounds from virtual screening, Surflex Docking (Tripos Associates Inc., St. Louis, MO, USA) 
was used to generate an ensemble of docking conformations. The top 62 hit compounds with the 
highest QFIT score from screening after UNITY filtering were further screened using molecular 
docking into the binding site of nNOS to select the compounds with the ability to form favorable 
interactions with the active site. The docked compounds were filtered based on scoring function 
and interaction with the crucial residues [24] in the binding site. Finally, ten compounds were 
selected on the basis of the dock score and favorable interactions with the key residues. The results 
of the hit compounds with their dock score and QFIT values are shown in Table 3. Among the 
active compounds reported [24], AG_205/36953325 has a similar linker length and two aromatic 
ring centers on both ends. There is also a hydrogen bond donor in the aromatic ring center and at 
least one hydrogen bond donor on the linker. The phenolic hydroxyl makes a hydrogen bond with 
the NOS active site GLU592, which is conserved in all mammalian NOS isoforms [24], and the 
hydrophobic phenyl ring π-stacks with the heme (HEM801) next to the GLU. The long, flexible 
linker extending from the phenyl ring allows the 2-phenyl-2,3-dihydro-1H-pyrazole to reach and to 
π-stack with TYR706 (Figure 6). The binding mode of this hit compound is similar to that of the 
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reported co-crystallized compound [24] and indicates that the identified hit compounds may have 
the same mechanism of action as known nNOS inhibitors. 
Table 3. Chemical structures of the hit compounds and their dock scores and QFIT values. 




















































































Table 3. Cont. 



















Figure 6. (a) Mapping of the hit molecule (AG_205/36953325) by MODEL 012 from 
SPECS databases; (b) The orientation of AG_205/36953325 in the active site of nNOS;  
(c) The secondary structure of the active site and AG_205/36953325; and (d) The 
MOLCAD (a software package of SYBYL) cavity depth potential surfaces structure of 
the binding site within AG_205/36953325. The cavity depth color ramp ranges from 
blue (outside of the pocket) to light red (cavities deep inside the pocket). 
 
3. Experimental Section 
3.1. Compounds and Biological Data 
Fifty-nine novel nNOS inhibitors were taken from the literature [15–17,21,22] with their biological 
activities in terms of IC50 values; 49 compounds were used as a training set and the remaining  
10 compounds were used as a test set, based on random selection. The compounds in the test set 
94 
 
have a range of biological activity values similar to that of the training set. The IC50 values of the 
inhibitors were converted into pIC50 (log (1/IC50)) and used as dependent variables in the 
Pharmacophore generation and CoMFA calculations. The structures of the compounds and  
their pIC50 values are given in Table 2. All molecular modeling calculations were conducted  
using SYBYL X 1.3 (Tripos Associates Inc.). Molecular building was performed with a molecule 
sketch program in the same software. The molecular geometry of each compound was first 
minimized using the standard Tripos molecular mechanics force field with 0.01 kcal/(mol A) 
energy gradient convergence criterion. Partial atomic charges were calculated by the  
Gasteiger-Hückel method and energy minimizations were performed using the Conjugate Gradient 
method with 1000 iterations [36,37]. 
3.2. Pharmacophore Generation 
Pharmacophore models were generated and analyzed using the GALAHAD module. In this 
study, ten compounds (13, 16, 19, 21, 24, 30, 40, 41, 43, and 52) were selected to carry out the 
pharmacophore hypothesis, and the genetic algorithm was used to create conformers for all 
molecules. The compounds that were selected to generate the pharmacophore hypothesis are highly 
active. All of the ligands were aligned with a population size value of 60, a maximum generation 
value of 60 and a value of molecular required hitting of 5. Twenty models were generated with 
default parameters. 
3.3. CoMFA Field Calculation Partial Least Square Analysis 
The standard CoMFA procedure as implemented by SYBYL X 1.3 (Tripos Associates Inc.) was 
performed. Each set of aligned molecules was positioned inside a 3D cubic lattice with a grid 
spacing of 2.0 A (default distance) in all Cartesian directions and was generated to enclose the 
molecule aggregate. The fields generated were automatically scaled by the CoMFA standard in 
SYBYL. The partial least squares (PLS) methodology was used to derive a linear relationship for 
the CoMFA, and cross-validation was performed using the leave-one-out (LOO) method to choose 
the optimum number of components (ONC) and assess the statistical significance of each model. In 
PLS, the independent variables were the CoMFA descriptors, and the pIC50 values were used as 
dependent variables. The ONC was the number of components that led to the highest cross-
validated correlated correlation coefficient q2 (or r2cv). Non-cross-validation was performed to 
calculate conventional r2ncv using the same number of components [38–40]. 
3.4. Virtual Screening 
The selected pharmacophore model was validated and converted into a UNITY query for 
pharmacophore guided virtual screening studies. The query was screened against the SPECS 
database. The flex search option was implemented to perform virtual screening. Primary filters 
such as Lipinski’s rule of five were applied to reduce the dataset. Further screening of the hits was 
carried out using the Surflex Dock in SYBYL. 
The docking study was performed to validate the hits obtained from the virtual screening. The 
crystal structure of nNOS was retrieved from the RCSB Protein Data Bank (PDB code: 4EUX) [24]. 
95 
 
The nNOS structure was utilized in subsequent docking experiments without energy minimization. 
Protein structures were prepared using the biopolymer module of SYBYL. Hydrogen atoms were 
added to the structure, atom types and charges were assigned using AMBER7 FF99 force field, and 
side chain amides were modified. The ligand method was used as the mode of construction for the 
protomol, threshold and bloat using default values to determine the extent of the protomol. 
4. Conclusions 
nNOS is a therapeutic target for central nervous system diseases that has attracted interest from 
pharmaceutical companies and researchers. Selective inhibition of nNOS activity represents an 
exciting drug approach for the development of new therapeutic agents to treat neurodegenerative 
diseases. In this study, we described a rational strategy for identifying novel nNOS inhibitors using 
a pharmacophore-based virtual screening protocol. The best pharmacophore model (MODEL 012) 
was established and showed good statistical parameters in the validation process. MODEL 012 was 
further employed as a 3D search query to screen the SPECS compound database. Molecular docking 
studies were also performed to improve the reliability and accuracy of the virtual screening. Ten hit 
compounds were identified as potential selective nNOS inhibitors and exhibited good search 
scoring, high docking scores, similar binding mode to experimentally proven compounds and 
favorable drug-like properties. The pharmacophore models developed in this work, and the 
information gained about the interactions between nNOS and the potential selective inhibitors, 
indicated that the combination of pharmacophore, molecular docking, and virtual screening efforts is 
a successful approach for identifying effective inhibitory compounds that may have an impact on 
future experimental studies in selective nNOS inhibition. The identified hit compounds were 
structurally different from available inhibitors and may serve as potential leads or starting points 
for structural optimization to identify novel nNOS inhibitors. 
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Synthesis, Preliminary Bioevaluation and Computational 
Analysis of Caffeic Acid Analogues 
Zhiqian Liu, Jianjun Fu, Lei Shan, Qingyan Sun and Weidong Zhang 
Abstract: A series of caffeic acid amides were designed, synthesized and evaluated for  
anti-inflammatory activity. Most of them exhibited promising anti-inflammatory activity against 
nitric oxide (NO) generation in murine macrophage RAW264.7 cells. A 3D pharmacophore model 
was created based on the biological results for further structural optimization. Moreover, 
predication of the potential targets was also carried out by the PharmMapper server. These amide 
analogues represent a promising class of anti-inflammatory scaffold for further exploration and 
target identification. 
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1. Introduction 
Inflammation is a hallmark of many diseases, which may lead to various diseases including 
sepsis, arthritis, atherosclerosis, diabetes and even cancer [1,2]. Nowadays, several steroidal  
anti-inflammatory drugs (SAID) and nonsteroidal anti-inflammatory drugs (NSAID) have been 
developed. However, they still have some unexpected side effects and the inflammation 
mechanism is not exactly clear. Currently, the most important targets are attracting a great deal of 
interest in contemporary anti-inflammatory drug design and discovery, including signal transducers 
and activators of transcription (STAT) [3], interleukin (IL) [4], stem cell factor (SCF) [5], 
macrophage migration inhibitory factor (MIF) [6], Annexin-1 [7], CC chemokine receptor  
(CCR) [8], Adenosine A2A receptor (A2A-R) [9], melanocortin receptor (MC-R) [10] and NF-κB 
signaling [11]. Very recently, our group has identified that 5-lipoxygenase was a potential target of 
(+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate [12]. 
Caffeic acid, a common natural product from Eucalyptus globulus [13], Salvinia molesta [14], 
Phellinus linteus [15] and coffee, was reported to possess promising in vitro and in vivo  
anti-inflammatory properties [16]. The caffeic acid is usually found as various simple derivatives 
including amides, esters, sugar esters and glycosides [17]. Yuu Osanai’s group showed that caffeic 
acids with the ester functional group had good anti-inflammatory activity but with high  
cyctoxicity [18] (Figure 1). These findings prompted us to look for new caffeic acid amides with 
different substituent against inflammation while reducing cyctoxicity. In this report, 20 caffeic acid 
aimdes were rationally designed, synthesized and evaluated the inhibition of no production in 
murine macrophage RAW 264.7 cells. Based on the biological result, a 3D pharmacophore model 
was generated by using the seven active compounds with HipHop approach, which has been 
recognized as a time-saving and cost-effective technique for discovering new active  
compounds [19,20]. Furthermore, potential drug target predication was then carried out using 
pharmacophore-mapping approach [21]. The biological validation is ongoing now. 
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2. Results and Discussion 
2.1. Biological Studies 
A series of caffeic acid amides was synthesized according to general procedure [22] (Scheme 1). 
Firstly, R1 and R2 were first replaced with different alkyl groups (Compounds 3a–3f). 
Unfortunately, only the n-Butyl derivative showed moderate nitric oxide (NO) inhibition with an 
IC50 value of 6.1 μM. The other alkyl derivatives with cyclic or di-substituted groups were 
completely inactive in the in vitro inhibition assay at 10 μM, probably due to the limited binding 
space (Table 1). Then, aromatic groups (Compounds 3g–3r) were introduced and four compounds 
demonstrated good inhibitory activity. Structure−activity relationship (SAR) analysis identified 
that the type and position of the substituents were important for the inhibitory activity. Substituents 
on the 3 (Compound 3i, IC50 = 7.9 μM) and 4 (Compound 3j, IC50 = 5.2 μM and Compound 3k, 
IC50 = 3.7 μM) positions of the benzene ring were favorable for the inhibition of NO production but 
not suitable for 3-chloro (Compound 3n) and bromo (Compound 3o) derivatives. Similarly, the 
derivatives with 2-substituents (Compounds 3l, 3m and 3q) were absolutely inactive. Interestingly, 
the compounds with 3,5-difluorophenylo group (Compound 3h, IC50 = 4.1 μM) and the 3,5-
bis(trifluoromethyl)phenyl group (Compound 3g, IC50 > 10 μM) were totally different. Encouraged 
by the above results, privileged bioactive structures with aromatic ring, such as indol (Compound 
3s) and piperonyl (Compound 3t), were then synthesized. Both of them showed promising 
inhibitory activity with the IC50 of 6.7 and 5.0 μM, respectively, which can be taken as lead 
structures for further exploration. To our delight, the amides were much better than the original 
caffeic acid, which only had an IC50 value of 165 μM. 





Table 1. Synthesis of caffeic acid amide (3a–3t) and inhibitory effect of caffeic acid 
amides on Lipopolysaccharide (LPS) induced nitrite production. 
Compounds R1 R2 Nitric Oxide Inhibition/IC50 (μM) 
f n-butyl H 6.1 
3b cyclopropylmethanyl H >10 
3c –CH2)5– –(CH2)5– >10 
3d –(CH2)4– –(CH2)4– >10 
3e –(CH2)2– –(CH2)2– >10 
3f n-butyl n-butyl >10 
3g 3,5-bis(trifluoromethyl)phenyl H >10 
3h 3,5-difluorophenyl H 4.1 
3i 3-(trifluoromethyl)phenyl H 7.9 
3j 4-methoxyphenyl H 5.2 
3k 4-fluorophenyl H 3.7 
3l 2-(hydroxymethyl)phenyl H >10 
3m 2-acetylphenyl H >10 
3n 3-chlorophenyl H >10 
3o 3-bromophenyl H >10 
3p 4-methanylphenyl H >10 
3q 2-methanylphenyl H >10 
3r phenylmethanyl H >10 
3s 2-(1H-indol-3-yl)ethyl H 6.7 
3t 2-(benzo[d][1,3]dioxol-5-yl)ethyl H 5.0 
caffeic acid - - 165 a 
a data from the reference [2]. 
2.2. Pharmacophore Model 
A set of the seven most potent Compounds 3a, 3h–3k, 3s and 3t was selected as a training set to 
generate the 3D pharmacophore model. The common feature pharmacophore generation run resulted 
in 10 pharmacophore models. All the 10 models were generated with three pharmacophoric features, 
along with good ranking scores ranging from 117.3 to 119.49. As all pharmacophore models didn’t 
have much difference in their 3D distance constraints, the best model was chosen based on the 
ranking score of a pharmacophore model and the fit values of the training set compounds. As a 
result, “Hypo 1” was selected with best ranking score of 119.49 and good fit values from the 
mapping of the training set compounds upon the chemical features. The pharmacophore model 
“Hypo 1” containing three hydrophobic (HY), two hydrogen bond acceptor (HBA) and two 
hydrogen bond donor (HBD) features are shown in Figure 2. The best pharmacophore model, 
Hypo1, was predicted using seven active compounds. It can map all seven active compounds 
(Figures S1–S7). The above results mimicked the 3D model of the newly synthesized active small 




Figure 2. Pharmacophore model of seven active compounds. Three-dimensional spatial 
arrangement of the best pharmacophore hypothesis “Hypo 1”. Green color represents 
hydrogen bond acceptor (HBA), magenta represents hydrogen bond donor (HDB) and 
cyan represents hydrophobic (HY) features. 
 
2.3. Target Predication and Molecular Docking 
Despite our synthesized compounds showed promising inhibition of NO production, the exact 
molecular mechanism by which exerts their effects is not yet clearly understood. Potential drug 
target predication was then carried out using pharmacophore-mapping approach [21]. Binding 
properties for Compounds 3a, 3g, 3h–3k, 3s and 3t on potential targets were estimated by a reverse 
pharmacophore mapping server [23]. These compounds were divided into three categories: 
aliphatic group (Compound 3a), aromatic group (Compounds 3h–3k) and heterocyclic group 
(Compounds 3s and 3t). All the predicted targets of these three groups were ranked by the fit score. 
Among the top 0.3% of the predicted target candidates, there were three common targets (GTPase 
HRas, Chorismate synthase and Orotidine 5-phosphate decarboxylase), indicating that above 
compounds may target different proteins comparing with the published caffeic acid ester. Further 
molecular docking revealed a good interaction between the ligands and the protein active site. 
Compound 3k has formed hydrogen interactions with Ser17 and Thr35 (Figure 3). In the second 
potential protein, it has participated in hydrogen bonds interaction with the amino acids Ala133, 
Asn251, Asp399 and Thr315 (Figure 4). The active site of 5-phosphate decarboxylase surrounds 
and binds 3k with hydrogen bonds at Val1182 and Asp1020 (Figure 5). These three docking 




Figure 3. The proposed binding mode of Compound 3k within the active site of 
GTPase HRas (PDB code: 5P21). 
 
Figure 4. The proposed binding mode of Compound 3k within the active site of 




Figure 5. The proposed binding mode of Compound 3k within the active site of 
Orotidine 5-phosphate decarboxylase (PDB code: 1LOS) and the proposed binding 
mode of compound 3k within the active site of Orotidine 5-phosphate decarboxylase (PDB 
code: 1LOS). 
 
3. Experimental Section 
3.1. Chemistry 
All other commercial reagents and solvents were used as received without further purification. 
Anhydrous solvent and reagents were analytical pure and dried through routine protocols. The 
reactions were monitored using analytical thin layer chromatography (TLC) with Merck silica gel 
60, F-254 precoated plates (0.25 mm thickness). And the TLC plates were detected under UV light. 
Flash column chromatography was performed with Merck silica gel 60 (Merck KGaA, Darmstadt, 
Germany) (200–400 mesh) or the crude product was purified by precipitation from dichloromethane 
with diethyl ether. 1H NMR and 13C NMR spectra were recorded on Bruker DRX 400 (Bruker Co., 
Bruker, Germany) at 400, 500 and 100 MHz, using TMS as an internal standard and DMSO-d6 
(Sigma-Aldrich Co., St. Louis, MO, USA) as solvents. Chemical shifts (δ values) and coupling 
constants (J values) are given in ppm and Hz, respectively. ESI-MS (Agilent Technologies, Palo 
Alto, CA, USA) was recorded on a Waters ZQ 4000 LC-MS (Waters, Milford, MA, USA) 
spectrometer. The purity of the final compounds was determined using CH3CN/H2O (85:15) with 
0.1% triethylamine as the mobile phase with a flow rate of 1.0 mL/min on a C18 column. 
3.1.1. General Procedure for the Preparation of Amine (3a–3t) 
A solution of the caffeic acid (180 mg, 1 mmol), the dicyclohexyl carbodiimide (DCC, 206 mg,  
1 mmol) and amide (1 mmol) was refluxed in THF and the progress of the reaction was monitored 
by TLC. The solvent was removed under vacuum. The residue was purified by flash 
chromatography using dichloromethane with diethyl ether (2:1–1:1) as the eluent [18]. 
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(E)-N-Butyl-3-(3,4-dihydroxyphenyl)acrylamide (3a). Yield: 65%; 1H NMR (DMSO-d6, 500 MHz) 
δ: 9.30 (s, 1H), 9.07 (s, 1H), 7.90 (t, J = 5.6 Hz, 1H), 7.19 (d, J = 15.7 Hz, 1H), 6.91 (d, J = 2.0 Hz, 
1H), 6.80 (dd, J = 8.1, 1.9 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.29 (d, J = 15.7 Hz, 1H), 3.30 (s, 2H), 
3.12 (dd, J = 12.8, 6.8 Hz, 2H), 1.97 (s, 2H), 1.48–1.36 (m, 2H), 1.36–1.16 (m, 2H), 0.90–0.81 (m, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.6, 139.2, 126.8, 120.6, 119.0, 116.14, 114.18, 38.66, 31.75, 
20.04, 14.09. ESI-MS (m/z): 236.12 [M + 1]. High performace liquid chromatograph (HPLC) purity: 
97%. Anal. calcd for C13H17NO3: C 66.36, H 7.28, N 5.95, O 20.40, found: C 66.27, H 7.18, N 5.90. 
(E)-N-(Cyclopropylmethyl)-3-(3,4-dihydroxyphenyl)acrylamide (3b). Yield: 55%; 1H NMR 
(DMSO-d6, 400 MHz) δ: 9.36 (s, 1H), 9.13 (s, 1H), 8.05–8.08 (m, 1H), 7.22 (d, J = 16 Hz, 1H), 6.94 
(s, 1H), 6.83 (d, J = 8.0 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 6.35 (d, J = 16.0 Hz, 1H), 3.04 (t, J = 6.0 Hz, 
2H), 0.40–0.44 (m, 2H), 0.16–0.19 (m, 2H). ESI-MS (m/z): 234.11 [M + 1]. HPLC purity: 96.5%. 
(E)-3-(3,4-Dihydroxyphenyl)-1-(piperidin-1-yl)prop-2-en-1-one (3c). Yield: 35%; 1H NMR 
(DMSO-d6, 400 MHz) δ: 9.42 (s, 1H), 8.97 (s, 1H), 7.3 (d, J = 15.2 Hz, 1H), 7.08 (s, 1H), 6.89–
6.98 (m, 2H), 6.73 (d, J = 15.2 Hz, 1H), 3.51–3.59 (m, br, 4H), 1.48–1.60 (m, 6H). ESI-MS (m/z): 
248.02 [M + 1]. HPLC purity: 98%. 
(E)-3-(3,4-Dihydroxyphenyl)-1-(pyrrolidin-1-yl)prop-2-en-1-one (3d). Yield: 45%; 1H NMR 
(DMSO-d6, 400 MHz) δ: 9.47 (s, 1H), 9.10 (s, 1H), 7.29 (d, J = 15.2 Hz, 1H), 7.05 (s, 1H), 6.96  
(d, J = 8.0 Hz, 1H), 6.74 (d, J = 7.6 Hz, 1H), 6.64 (d, J = 15.2 Hz, 1H), 3.59 (t, J = 6.0 Hz, 2H), 3.67  
(t, J = 6.0 Hz, 2H), 1.90 (m, 2H), 1.79 (m, 2H). ESI-MS (m/z): 234.1 [M + 1]. HPLC purity: 97%. 
(E)-1-(Aziridin-1-yl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one (3e). Yield: 69%; 1H NMR (DMSO-d6, 
400 MHz) δ: 9.37 (s, 1H), 9.14 (s, 1H), 7.22 (d, J = 15.6 Hz, 1H), 6.92 (s, 1H), 6.82 (d, J = 8.0 Hz, 
1H), 6.73 (d, J = 8.0 Hz, 1H), 6.23 (d, J = 15.6 Hz, 1H), 0.64–0.67 (m, 2H), 0.42–0.43 (m, 2H). 
ESI-MS (m/z): 206.07 [M + 1]. HPLC purity: 97.2%. 
(E)-N,N-Dibutyl-3-(3,4-dihydroxyphenyl)acrylamide (3f). Yield: 57%; 1H NMR (DMSO-d6, 400 MHz) 
δ: 9.41 (s, 1H), 9.04 (s, 1H), 7.30 (d, J = 15.2 Hz, 1H), 7.04 (s, 1H), 6.94 (d, J = 8.0 Hz, 1H),  
6.73–6.77 (m, 2H), 3.41 (t, J = 7.2 Hz, 2H), 3.30(t, J = 7.2 Hz, 2H), 1.0–1.5 (m, 8H),  
0.87–0.94 (m, 6H). ESI-MS (m/z): 292.02 [M + 1]. HPLC purity: 98%. 
(E)-N-(3,5-Bis(trifluoromethyl)phenyl)-3-(3,4-dihydroxyphenyl)acrylamide (3g). Yield: 90%;  
1H NMR (DMSO-d6, 400 MHz) δ: 10.46 (s, 1H), 9.50 (s, 1H), 9.24 (s, 1H), 7.39–7.48 (m, 3H),  
7.02 (s, 1H), 6.88–6.94 (m, 2H), 6.78 (d, J = 8.0 Hz, 1H), 6.47 (d, J = 15.2 Hz, 1H). ESI-MS (m/z): 
392.06 [M + 1]. HPLC purity: 96%. 
(E)-N-(3,5-Difluorophenyl)-3-(3,4-dihydroxyphenyl)acrylamide (3h). Yield: 71%; 1H NMR 
(DMSO-d6, 500 MHz) δ: 7.46–7.22 (m, 3H), 7.00 (d, J = 1.7 Hz, 1H), 6.95–6.80 (m, 2H), 6.76 (d, 
J = 8.1 Hz, 1H), 6.45 (d, J = 15.6 Hz, 1H). 13C NMR (126 MHz, DMSO) δ: 164.9, 163.7, 161.9, 
148.5, 146.0, 142.4, 126.2, 121.5, 116.2, 114.4, 102.2. ESI-MS (m/z): 292.07 [M + 1]. HPLC purity: 
97.2%. Anal. calcd for C15H11F2NO3: C 61.86, H 3.81, F 13.05, N 4.81, O 16.48, found: C 61.76, H 




(E)-3-(3,4-Dihydroxyphenyl)-N-(3-(trifluoromethyl)phenyl)acrylamide (3i). Yield: 59%; 1H NMR 
(DMSO-d6, 500 MHz) δ: 8.18 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.53 (dd, J = 14.6, 6.6 Hz, 1H), 
7.43 (d, J = 15.6 Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 7.00 (d, J = 1.9 Hz, 1H), 6.91 (d, J = 8.2, 2.0 
Hz, 1H), 6.76 (d, J = 8.1 Hz, 1H), 6.50 (d, J = 15.6 Hz, 1H). 13C NMR (126 MHz, DMSO) δ: 
164.91, 148.38, 146.06, 142.00, 140.66, 130.40, 126.38, 122.99, 121.45, 119.73, 118.14–117.25, 
116.24, 115.50, 114.43. ESI-MS (m/z): 324.08 [M + 1]. HPLC purity: 98%. Anal. calcd  
for C16H12F3NO3:C 59.45, H 3.74, F 17.63, N 4.33, O 14.85, found: C59.35, H 3.50, F 17.53,  
N 4.31, O 14.65. 
(E)-3-(3,4-Dihydroxyphenyl)-N-(4-methoxyphenyl)acrylamide (3j). Yield: 78%; 1H NMR (DMSO-d6, 
500 MHz) δ: 9.90 (s, 1H), 7.58 (d, J = 9.0 Hz, 2H), 7.35 (d, J = 15.6 Hz, 1H), 6.98 (d, J = 1.8 Hz, 
1H), 6.90–6.82 (m, 3H), 6.75 (d, J = 8.1 Hz, 1H), 6.49 (d, J = 15.6 Hz, 1H), 3.71 (s, 3H). 13C NMR 
(DMSO-d6, 126 MHz,) δ: 163.9, 155.5, 147.9, 146.0, 140.6, 133.1, 126.7, 121.0, 118.99 (s, 3H), 
116.2, 114.3, 55.5. ESI-MS (m/z): 286.1 [M + 1]. HPLC purity: 96.6%. Anal. calcd for C15H16NO4: 
C 67.36, H 5.34, N 4.91, O 22.43, found: C 67.20, H 5.22, N 4.90. O 22.25. 
(E)-3-(3,4-Dihydroxyphenyl)-N-(4-fluorophenyl)acrylamide (3k). Yield: 61%; 1H NMR (DMSO-d6, 
500 MHz) δ: 10.09 (s, 1H), 9.33 (br, 2H), 7.68 (d, J = 14.1 Hz, 2H), 7.38 (d, J = 15.6 Hz, 1H),  
7.13 (d, J = 15.6 Hz, 2H), 6.98 (s, 1H), 6.88 (dt, J = 15.2, 7.6 Hz, 1H), 6.75 (d, J = 8.1 Hz, 1H), 
6.48 (d, J = 6.0 Hz, 1H). 13C NMR (DMSO-d6, 126 MHz) δ: 164.3, 159.2, 157.3, 146.0, 141.2, 
121.2, 118.6, 116.2, 115.83, 115.7, 114.3. ESI-MS (m/z): 274.08 [M + 1]. HPLC purity: 97.4%. 
Anal. calcd for C15H12FNO3:C 65.93, H 4.43, F 6.95, N 5.13, O 17.57, found: C 65.65, H 4.35,  
F 6.72, N 5.05, O 17.37. 
(E)-3-(3,4-Dihydroxyphenyl)-N-(2-(hydroxymethyl)phenyl)acrylamide (3l). Yield: 63%; 1H NMR 
(DMSO-d6, 400 MHz) δ: 9.48 (s, 1H), 9.46 (s, 1H), 9.17 (s, 1H), 7.76 (d, J = 4.0 Hz, 1H),  
7.36–7.43 (m, 2H), 7.25 (t, J = 8.0 Hz, 1H), 7.15 (t, J = 8.0 Hz, 1H), 7.03 (s, 1H), 6.92 (d, J = 8.8 Hz, 
1H), 6.77 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 15.2 Hz, 1H), 4.53 (s, 2H). ESI-MS (m/z): 286.1 [M + 1]. 
HPLC purity: 97.6%. 
(E)-N-(2-Acetylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide (3m). Yield: 53%; 1H NMR (DMSO-d6, 
400 MHz) δ: 11.39 (s, 1H), 9.55 (s, 1H), 9.16 (s, 1H), 8.42 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 8.0 Hz, 
1H), 7.62 (t, J = 7.6 Hz, 2H), 7.44 (d, J = 15.2 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.09 (s, 1H), 7.01 (d, 
J = 8.0 Hz, 1H), 6.78 (d, 2H, J = 8.0 Hz), 6.53 (d, J = 15.2 Hz, 1H), 2.64 (s, 3H). ESI-MS (m/z): 
298.1 [M + 1]. HPLC purity: 97.8%. 
(E)-N-(3-Chlorophenyl)-3-(3,4-dihydroxyphenyl)acrylamide (3n). Yield: 72%; 1H NMR (DMSO-d6, 
400 MHz) δ: 10.27 (s, 1H), 9.51 (s, 1H), 9.23 (s, 1H), 7.93 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.42 
(d, J = 15.2 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 7.01 (s, 1H), 6.92 (d, J = 8.0 Hz, 
1H), 6.78 (d, J = 8.0 Hz, 1H), 6.50 (d, J = 15.2 Hz, 1H). ESI-MS (m/z): 290.02 [M + 1]. HPLC  
purity: 97.9%. 
(E)-N-(3-Bromophenyl)-3-(3,4-dihydroxyphenyl)acrylamide (3o). Yield: 67%; 1H NMR (DMSO-d6, 
400 MHz) δ: 10.24 (s, 1H), 9.51 (s, 1H), 9.22 (s, 1H), 8.06 (s, 1H), 7.55 (d, J = 8.0 Hz, 1H),  
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7.42 (d, J = 15.2 Hz, 1H), 7.22–7.30 (m, 2H), 7.01 (s, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.77 (d, J = 8.0 
Hz, 1H), 6.50 (d, J = 15.2 Hz, 1H). ESI-MS (m/z): 334.16 [M + 1]. HPLC purity: 97.6%. 
(E)-3-(3,4-Dihydroxyphenyl)-N-p-tolylacrylamide (3p). Yield: 76%; 1H NMR (DMSO-d6, 400 MHz) 
δ: 9.98 (s, 1H), 9.44 (s, 1H), 9.20 (s, 1H), 7.57 (d, J = 6.8 Hz, 2H), 7.38 (d, J = 15.2 Hz, 1H),  
7.20 (d, J = 6.8 Hz, 2H), 7.00 (s, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H),  
6.52 (d, J = 15.2 Hz, 1H), 2.26 (s, 3H). ESI-MS (m/z): 270.11 [M + 1]. HPLC purity: 97.3%. 
(E)-3-(3,4-Dihydroxyphenyl)-N-o-tolylacrylamide (3q). Yield: 68%; 1H NMR (DMSO-d6, 400 MHz) 
δ: 9.45 (s, 1H), 9.32 (s, 1H), 9.17 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 15.2 Hz, 1H),  
7.16–7.23 (m, 2H), 7.01–7.08 (m, 2H), 6.91 (d, J = 8.0 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H),  
6.68 (d, J = 15.2 Hz, 1H), 2.24 (s, 3H). ESI-MS (m/z): 270.1 [M + 1]. HPLC purity: 96%. 
(E)-N-Benzyl-3-(3,4-dihydroxyphenyl)-N-methylacrylamide (3r). Yield: 64%; 1H NMR (DMSO-d6,  
400 MHz) δ: 9.41 (s, 1H), 9.00 (s, 1H), 7.21–7.40 (m, 6H), 6.89–7.01 (m, 3H), 6.71–6.76 (m, 1H),  
4.69 (s, 2H), 2.98 (s, 3H). ESI-MS (m/z): 284.12 [M + 1]. HPLC purity: 97%. 
(E)-N-(2-(1H-Indol-3-yl)ethyl)-3-(3,4-dihydroxyphenyl)acrylamide (3s). Yield: 91%; 1H NMR 
(DMSO-d6, 500 MHz) δ: 10.78 (s, 1H), 9.20 (d, J = 101.6 Hz, 2H), 8.07 (t, J = 5.7 Hz, 1H),  
7.54 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 15.6 Hz, 1H), 7.14 (s, 1H), 7.04 (dd, 
J = 11.1, 4.0 Hz, 1H), 7.00–6.88 (m, 2H), 6.81 (dd, J = 8.2, 1.9 Hz, 1H), 6.73 (d, J = 8.1 Hz, 1H), 6.32 
(d, J = 15.7 Hz, 1H), 3.44 (d, J = 13.4, 7.1 Hz, 2H), 2.86 (t, J = 7.4 Hz, 2H). 13C NMR (DMSO-d6, 
126 MHz) δ: 165.7, 147.6, 145.9, 139.3, 136.6, 127.6, 126.8, 123.0, 121.3, 120.7, 119.1, 118.6, 
116.1, 114.2, 112.2, 111.7, 31.0, 25.7. ESI-MS (m/z): 323.13 [M + 1]. HPLC purity: 98%. Anal. 
calcd for C20H20N2O3: C 71.41, H 5.99, N 8.33, O 14.24, found: C 71.26, H 5.55, N 8.12, O 14.17. 
(E)-N-(2-(Benzo[d][1,3]dioxol-5-yl)ethyl)-3-(3,4-dihydroxyphenyl)acrylamide (3t). Yield: 52%; 1H 
NMR (DMSO-d6, 500 MHz) δ: 9.37 (s, 1H), 9.14 (s, 1H), 8.03 (t, J = 5.5 Hz, 1H), 7.22 (d, J = 15.7 
Hz, 1H), 6.93 (s, 1H), 6.82 (d, J = 7.9 Hz, 3H), 6.73 (d, J = 8.1 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 
6.31 (d, J = 15.7 Hz, 1H), 5.96 (s, 2H), 3.37–3.29 (m, 4H), 2.69 (dd, J = 18.5, 11.2 Hz, 2H).13C 
NMR (DMSO-d6, 126 MHz) δ: 165.7, 161.3, 147.5, 145.9, 139.3, 133.5, 126.8, 121.9, 120.7, 
118.9, 116.1, 114.2, 109.4, 108.5, 101.0, 35.2, 35.0. ESI-MS (m/z): 228.3 [M + 1]. HPLC purity: 
97.7%. Anal. calcd for C18H17NO5: C 66.05, H 5.23, N 4.28, O 24.44, found: C 65.95, H 5.13,  
N 4.15, O 24.26. 
3.2. Biology 
3.2.1. Cell Culture 
RAW 264.7 murine macrophages were obtained from the Shanghai Institute of Cell Biology, 
Chinese Academy of Sciences (Shanghai, China) and maintained in DMEM recommended by the 
suppliers, supplemented with 10% fetal bovine serum (Gibco, Paisley, UK), penicillin (100 U/mL) 




3.2.2. Measurement of Nitric Oxide 
The amount of NO was assessed by determining the nitrite concentration with Griess reagent. 
Briefly, in the experiment to assess NO in culture supernatants, RAW 264.7 macrophages were 
seeded into 48-well plates (2 × 106 cells per mL) for 18 h. Then, the cells were pretreated each 
sample, aminoguanidine or vehicle solution for 20 min, then stimulated with LPS (1 μg/mL) for 18 
h. Samples of supernatants (100 mL) were incubated with 50 mL 1% sulfanilamide, then 50 mL of 
0.1% naphthylethylenediamine in 2.5% phosphoric acid solution. The absorbance at 570 nm was 
read and referred to a standard curve of sodium nitrite solution to determine the nitrite 
concentration. In the other experiment to determine the NO concentration of exudates from rat air 
pouches, the exudates (50 mL) were incubated with nitrate reductase solution (200 mL; Jiancheng 
Bioengineering Institute, Nanjing, China) at 37 °C for 1 h. Nitrate was converted into nitrite. After 
centrifugation, the nitrite concentration in the cell-free supernatants was assessed with Griess 
reagent as described above [24]. 
3.3. Computational Protocols 
3.3.1. Pharmacophore Generation 
All the studies were carried out using Discovery Studio (DS) 2.5 unless it is mentioned. Seven 
most active compounds as shown in Figure 2 were selected as a training set to generate qualitative 
pharmacophore models to be used in future database screening to identify new scaffolds for drug 
discovery. The 2D chemical structures of the training set compounds were built using ChemSketch 
program version 12, and subsequently converted into 3D structures using DS. All compounds in 
the training set were given a Principal value of 2 and a Maximum Omitted Feature value of 0 to 
make sure that all the features of these compounds are considered during pharmacophore 
generation. Diverse conformational models for every training set compound were generated to 
cover the flexibility of their chemical nature using polling algorithm. All the compounds were 
energetically minimized using CHARMM force field implemented in DS. Diverse Conformation 
Generation protocol with BEST flexible search option implemented in DS was employed with the 
default value of generating maximum of 250 conformers within the energy range of 20 kcal/mol, 
with respect to the global minimum. Feature mapping protocol was employed prior to the original 
pharmacophore generation calculation to identify the chemical features present in the training set 
compounds. The chemical features such as hydrogen bond acceptor (HBA), hydrogen bond donor 
(HBD) and hydrophobic (HY) features were used during pharmacophore generation. These 
chemical features were selected based on the feature mapping results and the possible interaction 
points. All the other parameters were maintained at their default settings. The seven compounds in 
the training set along with the generated conformational models were used in pharmacophore model 
generation. Common feature pharmacophore models, generally, are developed by comparing a set 
of conformational models and a number of 3D configurations of chemical features shared among 
the training set compounds. Common Feature Pharmacophore Model Generation protocol 
implemented in DS was used to generate pharmacophore models. Minimum interfeature distance 
was 0.5. The other parameters were default. 
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3.3.2. Molecular Docking Study 
All the molecular docking studies were performed by GOLD 5.1 program with ChemPLP 
function score (Cambridge Crystallographic Data Center, London, UK). X-ray crystal structures 
(PDB ID: 1LOS, PDB ID: 1QXO, PDB ID: 5P21) were used to define the binding site for 
molecular docking studies. The radius of 12 Å around the active compound was defined to form the 
active site of the protein. 
4. Conclusions 
In summary, we rationally designed a series of caffeic acid amide analogues. The preliminary 
biological evaluations revealed that this class of compounds possessed moderate to good  
anti-inflammatory activity. A 3D pharmacophore model was then generated based on the biological 
activity and the better understanding of this feature could provide meaningful insights for further 
optimization. Potential targets were also predicted by the PharmMapper server. A further study of 
the structural modification and biological target validation are in process in our laboratory and will 
be reported elsewhere. 
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Abstract: In the present investigation, new hydrazinecarbothioamides 4–6 were synthesized by 
reaction of 4-(4-X-phenylsulfonyl)benzoic acids hydrazides (X= H, Cl, Br) 1–3 with  
2,4-difluorophenyl isothiocyanate and further these were treated with sodium hydroxide to obtain 
1,2,4-triazole-3-thione derivatives 7–9. The reaction of 7–9 with α-halogenated ketones, in basic media, 
afforded new S-alkylated derivatives 10–15. The structures of the synthesized compounds have been 
established on the basis of 1H-NMR, 13C-NMR, IR, mass spectral studies and elemental analysis. 
The antioxidant activity of all compounds has been screened. Hydrazinecarbothioamides 4–6 
showed excellent antioxidant activity and 1,2,4-triazole-3-thiones 7–9 showed good antioxidant 
activity using the DPPH method. 
Reprinted from Int. J. Mol. Sci. Cite as: Barbuceanu, S.-F.; Ilies, D.C.; Saramet, G.; Uivarosi, V.; 
Draghici, C.; Radulescu, V. Synthesis and Antioxidant Activity Evaluation of New Compounds 
from Hydrazinecarbothioamide and 1,2,4-Triazole Class Containing Diarylsulfone and  
2,4-Difluorophenyl Moieties. Int. J. Mol. Sci. 2014, 15, 10908-10925. 
1. Introduction 
Oxidation processes are intrinsic to the energy management of all living organisms and are 
therefore kept under strict control by several cellular mechanisms [1]. 
Free radicals are molecules, ions or atoms with unpaired electrons in their outermost shell of 
electrons [2]. These species, which are constantly formed in human body, can become toxic when 
generated in excess or in the presence of a deficiency in the naturally occurring antioxidant 
defenses. High levels of free radicals can cause damage to biomolecules such as lipids, proteins, 
enzymes and DNA in cells and tissues. This may result in many diseases such as: cancer, diabetes, 
cardiovascular and autoimmune diseases, and neurodegenerative disorders, aging, and other diseases 
through the violent reactivity of the free radicals [3–5]. 
Antioxidants are important compounds that reduce or neutralize the free radicals, thus protecting  
the cells from oxidative injury [6]. Therefore, considerable research has been directed towards the 
identification of new antioxidants to prevent radical-induced damage. 
Over the years triazoles have become an important class of heterocyclic compounds in organic 
synthesis due to their various biological properties. It is well known that 1,2,4-triazole derivatives 
have therapeutic applications. Thus, there are various drugs incorporating in their structure the 
1,2,4-triazole ring used as antifungal [7–9], antiviral [10] agents, aromatase inhibitors [11], etc. 
Among the 1,2,4-triazole derivatives, the mercapto- and the thione-substituted 1,2,4-triazole ring 
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systems have been studied and so far a variety of biological properties have been reported for a 
large number of these compounds including antioxidant [12–14], antibacterial, antifungal [12,15–18], 
anticancer [17,19], hypolipidemic [20], anti-inflammatory [21] activity. Moreover, various S-alkylated 
1,2,4-triazole-3-thiones showed antibacterial [22], antifungal [18,22], anti-inflammatory [23], and 
hypolipidemic [20] activities. 
It has been reported that structural properties of triazoles, like moderate dipole character, 
hydrogen bonding capability, rigidity and stability under in vivo conditions are the main reasons for 
their superior pharmacological activities [24]. 
Many synthetic procedures exist for the synthesis of substituted 1,2,4-triazole-3-thiones. 
However, the development of simple, facile and efficient methodologies to get five-membered 
heterocycles is one of the major aspects in organic synthesis. Hydrazinecarbothioamides are 
valuable intermediates in a variety of synthetic transformations and useful as building blocks in  
the synthesis of biologically active heterocycles including synthesis of 1,2,4-triazole-thiones.  
In addition, hydrazinecarbothioamides derivatives exhibit various biological properties such as 
antioxidant [13,14,25,26], antibacterial [27], and antimycobacterial [28]. 
Moreover, sulfone derivatives provide examples of an important class of bioactive compounds 
with biological activities including antibacterial, and anti-HIV-1 [29,30]. 
On the other hand, incorporation of one or several fluorine atoms into an organic molecule  
can enhance their biological potency, bioavailability, metabolic stability and lipophilicity. 
Enhanced lipophilicity may lead to easier absorption and transportation of molecules within 
biological systems [31]. 
Considering these published data and as a sequel to our research on the design and synthesis of 
biologically active new heterocycles from the triazole class [32–35], it was thought worthwhile to 
synthesize the novel title compounds and to evaluate them for their antioxidant activity. 
In this study, we present the design, synthesis, characterization and evaluation of the antioxidant 
activity of the new hydrazinecarbothioamides, 1,2,4-triazole-3-thiones and some S-alkylated 1,2,4-
triazole derivatives incorporating in their molecule diarylsulfone and 2,4-difluorophenyl moieties. 
2. Results and Discussion 
2.1. Chemistry 
The reaction sequences employed for synthesis of title compounds are showed in Scheme 1. In 
the present work, 2-(4-(4-X-phenylsulfonyl)benzoyl)-N-(2,4-difluorophenyl)hydrazinecarbo-thioamides 
4–6 were synthesized by reaction of 4-(4-X-phenylsulfonyl)benzoic acid hydrazides 1–3 (X = H, Cl, 
Br) with 2,4-difluorophenyl isothiocyanate, in absolute ethanol, at reflux. The 4-(4-X-
phenylsulfonyl)benzoic acid hydrazides precursors 1–3 were prepared starting from Friedel-Crafts 
reaction of benzene or halobenzene with p-tosyl chloride, according to a previously reported 
method [36,37]. The hydrazinecarbothioamides 4–6 were refluxed in 8% sodium hydroxide 
solution to obtain 5-(4-(4-X-phenylsulfonyl)phenyl)-4-(2,4-difluorophenyl)-2H-1,2,4-triazole-
3(4H)-thiones 7–9 in equilibrium with thiole tautomer. The treatment of 1,2,4-triazoles 7–9 with α-
halogenated ketones (2-bromoacetophenone or 2-bromo-4′-fluoroacetophenone), in basic media, 
produced the new S-alkylated 1,2,4-triazoles namely (2-(5-(4-(4-X-phenylsulfonyl)phenyl)-4-(2,4-
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difluorophenyl)-4H-1,2,4-triazol-3-ylthio)-1-(phenyl/4-fluorophenyl)ethanones 10–15 and not  
N-alkylated derivatives. 
Scheme 1. Synthetic route of the title compounds. 
 
The structures of all synthesized compounds 4–15 were proven by 1H-NMR, 13C-NMR, MS 
spectra and elemental analysis. 
The IR spectra of hydrazinecarbothioamide derivatives 4–6 exhibit a new absorption band at  
1243–1258 cm−1 corresponding to C=S stretching vibration which confirms the nucleophilic 
addition reaction of 4-(4-X-phenylsulfonyl)benzoic acid hydrazides 1–3 to 2,4-difluorophenyl 
isothiocyanate. Also, in the IR spectra of these compounds 4–6 was presented as a strong 
characteristic absorption band for carbonyl group at 1663–1682 cm−1. The stretching bands 
corresponding to NH groups were observed in range 3150–3319 cm−1. In the IR spectra of 
compounds 7–9 no absorption band was detected about 1663–1682 cm−1 indicating the absence of 
C=O group of hydrazinecarbothioamides 4–6 which is evidence for the conversion of these compounds 
to 1,2,4-triazoles. Compounds 7–9 can exist in two tautomeric forms, 5-(4-(4-X-phenylsulfonyl)phenyl)-
4-(2,4-difluorophenyl)-4H-1,2,4-triazole-3-thioles and 5-(4-(4-X-phenylsulfonyl)phenyl)-4-(2,4-
difluorophenyl)-2H-1,2,4-triazole-3(4H)-thiones 7–9. The spectral analysis (IR, 1H-NMR, 13C-
NMR) shows that these compounds exist in the latter tautomeric form. Thus, in the IR spectra, the 
νS-H vibration band (~2500–2600 cm−1) was absent and the νC=S vibration band was observed in 
region 1247–1255 cm−1. Also, the presence of the νNH absorption band in 3278–3414 cm−1 region is 
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an additional proof for the thione tautomeric form [13,38,39]. The structure of compounds 10–12 and 
13–15 obtained by alkylation of triazoles 7–9 with α-halogenated ketones was confirmed by the 
presence in their IR spectra of a new strong stretching band in a 1678–1703 cm−1 region characteristic 
to C=O group. Also, new bands appeared in 2920–2965 cm−1 region due to the presence of 
methylene group (νCH2). The disappearance of C=S stretching band in IR spectra supported the S-
alkylation leading to the formation of compounds 10–15. 
Reaction of hydrazides 1–3 with 2,4-difluorophenyl isothiocyanate has been proven in 1H-NMR 
spectra of compounds 4–6 by the presence of three singlet signals at ~9.62, ~10.04 and ~10.90 ppm 
assigned to protons from three NH groups. Intramolecular cyclization of hydrazinecarbothioamides 
was confirmed in 1H-NMR spectra of compounds 7–9 by presence of a unique singlet at 14.42–14.48 
ppm which can be attributed of NH proton from 1,2,4-triazol-3-thione nucleus [38]. The 1H-NMR 
spectra of all alkylated triazoles 10–15 displayed a singlet signal at δ = 4.99 (for 13–15) and 5.02 ppm 
(10–12) assignable to S-CH2 protons. The absence of the signal due to NH in 1H-NMR spectra of 
compounds 10–15 and the presence of a new singlet for S-CH2 confirmed that 1,2,4-triazole-3-thiones 
7–9 were converted into alkylated derivatives (10–15) in the reaction with α-halogenated ketones. 
The 13C-NMR spectra of hydrazinecarbothioamides 4–6 showed two important signals characteristic 
of carbon atoms from C=O and C=S groups at δ 164.71–164.75 and 182.47 ppm, respectively [40]. In 
13C-NMR of compounds 7–9 the C-3 and C-5 heterocyclic carbon from triazole nucleus resonated 
at 169.52–169.54 and 149.01–149.03 ppm, respectively. The signal of the C-3 quaternary carbon 
atom at ~169 ppm is characteristic of C=S group [12,13,41–43] which indicates the presence of the 
thione tautomeric form in solution. The most significant proof of the alkylation of triazoles 7–9 with 
2-bromoacetophenone or 2-bromo-4'-fluoroacetophenone was the presence in 13C-NMR spectra of 
compounds 10–12 and 13–15 of two new signals at 191.42–192.73 and 40.33–40.46 ppm 
corresponding to C=O and S-CH2 carbon atoms from a phenacyl/4-fluorophenacyl group. In 
addition, the formation of S-alkylated and not of N-alkylated products was confirmed by the 
absence of a C=S characteristic peak at ~169 ppm in 13C-NMR spectra of 10–15. The C-3 and C-5 
heterocyclic carbons from these alkylated compounds resonate at 153.09–153.16 ppm (more 
shielded than the C-3 heterocyclic carbon from 1,2,4-triazoles 7–9) and 153.01–153.09 ppm, 
respectively [12,43,44]. 
Moreover, the signals present in the NMR spectra corresponding to aromatic protons and 
carbons from 2,4-difluorophenyl-, 4-fluorophenyl- and 5-(4-(4-X-phenylsulfonyl)phenyl)-fragments 
prove the structure of the synthesized compounds. Further confirmations of the structure of the 
compounds were carried out by mass spectrometry and microanalysis (see experimental part). 
2.2. Antioxidant Activity 
The free radical scavenging activity of all compounds 4–15 was carried out in the presence of 
the stable free radical (1,1-diphenyl-2-picrylhydrazyl) DPPH using ascorbic acid (AA), tert-butyl-
4-hydroxyanisole (BHA) and 2,6-bis(1,1-dimethylethyl)-4-methylphenol (BHT) antioxidant agents 
as positive control.  
Although a number of methods are available for determination of the antioxidant activity, the 




The DPPH solution has a deep purple color, with a strong absoption at 517 nm, and turns to 
yellow in the presence of antioxidants, which neutralizes the free radicals by pairing the DPPH odd 
electron with a hydrogen atom or by electron donation. Reduction of DPPH absorption at 517 nm 
represents the capacity of antioxidants to scavenge free radical [46]. 
The inhibitory effects of different concentrations of synthesized compounds on DPPH radical 
are presented in Tables 1 and 2. The antioxidant activity is expressed in terms of % inhibition and 
IC50 (effective concentration for scavenging 50% of the initial DPPH) value (μM). 
Based on the experimental results, among all the compounds synthesized, hydrazinecarbothioamides  
4–6 showed higher scavenging activity towards DPPH. These compounds have shown a strong 
inhibitory effect on DPPH radical at 250 μM concentration and inhibition rates were: 97.18% ± 1.42% 
(for 4), 96.90% ± 1.39% (for 5), 97.11% ± 1.12% (for 6) better than the positive control AA  
(91.26% ± 0.49%) and BHA (89.30% ± 1.37%) and much stronger than BHT (23.05% ± 1.32%). 
These compounds 4–6 inhibited the DPPH activity with an IC50 = 39.39 μM (4), 39.79 μM (5)  
and 42.32 μM (6) which is better than the specific inhibitor BHA (IC50 = 51.62 μM) and AA  
(IC50 = 107.67 μM) and much stronger than BHT (423.37 μM). 
The 1,2,4-triazole-3-thiones 7–9 obtained by cyclization of hydrazinecarbothioamides  
showed (at the same concentration, 250 μM) a good antioxidant activity (7: 67.70% ± 1.68%,  
8: 72.45% ± 1.42%, 9: 58.52% ± 1.55%) but lower than AA (91.26% ± 0.49%) and BHA  
(89.30% ± 1.37%). However, triazoles had higher antioxidant activity than BHT. As deduced from the 
IC50 data, the triazole with the lowest anti-radical capacity were found to be derivative 9 (with 182.60 
μM) followed by 7 (147.79 μM) and 8 was found to be slightly more active (133.80 μM) than its 
counterparts 7 and 9 (Table 1). 
The S-alkylated 1,2,4-triazoles 10–15 showed weak inhibitory effect at 250 μM concentration, 
in the range of 7.73%–15.04% (Table 2). However, the presence of the third fluorine atom on 
phenyl radical linked to ketone groups determines a slight increase of antioxidant activity of 
compounds 13–15 compared with 10–12. Because these compounds presented a weaker action even 
than BHT, IC50 was not calculated. 
Table 1. Antioxidant activity of compounds 4–9 by DPPH method. 
Compd. Scavenging Effect (%) 
IC50 
(μM) 
- 25 μM 50 μM 75 μM 100 μM 125 μM 250 μM - 
4 30.54 ± 1.32 64.37 ± 1.35 74.86 ± 1.40 85.39 ± 1.45 95.99 ± 1.50 97.18 ± 1.42 39.39 
5 30.39 ± 1.18 63.58 ± 1.62 74.12 ± 1.34 84.69 ± 1.83 95.36 ± 1.87 96.90 ± 1.39 39.79 
6 29.14 ± 1.53 59.28 ± 1.23 71.23 ± 1.32 83.23 ± 1.42 95.35 ± 1.18 97.11 ± 1.12 42.32 
7 15.88 ± 1.03 24.74 ± 1.32 33.30 ± 1.67 37.93 ± 1.49 46.14 ± 1.45 67.70 ± 1.68 147.79 
8 15.56 ± 0.95 24.36 ± 1.19 32.18 ± 1.48 40.58 ± 1.41 48.38 ± 1.54 72.45 ± 1.42 133.80 
9 13.96 ± 0.97 22.99 ± 1.05 31.74 ± 1.56 38.63 ± 1.59 43.03 ± 1.63 58.52 ± 1.55 182.60 
AA 0.70 ± 1.00 1.08 ± 0.84 17.48 ± 1.03 34.91 ± 0.69 84.12 ± 0.48 91.26 ± 0.49 107.67 
BHA 23.27 ± 1.39 48.99 ± 1.42 64.77 ± 1.32 73.89 ± 1.59 81.74 ± 1.45 89.30 ± 1.37 51.62 




Table 2. Antioxidant activity of compounds 10–15 by DPPH method. 
Compd. Concentration (μM) Scavenging Effect (%) 
10 250 12.67 ± 0.82 
11 250 8.24 ± 1.20 
12 250 7.73 ± 0.96 
13 250 13.23 ± 0.48 
14 250 15.04 ± 0.43 
15 250 12.73 ± 0.50 
AA 250 91.26 ± 0.49 
BHA 250 89.30 ± 1.37 
BHT 250 23.05 ± 1.32 
The higher antioxidant activity of hydrazinecarbothioamides 4–6 can be explained by the 
existence of the thiourea fragment [13] that determines stabilization of free radicals of nitrogen 
atoms (occurring due to the elimination of hydrogen atoms linked to these) by double conjugation, 
mainly with the thione group. The conjugation between free radicals of the nitrogen atom and π 
electrons of the aromatic ring represents an additional factor for increasing the stability of the 
radical structure. The probable mechanism for the reaction of compounds 4–6 with DPPH radical is 
presented in Scheme 2. 
Scheme 2. The probable mechanism for the reaction of compounds 4–6 with  
DPPH radical 
 
Heterocyclization to 1,2,4-triazole-3-thiones creates only the possibility to conjugate free 
radicals on the nitrogen atom N-2 with the thione group, which would explain the lower stability of 
this radical, probably responsible for a weaker antioxidant activity (Scheme 3). 
S-alkylation decreases almost entirely the possibilities of conjugation with thione group,  
causing the least stable radical structure and the weakest antioxidant activity, according to  
this interpretation. 
The compounds tested displayed a considerable lipophilic character, with estimated mean logP 
values of 4.65 ± 0.71 (ADMET Predictor, Simulation Plus Inc., Lancaster, CA, USA). Based on the 
preliminary evaluation of biorelevant molecular descriptors and physico-chemical properties, it 
appears that the evaluated compounds are typical, low solubility—high permeability entities. 
Therefore, their bioavailability will dependent on the nature of the administration pathways. For 
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oral route, the solubility in the hydrophilic gastro-intestinal fluids is probably the limiting step for 
absorption. The in-vivo distribution process may include binding and accumulation phenomenon in 
various organs, likely to be of interest for the antioxidant activity. Moreover, the high lipophilicity 
can limit the distribution to deeper skin layers or the systemic exposure, which is a considerable 
advantage for the safety profile. None of the compounds seems to present a high risk of low 
bioavailability, based on current mnemotic rules [47]. 
Scheme 3. The probable mechanism for the reaction of compounds 7–9 with DPPH radical. 
 
The lipophilicity, as estimate by logP values, was not directly correlated with the antioxidant 
activity (Supplementary data). Nevertheless, a rank order relationship seems apparent. The 
compounds showing higher scavenging activity towards DPPH (4–6) presented the lowest 
lipophilicity (except for triazole 7 which has lower antioxidant activity than 
hydrazinecarbothioamides 5 and 6 although it has lower lipophilicity than these derivatives). 
3. Experimental 
3.1. Chemistry 
All reactants and solvents were obtained commercially with the highest purity and were used 
without further purification. Melting points were determined on a Boetius apparatus and are 
uncorrected. The IR spectra were recorded in KBr using a Vertex 70 Bruker spectrometer. 
Elemental analyses were performed on a ECS-40-10-Costeh micro-dosimeter (and are within 
±0.4% of the theoretical values). The NMR spectra were recorded on a Varian Gemini 300 BB 
instrument operating at 300 MHz for a 1H and 75 MHz for 13C. Chemical shifts (δ, ppm) were 
assigned according to the internal standard signal of tetramethylsilane in DMSO-d6 (δ = 0 ppm). 
Coupling constants, J, are expressed in hertz (Hz). Mass spectra were recorded on 1200 L/MS/MS 
triple quadrupole (Varian, Palo Alto, CA, USA) spectrometer. In case of compounds 4–9, solutions 
of 2 μg/mL in methanol/ammonia (1/1, v/v) were directly injected into the electrospray interface 
(ESI), after a tenth dilution with methanol, at a flow rate of 20 μL/min. The instrument was 
operated in positive and negative ions mode. In case of compounds 10–15, methanolic solutions of 
0.1 μg/mL (with 0.1% ammonia) were directly infused into APCI (Atmospheric Pressure Chemical 
Ionization) source with a Prostar 240 SDM Pump (Varian). Parameters for APCI operation were set 
up as follows: air drying gas at 300 °C and 20 psi, nitrogen as nebulising gas at 40 psi, air as 
auxiliary gas at 20 psi, APCI torch at 300 °C, and corona discharge needle current at 10 μA. APCI 
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generated only positive ions. Protonated molecular ions were fragmented by collision with argon  
at 1.5 mTorr. 
3.1.1. General Procedure for the Preparation of 2-(4-(4-X-Phenylsulfonyl)benzoyl)-N-(2,4-
difluorophenyl)hydrazinecarbothioamides 4–6 
Appropriate acid hydrazide 1–3 (5 mmol) in absolute ethanol (25 mL) and 2,4-difluorophenyl 
isothiocyanate (5 mmol) was heated under reflux for 10 h. The precipitate formed was cooled, 
filtered, washed with cold ethanol, dried and recrystallized from ethanol. 
N-(2,4-Difluorophenyl)-2-(4-(phenylsulfonyl)benzoyl)hydrazinecarbothioamide 4. Yield: 
92.0%; m.p. 176–178 °C; IR (KBr, ν, cm−1): 3267, 3169, 3150 (NH), 3067, 3001 (aromatic C-H), 
1663 (C=O), 1539, 1510, 1483 (C=C), 1320, 1309, 1155 (SO2), 1258 (C=S), 1144 (C-F); 1H-NMR 
(DMSO-d6, * ppm): 10.89 (s, 1H; NH); 10.03 (s, 1H, NH); 9.61 (s, 1H, NH); 8.13 (d, 2H, J = 8.8 
Hz, aromatic protons); 8.09 (d, 2H, J = 8.8 Hz; aromatic protons); 7.99 (dd, 2H, J = 7.4, 1.4 Hz, 
aromatic protons); 7.70 (tt, 1H, J = 7.4, 1.4 Hz, aromatic proton); 7.63 (t, 2H, J = 7.4 Hz, aromatic 
protons); 7.29 (m, 2H, aromatic protons); 7.07 (wt, 1H, J = 8.4 Hz, aromatic proton); 13C-NMR 
(DMSO-d6, * ppm): 182.47 (C=S), 164.75 (C=O), 160.57 (dd, JC-F = 245.1; 11.2 Hz), 158.55 (dd, 
JC-F = 248.5; 13.7 Hz), 143.84, 140.64, 137.01, 134.12, 131.87 (d, JC-F = 9.5 Hz), 129.95, 129.40, 
127.57, 127.40, 123.81 (d, JC-F = 12.9 Hz), 111.07 (d, JC-F = 22.6 Hz), 104.28 (t, JC-F = 25.5 Hz); 
(ESI-MS) m/z: 448 [M + H]+, 319 (38) [C6H5SO2C6H4CONHNHCS]+, 277 (100, BP) 
[C6H5SO2C6H4CONHNH2 + H]+, 245 (19) [C6H5SO2C6H4CO]+; (ESI-MS) m/z: 446 [M − H]−, 426 
(2) [M − H-HF]−, 412 (11) [M − H-H2S]−, 275 (100, BP) [C6H5SO2C6H4CONHNH]−; Anal. calcd 
for C20H15F2N3O3S2 (447.48 g/mol): C, 53.68; H, 3.38; N, 9.39. Found: C, 53.61; H, 3.30;  
N, 9.28%. 
2-(4-(4-Chlorophenylsulfonyl)benzoyl)-N-(2,4-difluorophenyl)hydrazinecarbothioamide 5. Yield: 
90%; m.p. 170–172 °C; IR (KBr, ν, cm−1): 3290, 3160 (NH), 3090, 3010 (aromatic C-H),  
1680 (C=O), 1531, 1478 (C=C), 1319, 1294, 1156 (SO2), 1243 (C=S), 1145 (C-F), 761 (C-Cl);  
1H-NMR (DMSO-d6, * ppm): 10.90 (s, 1H, NH); 10.03 (s, 1H, NH); 9.61 (s, 1H, NH); 8.12 (d, 2H,  
J = 8.9 Hz, aromatic protons); 8.09 (d, 2H, J = 8.9 Hz, aromatic protons); 8.01 (d, 2H, J = 8.5 Hz, 
aromatic protons); 7.71 (d, 2H, J = 8.5 Hz, aromatic protons); 7.07 (wt, 1H, J = 8.4 Hz, aromatic 
protons); 7.29 (m, 2H, aromatic protons); 13C-NMR (DMSO-d6, * ppm): 182.47 (C=S),  
164.71 (C=O), 160.65 (dd, JC-F = 246.0; 11.3 Hz), 157.80 (dd, JC-F = 245.0; 13.7 Hz), 143.36, 
139.45, 138.98, 137.20, 131.82 (d, JC-F = 9.7 Hz), 130.11, 129.58, 129.47, 127.54,  
123.72 (d, JC-F = 19.9 Hz), 111.08 (d, JC-F = 21.8 Hz), 104.28 (t, JC-F = 25.5 Hz); (ESI-MS) m/z: 
482 [M + H]+, 484 [M + H]+, 353 (31) [35ClC6H4SO2C6H4CONHNHCS]+, 355 (58) 
[37ClC6H4SO2C6H4CONHNHCS]+, 311 (100, BP) [35ClC6H4SO2C6H4CONHNH2 + H]+, 313 (100, 
BP) [37ClC6H4SO2C6H4CONHNH2 + H]+, 279 (5) [35ClC6H4SO2C6H4CO]+, 281 (24) 
[37ClC6H4SO2C6H4CO]+; (ESI-MS) m/z: 480 [M − H]−, 482 [M − H]−, 446 (9) [35ClM-H-H2S]−, 
448 (9) [37ClM-H-H2S]−, 309 (100, BP) [35ClC6H4SO2C6H4CONHNH]−, 311 (100, BP) 
[37ClC6H4SO2C6H4CONHNH]−; Anal. calcd for C20H14ClF2N3O3S2 (481.92 g/mol): C, 49.84; H, 
2.93; N, 8.72. Found: C, 49.75; H, 2.87; N, 8.60%. 
2-(4-(4-Bromophenylsulfonyl)benzoyl)-N-(2,4-difluorophenyl)hydrazinecarbothioamide 6. Yield: 
88%; m.p. 175–177 °C; IR (KBr, ν, cm−1): 3319, 3280 (NH), 3088, 3044, 3010 (aromatic C-H), 
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1682 (C=O), 1573, 1536, 1481 (C=C), 1321, 1293, 1157 (SO2), 1245 (C=S), 1144 (C-F), 576 (C-Br); 
1H-NMR (DMSO-d6, * ppm): 10.90 (s, 1H, NH); 10.04 (s, 1H, NH); 9.62 (s, 1H, NH); 8.11 (d, 2H,  
J = 8.5 Hz, aromatic protons); 8.10 (d, 2H, J = 8.5 Hz, aromatic protons); 7.92 (d, 2H, J = 8.7 Hz; 
aromatic protons); 7.85 (d, 2H, J = 8.7 Hz, aromatic protons); 7.29 (m, 2H, aromatic protons);  
7.07 (wt, 1H, J = 8.8 Hz, aromatic proton); 13C-NMR (DMSO-d6, * ppm): 182.47 (C=S),  
164.71 (C=O), 160.65 (dd, JC-F = 243.0; 11.2 Hz), 157.40 (dd, JC-F = 243.0; 13.2 Hz), 143.33, 139.86, 
137.20, 133.05, 131.93 (d, JC-F = 9.6 Hz), 129.60, 129.46, 128.46, 127.54, 123.70,  
111.08 (d, JC-F = 20.9 Hz), 104.28 (t, JC-F = 25.2 Hz); (ESI-MS) m/z: 526 [M + H]+, 528 [M + H]+, 397 
(40) [79BrC6H4SO2C6H4CONHNHCS]+, 399 (33) [81BrC6H4SO2C6H4CONHNHCS]+, 355 (100, BP) 
[79BrC6H4SO2C6H4CONHNH2 + H]+, 357 (100, BP) [81BrC6H4SO2C6H4CONHNH2 + H]+, 323 (1) 
[79BrC6H4SO2C6H4CO]+, 325 (32) [81BrC6H4SO2C6H4CO]+, 172 (5) [2,4-diFC6H3NHCS]+, 130 (6) 
[2,4-diFC6H3NH2 + H]+; (ESI-MS) m/z: 524 [M − H]−, 526 [M − H]−, 504 (3) [M − H-HF]−,  
506 (4) [M − H-HF]−, 490 (7) [M − H-H2S]−, 492 (11) [M − H-H2S]−, 353 (100, BP) 
[79BrC6H4SO2C6H4CONHNH]−, 355 (100, BP) [81BrC6H4SO2C6H4CONHNH]−; Anal. calcd for 
C20H14BrF2N3O3S2 (526.37 g/mol): C, 45.64; H, 2.68; N, 7.98. Found: C, 45.58; H, 2.60; N, 7.88%. 
3.1.2. General Procedure for the Preparation of 5-(4-(4-X-Phenylsulfonyl)phenyl)-4-(2,4-
difluorophenyl)-2H-1,2,4-triazole-3(4H)-thiones 7–9 
The corresponding hydrazinecarbothioamide 4–6 (3 mmol) was refluxed in aqueous sodium 
hydroxide solution (8%, 45 mL) for 5 h. The filtrate obtained by filtration of reaction mixture was 
cooled and acidified to pH~5 with hydrochloric acid (1%). The precipitated obtained was filtered, 
washed with water, dried and recristallized from CHCl3/petroleum ether (1:2, v/v). 
4-(2,4-Difluorophenyl)-5-(4-(phenylsulfonyl)phenyl)-2H-1,2,4-triazole-3(4H)-thione 7 Yield: 
71%; m.p. 256–258 °C; IR (KBr, ν, cm−1): 3414 (NH), 3065, 3015 (aromatic C-H), 1614, 1580, 
1518, 1474 (C=N + C=C), 1338, 1290, 1160 (SO2), 1247 (C=S), 1143 (C-F); 1H-NMR (DMSO-d6, 
* ppm): 14.48 (s, 1H, NH); 8.00 (d, 2H, J = 8.6 Hz, aromatic protons); 7.95 (dd, 2H, J = 7.7, 1.5 
Hz, aromatic protons); 7.73 (td, 1H, J = 8.7, 6.1 Hz, aromatic proton); 7.70 (t, 1H, J = 7.7, 1.5 Hz, 
aromatic proton); 7.61 (t, 2H, J = 7.7 Hz, aromatic protons); 7.58 (d, 2H, J = 8.6 Hz, aromatic 
protons); 7.54 (ddd, 1H, J = 10.2, 8.9, 2.7 Hz, aromatic protons); 7.31 (dddd, 1H, J = 9.8, 6.1, 2.7, 1.5 
Hz, aromatic proton); 13C-NMR (DMSO-d6, * ppm): 169.52 (C3-triazolic ring),  
162.96 (dd, JC-F = 251.4; 11.4 Hz), 157.72 (dd, JC-F = 252.8; 13.5 Hz), 149.03 (C5-triazolic ring), 
142.85, 140.24, 134.17, 132.75 (d, JC-F = 10.6, Hz), 129.93, 129.86, 128.80, 128.03, 127.62,  
118.39 (d, JC-F = 12.7 Hz), 112.99 (d, JC-F = 22.9 Hz), 105.68 (t, JC-F = 23.8 Hz); (ESI-MS) m/z: 
430 [M + H]+; 356 (8) [M + H-SCNNH2]+; 289 (100, BP) [M + H-C6H5SO2]+; 172 (10.9) 
[F2C6H3NCS + H]+; 153 (62) [FC6H4NCS]+; (ESI-MS) m/z: 428 [M − H]−; 408 (15.4) [M − H-
HF]−; 388 (15.4) [M − H-2HF]−; 267 (7,3) [M − H-HF-C6H5SO2]−; 141 (100, BP) [C6H5SO2]−; 
Anal. calcd for C20H13F2N3O2S2 (429.46 g/mol): C, 55.93; H, 3.05; N, 9.78. Found: C, 55.83; H, 
2.98; N, 9.65%. 
5-(4-(4-Chlorophenylsulfonyl)phenyl)-4-(2,4-difluorophenyl)-2H-1,2,4-triazole-3(4H)-thione 8 
Yield: 73%; m.p. 245–247 °C; IR (KBr, ν, cm−1): 3278 (NH), 3091, 3053 (aromatic C-H), 1614, 
1580, 1518, 1468 (C=N + C=C), 1338, 1276, 1159 (SO2), 1248 (C=S), 1144 (C-F), 768 (C-Cl);  
1H-NMR (DMSO-d6, * ppm): 14.42 (s, 1H, NH); 8.01 (d, 2H, J = 8.5 Hz, aromatic protons); 7.96 
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(d, 2H, J = 8.8 Hz, aromatic proton); 7.73 (td, 1H, J = 8.8, 6.0 Hz, aromatic proton); 7.68 (d, 2H,  
J = 8.8 Hz, aromatic protons); 7.59 (d, 2H, J = 8.5 Hz, aromatic protons); 7.53 (ddd, 1H, J = 10.2, 
9.1, 2.7 Hz, aromatic protons); 7.31 (dddd, 1H, J = 9.8, 6.4, 2.7, 1.5 Hz, aromatic proton);  
13C-NMR (DMSO-d6, * ppm): 169.54 (C3-triazolic ring), 162.98 (dd, J = 250.8; 11.7 Hz),  
149.01 (C5-triazolic ring), 157.27 (dd, JC-F = 253.1, 13.1 Hz), 142.39, 139.36, 139.04,  
132.77 (d, JC-F = 10.5 Hz), 130.78, 130.11, 129.63, 128.86, 128.13, 118.40 (d, JC-F = 12.6 Hz),  
113.01 (d, JC-F = 22.6 Hz), 105.70 (t, JC-F = 23.5 Hz); (ESI-MS) m/z: 464 [M + H]+; m/z: 466 [M + H]+; 
289 (100, BP) [M + H-ClC6H4SO2]+; (ESI-MS) m/z: 462 [M − H]−; m/z: 464 [M − H]−; Anal. calcd 
for C20H12ClF2N3O2S2 (463.91 g/mol): C, 51.78; H, 2.61; N, 9.06. Found: C, 51.89; H, 2.47;  
N, 8.96%. 
5-(4-(4-Bromophenylsulfonyl)phenyl)-4-(2,4-difluorophenyl)-2H-1,2,4-triazole-3(4H)-thione 9 
Yield: 81%; m.p. 264–266 °C; IR (KBr, ν, cm−1): 3414 (NH), 3095, 3073, 3028 (aromatic C-H), 
1614, 1572, 1516, 1471 (C=N + C=C), 1330, 1272, 1169 (SO2), 1255 (C=S), 1145 (C-F),  
578 (C-Br); 1H-NMR (DMSO-d6, * ppm): 14.43 (s, 1H, NH); 8.00 (d, 2H, J = 8.5 Hz, aromatic 
protons); 7.88 (d, 2H, J = 8.8 Hz, aromatic protons); 7.83 (d, 2H, J = 8.8 Hz, aromatic protons);  
7.73 (td, 1H, J = 8.8, 6.1 Hz, aromatic protons); 7.59 (d, 2H, J = 8.5 Hz, aromatic protons);  
7.54 (ddd, 1H, J = 10.2, 9.0, 2.9 Hz, aromatic proton); 7.31 (dddd, 1H, J = 9.7, 6.5, 2.9, 1.4 Hz, 
aromatic proton); 13C-NMR (DMSO-d6, * ppm): 169.54 (C3-triazolic ring), 162.98 (dd, JC-F = 251.0, 
11.5 Hz), 149.01 (C5-triazolic ring), 157.50 (dd, JC-F = 254.0; 13.4 Hz), 142.35, 139.49, 133.06, 
132.78 (d, JC-F = 10.6, Hz), 130.08, 129.66, 128.88, 128.51, 128.14, 118.48 (d, JC-F = 12.6 Hz), 
113.03 (d, JC-F = 22.9 Hz), 105.66 (t, JC-F = 23.5 Hz); (ESI-MS) m/z: 508 [M + H]+; m/z:  
510 [M + H]+; 289 (100, BP) [M + H-BrC6H4SO2]+; 155 (24.8) [79BrC6H4]+; 157 (25.6) 
[81BrC6H4]+; 129 (63.2) [F2C6H3NH2]+; Anal. calcd for C20H12BrF2N3O2S2 (508.36 g/mol): C, 
47.25; H, 2.38; N, 8.27. Found: C, 47.13; H, 2.30; N, 8.13%. 
3.1.3. General Procedure for the Preparation of 2-(5-(4-(4-X-Phenylsulfonyl)phenyl)-4-(2,4-
difluorophenyl)-4H-1,2,4-triazol-3-ylthio)-1-(phenyl/4-fluorophenyl)ethanones 10–15  
To a solution of sodium ethoxide (23 mg of sodium in 10 mL of absolute ethanol) was added the 
corresponding triazole 7–9 (1 mmol). The reaction mixture was stirred at room temperature until a 
solution was obtained. To this solution was added the corresponding α-halogenated ketone  
(1 mmol) and stirring was continuated for 10 h. The reaction mixture was poured into ice water and 
the precipitate was filtered off, washed with water and recristallized from ethanol. 
2-(4-(2,4-Difluorophenyl)-5-(4-(phenylsulfonyl)phenyl)-4H-1,2,4-triazol-3-ylthio)-1-
phenylethanone 10 Yield: 70%; m.p. 176–178 °C; IR (KBr, ν, cm−1): 3070, 3038 (aromatic C-H), 
2965, 2922 (CH2), 1685 (C=O), 1614, 1598, 1515 (C=N + C=C), 1312, 1291, 1161 (SO2), 1146 
(C-F); 1H-NMR (DMSO-d6, * ppm): 8.03 (dd, 2H, J = 7.7, 1.3 Hz, aromatic protons); 8.00 (d, 2H, 
J = 8.6 Hz, aromatic protons); 7.97 (dd, 2H, J = 7.7, 1.4 Hz, aromatic proton); 7.87 (dt, 1H, J = 8.8, 
5.8 Hz, aromatic proton); 7.71 (m, 1H, aromatic proton); 7.65 (t, 2H, J = 7.7 Hz, aromatic proton); 
7.62 (d, 2H, J = 8.6 Hz, aromatic protons); 7.60 (m, 2H, aromatic protons); 7.56 (t, 2H, J = 7.7 Hz, 
aromatic protons); 7.40 (m, 1H, aromatic proton); 5.02 (s, 2H, S-CH2-); 13C-NMR (DMSO-d6,  
* ppm): 192.73 (C=O), 163.34 (dd, JC-F = 251.9; 11.7 Hz), 156.66 (dd, JC-F = 253.4; 13.8 Hz), 
153.11 (C3-triazolic ring), 153.05 (C5-triazolic ring), 142.27, 140.36, 135.14, 134.07, 133.82, 
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131.59 (d, JC-F = 10.9 Hz), 130.66, 129.87, 128.83, 128.41, 128.30, 128.04, 127.54,  
117.50 (d, JC-F = 12.0 Hz), 113.56 (d, JC-F = 25.2 Hz), 106.84 (t, JC-F = 23.2 Hz), 40.46 (S-CH2-); 
(APCI-MS) m/z: 548 [M + H]+; 514 (5.6) [M + H-H2S]+; 430 (15.3) [M + H-C6H5COCH]+; 398 
(98.8) [M + H-C6H5COCHS]+; 105 (88.8) [C6H5CO]+; 91 (100, BP) [tropylium]+; Anal. calcd for 
C28H19F2N3O3S2 (547.60 g/mol): C, 61.41; H, 3.50; N, 7.67. Found: C, 61.23; H, 3.29; N, 7.48%. 
2-(5-(4-(4-Chlorophenylsulfonyl)phenyl)-4-(2,4-difluorophenyl)-4H-1,2,4-triazol-3-ylthio)-
1-phenylethanone 11 Yield: 84%; m.p. 191–193 °C; IR (KBr, ν, cm−1): 3084, 3040 (aromatic  
C-H), 2959, 2921 (CH2), 1678 (C=O), 1612, 1598, 1580, 1516 (C=N) + C=C), 1328, 1283, 1161 
(SO2), 1146 (C-F), 767 (C-Cl); 1H-NMR (DMSO-d6, * ppm): 8.03 (dd, 2H, J = 7.7, 1.4 Hz, aromatic 
protons); 8.00 (d, 2H, J = 8.8 Hz, aromatic protons); 7.96 (d, 2H, J = 8.8 Hz, aromatic protons);  
7.70 (d, 2H, J = 8.8 Hz, aromatic proton); 7.65 (m, 1H, aromatic proton); 7.63 (d, 2H, J = 8.8 Hz, 
aromatic protons); 7.61 (dt, 1H, J = 8.8, 6.0 Hz, aromatic proton); 7.56 (t, 2H, J = 7.7 Hz, aromatic 
protons); 7.40 (ddd, 1H, J = 10.2, 9.1, 2.8 Hz, aromatic proton); 7.24 (m, 1H, aromatic proton); 
5.02 (s, 2H, S-CH2-); 13C-NMR (DMSO-d6, * ppm): 192.72 (C=O), 163.35 (dd, JC-F = 251.9, 11.7 Hz), 
156.57 (dd, JC-F = 253.4, 13.5 Hz), 153.09 (C3-triazolic ring), 153.06 (C5-triazolic ring), 141.80, 
139.22, 139.16, 135.14, 133.82, 131.59 (d, JC-F = 10.6 Hz), 130.86, 130.03, 129.55, 128.83, 128.41, 
128.34, 128.13, 117.55 (d, JC-F = 9.2 Hz), 113.57 (d, JC-F = 20.4 Hz), 106.84 (t, JC-F = 23.5 Hz), 
40.35 (S-CH2-); (APCI-MS) m/z: 582 [M + H]+; m/z: 584 [M + H]+; 476 (67.2) [M + H-
C6H5CHO]+; 478 (82.3) [M + H-C6H5CHO]+; 464 (28.5) [M + H-C6H5COCH]+; 466 (30.2) [M + H-
C6H5COCH]+; 444 (40.1) [M + H-C6H5COCH-HF]+; 446 (41.2) [M + H-C6H5COCH-HF]+; 432 (28.4) 
[M + H-C6H5COCHS]+; 434 (84.1) [M + H-C6H5COCHS]+; 305 (5.7) [M + H-C6H5COCHS-
F2C6H3NH2]+; 307 (7.2) [M + H-C6H5COCHS-F2C6H3NH2]+; 159 (23.4) [35ClC6H4SO]+; 161 
(10.3) [37ClC6H4SO]+; 105 (100, BP) [C6H5CO]+; 91 (95.2) [tropylium]+; Anal. calcd for 
C28H18ClF2N3O3S2 (582.04 g/mol): C, 57.78; H, 3.12; N, 7.22. Found: C, 57.67; H, 3.04;  
N, 7.07%. 
2-(5-(4-(4-Bromophenylsulfonyl)phenyl)-4-(2,4-difluorophenyl)-4H-1,2,4-triazol-3-ylthio)-
1-phenylethanone 12 Yield: 82%; m.p. 213–215 °C; IR (KBr, ν, cm−1): 3083, 3050 (aromatic  
C-H), 2960, 2922 (CH2), 1703 (C=O), 1615, 1598, 1572, 1517 (C=N + C=C), 1321, 1282, 1160 
(SO2), 1142 (C-F), 580 (C-Br); 1H-NMR (DMSO-d6, * ppm): 8.03 (dd, 2H, J = 7.7, 1.4 Hz, 
aromatic protons); 8.00 (d, 2H, J = 8.8 Hz, aromatic protons); 7.89 (d, 2H, J = 8.8 Hz, aromatic 
protons); 7.87 (dt, 1H, J = 8.8, 5.8 Hz, aromatic proton); 7.83 (d, 2H, J = 8.8 Hz, aromatic protons); 
7.69 (tt, 1H, J = 7.7, 1.4 Hz, aromatic proton); 7.65 (m, 1H, aromatic proton); 7.63 (d, 2H, J = 8.8 Hz, 
aromatic protons); 7.56 (t, 2H, J = 7.7 Hz, aromatic protons); 7.39 (m, 1H, aromatic proton); 5.02 (s, 
2H, S-CH2-); 13C-NMR (DMSO-d6, * ppm): 192.71 (C=O), 163.26 (dd, JC-F = 251.7, 11.7 Hz), 156.65 
(dd, JC-F = 253.4, 13.5 Hz), 153.11 (C3-triazolic ring), 153.06 (C5-triazolic ring), 141.75, 139.57, 
135.13, 133.80, 132.98, 131.59 (d, JC-F = 10.6 Hz), 130.86, 129.56, 129.30, 128.83, 128.41, 128.35, 
128.13, 117.51 (d, JC-F = 12.9 Hz), 113.59 (d, JC-F = 22.3 Hz), 106.85 (t, JC-F = 23.5 Hz),  
40.46 (S-CH2-); (APCI-MS) m/z: 626 [M + H]+; m/z: 628 [M + H]+; 476 (31.9) [M + H-
C6H5COCHS]+; 478 (26.3) [M + H-C6H5COCHS]+; 434 (12.7) [M + H-C6H5COCH2SNCNH]+;  
436 (33.2) [M + H-C6H5COCH2SNCNH]+; 159 (23.4) [79BrC6H4SO]+; 161 (10.3) [81BrC6H4SO]+; 
105(100, BP) [C6H5CO]+; 91 (95.2) [tropylium]+; Anal. calcd for C28H18BrF2N3O3S2 (626.49 g/mol): 




fluorophe-nyl)ethanone 13 Yield: 72%; m.p. 152–154 °C; IR (KBr, ν, cm−1): 3071, 3035 (aromatic 
C-H), 2960, 2922 (CH2), 1682 (C=O), 1614, 1598, 1515 (C=N + C=C), 1313, 1281, 1161 (SO2),  
1145 (C-F); 1H-NMR (DMSO-d6, * ppm): 8.11 (dd, 2H, J = 8.8, 5.5 Hz, aromatic protons), 7.99 (d, 
2H, J = 8.5 Hz, aromatic protons); 7.95 (dd, 2H, J = 7.4, 1.5 Hz, aromatic protons); 7.86 (dt, 1H,  
J = 8.8, 5.8 Hz, aromatic proton); 7.71 (tt, 1H, J = 7.4, 1.5 Hz, aromatic protons); 7.65 (m, 1H 
aromatic proton); 7.63 (d, 2H, J = 8.5 Hz, aromatic protons); 7.62 (t, 2H, J = 7.4 Hz, aromatic 
protons); 7.39 (t, 2H, J = 8.8 Hz, aromatic protons); 7.30 (m, 1H, aromatic proton); 4.99 (s, 2H,  
S-CH2-); 13C-NMR (DMSO-d6, * ppm): 191.45 (C=O), 165.36 (d, JC-F = 252.8 Hz), 163.04 (dd,  
JC-F = 250.5; 11.7 Hz), 156.76 (dd, JC-F = 250.9; 13.2 Hz), 153.16 (C3-triazolic ring), 153.01  
(C5-triazolic ring), 142.32, 140.38, 134.10, 131.95 (d, JC-F = 2.7 Hz), 131.60 (d, JC-F = 9.6 Hz), 
131.55 (d, JC-F = 9.4 Hz), 130.67, 129.90, 128.34, 128.07, 127.57, 117.48 (d, JC-F = 9.8 Hz), 115.92 
(d, JC-F = 21.9 Hz), 113.60 (d, JC-F = 22.7 Hz), 106.16 (dd, JC-F = 235.0, 27.3 Hz), 40.34 (S-CH2-); 
(APCI-MS) m/z: 566 [M + H]+; 428 (18.9) [M + H-FC6H4COCH3]+; 398 (35.3) [M + H-
FC6H4COCHS]+; 356 (16.8) [M + H-FC6H4COCH2SNCNH]+; 137 (26.5) [FC6H4COCH2]+; 123 
(82.2) [FC6H4CO]+; 109 (100, BP) [FC6H4N]+; Anal. calcd for C28H18F3N3O3S2 (565.59 g/mol): C, 
59.46; H, 3.21; N, 7.43. Found: C, 59.23; H, 3.07; N, 7.26%. 
2-(5-(4-(4-Chlorophenylsulfonyl)phenyl)-4-(2,4-difluorophenyl)-4H-1,2,4-triazol-3-ylthio)-1-
(4-fluorophenyl)ethanone 14 Yield: 85%; m.p. 226–228 °C; IR (KBr, ν, cm−1): 3068, 3030 (aromatic 
C-H), 2965, 2920 (CH2), 1682 (C=O), 1615, 1599, 1514 (C=N + C=C), 1322, 1282, 1158 (SO2); 
1145 (C-F), 768 (C-Cl); 1H-NMR (DMSO-d6, * ppm): 8.11 (dd, 2H, J = 8.8, 5.5 Hz, aromatic 
protons), 8.00 (d, 2H, J = 8.5 Hz, aromatic protons), 7.97 (d, 2H, J = 8.7 Hz, aromatic protons);  
7.86 (dt, 1H, J = 8.8, 5.8 Hz, aromatic proton); 7.69 (d, 2H, J = 8.7 Hz, aromatic protons); 7.65 (m, 1H, 
aromatic proton), 7.63 (d, 2H, J = 8.5 Hz, aromatic protons); 7.39 (t, 2H, J = 8.8 Hz, aromatic 
protons); 7.38 (m, 1H, aromatic proton); 4.99 (s, 2H, S-CH2-); 13C-NMR (DMSO-d6, * ppm): 191.42 
(C=O), 165.34 (d, JC-F = 252.5 Hz), 163.18 (dd, JC-F = 250.4, 11.8 Hz), 156.72 (dd, JC-F = 250.8, 
13.1 Hz), 153.09 (C3-triazolic ring), 153.04 (C5-triazolic ring), 141.81, 139.22, 139.16, 131.94 (d, 
JC-F = 2.7 Hz), 131.59 (d, JC-F = 9.7 Hz), 131.52 (d, JC-F = 9.7 Hz), 130.85, 130.05, 128.55, 128.36, 
128.14, 117.64 (d, JC-F = 9.8 Hz), 115.89 (d, JC-F = 21.9 Hz), 113.57 (d, JC-F = 19.6 Hz), 106.20 (dd, 
JC-F = 235.0, 27.3 Hz), 40.33 (S-CH2-); (APCI-MS) m/z: 600 [M + H]+; m/z: 602 [M + H]+; 123 
(52.2) [FC6H4CO]+; 123 (48.3) [FC6H4CO]+; 109 (100, BP) [FC6H4N]+; Anal. calcd for 
C28H17ClF3N3O3S2 (600.03 g/mol): C, 56.05; H, 2.86; N, 7.00. Found: C, 55.97; H, 2.76; N, 6.87%. 
2-(5-(4-(4-Bromophenylsulfonyl)phenyl)-4-(2,4-difluorophenyl)-4H-1,2,4-triazol-3-ylthio)-
1-(4-fluorophenyl)ethanone 15 Yield: 80%; m.p. 228–230 °C; IR (KBr, ν, cm−1): 3080, 3067 
(aromatic C-H), 2963, 2920 (CH2), 1682 (C=O), 1612, 1598, 1574, 1515 (C=N + C=C), 1323, 
1282, 1159 (SO2), 1144 (C-F), 578 (C-Br); 1H-NMR (DMSO-d6, * ppm): 8.11 (dd, 2H, J = 8.9, 5.4 
Hz, aromatic protons), 8.00 (d, 2H, J = 8.5 Hz, aromatic protons), 7.89 (d, 2H, J = 8.8 Hz, aromatic 
protons); 7.86 (dt, 1H, J = 8.8, 5.8 Hz, aromatic proton); 7.64 (d, 2H, J = 8.5 Hz, aromatic protons); 
7.83 (d, 2H, J = 8.8 Hz, aromatic protons); 7.60 (m, 1H, aromatic proton); 7.38 (t, 2H, J = 8.9 Hz, 
aromatic protons); 7.30 (m, 1H, aromatic proton); 4.99 (s, 2H, S-CH2-); 13C-NMR (DMSO-d6, * 
ppm): 191.42 (C=O), 165.34 (d, JC-F = 252.5 Hz), 163.36 (dd, JC-F = 250.2, 11.8 Hz), 156.64 (dd, 
JC-F = 252.0, 13.4 Hz), 153.10 (C3-triazolic ring), 153.05 (C5-triazolic ring), 141.78, 139.58, 
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132.99, 131.92 (d, JC-F = 2.6 Hz), 131.59 (d, JC-F = 9.6 Hz), 131.52 (d, JC-F = 2.7 Hz), 130.86, 
129.57, 129.15, 128.36, 128.13, 117.52 (d, JC-F = 9.4 Hz), 115.89 (d, JC-F = 21.9 Hz), 113.57 (d,  
JC-F = 20.0 Hz), 106.20 (dd, JC-F = 235.0, 27.3 Hz), 40.33 (S-CH2-); (APCI-MS) m/z: 644 [M + H]+; 
m/z: 646 [M + H]+; 476 (31.9) [M + H-FC6H4COCHS]+; 478 (26.3) [M + H-FC6H4COCHS]+; 137 
(26.5) [FC6H4COCH2]+; 137 (37.2) [FC6H4COCH2]+; 123 (100, BP) [FC6H4CO]+; 109 (43.1) 
[FC6H4N]+; 109 (74.2) [FC6H4N]+; Anal. calcd for C28H17BrF3N3O3S2 (644.48 g/mol): C, 52.18; H, 
2.66; N, 6.52. Found: C, 52.07; H, 2.57; N, 6.36%. 
3.2. Antioxidant Activity 
The antioxidant activity of all the synthesized compounds was evaluated by DPPH  
method [14,38] with some modifications and compared with standards (AA, BHA and BHT). 
The 400 μM solution of DPPH (2 mL) in ethanol was added to tested sample solutions (2 mL) 
of different concentrations (50, 100, 125, 200, 250 and 500 μM) in acetone - ethanol 4:96 v/v. The 
samples were kept in the dark at room temperature. After 30 min the absorbance values were 
measured at 517 nm and were converted into the percentage antioxidant activity (%) using the 
formula [48]: 
% = {1 − [(Asample − Asampleblank)/Acontrol] × 100 (3) 
where Acontrol was the absorbance of DPPH solution without sample, Asample was the absorbance  
of sample solution with DPPH, Asampleblank was the absorbance of the sample solutions without  
the DPPH. 
All analyses were undertaken on three replicates and the results averaged. The IC50 values were 
calculated by linear regression plots, where the abscissa represented the concentration of tested 
compound solution (50, 100, 125, 200, 250 and 500 μM) and the ordinate represented the average 
percent of antioxidant activity from three separate tests. The absorbance was measured on a 
SPECORD 40 Analytik Jena spectrophotometer. 
4. Conclusions 
New hydrazinecarbothioamides, 1,2,4-triazole-3-thiones and S-alkylated 1,2,4-triazole 
derivatives were synthesized and characterized by IR, 1H-NMR, 13C-NMR and mass spectral data. 
All the synthesized compounds 4–15 have been investigated for their antioxidant activity. Some  
of these compounds were found to be significant scavengers of free radicals. The 
hydrazinecarbothioamides 4–6 showed excellent antioxidant activity, more than the standards. 1,2,4-
Triazole-3-thiones showed good antioxidant activity, but lower than the key intermediates from 
hydrazinecarbothioamide class, unlike S-alkylates derivatives that had very low action. These 
results obtained by preliminary screening of antioxidant activity suggested that the molecules from 
hydrazinecarbothioamide class might serve as interesting compounds for the development of new 
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3. In Vitro/In Vivo Pharmacological Models 
 
Perineural Dexmedetomidine Attenuates Inflammation in  
Rat Sciatic Nerve via the NF-κB Pathway 
Yan Huang, Yi Lu, Lei Zhang, Jia Yan, Jue Jiang and Hong Jiang 
Abstract: Recent studies have shown that dexmedetomidine exerts an anti-inflammatory effect by 
reducing serum levels of inflammatory factors, however, the up-stream mechanism is still 
unknown. The transcription factor NF-κB enters the nucleus and promotes the transcription of its 
target genes, including those encoding the pro-inflammatory cytokines IL-6 and TNF-α. In this 
study, we established a rat model that simulates a clinical surgical procedure to investigate the anti-
inflammatory effect of perineural administration of dexmedetomidine and the underlying 
mechanism. Dexmedetomidine reduced the sciatic nerve levels of IL-6 and TNF-α at both the 
mRNA and protein level. Dexmedetomidine also inhibited the translocation of activated NF-κB to 
the nucleus and the binding activity of NF-κB. The anti-inflammatory effect is confirmed to be 
dose-dependent. Finally, pyrrolidine dithiocarbamate also reduced the levels of IL-6 and TNF-α 
and the activation of NF-κB. In conclusion, dexmedetomidine inhibited the nuclear translocation 
and binding activity of activated NF-κB, thus reducing inflammatory cytokines. 
Reprinted from Int. J. Mol. Sci. Cite as: Huang, Y.; Lu, Y.; Zhang, L.; Yan, J.; Jiang, J.; Jiang, H. 
Perineural Dexmedetomidine Attenuates Inflammation in Rat Sciatic Nerve via the NF-κB 
Pathway. Int. J. Mol. Sci. 2014, 15, 4049-4059. 
1. Introduction 
Dexmedetomidine, a highly selective α2-adrenoceptor agonist, is widely used in clinical 
anesthesia, intensive care unit (ICU) management and pain treatment as a sedative agent [1–3]. 
Recent studies found that dexmedetomidine has an anti-inflammatory effect through reducing the 
serum levels of inflammatory factors, which may extend its application in the clinic [4–6]. 
However, the upstream mechanism by which dexmedetomidine reduces inflammatory factors 
levels remains largely unknown. 
The NF-κB family contains five members, RelA (also known as p65), RelB, c-Rel, p105/p50, 
and p100/p52, which make homo- and heterodimers. NF-κB is a transcription factor that recognizes 
a common consensus DNA sequence and regulates a large number of target genes, especially genes 
involved in inflammation, injury and stress [7]. Interleukin (IL)-6 and tumor necrosis factor (TNF)-α 
are cytokines that play essential roles in inflammation. Studies have shown that NF-κB exists as a 
p65 and p50 heterodimer in the cytoplasm. Activated NF-κB enters the nucleus, where it can 
promote the transcription of its target genes, including the pro-inflammatory cytokines IL-6 and 
TNF-α. Pyrrolidine dithiocarbamate (PDTC), a selective NF-κB inhibitor and antioxidant, can 
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inhibit the NF-κB pathway by blocking the entrance of activated NF-κB to the nucleus and the 
binding of NF-κB to the promoter regions of IL-6 and TNF-α [8–10]. 
Peripheral nerve block is a common regional anesthetic technique performed everyday throughout 
the world as an alternative to general anesthesia and is performed for postoperative analgesia [11–13]. 
Dexmedetomidine is usually injected in the peripheral nerve to prolong the duration of the peripheral 
nerve block as an adjuvant for local anesthetics [14–17]. In this study, perineural administration of 
dexmedetomidine not only blocked NF-κB translocation to the nucleus and NF-κB binding activity 
but also reduced IL-6 and TNF-α levels in rats. PDTC, an NF-κB inhibitor, can also reduce IL-6 and 
TNF-α levels by inhibiting NF-κB activity following perineural administration. In summary, 
dexmedetomidine can inhibit inflammation through the NF-κB pathway. 
2. Results 
2.1. Perineural High Doses of Dexmedetomidine Reduced the IL-6 and TNF-α Levels in the  
Sciatic Nerve 
Rats were anesthetized and injected perineurally with either a high dose of dexmedetomidine  
(DH, 20 μg/kg) or normal saline (C). Sciatic nerves were harvested 30, 60 and 90 min after 
injection. Real-time PCR revealed that dexmedetomidine reduced the mRNA levels of both IL-6 
and TNF-α at all of the examined time points (Figure 1A,B). The protein levels of both IL-6 and 
TNF-α were significantly decreased after perineural injection of dexmedetomidine at all time 
points, as shown by both ELISA (Figure 1C,D) and Western blotting (Figure 1E–G). These results 
suggested that perineural injection of 20 μg/kg dexmedetomidine reduces the sciatic nerve levels of 
IL-6 and TNF-α at the level of both mRNA and protein. 
2.2. Perineural Dexmedetomidine Decreased NF-κB Translocation to the Nucleus and 
Transcriptional Binding Activity 
As previous studies have shown [16–19], activated NF-κB should translocate to the nucleus and 
bind to the promoter region of multiple genes, including cytokine genes, inducing the expression of 
cytokine mRNA and protein. Thus, we assessed the effects of perineural administration of 
dexmedetomidine on the nuclear levels of NF-κB in sciatic nerve tissue. The sciatic nerve tissues 
were subjected to Western blot analysis for the total NF-κB protein level, and the nuclear extracts 
were assessed for the nuclear NF-κB protein level. The Western blot of NF-κB showed that 
perineural administration of dexmedetomidine decreased the nuclear level of NF-κB compared 
with the control group at 30, 60 and 90 min (Figure 2A,B), but no significant differences were 
detected in the total level of NF-κB (Figure 2A,C). These findings indicate that perineural 
administration of dexmedetomidine may prevent NF-κB translocation into the nucleus in the sciatic 
nerve and thus may decrease the subsequent expression of inflammatory factors. 
We then used EMSA to test the effect of dexmedetomidine on the transcriptional binding 
activity of NF-κB in nuclear extracts prepared from sciatic nerve tissues [20]. In Figure 2D, lane 1 
is a negative control (double-distilled water), lane 2 represents the control group with perineural 
administration of normal saline, lane 3 represents the DH group with perineural 20.0 μg/kg 
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dexmedetomidine, and lane 6 shows the cold probe. We can clearly see that perineural 
administration of 20.0 μg/kg dexmedetomidine reduced the transcriptional binding activity of  
NF-κB compared with the control group. 
 
Figure 1. Perineural high doses (20 μg/kg) of dexmedetomidine reduced IL-6 and 
TNF-α levels in the sciatic nerve. (A,B) RT-PCR showed that high doses of 
dexmedetomidine reduced the IL-6 and TNF-α mRNA levels in the sciatic nerve; (C,D) 
ELISA showed that high dose of dexmedetomidine reduced the IL-6 and TNF-α protein 
levels in the sciatic nerve; (E–G) Western blotting showed that high dose of 




Figure 2. Perineural administration of 20 μg/kg dexmedetomidine decreased the 
translocation to the nucleus and transcriptional binding activity of NF-κB. (A) Western 
blot showed that 20 μg/kg dexmedetomidine decreased NF-κB translocation into the 
nucleus; (B) Dexmedetomidine (20 μg/kg) decreased the nuclear NF-κB protein level;  
(C) Dexmedetomidine (20 μg/kg) did not alter the total NF-κB protein level; (D) EMSA 
showed that 20 μg/kg dexmedetomidine decreased the transcriptional binding activity 
of NF-κB (lane 3); PDTC also decreased NF-κB transcriptional binding activity  
(lane 5). NF-κB, nuclear factor-kappa B; PDTC, pyrrolidine dithiocarbamate. 
 
2.3. Only High Dose Dexmedetomidine Attenuated the NF-κB Translocation to the Nucleus 
Based on the above conclusions, we further tested whether different doses of dexmedetomidine 
have the same effect on attenuating the translocation of NF-κB. We further tested the DM and DL 
groups, which received a middle dose and a low dose of dexmedetomidine (10.0 and 5 μg/kg, 
respectively). Western blotting was used to analyze the total NF-κB protein level and the nuclear 
NF-κB protein level. The results showed that only the high dose of dexmedetomidine (DH) 
attenuated NF-κB translocation to the nucleus, whereas the total and nuclear protein levels of  
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NF-κB were unchanged in the DM and DL groups (Figure 3A–C). These results suggested that 
perineurally administered dexmedetomidine attenuates the inflammatory response above a certain 
threshold dose. 
Figure 3. Only the high dose (20 μg/kg) of dexmedetomidine attenuated NF-κB 
translocation to the nucleus. (A) Western blotting showed that only the high dose of 
dexmedetomidine decreased NF-κB translocation to the nucleus; (B) The high dose of 
dexmedetomidine decreased the nuclear NF-κB protein level, but the middle doses  
(10 μg/kg) and low doses (5 μg/kg) did not have an effect; (C) Dexmedetomidine did 
not alter the total NF-κB protein level in any of the groups. NF-κB, nuclear  
factor-kappa B. 
 
2.4. The Inflammation of the Sciatic Nerve Could Be Attenuated by PDTC via the NF-κB Pathway 
PDTC, a selective NF-κB inhibitor and antioxidant, inhibits the NF-κB pathway by blocking the 
translocation of activated NF-κB to the nucleus [10]. Here, we assessed whether inflammation of 
the sciatic nerve could be attenuated by PDTC via the NF-κB pathway in a manner similar to that 
of dexmedetomidine. Western blot analysis confirmed that both the translocation of NF-κB to 
nucleus and the downstream expression of IL-6 and TNF-α protein were down-regulated by  
PDTC (Figure 4A–F). RT-PCR (Figure 4G,H) and ELISA (Figure 4I,J) further confirmed the 
down-regulation of the inflammatory factors IL-6 and TNF-α. EMSA showed that the 
transcriptional binding activity of NF-κB was reduced by PDTC compared with the control group 
(Figure 2D, lane 5). These changes were in accordance with our results with dexmedetomidine and 
suggest that perineural administration of dexmedetomidine has a similar, or at least partly similar, 
anti-inflammatory effect as PDTC, via the NF-κB signalling pathway. 
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Figure 4. PDTC attenuated the inflammation of the sciatic nerve via the NF-κB 
pathway. (A,C,D) Western blotting showed that PDTC decreased NF-κB translocation 
into the nucleus; (B,E,F) Western blotting showed that PDTC reduced the IL-6 and 
TNF-α protein levels in the sciatic nerve; (G,H) RT-PCR showed that PDTC reduced 
the IL-6 and TNF-α mRNA levels in the sciatic nerve; (I,J) ELISA showed that PDTC 
reduced the IL-6 and TNF-α protein level in the sciatic nerve.  
 
3. Discussion 
Dexmedetomidine is widely used in clinical anesthesia as a most closely ideal sedative because 
of its analgesia and sedation effects without respiratory depression [18–21]. Recent studies  
found that dexmedetomidine has an anti-inflammatory effect by reducing the serum levels of 
inflammatory cytokines, however, the upstream mechanism is still unknown [4–6]. In the present 
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study, we used a surgical procedure and perineural injection to induce a background inflammatory 
response (e.g., increasing IL-6 and TNF-α levels) in sciatic nerve tissue to investigate the  
anti-inflammatory effect of perineural administration of dexmedetomidine and the underlying 
mechanism. We found that, in the sciatic nerves of rats, perineural administration of 20 μg/kg 
dexmedetomidine reduced the level of IL-6 and TNF-α, prevented NF-κB translocation to the 
nucleus and decreased the transcriptional binding activity of NF-κB. These results, in accordance 
with perineural administration of the NF-κB pathway inhibitor PDTC, suggested that dexmedetomidine 
reduced inflammation by inhibiting the NF-κB signaling pathway. 
Dexmedetomidine is usually intravenously administered during clinical anesthesia as a sedative 
agent. Currently, perineural administration of dexmedetomidine is widely used in peripheral nerve 
anesthesia as an adjuvant for local anesthetics to prolong the duration of a peripheral nerve  
block [3,17,22]. Here, we incised the skin and subcutaneous fat of rats to simulate the clinical 
surgical procedure. We then exposed the sciatic nerve and injected dexmedetomidine to investigate 
the inflammatory cytokine levels in the sciatic nerve tissue. As a result, we confirmed that 
perineural administration of dexmedetomidine inhibited the translocation of activated NF-κB to the 
nucleus and the binding activity of activated NF-κB, thus reducing the level of inflammatory 
cytokines. The anti-inflammatory effect of perineural administration of dexmedetomidine may 
extend its application in clinical anesthesia. 
In a previous study [16], dexmedetomidine added to ropivacaine was shown to increase the 
duration of the sensory block in a dose-dependent fashion, varying from 0.5 to 20 μg/kg, in rats. 
Interestingly, in our study, NF-κB translocation to the nucleus was not inhibited in the DM and DL 
groups (which received dexmedetomidine doses of 10.0 and 5 μg/kg, respectively), but the DH 
group (20 μg/kg) did show an effect. The results indicate that a dose threshold needs to be crossed 
before an anti-inflammatory effect occurs. Furthermore, Brummett’s study confirmed that a high 
dose of dexmedetomidine, up to 40 μg/kg, was considered safe for rats because the histopathological 
evaluation showed that nerve axon and myelin were not altered by dexmedetomidine and there was 
no neurotoxicity or side-effects for the rats [15]. Similarly, there was no neurotoxicity or  
side-effect noted at 24 h or 14 days in our study. Based on these results, a high perineural dose of 
dexmedetomidine may be recommended for routine use as an adjuvant for local anesthetics owing 
to its anti-inflammatory and analgesia-prolonging effect. 
4. Experimental Section 
All of the investigators followed the Shanghai Ninth People’s Hospital Animal Study 
Guidelines, and the study was approved by the Shanghai Ninth People’s Hospital Committee for 
the Use and Care of Animals (Shanghai, China). 
For blinding, all of the drug solutions were prepared in syringes without labels by an 
investigator other than the one performing the perineural sciatic injection. The investigators who 
harvested the tissue and performed the later Western blotting, real-time PCR, ELISA and EMSA 





Forty-eight Sprague-Dawley rats, weighing 180 to 220 g, were obtained from Shanghai Ninth 
People’s Hospital SPF Animal Center (Shanghai, China). The rats were housed at 23 °C with a 
light-dark cycle and allowed free access to food and water. 
4.2. Study Groups 
The Sprague-Dawley rats were divided into four groups for further intervention. Control group 
rats received only normal saline. The DH group received a high dose of dexmedetomidine  
(20.0 μg/kg), whereas the DM and DL groups received a middle dose and a low dose of 
dexmedetomidine (10.0 and 5 μg/kg, respectively). 
4.3. Drug Preparation 
An investigator who was not involved in either the perineural sciatic injection or the subsequent 
analysis prepared the drugs. Dexmedetomidine and normal saline were used to make final drug 
solutions. Each rat received a total volume of 0.2 mL for a perineural sciatic injection. The doses of 
dexmedetomidine were based on the individual rats’ body weight for 20.0 μg/kg (DH), 10.0 μg/kg 
(DM), 5.0 μg/kg (DL) respectively. 
4.4. Animal Model and Perineural Injection 
To investigate the anti-inflammatory effect of perineural administration of dexmedetomidine, 
we established a rat model of surgical-induced inflammation. Rats were anesthetized and 
maintained using 3.0% isoflurane. As previously described [15], an incision was made over the 
thigh, and the muscle and fascia were dissected to expose the sciatic nerve directly below the clear 
fascial covering. A total volume of 0.2 mL was injected into the perineural space below the clear 
fascia covering the nerve using a 30-gauge needle and tuberculin syringe. After injection, the 
muscle and skin of the thigh were sutured, and the isoflurane was discontinued. The animal model 
of surgical-induced inflammation was confirmed by increasing the inflammatory factor, such as  
IL-6 and TNF-α, after the surgical procedure. 
4.5. Nuclear Extraction and Western Blotting 
A nuclear extraction kit (Ab110168, Abcam, Cambridge, MA, USA) was used for the preparation 
of nuclear extracts from sciatic nerve tissues. For Western blotting, frozen rat sciatic nerve tissues 
were homogenized and the lysates were prepared in ice-cold lysis buffer. Nuclear extracts or total 
protein were collected and normalized for equal amounts of total protein measured by the 
bicinchoninic acid (BCA) method. Seventy micrograms of protein from each sample was separated 
on a sodium dodecyl sulfate polyacrylamide gel and transferred to PVDF membranes. The 
membranes were blocked with 5% nonfat milk and incubated overnight with primary anti-NF-κB 
antibody (1:1000; sc-109, Santa Cruz, CA, USA), anti-IL-6 antibody (1:1000; ab6672, Abcam, 
Cambridge, MA, USA), anti-TNF-α antibody (1:1000; AB1837P; Millipore, Billerica, MA, USA), 
and anti-β-actin (1:5000, Sigma, St. Louis, MO, USA) at 4 °C, followed by incubation with the 
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suitable HRP-conjugated secondary antibody for 4 h. β-actin protein was immunodetected as the 
internal standard. 
4.6. Real-Time PCR and ELISA 
The levels of IL-6 and TNF-α mRNA were detected by real-time polymerase chain  
reaction (RT-PCR) in the sciatic nerve tissues as described [11]. RNA was isolated following the 
protocol of the RNeasy Mini Kit (Qiagen, Inc., Valencia, CA, USA), while concentration 
determined using a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, Wilmington,  
DE, USA). Primers of Rat IL-6 is 5ꞌ -GACTGATGTTGTTGACAGCCACTGC-3ꞌ ; 5ꞌ -
TAGCCACTCCTTCTGTGACTCTAACT-3ꞌ , TNF-α 5ꞌ -TTC TGT CTA CTG AAC TTC GGG 
GTG ATG GGT CC-3ꞌ ; 5ꞌ -GTA TGA GAT AGC AAA TCG GCT GAC GGT GTG GG-3ꞌ  and 
Rat GAPDH 5ꞌ -CCT TCA TTG ACC TCA ACT AC-3ꞌ  ;5ꞌ -GGA AGG CCA TGC CAG TGA 
GC-3ꞌ . RT-PCR was carried out using the QuantiTect SYBR Green RT-PCR Kit (Qiagen). The 
quantity of the target mRNA was normalised against a house-keeping gene, GAPDH, which served 
as an internal control. 
The levels of IL-6 and TNF-α proteins in the sciatic nerve were measured using ELISA kits 
according to the manufacturer’s instructions. ELISA kits for TNF-α and IL-6 were obtained from R 
& D Systems (Minneapolis, MN, USA). 
4.7. Electrophoretic-Mobility Shift Assay (EMSA) 
An electrophoretic-mobility shift assay (EMSA) kit (GS-0030, Signosis, Santa Clara, CA, USA) 
was used to assess the transcriptional binding activity of NF-κB as a previous study described [11]. 
The nuclear extract (5 mg) was incubated with 1 μL poly d(I-C), 2.0 μL 5× Binding Buffer and 1.0 
μL of transcription factor (TF) probe in a 0.5 mL microcentrifuge tube at 20–23 °C for 30 min in a 
PCR machine. We added 1.0 μL of cold TF probe into this reaction for the cold probe control. 
Samples were then loaded onto a 6.5% non-denaturing polyacrylamide gel and separated at 100 V, 
and the proteins were transferred to a membrane at 60 V for 1 h at 4 °C. The membrane was 
imaged using a chemiluminescence imaging system (Bio-Rad, Hercules, CA, USA). 
4.8. Statistics 
Data are shown as mean (SD). Student’s t-test, one-way and two-way analysis of variance 
(ANOVA) were used to compare the differences among the experimental groups and the control 
group. p < 0.05 (*) was considered statistically significant. The significance testing was two-tailed. 
Normality tests showed that the data were normally distributed, and the GraphPad software Prism 5 
(GraphPad Software Inc., San Diego, CA, USA) was used to analyze the data. 
5. Conclusions 
In conclusion, we have established a rat model that simulates a clinical surgical procedure to 
investigate the anti-inflammatory effect of perineural administration of dexmedetomidine and the 
underlying mechanism. Dexmedetomidine (20 μg/kg) inhibited the translocation of activated  
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NF-κB to the nucleus and its binding activity, thus reducing inflammatory cytokine levels. These 
results suggest a potential application for dexmedetomidine as an adjuvant in peripheral nerve 
anesthesia. Future research should focus on finding clinical evidence to support the use of 
dexmedetomidine as an anti-inflammatory adjuvant for perineural administration in humans. 
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Inhibitory Effects of Palmultang on Inflammatory Mediator 
Production Related to Suppression of NF-κB and MAPK 
Pathways and Induction of HO-1 Expression in Macrophages 
You-Chang Oh, Yun Hee Jeong, Won-Kyung Cho, Min-Jung Gu and Jin Yeul Ma 
Abstract: Palmultang (PM) is an herbal decoction that has been used to treat anorexia, anemia, 
general prostration, and weakness due to chronic illness since medieval times in Korea, China, and 
Japan. The present study focused on the inhibitory effects of PM on the production of 
inflammatory factors and on the activation of mechanisms in murine macrophages. PM suppressed 
the expression of nitric oxide (NO), inflammatory cytokines and inflammatory proteins by 
inhibiting nuclear factor (NF)-κB and mitogen-activated protein kinase (MAPK) signaling pathways 
and by inducing heme oxygenase (HO)-1 expression. Collectively, our results explain the anti-
inflammatory effect and inhibitory mechanism of PM in macrophages stimulated with 
lipopolysaccharide (LPS). 
Reprinted from Int. J. Mol. Sci. Cite as: Oh, Y.-C.; Jeong, Y.H.; Cho, W.-K.; Gu, M.-J.; Ma, J.Y. 
Inhibitory Effects of Palmultang on Inflammatory Mediator Production Related to Suppression of 
NF-κB and MAPK Pathways and Induction of HO-1 Expression in Macrophages. Int. J. Mol. Sci. 
2014, 15, 8443-8457. 
1. Introduction 
Palmultang (PM) is a traditional herbal medication that has been used since medieval times in  
East Asia. Currently, PM is usually prescribed as an herbal medicine for the treatment of various 
symptoms associated with body weakness. Previous studies demonstrated that PM was an effective 
treatment for endometriosis [1]. In addition, a recent study revealed that PM has a beneficial effect 
on reproductive function in female mice [2]. However, the effects of PM on inflammation and 
inflammatory mechanisms still remain unknown. 
Macrophages play a key role in the regulation of inflammatory and immune responses [3,4]. 
Activation of macrophages is induced by LPS stimulation, and activated macrophages secrete 
inflammatory factors, such as NO, prostaglandin (PG)E2 and inflammatory cytokines [5,6]. NO and 
PGE2 are synthesized by inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, 
respectively, and the expression of iNOS is closely related to the induction of HO-1. HO-1 is a  
stress-inducible protein that catalyzes the oxidative degradation of heme; two other heme 
oxygenase isoforms, HO-2 and HO-3, have also been identified [7]. Enhancing the production of 
HO-1 reduces the expression of iNOS and the level of free radicals [8]. 
NF-κB plays an important role in the expression of inflammatory genes. When unstimulated,  
NF-κB is present in the cytoplasm attached to IκBα; NF-κB is released through degradation of IκBα 
when induced by LPS [9]. Activated NF-κB can be transferred from the cytoplasm to the nucleus, 
where it binds to promoters and induces the expression of various inflammatory genes [10,11]. 
MAPK signaling pathways play an important role in transmitting inflammatory signals [12] and 
comprise extracellular signal-regulated kinase (ERK), p38, and c-Jun NH2-terminal kinase (JNK) 
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pathways. MAPKs are activated by phosphorylation and induce activation of the NF-κB pathway 
and expression of the iNOS gene. 
In the present study, we evaluated the suppressive effect of PM on inflammation induced by 
LPS in RAW 264.7 macrophages. Further, we researched whether the effects of PM on NF-κB and 
MAPK signaling pathways and on induction of HO-1 explain the anti-inflammatory mechanism  
of PM. 
2. Results and Discussion 
2.1. PM Did not Show Cytotoxicity and Had Inhibitory Activity against NO and Inflammatory 
Cytokine Production in Macrophages 
In the present study, we demonstrated anti-inflammatory activity of PM in murine macrophages 
stimulated with LPS. First, we investigated the cytotoxicity of PM in RAW 264.7 macrophages at 
concentrations of 10–1000 μg/mL. As shown in Figure 1A, PM did not show cytotoxicity at 
concentrations up to 1000 μg/mL, indicating that it is not toxic to macrophages. Based on this 
result, we did experiments using up to 1000 μg/mL concentrations of PM. 
The overproduction of NO is associated with various inflammatory diseases [13,14], so we 
preferentially investigated the inhibitory effect of PM on the production of NO induced by  
LPS stimulation. As shown in Figure 1B, the positive control, dexamethasone, which is known to 
be an anti-inflammatory drug, exerted a strong inhibitory effect on NO production. In addition, we 
discovered that PM dose-dependently repressed NO secretion to a statistically significant degree. 
Notably, PM inhibited NO production by more than 70% at a concentration of 500 μg/mL. 
Further, we examined the inhibitory effect of PM on the production of the pro-inflammatory 
cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1β. Cytokine expression was 
analyzed by ELISA and RT-PCR. PM did not inhibit TNF-α secretion (Figure 1C) and did not 
suppress the expression of TNF-α mRNA (Figure 1F). By contrast, PM effectively inhibited both 
IL-6 production and mRNA expression in a dose-dependent fashion (Figure 1D,F). Likewise, PM 
strongly suppressed IL-1β cytokine and mRNA production at high concentrations (Figure 1E,F). 
2.2. PM Strongly Suppresses Expression of iNOS but not COX-2 in LPS-Stimulated Macrophages 
and Induces HO-1 Induction 
Because COX-2 and iNOS are enzymes for PGE2 and NO synthesis, respectively, we further 
investigated the inhibitory effects of PM on COX-2 and iNOS expression using Western blots and  
RT-PCR. As shown in Figure 2A, PM did not affect expression of COX-2 at the protein or mRNA 
level. By contrast, PM showed a strong dose-dependent inhibitory effect on iNOS expression that 
was statistically significant (Figure 2B). The inhibitory effect of PM on iNOS production was 
believed to contribute to the suppression of NO secretion. These results indicate that PM has 




Figure 1. (A) The cytotoxicity of PM in RAW 264.7 cells. And the suppressive  
effect of PM on (B) NO production and (C–F) TNF-α, IL-6 and IL-1β expression 
induced by LPS stimulation in macrophages. RAW 264.7 cells were pretreated with 
PM for 30 min before incubation with LPS for (A–E) 24 h or (F) 6 h. (A) Cytotoxicity 
was determined using CCK; (B) The culture supernatant was analyzed for nitrite 
production; (C–E) Production of cytokines was measured by ELISA and (F) mRNA 
levels were analyzed by RT-PCR. RNA values were quantitated using the i-MAX™ 
Gel Image Analysis System (Core Bio, Seoul, Korea). As a control, cells were 
incubated with vehicle alone. * p < 0.01 and ** p < 0.001 were calculated via 
comparisons with the LPS-stimulation value. 
 
Increased HO-1 induction has a direct effect on iNOS expression [8]. Therefore, we investigated 
whether the inhibitory effect of PM on iNOS expression was associated with increased HO-1 
production. We assessed HO-1 induction in PM-treated macrophages using Western blot and RT-
PCR analyses. First, we measured the induction of HO-1 at 3–24 h after treatment with 1000 
μg/mL PM. Protein and mRNA levels of HO-1 were highest at 6 and 3 h, respectively (Figure 2C). 
Based on the results in Figure 2C, we investigated HO-1 protein and mRNA expression at the 
indicated time points. PM induced HO-1 expression at the protein and mRNA levels at concentrations 
of 500 and 1000 μg/mL in a dose-dependent manner (Figure 2D). These results suggest that 




Figure 2. Inhibitory effect of PM on expression of (A) COX-2 and (B) iNOS. And the 
inductive effect of PM on (C,D) HO-1 in macrophages. Cells were treated with (A,B) 
LPS alone or LPS plus PM for 24 h and (C,D) with PM alone for the indicated time 
periods. Protein levels were determined by Western blot analysis, as described in the 
Materials and Methods, and quantitated using the Davinch-chemi™ CAS-400SM 
Chemiluminescence Imaging System (Core Bio, Seoul, Korea). Expression of mRNA 
was analyzed by RT-PCR. * p < 0.01 and ** p < 0.001 were calculated via comparisons 
with the (A,B) LPS-stimulation value or (D) vehicle alone. 
 
2.3. PM Inhibited NF-κB Pathway Activation via Blockade of IκBα Degradation in Macrophages 
upon LPS Stimulation 
We demonstrated a repressive effect of PM on secretion of the inflammatory cytokine IL-6.  
NF-κB is a key transcriptional factor associated with the cellular response to stimuli, such as  
LPS [15–17] and with the production of NO, PGE2, inflammatory cytokines, and iNOS [18–20]. To 
investigate whether the inhibitory effect of PM on the expression of inflammatory mediators is 
associated with activity of the NF-κB pathway, we measured the effect of PM on NF-κB activation 
by analyzing translocation of p65 to the nucleus and the phosphorylation of IκBα. Western blot 
analysis showed that PM significantly repressed translocation of p65 to the nucleus at a 
concentration of 100 μg/mL or greater (Figure 3A). In addition, the phosphorylation level of IκBα 
was depressed dose-dependently after PM treatment (Figure 3B). Thus, PM inhibited the nuclear 
transcription of p65 by dose-dependently inhibiting IκBα degradation induced by LPS stimulation. 
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These findings are consistent with previous studies showing that an NF-κB response drives the 
expression of the iNOS and IL-6 genes [21–23]. 
Figure 3. Inhibitory effects of PM on (A) translocation of NF-κB to the nucleus and  
(B) phosphorylation of IκBα. Cells were treated with LPS alone or with LPS and  
PM for 30 min (IκBα) or 1 h (NF-κB). Proteins in the cytosol or nucleus were  
analyzed by Western blotting. **p < 0.001 were calculated via comparisons with the  
LPS-stimulation value. 
 
2.4. PM Suppressed LPS-Induced Phosphorylation of MAPKs in RAW 264.7 Cells 
Because MAPKs activated by phosphorylation upon LPS stimulation are related to iNOS 
expression and NF-κB pathway activation in macrophages [24], we examined the inhibitory effect 
of PM on the phosphorylation of MAPKs. We assessed the phosphorylation levels of MAPKs, 
including ERK 1/2, p38 and JNK. When RAW 264.7 cells were stimulated with LPS after 
pretreatment with PM, the levels of phosphorylated ERK and JNK MAPK were significantly decreased 
with no change in non-phosphorylated MAPK levels (Figure 4A,C). By contrast, PM showed only a 
slight inhibitory effect on p38 phosphorylation (Figure 4B). These results indicate that the 
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inhibitory effect of PM on the phosphorylation of MAPKs is directly related to inhibition of NF-κB 
activation and reduced production of inflammatory factors in RAW 264.7 cells. 
Figure 4. Inhibitory effect of PM on the phosphorylation of (A) ERK; (B) p38 and  
(C) JNK MAPK in macrophages. RAW 264.7 cells were treated with PM for 30 min 
and then incubated with LPS for 30 min. Cell lysates were analyzed by Western 
blotting using specific antibodies. ** p < 0.001 were calculated via comparisons with 
the LPS-stimulation value. 
 
2.5. HPLC Analysis and Previous Reports on the Main Constituents of PM 
HPLC-diode array detector (DAD) analysis conditions were successfully established for the 
separation of peaks in PM extracts. The retention times of eight peaks were as follows:  
5-hydroxymethylfurfural (5-HMF), 10.30 min; paeoniflorin, 27.22 min; albiflorin, 30.28 min; ferulic 
acid, 35.20 min; nodakenin, 36.76 min; decursinol, 43.86 min; glycyrrhizin, 48.69 min; and 
decursin, 60.93 min. Figure 5 shows chromatograms of the reference components and of a 60% 
methanol extract of PM, with detection of eluents at 205 nm (for decursinol), 250 nm (for 5-HMF, 
albiflorin, ferulic acid, nodakenin, glycyrrhizin, and decursin), 330 nm (for paeoniflorin), with 
ultraviolet rays (UV) wavelengths selected according to the results of Figure 6. These compounds were 
identified by comparing the retention time and DAD spectra with those of authentic standard 
compounds. Peak purity checking and identification were conducted using a 190–400 nm UV scan 




Figure 5. HPLC chromatograms of (A) a standard mixture and (B) PM at 250 nm.  
1, 5-HMF, 10.30 min; 2, paeoniflorin, 27.22 min; 3, albiflorin, 30.28 min; 4, ferulic 
acid, 35.20 min; 5, nodakenin, 36.76 min; 6, decursinol, 43.86 min; 7, glycyrrhizin, 
48.69 min; and 8, decursin, 60.93 min. 
 
Figure 6. Chemical structures and HPLC DAD spectra of the main constituents of PM. 
 
Calibration curves were obtained using standard solutions containing 1.25–10,000 μg/mL for  
5-HMF, ferulic acid, nodakenin, decursinol, glycyrrhizin, and decursin, 20–20,000 μg/mL for 
peaoniflorin and albiflorin as marker components. Calibration curve showed good linearity  
(r2 > 0.9990). The limits of detection (LOD) and limits of quantification (LOQ) were 0.16–0.50 μg/mL 
for 5-HMF, 0.22–0.68 μg/mL for ferulic acid, 0.13–0.40 μg/mL for nodakenin, 0.10–0.29 μg/mL 
for decursinol, 0.63–0.19 μg/mL for glycyrrhizin and 0.45–0.12 μg/mL for decursin, 48.17–16.05 
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μg/mL for peaoniflorin, 3.30–10.00 μg/mL for albiflorin (Table 1). The amounts of compounds  
1–8 (5-HMF, peaoniflorin, albiflorin, ferulic acid, nodakenin, decursinol, glycyrrhizin, and decursin, 
respectively) were 11.09, 2.59, 2.30, 3.36, 8.23, 5.11, 0.36, and 1.17 mg/g, respectively. The 
analytical results for each component identified are summarized in Table 2. 
Table 1. Linearity, correlation coefficient, limits of detection (LOD), and limits of 
quantification (LOQ) of the marker compound (n = 3). 
Compound 

















5-HMF 1.25–10,000 y = 403917x − 87212 0.9993 0.16 0.50 
Ferulic acid 1.25–10,000 y = 273782x + 89791 0.9998 0.23 0.68 
Nodakenin 1.25–10,000 y = 239585x − 25958 1.0000 0.13 0.40 
Decursinol 1.25–10,000 y = 598246x + 235041 0.9996 0.10 0.29 
Glycyrrhizin  1.25–10,000 y = 43887x + 38994 0.9991 0.63 0.19 
Decursin 1.25–20,000 y = 116410x + 1188529 1.0000 0.45 0.12 
Peaoniflorin  20–20,000 y = 1871.8x + 16715 0.9990 16.05 48.17 
Albiflorin  20–20,000 y = 8026.8x + 6805.9 0.9993 3.33 10.00 
a y = peak area (mAU) of the components, x = concentration (μg·mL−1) of the components;  
b LOD = 3× signal-to-noise (S/S) ratio; c LOQ = 10× signal-to-noise (S/S) ratio. 
Table 2. Content of the eight marker compounds of Palmultang (n = 3). 
Compound 
Content (mg/g) 
Mean SD RSD (%) 
5-HMF 11.09 0.35 3.11 
Ferulic acid 2.59 0.00 0.15 
Nodakenin 2.30 0.00 0.02 
Decursinol 3.36 0.02 0.72 
Glycyrrhizin 8.23 0.01 0.13 
Decursin 5.11 0.00 0.01 
Peaoniflorin 0.36 0.00 0.34 
Albiflorin 1.17 0.03 2.41 
A previous study reported that 5-HMF prevents TNF-α-induced monocytic cell adhesion to 
human umbilical vein endothelial cells (HUVECs) by suppression of vascular cell adhesion molecule-1 
expression, reactive oxygen species generation and NF-κB activation [25]. Additionally, it was 
demonstrated that paeoniflorin suppresses TNF-α-induced chemokine production in human dermal 
microvascular endothelial cells by blocking NF-κB and ERK pathways [26]. Another recent study 
demonstrated that nodakenin exerts a suppressive effect on LPS-induced inflammatory responses in 
macrophages by inhibiting TNF receptor-associated factor 6 and NF-κB pathways, and it protects 
mice from lethal endotoxin shock [27]. A further recent study showed that glycyrrhizin inhibits NO 
and PGE2 production in a bimodal fashion [28]. Another study demonstrated that decursin inhibits 
induction of inflammatory mediators by blocking NF-κB activation in macrophages [29]. These 
facts suggest that the anti-inflammatory activity of PM might be related to active components of 




3. Experimental Section 
3.1. Materials and Reagents 
Products related to cell culture (RPMI 1640, fetal bovine serum (FBS) and antibiotics) were 
purchased from Lonza (Basel, Switzerland). LPS and bovine serum albumin (BSA) were obtained 
from Sigma (St. Louis, MO, USA). The Cell-Counting Kit (CCK) was obtained from Dojindo 
Molecular Technologies, Inc. (Kumamoto, Japan). Various primary and secondary antibodies for 
Western blot analysis were purchased from Cell Signaling Technology, Inc. (Boston, MA, USA). 
Enzyme-linked immunosorbent assay (ELISA) antibody sets for cytokine detection were obtained 
from eBioscience (San Diego, CA, USA). An RNA extraction kit was purchased from iNtRON 
(Sungnam, Korea). DNA synthesizing kits and oligonucleotide primers were obtained from 
Bioneer (Daejeon, Korea). 5-(Hydroxy-methyl)furfural (5-HMF) and ferulic acid were purchased 
from Sigma (St. Louis, MO, USA). Paeoniflorin and glycyrrhizin were purchased from Tokyo 
Chemical Industry Co., Ltd. (Tokyo, Japan). Decursinol was purchased from Elcom Science 
(Seoul, Korea), nodakenin from Chem Faces (Wuhan, China), albiflorin from Wako (Osaka, 
Japan), and decursin from the Ministry of Food and Drug Safety (Osong, Korea). The purity of all 
representative standards was confirmed by high-performance liquid chromatography (HPLC) to be 
higher than 97%. HPLC grade solutions, acetonitrile and trifluoroacetic acid were purchased from 
J. T. Baker Inc. (Philipsburg, NJ, USA). Distilled water (DW) was filtered through a 0.45 μm 
membrane filter from ADVANTEC (Tokyo, Japan) before analysis. 
3.2. Preparation of PM Extract 
PM is composed of eight medicinal herbs listed in Table 3. All herbs were purchased from 
Yeongcheon Herbal Market (Yeongcheon, Korea). All voucher specimens were deposited in an 
herbal tank, placed in 19,200 mL of DW and then extracted by heating for 3 h at 115 °C and under 
high pressure (Gyeongseo Extractor Cosmos-600, Inchon, Korea). After extraction, the solution 
was filtered using standard testing sieves (150 μm) (Retsch, Haan, Germany), freeze-dried and kept 
in desiccators at 4 °C before use. The acquisition was 591 g and the yield was 30.8%. The freeze-
dried extract powder was then dissolved in DW, centrifuged at 14,000 rpm for 10 min and 
supernatant was filtered (pore size, 0.2 μm) and kept at 4 °C prior to use. 
Table 3. Herbal components and amount of Palmultang (PM) decoction. 
Herbs Amount of Herbs (g) 
Ginseng Radix 240 
Atractylodes Rhizome White 240 
Poria 240 
Glycyrrhizae Radix et Rhizoma 240 
Angelica Gigas Root 240 
Prepared Rehmannia Root 240 
Peony Root 240 
Cinidium Rhizome 240 
Total weight 1920 
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3.3. Cell Culture and Drug Treatment 
RAW 264.7 cells were obtained from the Korea Cell Line Bank (Seoul, Korea) and grown in 
complete RPMI 1640 medium. The cells were incubated in a humidified 5% CO2 atmosphere at  
37 °C. To stimulate the cells, the medium was replaced with fresh RPMI 1640 medium, and LPS 
(200 ng/mL) was added in the presence or absence of various concentrations of PM (10, 100, 500, 
and 1000 μg/mL) for the indicated time periods. 
3.4. Cell Viability Assay 
PM was added to the cells, which were incubated for 24 h at 37 °C in 5% CO2. CCK solutions 
were added to each well, and the cells were incubated for an additional 1 h. The optical density was 
then read at 450 nm using an ELISA reader (Infinite M200, Tecan, Männedorf, Switzerland). 
3.5. Determination of NO, TNF-α, IL-6 and IL-1β Cytokine Production 
The cells were pretreated with PM and stimulated with LPS for 24 h. NO production was 
analyzed by measuring nitrite using Griess reagent (1% sulfanilamide, 0.1% 
naphthylethylenediamine dihydrochloride, 2.5% phosphoric acid) according to a previous  
study [30]. Secretion of the inflammatory cytokines TNF-α, IL-6 and IL-1β was analyzed using a 
mouse ELISA antibody set (eBioscience, San Diego, CA, USA). The inhibitory effects of PM were 
determined at 570 and 450 nm for NO and cytokines, respectively, using an ELISA reader. 
3.6. Preparation of Whole-Cell, Cytosolic and Nuclear Fractions and Western Blot Analysis 
The expression of various proteins was analyzed by Western blot analysis according to standard 
procedures. Cells were stimulated with LPS with or without PM for the indicated time periods at 37 °C. 
After incubation, the cells were harvested and resuspended in radio immunoprecipitation assay 
(RIPA) lysis buffer (Millipore, Bedford, MA, USA) containing protease and phosphatase inhibitor 
cocktail (Roche, Basel, Switzerland) to obtain whole-cell lysates. Cytosolic and nuclear fractions 
were isolated using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, 
Rockford, IL, USA) according to the procedure described by the manufacturer. After cell debris 
was removed by centrifugation, the concentration of protein was determined by Bradford’s method, 
and equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). The proteins were transferred onto a nitrocellulose membrane 
(Millipore, Bedford, MA, USA) and blocked with 3% BSA in Tris-buffered saline containing 0.1% 
Tween 20 (TBS-T). The membrane was then incubated with each primary antibody at 4 °C 
overnight, followed by incubation with HRP-conjugated secondary antibodies. The specific proteins 
were detected using SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific, 
Rockford, IL, USA). 
3.7. RNA Extraction and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated using an easy-BLUE™ RNA extraction kit (iNtRON, Daejeon, Korea) 
according to the procedure described by the manufacturer. cDNA was synthesized using 
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AccuPower® CycleScript RT PreMix (Bioneer, Daejeon, Korea). The sequences of specific primers 
used for amplification by polymerase chain reaction are shown in Table 4. The following PCR 
conditions were applied for TNF-α, IL-6, IL-1β, COX-2, iNOS, HO-1, and β-actin: 35 cycles of 
denaturation at 94 °C for 30 s, annealing at the temperature indicated in Table 4 for 30 s, and extension 
at 72 °C for 30 s [30–34]. 
Table 4. Primer sequences and annealing temperatures used for RT-PCR analysis. 





























F, forward; R, reverse. 
3.8. Preparation of Standard Solutions and Samples 
An aqua 60% methanol standard stock solution containing compounds 5-HMF, ferulic acid, 
nodakenin, glycyrrhizin, decursinol, peaoniflorin, albiflorin, and decursin (each 1 mg/mL) were 
prepared and stored below −4 °C. Working standard solutions were prepared by serial dilution of 
stock solution with aqua 60% methanol. All calibration curves were obtains from assessement of 
peak areas of standards in the concentration ranges. A sample of 10 mg PM extract was prepared in 
1 mL DW, extracted by ultra-sonication, and filtered through a 0.2 μm syringe membrane filter 
from Whatman Ltd. (Maidstone, UK) before injection into the HPLC system for analysis. Sample 
solutions were stored at −4 °C in a refrigerator before analysis. 
3.9. General Experimental Procedures 
Analytical HPLC data were obtained using an L-2130 pump, L-2200 auto-sampler, L-2300 
column oven and L-2455 UV/VIS DAD. The output signal of the detector was recorded using 
EZChrom Elite software for the HPLC system (Hitachi, Tokyo, Japan). The OptimaPak C18 





3.10. Analytical Chromatographic Conditions 
The mobile phase consisted of water containing (A) 0.1% trifluoroacetic acid and (B) 
acetonitrile with gradient elution at a flow rate of 1.0 mL/min. The sample injection volume was  
20 μL, and the flow rate of the mobile phase was 1.0 mL/min (Table 5). The column temperature 
was maintained at 40 °C, and the wavelengths of the UV detector were set at 205, 250, and 330 nm. 






(Containing 0.1% TFA) 
Acetonitrile 
0 5 95 
5 5 95 
15 15 85 
25 15 85 
50 65 35 
60 65 35 
Flow rate 1.0 mL/min 
Inject volume 20 μL 
Column OptimaPak C18 (4.6 × 250 mm, 5 μm, RS tech Co., Daejeon, Korea) 
Column temperature 40 °C 
UV wavelength 205, 250 and 330 nm 
3.11. Statistical Analysis 
The results are expressed as mean ± SE values. Statistical significance for each treated group 
compared with the negative control was determined using the Student’s t test. Each experiment  
was repeated at least three times to yield comparable results. p values of <0.01 and <0.001 were 
considered significant. 
4. Conclusions 
In conclusion, PM shows significant inhibitory effects on the secretion of NO and expression of  
IL-6, IL-1β and iNOS in LPS-stimulated RAW 264.7 cells. These effects are due to inhibition of  
NF-κB activation through suppression of IκBα degradation and blockade of MAPK 
phosphorylation. Furthermore, the induction of HO-1 by PM inhibits inflammatory factor 
production. These results show that PM could be developed as a new anti-inflammatory agent 
derived from natural products. 
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Colonization and Infection of the Skin by S. aureus:  
Immune System Evasion and the Response to Cationic  
Antimicrobial Peptides 
Sunhyo Ryu, Peter I. Song, Chang Ho Seo, Hyeonsook Cheong and Yoonkyung Park 
Abstract: Staphylococcus aureus (S. aureus) is a widespread cutaneous pathogen responsible for 
the great majority of bacterial skin infections in humans. The incidence of skin infections by S. 
aureus reflects in part the competition between host cutaneous immune defenses and S. aureus 
virulence factors. As part of the innate immune system in the skin, cationic antimicrobial peptides 
(CAMPs) such as the β-defensins and cathelicidin contribute to host cutaneous defense, which 
prevents harmful microorganisms, like S. aureus, from crossing epithelial barriers. Conversely, S. 
aureus utilizes evasive mechanisms against host defenses to promote its colonization and infection 
of the skin. In this review, we focus on host-pathogen interactions during colonization and 
infection of the skin by S. aureus and methicillin-resistant Staphylococcus aureus (MRSA). We 
will discuss the peptides (defensins, cathelicidins, RNase7, dermcidin) and other mediators (toll-
like receptor, IL-1 and IL-17) that comprise the host defense against S. aureus skin infection, as 
well as the various mechanisms by which S. aureus evades host defenses. It is anticipated that 
greater understanding of these mechanisms will enable development of more sustainable 
antimicrobial compounds and new therapeutic approaches to the treatment of S. aureus skin 
infection and colonization. 
Reprinted from Int. J. Mol. Sci. Cite as: Ryu, S.; Song, P.I.; Seo, C.H.; Cheong, H.; Park, Y. 
Colonization and Infection of the Skin by S. aureus: Immune System Evasion and the Response to 
Cationic Antimicrobial Peptides. Int. J. Mol. Sci. 2014, 15, 8753-8772. 
1. Introduction 
Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that can live as a commensal 
organism on the skin and in the nose and throat. Approximately 30% of healthy people are 
asymptomatically colonized by S. aureus, which permanently colonizes the anterior nares in 10%–20% 
of the population and intermittently colonizes 30%–50%; the rest of the population never becomes 
colonized [1,2]. Importantly, this colonization is a known risk factor for infection [3–7], and  
S. aureus causes a range of infections, from minor skin infections to abscesses, endocarditis and 
sepsis. S. aureus is also a major cause of food poising induced by heat resistant enterotoxin A and 
is a leading cause of nosocomial infections [2], as colonized healthcare workers can transmit the 
pathogen to immunosuppressed patients. In addition, several cases of community-acquired 
methicillin-resistant S. aureus (CA-MRSA) infections have been recently reported [8–10]. Notably, 
these reports describe severe and even lethal infections by highly virulent strains of S. aureus in 
immunocompetent individuals. 
S. aureus is exposed to a large arsenal of highly efficient antimicrobial host factors during skin 
colonization and infection. However, a growing number of dedicated resistance mechanisms  
now contribute to the ability of S. aureus to evade host cutaneous defenses and survive during  
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colonization [11,12]. Furthermore, Glaser et al. recently reported that S. aureus small colony 
variants (SCVs) are less susceptible to the bactericidal activity of different human skin-derived 
AMP, which are associated with a higher resistance to the killing activity of human stratum 
corneum [13]. Both host cutaneous defense mechanisms and S. aureus virulence factors appear to 
be the focus of actively ongoing co-evolution, leading to major variations between different host 
species and bacterial strains, respectively [14,15]. Understanding how ones immune system 
combats the evasion strategies of S. aureus could be useful for the development of novel and more 
sustainable antimicrobial agents that are not subject to the evolution of microbial resistance. 
While bacterial resistance to most available antibiotics is increasing and our knowledge about 
the arsenal of host cutaneous defense strategies is growing, it is becoming increasingly attractive to 
consider endogenous antimicrobial peptides (AMPs) as sources for more sustainable antimicrobial 
agents. Of the variety of host defense molecules expressed by organisms, cationic AMPs (CAMPs) 
have proven to be particularly promising for future development as new antimicrobials. This 
review focuses on the role of host CAMPs in staphylococcal skin infections, and on the 
mechanisms underlying S. aureus resistance to CAMPs. 
2. Host-Pathogen Interactions during S. aureus Skin Colonization and Infection 
The epidermis is composed of proliferating basal and differentiated suprabasal keratinocytes, 
within which sweat glands, sebaceous glands and hair follicles are sparsely distributed. Langerhans 
cells in the epidermis as well as dendritic cells, macrophages, mast cells, T and B cells, plasma 
cells and natural killer cells in the dermis participate in immune responses within the skin. As 
mentioned, approximately 30% of healthy individuals are colonized by S. aureus [16] through a 
process that reflects the competition between host factors and commensal organisms that resist 
colonization and S. aureus virulence factors that facilitate colonization and, possibly, subsequent 
infection [17]. Among the constitutive properties of skin that help to prevent colonization and infection 
by S. aureus are its low temperature and acidic pH [18,19]. For instance, an epidermal structural 
component, filaggrin, is broken down during epidermal differentiation into urocanic acid and 
pyrrolidone carboxylic acid [20]. These acidic breakdown products then not only contribute to the 
low pH of the skin surface but also inhibit the growth of S. aureus and the expression of at least 
two factors involved in S. aureus colonization, clumping factor B (ClfB) and fibronectin binding 
protein A (FnbpA) [20]. In addition, commensal organisms such as S. epidermidis, P. acnes and the 
Malassezia species are normally present on the skin surface occupying microbial niches and thus 
preventing colonization and invasion by S. aureus and other pathogens [18,19]. Skin commensals 
have also been shown to directly inhibit S. aureus colonization of skin and nasal mucosa. For 
example, S. epidermidis secretes a serine protease, Esp, which inhibits S. aureus colonization by 
destroying its biofilms [21]. S. epidermidis also produces phenol-soluble modulins (PSMγ and PSMδ), 
which have direct antimicrobial activity against S. aureus [22] and activate toll-like receptor 2 (TLR2) 
on keratinocytes, leading to production of CAMPs (e.g., human β-defensin 2 [hBD2], hBD3 and 
RNase 7), which amplify the immune response and promote killing of S. aureus [23,24]. CAMPs 
such as hBD2, hBD3, LL-37 (cathelicidin) and RNase 7, which are produced by keratinocytes in 
the skin and corneal layer, have bacteriostatic or bactericidal activity against S. aureus [25–28], as 
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evidenced by the observation that S. aureus colonization is increased in skin lesions caused by 
atopic dermatitis due to reductions in the levels of β-defensins and cathelicidin [29]. 
To promote colonization of human nasal mucosa and skin, S. aureus expresses various factors 
that facilitate skin surface binding and survival. To bind to host surface components such as 
fibrinogen, fibronectin and cytokeratins, which are derived from epidermal keratinocytes or nasal 
epithelium, S. aureus utilizes microbial surface components recognizing adhesive matrix  
molecules (MSCRAMMs), which include fibronectin-binding protein A (Fnbp A) and Fnbp B, 
fibrinogen-binding proteins (ClfA and ClfB), iron-regulated surface determinant A (IsdA) and 
wall teichoic acid [30–33]. S. aureus-mediated fibronectin and fibrinogen binding is also enhanced 
by elevated levels of Th2 cytokines. For example, interleukin (IL)-4 is elevated in the skin lesions 
of atopic dermatitis patients, which are highly susceptible to S. aureus colonization [31]. S. aureus 
also produces superantigens such as staphylococcal enterotoxins A and B (SEA and SEB) and toxic 
shock syndrome toxin-1 (TSST-1), which skew the cutaneous immune response towards the Th2 
cytokines and thus contribute to the increased colonization of S. aureus in atopic dermatitis  
patients [34]. In addition, S. aureus expresses factors that enable it to directly counter host CAMP 
responses. For example, IsdA enhances bacterial cellular hydrophobicity, which renders S. aureus 
resistant to bactericidal fatty acids in sebum and to β-defensins and cathelicidin [35]. It also secretes a 
protein, aureolysin, which is an extracellular metalloproteinase that inhibits cathelicidin antimicrobial 
activity [36]. Virulence factors from S. aureus are also closely related with evasion from human 
innate immune defenses [37]. In the following section, the mechanisms by which S. aureus inhibits 
the activities of CAMPs will be described in detail. 
3. Methicillin-Resistant S. aureus (MRSA) Infection 
Antibiotic resistance is now recognized to be a serious hindrance to the management of  
S. aureus. For instance, β-lactam antibiotics (e.g., methicillin) have proven unfavorable for the 
management of toxic S. aureus infections, because even subinhibitory concentrations lead to 
increased expression of α-toxin through a stimulatory effect on exoprotein synthesis [38–40]. 
Instead, protein-synthesis-suppressing antibiotics such as clindamycin and linezolid are 
recommended for the treatment of S. aureus-induced toxicity syndromes, as concentrations below 
the MIC impair expression of S. aureus virulence factors [41,42]. Clindamycin at a concentration 
of 1/8 MIC inhibits the expression of α- and δ-haemolysin as well as coagulase [43]. In addition, 
the expression of protein A is reduced when S. aureus is exposed to clindamycin at concentrations 
below the MIC, leading to increased bacterial susceptibility to phagocytosis and suggesting 
additional therapeutic efficacy [44]. However, clindamycin cannot be used to treat toxic MRSA 
infections because MRSA is largely resistant to clindamycin. 
MRSA infections are caused by strains of S. aureus that have become resistant to the antibiotics 
commonly used to treat ordinary infections. Most MRSA infections occur in people who have been 
in hospitals or other health care settings, such as nursing homes and dialysis centers. When it 
occurs in these settings, it is known as health care-associated MRSA (HA-MRSA). HA-MRSA 
infections are typically associated with invasive procedures or devices, such as surgeries, 
intravenous tubing or artificial joints. However, another type of MRSA infection occurs in the 
wider community, among otherwise healthy individuals. This form, community-associated MRSA 
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(CA-MRSA) is spread by skin-to-skin contact. It often begins as a painful skin boil and generally 
causes skin and soft tissue infections, but it is also capable of causing invasive disease such as 
endocarditis, necrotizing pneumonia and sepsis [45–50]. HA-MRSA, by contrast, is considered a 
nosocomial pathogen typically associated with invasive disease, such as bloodstream infections, 
pneumonia, surgical site infections and urinary tract infections [45,51–53]. It is now recognized 
that these two entities are genetically distinct. Isolates of HA-MRSA are likely to be resistant to 
three or more antibiotic classes, whereas CA-MRSA is usually resistant only to β-lactams and 
macrolides [47,51,53,54]. 
Resistance to methicillin is mediated in S. aureus by PBP2a, a penicillin-binding protein with a 
low affinity for β-lactams. PBPs are membrane-bound enzymes that catalyze the transpeptidation 
reaction, which is necessary for cross-linkage of peptidoglycan chains [55]. PBP2a substitutes for 
the other PBPs and, because of its low affinity for all β-lactam antibiotics, enables staphylococci to 
survive exposure to high concentrations of these agents. Thus, resistance to methicillin confers 
resistance to all β-lactam agents, including cephalosporins. Expression of resistance in some 
MRSA strains is regulated by homologues of the regulatory genes for blaZ. These genes, mecI and 
mecR1, regulate the mecA response to β-lactam antibiotics in a fashion similar to the regulation of 
the blaZ response to penicillin by blaR1 and blaI. Katayama et al. demonstrated that mecA is 
carried on a mobile genetic element and is part of a genomic island designated staphylococcal 
cassette chromosome mec (SCCmec) [56]. To date, four different SCCmec elements varying in size 
from 21 to 67 kb have been characterized [57]. Such islands may also contain additional genes for 
antimicrobial resistance and insertion sequences, as well as genes whose function is uncertain. 
As S. aureus isolates from intensive care units and blood cultures have become increasingly 
resistant to greater numbers of antimicrobial agents [2,58], this has inevitably diminished the 
number of effective bactericidal antibiotics available to treat these often life-threatening infections. 
As rapidly as new antibiotics are introduced, staphylococci are developing efficient mechanisms to 
neutralize them. Recent reports of S. aureus isolates with intermediate or complete resistance to 
vancomycin portend a chemotherapeutic era in which effective bactericidal antibiotics against this 
organism may no longer be readily available [59,60]. Consequently the need to identify new alternative 
therapeutic targets and to develop novel drugs that can be used against these targets is increasing. 
4. Human AMPs Effective against S. aureus 
AMPs are a diverse group of polypeptides that are typically less than 50 amino acids in length 
and exhibit bactericidal activity under physiologic conditions [61–63]. Most AMPs are cationic and 
interact with the anionic microbial membrane leading to osmotic lysis [61–63]. Autolytic enzymes 
induced by AMPs may also be associated with bacterial cell death [64]. Whereas some AMPs are 
produced by keratinocytes and are normally present in the skin, others are induced during infection 
and inflammation/wounding [65,66]. In this section, we will focus on the specific bacteriostatic or 
bactericidal AMPs expressed by keratinocytes and by immune cells thought to contribute to host 




Table 1. Cationic antimicrobial peptides (CAMPs) that contribute to human cutaneous 
immune defenses against S. aureus. 
Peptides Cellular source in the skin Mechanism of S. aureus evasion References 
α-Defensins Neutrophils 




Keratinocytes, macrophages,  
and dendritic cells 
IsdA, dltABCD [26,29,35,74–76] 
hBD3 Keratinocytes dltABCD operon [23,24,27,75–80] 




IsdA, Aureolysin, MprF, dltABCD 
[25,29,35,36,69,71–
73,75] 
Dermcidin Sweat glands 
Extracellular proteases, dltABCD 
operon 
[82–84] 
RNase 7 Keratinocytes dltABCD operon [24,28,61,76] 
These include α-defensins (also called human neutrophil peptides [HNPs]), β-defensins  
(hBD1-4) cathelicidin (LL-37), RNase7 and dermcidin [61–63]. These AMPs not only have 
bactericidal activity against S. aureus, they also promote the recruitment of immune cells to sites of 
infection. For example, HNPs promote recruitment of macrophages, T cells and mast cells through 
a PKC-dependent mechanism [85], while hBD2 and hBD3 promote CCR6-mediated chemotaxis of 
immature dendritic cells and memory CD4+ T cells and CCR2-mediated chemotaxis of 
monocytes/macrophages [86,87]. In addition, LL-37 promotes chemotaxis of neutrophils, 
monocytes and T cells by activating formyl peptide receptor-like 1 [88,89]. Through these various 
mechanisms, AMPs enhance host defenses against S. aureus. 
4.1. Defensins 
Neutrophils express high levels of HNP1-3 and lower levels of HNP4, which together constitute 
nearly 50% of the peptides within neutrophil granules [67]. HNP2 has the highest degree of 
bactericidal activity against S. aureus, though HNP1, 3 and 4 also exhibit some activity against  
S. aureus [68]. 
Most AMPs expressed in humans belong to the β-defensin family. These amphipathic peptides 
have a β-sheet structure and are subcategorized according to the number and location of their 
disulfide bridges [90]. Four well-characterized human β-defensins (hBD1-4) are expressed by 
epithelial cells, including keratinocytes, as well as by activated monocytes/macrophages and 
dendritic cells [62,63]. hBD1 is constitutively expressed, while hBD2 and hBD3 are inducible by 
bacterial infection or cytokines [91]. hBD1 has no antimicrobial activity against S. aureus, while 
hBD2 and hBD4 show weak bacteriostatic activity against S. aureus in vitro [26,81]. By contrast, 
hBD3 exhibits strong bactericidal activity against S. aureus in vitro and in skin explants  
ex vivo [27,77]. In keratinocytes, production of hBD2, hBD3 and LL-37 can be induced by live or 
heat-killed S. aureus or by bacterial components such as lipopeptides and lipoteichoic  
acid [74,75,78–80]. Activation of the epidermal growth factor receptor through wounding of 
human skin also leads to increased hBD3 production, providing another mechanism for enhancing 
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antimicrobial activity against S. aureus [66,92]. Finally, defensins induce production of cytokines, 
including IL-8, and have chemotactic activity [93]. 
4.2. Cathelicidins 
Cathelicidins are a family of AMPs whose named reflects their resemblance to the precursor 
forms of the protein cathelin [94]. The N-terminal cathelin domain keeps the AMP precursor 
inactive until proteolytic cleavage releases the active C-terminal peptide. Although they may vary 
in structure, most mature cathelicidins are α-helical, amphipathic and cationic. Cathelicidin is 
constitutively expressed in neutrophils and has potent bactericidal activity against S. aureus. It is 
also called LL-37, referring its first two amino acids and total length of 37 amino acids [25,62,63]. 
Two other forms, RK-31 and KS-30, may be produced through alternative cleavage, especially on 
the skin [95]. Both KS-30 and RK-31 show greater antimicrobial activity than LL-37 and also 
differ from LL-37 in their ability to elicit cytokine release. Like defensins, LL-37 can induce both 
chemotaxis and cytokine release [93]. 
Vitamin D may also play a role in host defense against S. aureus skin infections, since it induces 
production of LL-37 in keratinocytes, neutrophils and monocytes/macrophages. However, the  
link between vitamin D and host defense against S. aureus has yet to be demonstrated in the  
skin [96–98]. 
4.3. RNase7 
The cationic peptide RNase 7 is produced by many cell types, including keratinocytes, and has 
bactericidal activity against a broad range of bacteria, including S. aureus [61,99]. The high levels 
of RNase 7 present in the stratum corneum prevents S. aureus colonization of skin explants [28]. 
4.4. Dermcidin 
Dermcidin is produced by human eccrine sweat glands and its processed forms have activity  
against numerous bacteria, including S. aureus [82,83,100,101]. While the DCD-1L and DCD-1 
processed forms of dermcidin are negatively charged [69], a further processed cationic form  
(SSl-25) also shows antimicrobial activity, suggesting that charge is of no importance to the mode 




Figure 1. Toll-like receptor-mediated cutaneous immune response against S. aureus.  
Toll-like receptor 2 (TLR2) and nucleotide-binding oligomerization domain containing 
2 (NOD2), which are expressed by keratinocytes, respectively recognize S. aureus 
lipopeptides/lipoteichoic acid and muramyl dipeptide. Both TLR2 and NOD2 signaling 
triggers the activation of nuclear factor-κB (NF-κB), which leads to the production of 
AMPs, cytokines, chemokines, adhesion molecules and granulopoesis factors, all of 
which contribute to the cutaneous host defense against S. aureus. 
 
5. Cutaneous Host Defense Involving TLR-Mediated AMP Activity against S. aureus 
Keratinocytes express pattern recognition receptors such as TLR2, which recognizes S. aureus 
lipopeptides and lipoteichoic acid, and nucleotide-binding oligomerization domain containing 2 
(NOD2), which recognizes the S. aureus peptidoglycan breakdown product muramyl dipeptide. 
Both the TLR2 and NOD2 signals lead to activation of nuclear factor-κB (NF-κB) and other 
transcription factors that induce transcription of the proinflammatory mediators (cytokines, 
chemokines, adhesion molecules and AMPs) involved in cutaneous host defense against S. aureus 
(Figure 1) [102,103]. Upon cutaneous S. aureus infection, the epidermal barrier is breached and 
keratinocytes and resident skin immune cells (e.g., Langerhans cells and γδ T cells in the 
epidermis, as well as dendritic cells, macrophages, fibroblasts, mast cells, B and T cells, plasma 
cells and natural killer cells in the dermis) produce pro-inflammatory cytokines, chemokines and 
adhesion molecules. These molecules promote the recruitment of neutrophils from the bloodstream, 
which help to control the infection by forming an abscess. Neutrophilic abscess formation is a 
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hallmark of S. aureus infections, which are typically pyogenic, and is required for bacterial 
clearance. Pro-inflammatory cytokines also induce the production of AMPs (e.g., β-defensins and 
cathelicidins) with bacteriostatic or bactericidal activity against S. aureus [104,105]. 
Figure 2. IL-1- and IL-17-mediated cutaneous immune response against S. aureus.  
Infection of the skin by S. aureus leads to the production of IL-1α, IL-1β and IL-17, 
which in turn triggers activation of nuclear factor-κB (NF-κB). These signaling 
pathways lead to the production of AMPs, cytokines, chemokines, adhesion molecules 
and granulopoesis factors, which recruit neutrophils from the circulation to the site of S. 
aureus infection in the skin. The recruited neutrophils form an abscess that helps 
control and limit the spread of the infection, and is ultimately required for bacterial 
clearance. IL-1R1, interleukin-1 receptor 1; IL-17R, interleukin-17 receptor. 
 
6. Cutaneous Host Defense Involving IL-1- and IL-17-Mediated AMP Activity  
against S. aureus 
IL-1α, which is produced and released by keratinocytes, and IL-1β, which is produced by 
resident and recruited immune cells (e.g., macrophages and dendritic cells), trigger activation of 
NF-κB. These signaling pathways lead to the production of β-defensins 2 and 3, cathelicidins  
and RNase 7. IL-1-mediated responses also result in the production of pro-inflammatory  
cytokines, chemokines and adhesion molecules that promote the recruitment of neutrophils from 
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the circulation to sites of S. aureus infection in the skin and abscess formation (Figure 2) [106]. In 
addition to IL-1, recent studies have uncovered the critical role played by IL-17, which is 
predominantly expressed by recruited T cell subsets (Th17 cells, NKT cells and γδ T cells) and 
natural killer cells in response to TLR2 activation. The IL-17 produced stimulates production of  
β-defensins 2 and 3 and cathelicidins by keratinocytes and induces neutrophil recruitment via 
induction of various chemokines (CXCL1, CXCL2 and IL-8) and granulopoesis factors (G-CSF 
and GM-CSF) [107]. 
7. Mechanisms by Which S. aureus Evades Skin-Derived CAMPs 
The importance of CAMPs in host cutaneous defense against S. aureus is evidenced by the 
mechanisms that have evolved in S. aureus to resist and evade these peptides. As shown in  
Figure 3, S. aureus counteracts CAMPs and antimicrobial fatty acids through at least four 
mechanisms: (i) production of CAMP-binding molecules, like the fibrinolytic enzyme staphylokinase 
(SAK), which binds to and inhibits α-defensins; (ii) proteolytic degradation of CAMPs by secreted 
proteases such as aureolysin, which cleaves and inactivates LL-37; (iii) reduction of the bacterial 
cell surface net negative charge by modification of teichoic acids using D-alanine or phospholipids 
with L-lysine; and (iv) alteration of bacterial cell surface hydrophobicity [11,108]. In the following 
sections, these mechanisms will be discussed in additional detail. 
Figure 3. Strategies by which S. aureus evades CAMPs. S. aureus counteracts CAMPs 
by secreting trapping molecules and proteases that inactivate CAMPs and by modifying 
the cell membrane hydrophobicity or net charge [108]. 
 
7.1. Secretion of Extracellular CAMP-Binding Molecules 
S. aureus resists α-defensins through the production of SAK, which binds human α-defensins 
with high affinity, thereby mediating significant α-defensin resistance. In vitro, SAK levels 
correlate inversely with the susceptibility of S. aureus isolates to α-defensins (Figure 3a) [70]. 
7.2. Proteolytic Degradation of CAMPs by Secreted Proteases 
S. aureus and many other bacterial species produce peptidases and proteases capable of cleaving 
CAMPs. In vitro, production of S. aureus protease correlates with staphylococcal resistance to  
CAMPs [36]. For example, S. aureus produces a metalloproteinase, aureolysin, which cleaves and 
inactivates LL-37 [36]. S. aureus also secretes extracellular proteases that degrade dermcidin, 
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neutralizing its antimicrobial activity [84], and similar observations have been made with the  
S. epidermidis protease SepA (Figure 3b) [84]. 
7.3. Resistance to CAMPs through Reduction of Bacterial Surface Net Negative Charges 
CAMPs and most other antimicrobial molecules, including lysozyme, phospholipase A2 and 
RNase5, have net positive charges. The surface of human cells is normally composed mainly of 
uncharged or zwitterionic lipids, whereas bacterial surfaces are composed of various anionic 
components, including as peptidoglycan, the phospholipids phosphatidylglycerol and cardiolipin, 
lipid A, and teichoic acids, which give it an anionic net charge [109]. Presumably, antimicrobial 
host factors have evolved to be cationic to achieve strong, selective affinity for the anionic  
surfaces of bacteria. However, some bacterial species, like S. aureus, are able to reduce the 
negative charge of their cell envelope, thereby becoming resistant to inactivation by many CAMPs 
(Figure 3c) [69,71–73,110–112]. 
7.3.1. Modification of Phospholipids with L-lysine 
To reduce anionic charge, S. aureus and other bacteria are able to modify most of their 
phosphatidylglycerol with L-lysine [113]. The lysinylation of phosphatidylglycerol is mediated by a 
membrane protein, multiple peptide resistance factor protein (MprF) [112,114], which neutralizes 
the bacterial cell envelope and thus reduces susceptibility to many CAMPs, including α-defensins, 
LL-37 and Group IIA-phospholipase A2 [69,71,110,111]. 
7.3.2. Modification of Teichoic Acids with D-alanine 
Products of the dltABCD operon attach positively charged D-alanine residues to negatively 
charged phosphate groups in the backbone of teichoic acids, rendering bacteria less susceptible to 
α-defensins and LL-37 [72,73]. Teichoic acids in S. aureus and other Gram-positive bacteria 
consist of alternating glycerolphosphate or ribitolphosphate units, which are substituted with  
N-acetyl-glucosamine or D-alanine [113]. These polymers are either anchored to the cytoplasmic 
membrane (lipoteichoic acid) or to the peptidoglycan cell wall (wall teichoic acid) and are anionic 
due to the presence of negatively charged phosphate groups. In a fashion similar to lysinylation of 
phospholipids, modification of teichoic acids with D-alanine leads to a partial neutralization of the 
polymer [73], which reduces the interaction of CAMPs with the bacterial surface, in turn reducing 
the susceptibility to cationic host defense molecules, including α-defensins and LL-37 [73]. 
Consistent with this scenario, an S. aureus mutant lacking D-alanine in its teichoic acids (dltA 
mutant) as well as clinical isolates expressing lower levels of dltA showed greater susceptibility to 
CAMPs, including dermcidin, RNase 7, hBD2 and hBD3 [76]. With dermcidin, cationic structures 
in the N-terminal part of the peptide appear crucial for interaction with the negative bacterial cell 
surface, which likely explains why D-alanylation influences its efficacy [83]. Also, several studies 
in animal models have demonstrated that alanylated teichoic acids contribute to an increased 




7.4. Resistance to CAMPs through Alteration of Bacterial Cell Surface Hydrophobicity 
Human skin is rich in antimicrobial fatty acids produced by sebaceous glands. S. aureus 
produces IsdA, which alters its surface hydrophobicity, thereby reducing the efficiency with which 
fatty acids gain access to the cells [35]. Indeed, by decreasing cellular hydrophobicity, IsdA renders 
S. aureus resistant to hBD2 and LL-37 on human skin (Figure 3d) [35]. 
8. Conclusions 
S. aureus is a frequent component of human skin and nose microbiota. However, it can also 
cause various skin diseases, sometimes leading to systemic infections. The ability of S. aureus to 
colonize and infect the skin is apparently dependent on specific mechanisms that subvert host 
cutaneous defenses. The existence of these multiple resistance mechanisms makes it clear that 
CAMPs play a key role in the host cutaneous defense against S. aureus. Peschel et al. proposed the 
coevolution of CAMP structures and bacterial resistance mechanisms, which has led to the 
existence of the currently observed CAMPs [118]. One mechanism that renders CAMPs resistant to 
degradation by proteases is stabilization through disulphide bridges [118]. Other modifications that 
increase the efficacy of CAMPs include variation in the amino acid sequence, increases in the net 
positive charge through incorporation of larger numbers of cationic amino acids, and combining 
multiple antimicrobial mechanisms in a single molecule. These potential modifications of CAMPs 
are reviewed in detail by Peschel and Sahl [118]. 
Ouhara et al. showed that several clinical isolates of MRSA strains exhibited reduced 
susceptibility to the human LL-37 but not to the hBD3 [119]. The greater resistance to LL-37 is 
based on the more positive net cell-surface charge in MRSA strains than methicillin-susceptible S. 
aureus strains (MSSA). The fact that the efficacy of hBD3 appears unaffected may be due to its 
more positive net charge, as compared to LL-37 (+11 vs. +6), which would favor stronger 
interaction with the bacterial cell surface [119]. This suggests targeting highly conserved bacterial 
CAMP resistance mechanisms such as lysinylation of phospholipids by MprF or the alanylation of 
teichoic acids by dltABCD could be an effective treatment strategy. Moreover, in addition to its 
essential role in mediating resistance to CAMPs [69,111], it appears MprF may dramatically reduce 
the susceptibility of S. aureus to the novel lipopeptide antibiotic daptomycin [120,121]. Thus, new 
therapeutics targeting CAMP resistance factors, like MprF, could not only render a pathogen 
susceptible to host antimicrobial defense, but might also act synergistically to combat infections in 
combination with currently available antibiotics. Although targeting resistance factors would not 
directly inactivate S. aureus, it would render it more susceptible to CAMPs, thus assisting host 
cutaneous defenses to successfully combat skin infections. 
The increasing numbers of reports of virulent and drug-resistant strains of S. aureus prompt 
further investigation into the mechanisms that enable this pathogen to cause infection and 
overcome the broad spectrum of human cutaneous antimicrobial defenses. We anticipate that future 
studies will provide further information about the host and bacterial determinants involved in skin 
colonization and infection by S. aureus. Targeted drug development around highly conserved 
bacterial resistance mechanisms against host CAMPs is a promising pharmacologic approach in 
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DADS Suppresses Human Esophageal Xenograft  
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Abstract: Diallyl disulfide (DADS) is a natural organosulfur compound isolated from garlic. 
DADS has various biological properties, including anticancer, antiangiogenic, and antioxidant effects. 
However, the anticancer mechanisms of DADS in human esophageal carcinoma have not been 
elucidated, especially in vivo. In this study, MTT assay showed that DADS significantly reduced 
cell viability in human esophageal carcinoma ECA109 cells, but was relatively less toxic in normal 
liver cells. The pro–apoptotic effect of DADS on ECA109 cells was detected by Annexin V-
FITC/propidium iodide (PI) staining. Flow cytometry analysis showed that DADS promoted 
apoptosis in a dose-dependent manner and the apoptosis rate could be decreased by caspase-3 
inhibitor Ac-DEVD-CHO. Xenograft study in nude mice showed that DADS treatment inhibited 
the growth of ECA109 tumor in both 20 and 40 mg/kg DADS groups without obvious side effects. 
DADS inhibited ECA109 tumor proliferation by down-regulating proliferation cell nuclear antigen 
(PCNA). DADS induced apoptosis by activating a mitochondria-dependent pathway with the 
executor of caspase-3, increasing p53 level and Bax/Bcl-2 ratio, and downregulating the 
RAF/MEK/ERK pathway in ECA109 xenograft tumosr. Based on studies in cell culture and animal 
models, the findings here indicate that DADS is an effective and safe anti-cancer agent for 
esophageal carcinoma. 
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Human Esophageal Xenograft Tumors through RAF/MEK/ERK and Mitochondria-Dependent 
Pathways. Int. J. Mol. Sci. 2014, 15, 12422-12441. 
1. Introduction 
Esophageal carcinoma is among the most common tumors in the world, ranking eighth in 
occurrence and sixth in mortality [1]. Approximately 70% of global esophageal carcinoma cases 
occur in China and the five–year survival rate is only 10% [2]. Generally, esophageal carcinoma 
patients in the primary stage can be cured by surgical resection. However, a majority of patients in 
the advanced stage eventually succumb to this disease [3]. Although surgery, radiotherapy and 
chemotherapy are regarded as important parts of the systemic therapy for metastatic esophageal 
carcinoma, the success of such treatments have been weakened by their severe systemic toxicities 
and local irritating effects. Therefore, in order to enhance efficacy and reduce toxicity, researchers 




Plant-derived herbal medicines have been used in several Asian countries including China for a 
long time. Some plant compounds have anticancer activity with low toxicity and could be used as 
alternative chemotherapeutic agents for carcinomas [5]. Garlic, as an herbal medicine, has 
antimicrobial, antiplatelet, antithrombotic, antiarthritic and antitumorigenic properties [6]. Diallyl 
disulfide (DADS), CH2=CH–CH2–S–S–CH2CH=CH2, is a lipid–soluble organic compound 
isolated from garlic. Scientific investigations have shown that DADS reduces the risk of 
cardiovascular disease and diabetes [7], serves as anti-oxidant [8], fights against infections [9], and 
exhibits significant protection effects against malignancies [10–12]. Moreover, in human breast 
cancer MCF–7 cells, the apoptotic effect of DADS is even superior to chemotherapy agents such as 
5F-dUMP (5-Fu) and cyclophosphamide (CTX) [13]. 
Considering limited data on DADS bioavailability, additional studies are warranted to check the 
effects of DADS in animal models of esophageal carcinoma [11,14]. Moreover, the molecular 
mechanisms of DADS on various carcinomas are still a matter of debate and the exact effects of 
DADS in vivo on esophageal carcinoma are still unclear. Therefore, in the present study, we used 
an ECA109 xenograft model in nude mice to study the effect of DADS on tumor growth. 
Additionally, we investigated the potential biomarkers and associated molecular alterations in 
ECA109 xenograft tumor. This is the first study to evaluate the potential effects and mechanisms of 
DADS on human esophageal carcinoma in vivo. 
2. Results and Discussion 
2.1. Diallyl Disulfide (DADS) Inhibits Cell Viability 
The MTT assay was used to detect the viability inhibitory effects of ECA109 cells and L02 cells 
incubated with various concentrations of DADS (10–60 μg/mL) for 24 h. DADS was dissolved in 
DMSO, and mixed with RPMI–1640 for experiments in vitro. The concentration of DMSO added 
to the medium of DADS was less than 0.01%. The medium with DMSO and in absence of DADS 
was used as the control group. In addition, we detected the difference of ECA109 cells incubated 
with DADS and cis-diammminedichloroplatinum (DDP) for 24 h. Our data showed that DADS 
obviously inhibited cell viability in a dose-dependent manner at concentrations of 10–60 μg/mL for 
24 h (p < 0.05, Figure 1). Moreover, DADS had much lower cytotoxicity to L02 normal liver cells 
than ECA109 esophageal carcinoma cells (p < 0.05, Figure 1). Our data shows that DDP was more 
effective than DADS on ECA109 cells in vitro (p < 0.05, Figure 2); DDP was used as positive 




Figure 1. Viability inhibitory effects of diallyl disulfide (DADS) on ECA109 cells and 
L02 cells. ECA109 and L02 cells were incubated with different doses of DADS (0, 10, 
20, 30, 40, 50, 60 μg/mL) for 24 h respectively. Cell viability was detected by MTT 
assay and was represented as the percentage of relative absorbance. Data are expressed 
as the mean ± SD from five independent experiments (* p < 0.05, ** p < 0.01 
compared with the control group, # p < 0.05, ## p < 0.01 ECA109 compared  
with L02). 
 
Figure 2. Viability inhibitory effects of DADS and cis-diammminedichloroplatinum 
(DDP) on ECA109 cells. ECA109 cells were incubated with different doses of DADS 
and DDP (0, 10, 20, 30, 40, 50, 60 μg/mL) for 24 h respectively. Cell viability was 
detected by MTT assay and was represented as the percentage of relative absorbance. 
Data are expressed as the mean ± SD from five independent experiments (* p < 0.05, 




2.2. DADS-Induced Apoptosis 
ECA109 cells were examined by phase contrast microscopy after being incubated with different 
concentrations of DADS (0, 20, 40, 80 μg/mL) for 24 h. The cells in the control group showed  
a typical intact appearance, whereas the DADS-treated cells displayed dose-dependent changes in 
cell shape. Membrane blebbing and formation of apoptotic bodies were found in 20 and 40 μg/mL 
DADS groups, while cellular shrinkage, poor adherence and floating shapes were found in the  
80 μg/mL DADS group (Figure 3a). 
As there were too many dead cells in the 80 μg/mL DADS group, we explored the apoptotic rate 
of ECA109 cells incubated with different concentrations of DADS (0, 20 and 40 μg/mL) for 24 h  
using Annexin V-FITC and propidium iodide (PI) staining and flow cytometry. Our data showed that 
the rate of apoptosis in the 0, 20 and 40 μg/mL DADS groups were (10.26 ± 1.45)%, (15.25 ± 2.99)% 
and (42.68 ± 4.08)% respectively. These results revealed that DADS induced the apoptosis of ECA109 
cells in a dose-dependent manner (p < 0.05, Figure 3c). On the other hand, ECA109 cells were 
pretreated with caspase-3 inhibitor (Ac-DEVD-CHO) and then exposed to DADS for 24 h. Our results  
indicated that Ac-DEVD-CHO was able to protect ECA109 cells against DADS-induced apoptosis  
(p < 0.05, Figure 3d). 
2.3. DADS Blocked the Growth of Xenograft Tumor 
To evaluate the effect of DADS on the development of esophageal carcinoma in vivo, 5 × 106 
ECA109 cells were injected into the flanks of nude mice. After three weeks, all the mice developed 
palpable tumors. The total of twenty-four mice were randomly divided into four groups (n = 6 per 
group). DADS was dissolved in DMSO, and mixed with phosphate buffered saline (PBS) for 
intraperitoneal injections in nude mice. The concentration of DMSO added to the medium was less 
than 0.01%. The PBS medium with DMSO in absence of DADS was utilized as the negative 
control group. Injections of DADS at 20 and 40 mg/kg body weight were done in therapy groups. 
Injections of DDP at 2 mg/kg body wt were performed in the positive control group. These 
injections were made every three days, eight times. Compared with the negative control group, we 
observed significant difference of tumor weight in the 20 mg/kg DADS group (p < 0.05, Figure 
4a), 40 mg/kg DADS group and DDP positive control group (p < 0.01, Figure 4a). At the end of 
the study, DADS decreased tumor volume from 292.02 ± 27.08 mm3 per mouse in the negative 
control group to 211.95 ± 20.14, 179.08 ± 15.95 and 122.64 ± 12.62 mm3 per mouse in 20 mg/kg 
DADS group (p < 0.05, Figure 4b), 40 mg/kg DADS group and DDP positive control group (p < 
0.01, Figure 4b) respectively. In addition, there was no sign of possible changes of body weight in 
the DADS groups compared with the negative control group (p > 0.05, Figure 4c). However, the 
data showed that there was significant loss of body weight in DDP positive control group compared 




Figure 3. Apoptotic effects of DADS on ECA109 cells. (a) Morphology of ECA109 
cells treated with different concentrations of DADS for 24 h and examined under phase 
contrast microscopy (×400); (b) DADS (0, 20 and 40 μg/mL) induced dose-dependent 
apoptosis in ECA109 cells. Ac-DEVD-CHO inhibited the apoptosis induced by DADS. 
Apoptosis was assessed using Annexin V-FITC/propidium iodide (PI) double staining; 
(c) Statistical analysis of the apoptosis rate of DADS; (d) Effects of Ac-DEVD-CHO 
against the apoptosis induced by DADS. Data are expressed as the mean ± SD from 
three independent experiments (* p < 0.05, ** p < 0.01 compared with the control group, 








Figure 4. Effects of DADS on ECA109 xenograft tumor. Nude mice were implanted 
with ECA109 cells. After the xenograft tumors became palpable, intraperitoneal 
injections were made eight times every three days, including the negative control 
group, 20 mg/kg DADS group, 40 mg/kg DADS group and 2 mg/kg DDP positive 
control group. Effects of DADS on (a) tumor volume; (b) tumor weight; and (c) body 
weight were recorded. Data shown in a–c are the average of six mice in each  






2.4. DADS Inhibited Cell Proliferation and Induced Apoptosis in Xenograft Tumor 
We analyzed the effects of DADS on ECA109 tumor proliferation and apoptosis by  
immunohistochemical staining of proliferation cell nuclear antigen (PCNA) and caspase-3 
respectively. By microscopic observation, a larger number of PCNA immunoreactive cells was 
observed in the negative control group (PBS medium with DMSO and in absence of DADS was 
utilized for intraperitoneal injections in nude mice) than in the 20 and 40 mg/kg DADS groups  
(Figure 5a), which accounted for 62.79% ± 9.58%, 32.31% ± 4.13% and 19.29% ± 6.49% 
respectively (p < 0.01, Figure 5b). However, more caspase-3 immunoreactive cells were observed 
in the DADS groups than the negative control group (Figure 5a). The quantification of caspase-3 
immunoreactive cells was 11.84% ± 2.99% in the control group, and was significantly increased to 
42.37% ± 7.39% and 54.28% ± 6.25% in the 20 mg/kg DADS group and 40 mg/kg DADS group, 
respectively (p < 0.01, Figure 5c). 
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Figure 5. Anti-proliferative and pro-apoptotic effects of DADS on ECA109 xenograft 
tumors. Tumors from the negative control group, 20 mg/kg DADS group and 40 mg/kg 
DADS group were processed for immunohistochemical staining of proliferation cell 
nuclear antigen (PCNA) (a,b) and caspase-3 (a,c). A representative picture had been 
shown for each case. Immunoreactive cells (yellow to brown) in xenograft tumors were 
enumerated and analyzed by Image-Pro Plus analysis system (Media Cybernetics, 
Bethesda, MD, USA) linked to an Olympus microscope (Olympus Corporation, Center 
Valley, PA, USA). The total number of cells was presented from all the samples in  
each group of five randomly selected microscopic fields. The data are expressed as the  






2.5. DADS Activated Mitochondria-Dependent Pathway and Up-Regulated Bax/Bcl-2 Ratio in 
Xenograft Tumors 
It is well known that mitochondria–mediated apoptosis involves the release of cytochrome C, as 
well as the activation of caspase-9 and caspase-3. Our results from qPCR indicated that the levels 
of cytochrome C, caspase-9 and caspase-3 were stimulated in DADS groups (p < 0.01, Figure 6a). 
Moreover, DADS significantly increased the expression levels of active caspase-3 and active 
caspase-9 in total proteins, as well as the expression levels of cytochrome C in cytoplasm proteins 
in 20 and 40 mg/kg DADS groups by western blot analysis (p < 0.01, Figure 6c,e–g). However, 
DADS did not affect caspase-8 expression levels (p > 0.05, Figure 6a). 
On the other hand, Bcl–2 and Bax are major proteins of the mitochondria apoptosis pathway.  
Our results of qPCR showed that the expression levels of Bcl-2 decreased in the DADS groups  
(p < 0.05, Figure 6a), whereas the expression level of Bax increased only in the 40 mg/kg DADS 
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group (p < 0.01, Figure 6a). Therefore, there was a significant up-regulation of the Bax/Bcl-2 ratio 
in the 40 mg/kg DADS group (p < 0.01, Figure 6b). In addition, the results of qPCR and Western 
blot suggested that DADS enhanced the expression levels of p53 in the 40 mg/kg group (p < 0.01,  
Figure 6a,e). 
2.6. DADS Alters the RAF/MEK/ERK Pathway in Xenograft Tumors 
Western blot analysis was used to evaluate the effects of DADS on the protein levels of RAF1, 
MEK1, phosphor-MEK1 (p-MEK1), ERK1/2 and p-ERK1/2 in ECA109 xenograft tumors. Our 
results showed a significant down-regulation of RAF1, p-MEK1, ERK1/2 and p-ERK1/2 protein 
expressions in 20 and 40 mg/kg DADS groups (p < 0.01, Figure 7b,d–f). The expression level of 
MEK1 decreased in 40 mg/kg DADS group (p < 0.01, Figure 7c). These results suggested that 
DADS had a profound effect on the apoptosis in ECA109 xenograft tumor, which might be 
correlated with the RAF/MEK/ERK pathway. 
Figure 6. DADS activated mitochondria-dependent pathway and shift in Bax/Bcl-2 
ratio in ECA109 xenograft tumors. The mRNA and protein expression levels of 
caspase-3, caspase-8, caspase-9, cytochrome C, Bax, Bcl-2 and p53 from the negative 
control group, 20 mg/kg DADS group and 40 mg/kg DADS group were assessed by 
qPCR and western blot. (a) The mRNA expressions of caspase-3, caspase-8, caspase-9, 
cytochrome C, Bax, Bcl-2 and p53; (b) Bax/Bcl-2 ratio; (c) Representative blots; 
Densitometric analysis was made on the expressions of p53 (7F5) (d); active caspase-3 
(e); active caspase-9 (f) and cytochrome C (g). β-Actin was used as the loading control. 
Data are expressed as the mean ± SD from three independent experiments (* p < 0.05, 
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Figure 7. DADS down-regulated RAF/MEK/ERK pathway in ECA109 xenograft 
tumor. The protein expression levels of RAF1, MEK1, phosphor-MEK1 (p-MEK1), 
ERK1/2 and p-ERK1/2 from the negative control group, 20 mg/kg DADS group and 40 
mg/kg DADS group were assessed by western blot analysis. (a) Representative blots. 
Densitometric analysis was made on the expressions of RAF1 (b); MEK1 (c); pMEK1 
(d); ERK1/2 (e) and pERK1/2 (f). β-Actin was used as the loading control. Data are 
expressed as the mean ± SD from three independent experiments (** p < 0.01 












DADS, a lipid-soluble organic compound isolated from garlic, is a potentially useful agent for 
cancer prevention and therapy, as it has the ability to reactivate the expression of genes in 
differentiation, cell cycle regulation, apoptosis and so on [10,12,15,16]. By using MTT assay, 
DADS showed a dose-dependent anti-viability effect on ECA109 cells in vitro. The viability 
inhibitory properties of DADS were attributed to its induction of apoptosis in human esophageal 
carcinoma ECA109 cells (Figures 1–3). Moreover, we demonstrated that DADS had much lower 
cytotoxicity to normal liver cells L02 in comparison with ECA109 carcinoma cells (Figure 1). In 
addition, as the data showed that DDP had greater effect on ECA109 cells than DADS in vitro 
(Figure 2), we used DDP as the positive control in an in vivo study. 
Studies of xenograft tumors represent well-established preclinical animal models for evaluating 
anticancer effects of test agents in vivo. Therefore, additional studies are warranted to check the 
effects of DADS by using animal models [11,14,17–19]. Researchers have injected DADS in nude 
mice at 30–200 mg/kg body wt intraperitoneally [17–19]. Consistent with these data, we selected 
suitable doses of DADS at 20 and 40 mg/kg body weight. Our study showed that DADS treatment 
inhibited the growth of ECA109 tumors in volume and weight at the two dosages used  
(Figure 4a,b). Importantly, intraperitoneal injections of DADS for eight times showed no apparent 
signs of toxicity. However, the data indicated that there was a significant loss of body weight in the 
DDP positive control group compared with the negative control group and DADS therapy groups 
(Figure 4c). Although we did not find a stronger anti-cancer effect of DADS compared to the 
traditional chemotherapy agent DDP, our study indicated that DADS could suppress the growth of 
ECA109 xenograft tumor effectively and had fewer side effects than DDP. Moreover, our data 
showed that DADS decreased the expression of tumor proliferation biomarker PCNA in the 20 and 
40 mg/kg DADS groups (Figure 5a,b). Therefore, we suggest that DADS might be a promising 
candidate drug for esophageal carcinoma patients. 
Apoptosis is programmed cell death that plays a major role during cancer treatment [20]. DADS 
has the ability to induce apoptosis of some human tumor cells. However, the apoptosis induced by 
DADS involves different apoptotic genes and proteins depending on the cell types of different 
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tumors [15,16]. The effects of DADS on esophageal carcinoma are still unclear, especially in vivo. 
Our study proved the apoptosis effect of DADS on ECA109 cells by using several methods. First, 
under light microscope, we observed morphology changes of apoptosis, such as membrane 
blebbing and formation of apoptotic bodies in the 20 and 40 μg/mL DADS groups, and cellular 
shrinkage, poor adherence and floating shapes in the 80 μg/mL DADS group (Figure 3a). Second, 
we detected the apoptosis rate by the double-staining of Annexin V-FITC and PI. Our results 
revealed that DADS induced the apoptosis of ECA109 cells in a dose-dependent manner  
(Figure 3b,c). In addition, the study indicated that DADS might inhibit the viability of ECA109 
cells by promoting apoptosis. 
Apoptosis signals are controlled by two distinct pathways, including the extrinsic pathway 
(death receptor pathway) and the intrinsic pathway (mitochondrial pathway) [21]. Caspases are 
cysteine proteases that play pivotal roles in apoptosis. Fourteen caspases have been identified based 
on their functions, which are divided into two groups (initiator caspases and effector caspases) [22]. 
Initiator caspases (caspase-2, -8, -9, and -10) are activated as a result of protein complex  
formation [23]. In the death receptor pathway, the activation of the death receptor leads to initiation 
of a caspase cascade by caspase-8. The mitochondrial pathway is characterized by the release of 
cytochrome C from mitochondria and the activation of a caspase cascade through caspase-9 [24]. 
Caspase-3, -6 and -7 function as executioners. Caspase-3 is a crucial executor that cleaves various 
substrates related to apoptosis [23,25]. Most of the apoptosis procedures induced by DADS are 
executed by caspase-3. However, some kinds of apoptosis are independent with caspase-3 [26–29]. 
In order to prove the apoptosis of DADS on ECA109 cells, we studied caspase-3 by qPCR and 
western blot in vitro and in vivo, as well as by immunohistochemical assay of xenograft tumor in 
vivo. Our results showed that the apoptosis of DADS was caspase-dependent, since caspase-3 was 
active during this procedure (Figures 5a,c and 6a,c,e) and that the pre–treatment with caspase-3 
inhibitor (Ac-DEVD-CHO) could dramatically block the apoptosis induced by DADS (Figure 
3b,d). Besides, many agents can activate cellular apoptotic programs through the mitochondria 
pathway, which triggers changes in regulatory factors [10]. Some soluble proteins including 
cytochrome C and Apaf-1, which can combine with caspase-9 to form the apoptosome, are released 
from the mitochondrial intermembrane space, and subsequently initiate an apoptosis cascade [30]. The 
mechanisms of apoptosis induced by DADS are different in various cells of different carcinomas. 
DADS induces apoptosis and promotes the activities of caspase-8 and caspase-9 in human colon 
cancer cell line (COLO 205) [26]. However, in the present study, our results of qPCR and western 
blot indicated that the activations of caspase-9 and caspase-3 as well as the release of cytochrome C 
from mitochondria to cytoplasm were stimulated in DADS groups (Figure 6a,c,f,g), which were 
involved in the typical mitochondrial apoptosis pathway [24]. Hence, these data suggested that the 
apoptosis effect induced by DADS on ECA109 cells was caspase-dependent in vitro as well as in 
vivo. In addition, our results indicated that one central mechanism of the apoptosis inducing by 
DADS in esophageal xenograft tumor was the activation of the mitochondrial pathway, but not the 
death receptor pathway. 
The activation of caspases has a close relationship with the transduction of apoptosis signalling. 
P53 is known to inhibit cell proliferation and induce caspase-mediated apoptosis. Bax is a key 
target of p53 transcription factor in apoptosis [31]. Bcl-2, an antiapoptotic protein, is able to bind 
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and inactivate Bax to modulate tumor cells responding apoptosis [32]. P53 and the Bax/Bcl-2 ratio 
play important roles in the apoptotic process. The molecular mechanisms of DADS on various 
carcinomas are still a matter of debate. DADS could up-regulate the p53 level to take part in the 
apoptotic processes of melanoma in the B16F-10 cell line and human cervical cancer Ca Ski cell 
line [33,34]. However, the effect of DADS is independent of p53 activity in the osteosarcoma 
Saos-2 cell line [35]. Moreover, p53 is increased in the colon cancer COLO 205 cell line, and is 
decreased in the colon cancer SW480 cell line by DADS treatment [26,36]. These experiments 
have indicated that DADS has various peculiarities in the treatment of different carcinomas. 
Moreover, even different cell lines of the same carcinoma are probably not alike under DADS 
treatment. P53 has been found to mutate in 83% esophageal squamous cell carcinomas [2], while 
p53 is highly expressed in the ECA109 cell line [37]. In the present study, our results of qPCR and 
Western blot suggested that DADS could enhance p53 expression levels in the two dosages of 
DADS groups, especially in the 40 mg/kg DADS group (Figure 6a,c,d). By qPCR assay, we found 
that mRNA expression levels of Bcl-2 were down-regulated in the two DADS groups, whereas the 
expression level of Bax was up-regulated in the 40 mg/kg DADS group (Figure 6a). Moreover, our 
data indicated the significant increase of the Bax/Bcl-2 ratio in the 40 mg/kg DADS group  
(Figure 6b), leading to the pro-apoptosis of ECA109 cells. Based on these observations, our study  
showed that the up-regulations of p53 expression levels and the Bax/Bcl-2 ratio were involved in 
DADS-induced cell death. 
The RAF/mitogen-activated protein kinase/extracellular signal-regulated kinase 
(RAF/MEK/ERK) pathway plays a prominent role in the regulation of cell growth [38]. The 
RAF/MEK/ERK pathway can be affected by the activation of p53 [39]. ERK is a downstream 
component of conserved signaling module activated by the serine/threonine kinase, RAF. RAF can 
be recruited to the cellular membrane and activate MEK, which phosphorylates and activates ERK 
in turn [38]. ERK phosphorylation may control transcription by targeting several different 
regulators such as transcription factors and histone proteins, which result in proliferation, 
differentiation and protection against apoptosis [40]. DADS has been shown to be a histone 
deacetylase (HDAC) inhibitor, which has the ability to affect the growth and survival of tumor 
cells [12]. Although some studies have indicated that DADS inhibits the phosphorylation of 
ERK1/2 during the apoptotic processes of the human leukemia HL-60 cell line and human colon 
cancer COLO 205 cell line [16,41], other studies have shown that DADS activates ERK1/2 in 
human non-small cell lung cancer H1299 cell line and human nasopharyngeal carcinoma CNE2 
cell line [15,42]. Moreover, DADS has no influence on ERK1/2 in apoptosis of the human prostate 
carcinoma DU145 cell line [10]. In the present study, our western blot results showed that the 
expression levels of RAF1, phosphor-MEK1 (p-MEK1), ERK1/2 and p-ERK1/2 were inhibited in 
both the 20 and 40 mg/kg DADS groups (Figure 7a,b,d–f), and that the expression level of MEK1 
was down-regulated in the 40 mg/kg DADS group (Figure 7a,c). Based on these findings, it 
seemed that the down-regulation of the RAF/MEK/ERK signaling pathway contributed to the 
apoptosis induced by DADS in the ECA109 xenograft tumor. Moreover, the RAF/MEK/ERK 




3. Experimental Section 
3.1. Reagents and Antibodies 
ECA109 human esophageal carcinoma cell line and L02 human normal liver cell line were 
purchased from the Chinese Academy of Shanghai Institute of Cell Biology. DADS and DDP were 
purchased from Sigma–Aldrich Chemical Company, St. Louis, MO, USA. DMSO, MTT, 
propidium iodide (PI), phosphate buffered saline (PBS) were purchased from Sigma–Aldrich. Fetal 
bovine serums (FBS), RPMI-1640 medium and 0.25% trypsin were purchased from Hyclone 
Company, Logan, UT, USA. Trizol was purchased from Invitrogen, Grand Island, NY, USA. 
Annexin V-FITC apoptosis kit was purchased from Roche Technology Company, Branchburg, NJ, 
USA. PrimeScript™ RT Master Mix kit and SYBR® Premix Ex Taq II kit were purchased from 
Takara Technology Company, Sakado-shi, Saitama, JAPAN. Enhanced chemiluminescence (ECL) 
kit was purchased from Amersham Life Science, Arlington Heights, UK. Materials and chemicals 
used for electrophoresis were obtained from Bio-Rad Laboratories, Hercules, CA, USA. ProteoJET 
cytoplasmic Protein Extraction kit was purchased from Fermentas, Pittsburgh, PA, USA. 
Antibodies to RAF1, MEK1, phosphor-MEK1 (p-MEK1), ERK1/2, phosphor-ERK1/2 (p-
ERK1/2), p53 (7F5), caspase-3, active caspase-3, caspase-9, active caspase-9, cytochrome C and 
proliferation cell nuclear antigen (PCNA) were purchased from Cell Signaling Technology 
Company, Danvers, MA, USA. The β-actin antibody was purchased from Santa Cruz 
Biotechnology, Dallas, TX, USA. Horseradish peroxidase- (HRP-) coupled goat anti-mouse IgG 
and anti-rabbit IgG (secondary antibody) were purchased from Santa Cruz Biotechnology. 
3.2. Cell Culture 
Human esophageal carcinoma cell line ECA109 and human normal liver cell line L02 were 
cultured in RPMI-1640 supplemented with 10% FBS under standard culture condition (37 °C, 95% 
humidified air and 5% CO2). Exponentially growing ECA109 cells were used for all assays. 
3.3. Cell Viability Assay 
Cell viability was tested by MTT assay. ECA109 cells and L02 cells were seeded in 96-well 
plates at 1 × 104 cells/well and incubated with DADS or DDP (10–60 μg/mL) in five replicates for 
24 h. Cells treated with PBS with DMSO and in absence of DADS were used as the negative 
control. After the incubation, 5 mg/mL MTT reagent (20 μL) was added into each well, followed 
by the addition of 150 μL DMSO. The plates were measured at 570 nm (A570) by 
spectrophotometer. The percentage of cell viability inhibition rate was calculated according to the 
following formula: 
Cell viability (%) = 1 − [(A570 (control) − A570 (sample)/A570 (control)] × 100% (4) 
3.4. Apoptosis Assay 
The apoptosis rate was determined by using an Annexin V-FITC detection kit. ECA109 cells of  
5 × 105 were incubated with different concentrations of DADS (0, 20, 40 μg/mL) and 10 μM 
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caspase-3 inhibitor (Ac-DEVD-CHO) with DADS for 24 h. The cells were resuspended in 100 μL 
binding buffer at 1 × 106 cells/mL, and incubated with 5 μL Annexin V-FITC and 10 μL PI for 15 
min in the dark. Then, these cells were added into 400 μL binding buffer and measured by flow 
cytometer. Apoptosis was analyzed by Cell Quest software (BD Biosciences, San Jose, CA, USA). 
3.5. Xenograft Tumor Assay in Vivo 
Female BALB/c nude mice (4–6 weeks old) were purchased from Beijing Experimental Animal 
Center. These mice were handled according to the Guidelines for the Care and Use of Laboratory 
Animals with the approval of  the Medical Ethics Committee of  the Second Affiliated Hospital of 
Xi’an Jiaotong University (ID: 2012120, 01 November 2012). Exponentially growing ECA109 
cells of 5 × 106 were suspended in 200 μL RPMI–1640 and injected subcutaneously into the flank 
of each mouse. After growth for three weeks, all the mice developed palpable tumors. Twenty-four 
mice were randomly divided into four groups (n = 6 per group). The intraperitoneal injections of PBS 
with DMSO and in absence of DADS as the negative control group, DADS at 20 and 40 mg/kg body 
weight as therapy groups, DDP at 2 mg/kg body weight as the positive control group were made 
every three days for eight times. Tumors were monitored every three days by measuring length and 
width with a vernier caliper (tumor volume = 0.5 × L × W2). All the mice were sacrificed three 
days after the last injection and the xenograft tumors were observed and measured. 
3.6. Immunohistochemical Staining 
Tumor samples were formalin-fixed and paraffin-embedded. Paraffin blocks were cut serially  
at 5 μm thick. The sections were incubated with a specific primary antibody, such as PCNA 
(1:100) and caspase-3 (1:100), for 1 h at 37 °C followed by the overnight incubation at 4 °C in 
humidity chamber. Then, they were incubated with an appropriate biotinylated secondary antibody 
(1:200–1:400) followed by conjugated horseradish peroxidase–streptavidin and 3,3'-
diaminobenzidine working solution, and then counterstained with hematoxylin. Immunoreactive 
cells (yellow to brown) were enumerated and analyzed by Media Cybernetics Image-Pro Plus 
analysis system linked to Olympus microscope. The total number of cells was presented from five 
randomly selected microscopic fields of every sample in each group (×400). 
3.7. Quantitative Real-Time PCR 
Total RNA was extracted from each tumor sample by Trizol method, and the quantity of RNA 
was assessed by spectrophotometry. The cDNA was obtained by reverse transcription with 1 μg 
total RNA by using PrimeScript™ RT Master Mix kit. qPCR was made with SYBR Premix Ex 
Taq™ II Perfect Real Time kit. All the reactions were performed on ABI qPCR System. The 
individual value was normalized by the loading control, β-actin. The mRNA expression was 
expressed as fold, and comparative cycle threshold (Ct) method was used to study the relative 




3.8. Western Blot Assay 
ECA109 xenograft tumors of the negative control group and the two DADS groups were 
washed with cold PBS and homogenized in RIPA lysis buffer. The homogenates were centrifuged 
at 10,000× g for 10 min at 4 °C, and supernatants were collected as total proteins. Moreover, 
cytoplasmic proteins were prepared by using ProteoJET cytoplasmic Protein Extraction kit 
according to the manufacturer’s instruction. 
The proteins were separated by 8%–12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membrane, and probed with a 
specific primary antibody, such as RAF1 (1:1000), MEK1 (1:1000), p-MEK1 (1:500), ERK1/2 
(1:1000), p-ERK1/2 (1:300), caspase-3 (1:1000), active caspase-3 (1:500), caspase-9 (1:1000), active 
caspase-9 (1:500), cytochrome C, p53 (7F5) (1:1000) and β-actin (1:1000), followed by an 
appropriate peroxidase–conjugated secondary antibody (1:5000–1:10,000). The individual value 
was normalized by the loading control, β-actin. Antigen-antibody complex signals were visualized 
using BeyoECL Plus (Amersham Life Science). In addition, densitometric analysis was performed 
by Image J software (National Institutes of Health, Bethesda, MD, USA). 
3.9. Quantification and Statistic Analysis 
Quantitative data were expressed as the mean ± SD from at least three independent experiments. 
The two-tailed student’s t-test was performed for paired samples, and one-way ANOVA or two-
factor factorial ANOVA was used for multiple groups. The p value less than 0.05 was considered 
significant. Statistical analyses were performed by SPSS 17.0 statistics software (IBM, Armonk, 
NY, USA). 
4. Conclusions 
In summary, the present study demonstrated that DADS suppresses esophageal tumors without 
any apparent signs of toxicity, which is in agreement with a strong increase of apoptosis both in 
vitro and in vivo. DADS inhibits ECA109 tumor proliferation through the down-regulation of 
PCNA. Moreover, DADS induces apoptosis by activating the mitochondria-dependent pathway 
executed by caspase-3, increasing p53 expression level and the Bax/Bcl-2 ratio, and down-regulating 
the RAF/MEK/ERK pathway in ECA109 xenograft tumors. Overall, our studies of DADS in cell 
culture and animal models indicate that DADS is a potentially effective and safe anti-cancer agent 
for esophageal carcinoma treatment. 
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4-Hydroxyphenylacetic Acid Attenuated Inflammation  
and Edema via Suppressing HIF-1α in Seawater  
Aspiration-Induced Lung Injury in Rats 
Zhongyang Liu, Ronggang Xi, Zhiran Zhang, Wangping Li, Yan Liu,  
Faguang Jin and Xiaobo Wang 
Abstract: 4-Hydroxyphenylacetic acid (4-HPA) is an active component of Chinese herb Aster 
tataricus which had been widely used in China for the treatment of pulmonary diseases. The aim 
of this study is to investigate the effect of 4-HPA on seawater aspiration-induced lung injury. 
Pulmonary inflammation and edema were assessed by enzyme-linked immunosorbent assay 
(ELISA), bronchoalveolar lavage fluid (BALF) white cell count, Evans blue dye analysis, wet to 
dry weight ratios, and histology study. Hypoxia-inducible factor-1α (HIF-1α) siRNA and 
permeability assay were used to study the effect of 4-HPA on the production of inflammatory 
cytokines and monolayer permeability in vitro. The results showed that 4-HPA reduced seawater 
instillation-induced mortality in rats. In lung tissues, 4-HPA attenuated hypoxia, inflammation, 
vascular leak, and edema, and decreased HIF-1α protein level. In primary rat alveolar epithelial 
cells (AEC), 4-HPA decreased hypertonicity- and hypoxia-induced HIF-1α protein levels through 
inhibiting the activations of protein translational regulators and via promoting HIF-1α protein 
degradation. In addition, 4-HPA lowered inflammatory cytokines levels through suppressing 
hypertonicity- and hypoxia-induced HIF-1α in NR8383 macrophages. Moreover, 4-HPA decreased 
monolayer permeability through suppressing hypertonicity and hypoxia-induced HIF-1α, which 
was mediated by inhibiting vascular endothelial growth factor (VEGF) in rat lung microvascular 
endothelial cell line (RLMVEC). In conclusion, 4-HPA attenuated inflammation and edema through 
suppressing hypertonic and hypoxic induction of HIF-1α in seawater aspiration-induced lung injury 
in rats. 
Reprinted from Int. J. Mol. Sci. Cite as: Liu, Z.; Xi, R..; Zhang, Z.; Li, W.; Liu, Y.; Jin, F.; Wang, X.  
4-Hydroxyphenylacetic Acid Attenuated Inflammation and Edema via Suppressing HIF-1α in 
Seawater Aspiration-Induced Lung Injury in Rats. Int. J. Mol. Sci. 2014, 15, 12861-12884. 
1. Introduction 
Drowning, one of the three leading causes of unintentional injury death, is a major but often 
neglected public health problem [1]. The acute lung injury (ALI) is a serious body injuries induced 
by water aspiration. Some ALI induced by near-drowning would deteriorate into acute respiratory 
distress syndrome (ARDS) without proper treatments [2–4]. A recent study showed that ALI 
induced by seawater aspiration is severer than that by freshwater, the reason of which could 
concern osmotic pressure [5]. Hypoxia and hypertonicity are the two impact factors in seawater 
aspiration-induced ALI which had an acuter and rapider course than that induced by 
lipopolysaccharide (LPS) [4,6–8]. Besides mechanical ventilation [9–11], therapies which could 
attenuate the injuries in lungs at the early stage of seawater aspiration-induced ALI are required to 
prevent the occurrence of ARDS. 
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Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor that mediates adaptive 
responses to changes in tissue oxygenation. It is a basic helix-loop-helix transcription factor that is 
composed of two subunits, HIF-1α and HIF-1β. HIF-1β is constitutively present, whereas HIF-1α 
protein is kept at a low or undetectable level by continuous HIF-prolyl hydroxylase domain (PHD) 
enzyme-mediated degradation which is suppressed by hypoxia [12]. More and more evidences 
have demonstrated that HIF-1α also responds to nonhypoxic stimuli such as hormones, growth factors, 
vasoactive peptides, cytokines, heat, LPS, and hypertonicity [13–16]. Furthermore, a previous study 
reported that LPS-induced lung injury could be inhibited by reducing HIF-1α expression [17]. Since 
both of the two impact factors, hypoxia and hypertonicity, in seawater aspiration-induced ALI affected 
HIF-1α which played important roles in inflammation and edema [18,19], HIF-1α could be a potential 
therapeutic target. 
4-Hydroxyphenylacetic acid (4-HPA) is an active component of Chinese herb Aster tataricus  
(fan hun cao) which had been widely used in China for the treatment of pneumonia, HBV, and 
carcinoma [20–22]. Some previous studies reported that 4-HPA, a metabolite of aromatic amino 
acid catabolism that is secreted in saliva, controlled the NadA gene expression and could become a 
potential hypopigmenting agent [23–25]. We also found that Aster tataricus extract and 4-HPA 
could inhibit HIF-1α expression in our preliminary experiments. Therefore, we hypothesized that 
4-HPA might attenuate ALI induced by seawater aspiration through inhibiting HIF-1α expression. 
The aim of this study is to investigate the effect of 4-HPA on seawater aspiration-induced  
lung injury. 
2. Results 
2.1. 4-Hydroxyphenylacetic Acid (4-HPA) Reduced Seawater Instillation-Induced Mortality in Rats 
As shown in Figure 1, treatment with 4-hydroxyphenylacetic acid (4-HPA) significantly 
reduced seawater instillation-induced death, the accumulative mortalities during 12 h in middle 
dose (100 mg/kg) and high dose (150 mg/kg) of 4-HPA treatment groups were both significantly 
lower than that in the seawater instillation group (p < 0.05). However, the accumulative mortalities 
between middle and high does groups had no significant difference and no protection was observed 
when rats received 4-HPA treatment at dose of 50 mg/kg. Therefore, 100 mg/kg 4-HPA was used 
in the following studies. 
2.2. 4-HPA Increased PaO2 and Decreased PaCO2 in Seawater Instillation Rats 
The response of PaO2 and PaCO2 after instillation of seawater with or without treatment of 4-
HPA at 0.5, 1, 2, 3, and 4 h was observed (Figure 2). The results showed that PaO2 dropped 
precipitously to its minimum at 0.5 h after instillation and then recovered gradually. The PaO2 of 
rats treated with both seawater instillation and 4-HPA were significantly higher (p < 0.05) than that 
treated with only seawater instillation at 2, 3, and 4 h. Similarly, 4-HPA decreased PaCO2 of rats 




Figure 1. Effects of 4-hydroxyphenylacetic acid (4-HPA) on seawater instillation-
induced mortality in rats. Drowning model rats were prepared with or without different 
does of 4-HPA (50, 100 or 150 mg/kg body weight, i.p.). 4-HPA was administered after 
seawater instillation for 10 min. The mortality of rats were recorded at 2, 4, 6, 8, 10, and 
12 h after seawater instillation in each group (n = 20). * p < 0.05 vs. seawater group, # p < 
0.01 vs. seawater group. 
 
Figure 2. Effects of 4-HPA on PaO2 and PaCO2 after seawater instillation in rats. At 0, 
0.5, 1, 2, 3, and 4 h after seawater instillation with or without 4-HPA treatment, blood 
samples were obtained from left carotid artery and then PaO2 (A) and PaCO2 (B) were 
measured by blood gas analyzer. Data are means ± standard deviation (SD) (n = 10), * 









2.3. 4-HPA Attenuated Inflammation, Vascular Leak, and Edema in Seawater Instillation-Induced 
Lung Injury in Rats 
Inflammatory cytokines such as TNF-α, IL-1β, and IL-6 play important roles in the 
inflammatory response in lungs. Therefore, we detected the TNF-α (Figure 3A), IL-1β (Figure 3B), 
and IL-6 (Figure 3C) content to study the inflammatory response in lung tissues. After seawater 
instillation, the contents of TNF-α, IL-1β, and IL-6 increased at 2, 4, and 6 h (p < 0.05), and 4-HPA 
markedly inhibited the expression of these cytokines (p < 0.05). Additionally, the degrees of 
inflammation and vascular leakage in lungs were measured by bronchoalveolar lavage fluid 
(BALF) white cell count (Figure 3D) and Evans blue dye analysis (Figure 3E), and lung edema was 
assessed by wet to dry weight ratios (Figure 3F). Seawater instillation caused a significant increase 
in BALF white cell count, Evans blue dye analysis, and wet to dry weight ratios in seawater group 
compared with control (p < 0.05). However, administration with 4-HPA markedly reduced the 
three at 2, 4, and 6 h (p < 0.05). There was no significant difference in BALF white cell count, 
Evans blue dye analysis, and wet to dry weight ratios between control and 4-HPA groups in the 
absence of seawater instillation. The histological results showed that seawater aspiration after 4 h 
induced pulmonary edema, infiltration of inflammatory cells in the lung tissues and alveoli, and 
alveolar damage (Figure 3I). However, 4-HPA treatment could improve the lung injury (Figure 3J). 
There was no obvious change in the lung structure in control and 4-HPA groups (Figure 3G,H). 
Figure 3. Effects of 4-HPA on inflammatory cytokines, vascular leakage, and edema 
after seawater instillation in lungs. After instillation of seawater for 0, 2, 4, and 6 h in 
the absence or presence of 4-HPA, TNF-α (A); IL-1β (B); and IL-6 (C) contents in lung 
tissues were assessed by ELISA and white cells in brochoalveolar lavage fluid (BALF) 
were counted (D); Pulmonary vascular leakage was determined by Evans blue dye 
analysis (E); Lung edema was assessed by wet to dry weight ratios (F); Lung tissues 
were stained with hematoxilin and eosin to reveal histopathological changes at 4 h after 
seawater aspiration. (G) Control group; (H) 4-HPA group; (I) Seawater group; and  
(J) Seawater + 4-HPA group. The data are presented as means ± SD from three 















2.4. 4-HPA Decreased Seawater Instillation-Induced HIF-1α Protein Level, but not mRNA Level,  
in Lung Tissues in Rats 
As shown in Figure 4, seawater instillation increased both HIF-1α protein and mRNA levels of 
lung tissue in rats at 2, 4, and 6 h (p < 0.05). However, 4-HPA decreased seawater instillation-
induced HIF-1α protein level at each time point (p < 0.05), but not mRNA level. In addition,  
4-HPA did not affect HIF-1α expression in the absence of seawater instillation. Since hypoxia did 
not affected HIF-1α mRNA level [26–28], there was hypertonicity which promoted HIF-1α mRNA 
level in seawater aspiration-induced lung injury. Therefore, there were two major injury factors and 
we focused on the effects of hypertonicity and hypoxia in the following studies in vitro. To 
examine that 4-HPA attenuates inflammation and edema in lung through inhibiting HIF-1α, a series 
of studies in vitro were performed as below. 
Figure 4. Effects of 4-HPA on seawater instillation-induced HIF-1α protein and mRNA 
levels in lungs. After instillation of seawater for 0, 2, 4, and 6 h in the absence or 
presence of 4-HPA, HIF-1α protein (C,D) and HIF-1α mRNA (A,B) levels of  
lung tissue were detected by Western blotting and RT-PCR. The ratios of HIF-1α to  
β-actin in protein and mRNA levels from three independent experiments were  
obtained by density scanning of the Western blotting and PCR band using an image 





















2.5. 4-HPA Decreased Hypertonicity and Hypoxia-Induced HIF-1α Protein Level, but not mRNA 
Level, in Primary Rat Alveolar Epithelial Cells (AEC) 
As shown in Figure 5, hypertonicity (25% seawater) together with hypoxia (3% O2) or hypertonicity 
alone promoted both HIF-1α protein and mRNA expression in primary rat alveolar epithelial  
cells (AEC) (p < 0.05). Moreover, hypertonicity and hypoxia synergistically increased HIF-1α protein 
level. However, hypoxia alone increased only HIF-1α protein (p < 0.05) but not mRNA level.  
4-HPA decreased hypertonicity, hypoxia, and both of the two induced HIF-1α protein levels, but not 
mRNA levels (p < 0.05). 
Figure 5. Effects of 4-HPA on hypertonicity, hypoxia, and both of the two induced 
HIF-1α protein and mRNA levels in primary AEC. Treated by hypertonicity, hypoxia, 
or both of the two with or without 4-HPA treatment for 4 h, primary rat alveolar 
epithelial cells (AEC) were harvested and HIF-1α protein and mRNA levels were 
assessed by Western blotting and RT-PCR. The ratios of HIF-1α to β-actin in protein 
and mRNA levels from three independent experiments were obtained by density 
scanning of the Western blotting and PCR band using an image analysis system. Data 
are means ± SD, * p < 0.05 vs. control group, # p < 0.05 vs. the groups with stimuli or 
stimulus in the absence of 4-HPA treatment. 
 
  
2.6. 4-HPA Decreased Hypertonicity and Hypoxia-Induced HIF-1α Protein Level through 
Inhibiting the Activations of Protein Translational Regulators, Including p70S6K1, S6 Ribosomal 
Protein, 4E-BP1, and eIF4E in Primary AEC 
Since 4-HPA did not decrease hypertonicity and hypoxia-induced HIF-1α protein level via the 
inhibition of its mRNA expression (Figure 5), posttranscriptional mechanisms were likely 
involved. As shown in Figure 6, hypertonicity together with hypoxia promoted the phosphorylation 
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but not the total protein levels of HIF-1α related translational regulators, including p70S6K1, S6 
ribosomal protein, 4E-BP1, and eIF4E (p < 0.05), which were attenuated by 4-HPA treatment  
(p < 0.05) in AEC. Additionally, 4-HPA did not affect these translational regulators under normal 
condition. However, the activations of these translational regulators were not promoted by either 
hypertonicity or hypoxia alone and not affected by 4-HPA under hypertonic or hypoxic condition 
(data not shown). 
Figure 6. Effects of 4-HPA on HIF-1α related protein translational regulators under 
hypertonicity and hypoxia conditions in primary AEC. Primary AEC were treated by 
hypertonicity and hypoxia in the absence or presence of 4-HPA for 4 h. Then, the cells 
were harvested for Western blotting and phosphorylation and total protein levels of 
HIF-1α related translational regulators, including p70S6K1 (A); S6 ribosomal protein (B); 
4E-BP1 (C); and eIF4E (D) were detected. The ratios of HIF-1α related translational 
regulators to β-actin in protein levels from three independent experiments were 
obtained by density scanning of the Western blotting. Data are means ± SD, * p < 0.05 

















2.7. 4-HPA Decreased Hypertonicity and Hypoxia-Induced HIF-1α Protein Level through 
Promoting HIF-1α Protein Degradation, Which Was Associated with Prolyl Hydroxylase Domain 
Enzyme Isoform-2 (PHD2) Elevation in Primary AEC 
In the presence of CHX (blocking ongoing protein synthesis), the half-life of HIF-1α protein 
was longer (p < 0.05) than that in the presence of 4-HPA treatment under hypertonic and hypoxic 
condition (Figure 7A) in primary AEC. Moreover, 4-HPA also increased the degradation of HIF-1α 
protein (p < 0.05) under hypoxic (Figure 7B) or hypertonic (Figure 7C) condition. As shown in  
Figure 7D, hypertonicity and hypoxia significantly decreased the protein level of prolyl 
hydroxylase domain enzyme isoform-2 (PHD2) which is an important enzyme isoform to regulate 
the stability of HIF-1α protein, and this effect was impaired by the treatment of 4-HPA. Our results 
provide the evidence that 4-HPA decreased hypertonicity and hypoxia-induced HIF-1α protein 
level through a mechanism that involves prolyl hydroxylase-dependent degradation. 
2.8. 4-HPA Decreased the Production of Inflammatory Cytokines through Suppressing 
Hypertonicity and Hypoxia-Induced HIF-1α in NR8383 Macrophages 
Hypertonicity and hypoxia increased HIF-1α protein level (p < 0.05), which was markedly 
inhibited by HIF-1α siRNA or 4-HPA (p < 0.05) in NR8383 macrophages (Figure 8A). Meanwhile, 
TNF-α, IL-1β, and IL-6 contents in the supernatant from the cells stimulated with hypertonicity and 
hypoxia for 4 h were much more than those of control (p < 0.05) (Figure 8B–D). 4-HPA and HIF-
1α siRNA similarly reduced the production of TNF-α, IL-1β, and IL-6. The scramble sequence 
exerted no significant impact on HIF-1α expression and the production of inflammatory cytokines 




Figure 7. Effects of 4-HPA on HIF-1α protein degradation under hypertonicty and 
hypoxia conditions in primary AEC. AEC were treated with hypertonicity (C); hypoxia 
(B); or both of the two (A) with or without 4-HPA treatment for 4 h, followed by 
incubation with 100 μM cycloheximide (CHX, blocking ongoing protein synthesis) 
from 0–30 min. Cell lysates were subjected to Western blotting using antibodies against 
HIF-1α and β-actin (the left panel) and the intensity of HIF-1α protein relative content 
was quantified (the right panel). The plot represented means ± SD from three independent 
experiments, * p < 0.05 vs. groups with 4-HPA treatment; and (D) prolyl hydroxylase 
domain enzyme isoform-2 (PHD2) protein of AEC which were treated with both 
hypertonicity and hypoxia in the presence and absence of 4-HPA was detected by 
Western blotting. Data are means ± SD, & p < 0.01 vs. control group, # p < 0.05 vs. 















2.9. 4-HPA Decreased Monolayer Permeability through Suppressing Hypertonicity and  
Hypoxia-Induced HIF-1α, Which Was Mediated by Inhibiting VEGF in Rat Lung Microvascular 
Endothelial Cell Line (RLMVEC) 
As shown in Figure 9, hypertonicity and hypoxia increased rat lung microvascular endothelial 
cell line (RLMVEC) monolayer permeability (p < 0.01), and HIF-1α siRNA, sFlt-1 (VEGF 
antagonist), or 4-HPA did not affected it significantly during normal culture condition. 
Furthermore, hypertonicity and hypoxia-induced elevation of RLMVEC monolayer permeability 
was suppressed by HIF-1α siRNA, sFlt-1, and 4-HPA, respectively (p < 0.05) and there was no 
significant difference between these suppression effects. VEGF is a standard target gene of HIF-1. 
Therefore, 4-HPA decreased monolayer permeability through suppressing hypertonicity and 




Figure 8. Effects of 4-HPA on inflammatory cytokines levels under hypertonicty and 
hypoxia conditions in NR8383 macrophages. (A) NR8383 cells were transfected with HIF-
1α siRNA and a scramble sequence. Twenty-four hours after transfection, the cells with 
or without transfection were stimulated with hypertonicity and hypoxia in the absence 
or presence of 4-HPA for 4 h and then harvested for Western blotting; The supernatants 
of the cells were collected to detect the content of TNF-α (B); IL-1β (C); and IL-6 (D) 
by ELISA. Data are means ± SD from three independent experiments, * p < 0.05 vs. 
control group, # p < 0.05 vs. 2H group. 2H: hypertonicity and hypoxia, 2H + Scram: 
hypertonicity and hypoxia + scramble sequence, 2H + SiHIF: hypertonicity and 











Figure 9. Effects of 4-HPA on monolayer permeability under hypertonicity and 
hypoxia conditions in rat lung microvascular endothelial cells (RLMVEC). RLMVEC 
were stimulated with HIF-1α siRNA, sFlt-1 (1 μM, vascular endothelial growth factor 
(VEGF)antagonist), 4-HPA, hypertonicity and hypoxia, hypertonicity and hypoxia + 
HIF-1α siRNA, hypertonicity and hypoxia + sFlt-1, hypertonicity and hypoxia + 4-HPA 
for 4 h, respectively. The RLMVEC monolayer permeability was measured with FITC-
albumin (50 μM). Data are means ± SD, * p < 0.01 vs. control group, # p < 0.05 vs. 
hypertonicity and hypoxia group. 
 
3. Discussion 
The acute lung injury (ALI) induced by seawater aspiration had an acuter and rapider course 
than that induced by LPS [4,6–8]. The majority death induced by seawater aspiration happened 
within the first 6 h (Figure 2), which is greatly shorter than 40 h in LPS-induced ALI [29]. As 
Figures 2 and 3 shown, PaO2 dropped precipitously to its minimum at 0.5 h and inflammation and 
edema in lungs were most serious at 4 h after seawater instillation in rats. These time points were 
also earlier than those of some other ALI [30,31]. Since the results (Figures 1–3) suggested that  
4-HPA could attenuate the injuries in lungs rapidly after treatment, the agent should be used in the 
early stage of seawater aspiration-induced ALI. 
The high level of PaCO2 after seawater instillation suggested that there was pulmonary 
ventilatory insufficiency and local lung hypoxia. The treatment of 4-HPA increased PaO2 and 
decreased PaCO2 in seawater instillation rats (Figure 2). Since PaO2 and PaCO2 could indicate, at 
least partially, the degree of hypoxia within local lung tissue, 4-HPA might attenuate hypoxia in 
lung tissues in rats, which in turn inhibited HIF-1α indirectly. On the one hand, 4-HPA attenuated 
inflammation and edema within lung tissues to improve pulmonary membrane oxygenation, which 
could help to increase PaO2. On the other hand, the Chinese traditional medicine used Aster 
tataricus of which 4-HPA is an active component to reduce and expel phlegm. Therefore, 4-HPA 
might have a similar function and decrease PaCO2 through improving obstructive ventilatory disorder, 
which was not investigated in the current study. 
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Hypoxia increases HIF-1α protein by elevating its protein stability but not by prompting its 
mRNA expression [4,6–8]. However, instillation of seawater increased not only HIF-1α protein but 
also its mRNA expression (Figure 4). Therefore, hypertonicity induced by seawater instillation 
could be the factor which was accounted for the increase of HIF-1α mRNA expression. This 
hypothesis was demonstrated by our following experiments in vitro (Figure 5). Some previous 
studies reported that HIF-1α also responded to nonhypoxic stimuli such as hormones, growth 
factors, vasoactive peptides, cytokines, heat, hypertonicity, and LPS [13–16]. Our study 
demonstrated again that hypertonicity was a nonhypoxic stimulus of HIF-1α (Figures 4 and 5). In 
addition, a previous study reported that LPS induced HIF-1α synergistically with hypoxia [32]. Our 
results showed that hypertonicity could synergize with hypoxia to increase HIF-1α protein (Figure 5). 
Since our results showed that hypertonicity and hypoxia synergistically increased only HIF-1α 
protein but not mRNA level, posttranscriptional mechanisms were likely involved in this 
synergistic effect. We found hypertonicity together with hypoxia promoted the phosphorylation but 
not the total protein levels of HIF-1α related translational regulators, including p70S6K1, S6 
ribosomal protein, 4E-BP1, and eIF4E, which were attenuated by 4-HPA treatment in AEC (Figure 6). 
4-HPA inhibited the synergistic effect of hypertonicity and hypoxia on HIF-1α probably through 
suppressing synergistic protein translational process, which need further study to demonstrate. 
Although HIF-1α related protein translational regulators were not affected by hypertonicity or 
hypoxia alone (data not shown), HIF-1α protein degradation was suppressed by hypertonicity or 
hypoxia alone, which could be inhibited by 4-HPA (Figure 7). The HIF-1α protein levels which 
can be detected by Western blotting are mainly decided by three processes which are the 
transcription, translation, and degradation of HIF-1α protein. 4-HPA impacted HIF-1α protein levels 
following either hypertonicity or hypoxia through promoting HIF-1α protein degradation (Figure 
7B,C) but not through impacting these translational regulators (data not shown). Moreover, 4-HPA 
decreased HIF-1α protein levels following both hypertonicity and hypoxia through both inhibiting 
the activations of protein translational regulators (Figure 6) and promoting HIF-1α protein 
degradation (Figure 7A). In addition, hypertonicity or hypoxia alone did not impact these 
translational regulators but hypertonicity together with hypoxia synergistically increased them. 
Therefore, this synergistic effects might be impacted by 4-HPA which was not investigated in the 
current study. Taken all together, there are hypertonic and hypoxic factors in seawater aspiration-
induced lung injury and these two main impact factors synergistically increased HIF-1α protein 
which was attenuated by 4-HPA. Therefore, our study focused on how the effects of the two factors 
together in vitro were affected by 4-HPA. 
HIF-1 is a transcription factor which is essential for regulating oxygen homeostasis. It also 
regulates the expression of target genes important in angiogenesis, erythropoiesis, energy 
metabolism, and cell survival. However, there would be more detrimental effects of HIF-1α than 
beneficial ones when the injury factor such as LPS leads to HIF-1α overexpression, which needs an 
agent to inhibit [17]. In our study, the greatly increased HIF-1α protein induced synergistically by 
hypertonic and hypoxic factors contributed to the seawater aspiration-induced lung injury and we 
found that 4-HPA was a proper agent to attenuate the ALI by inhibiting HIF-1α. 
4-HPA which can be secreted in saliva is a metabolite of aromatic amino acid catabolism. It is 
also an active component of some Chinese herb such as Aster tataricus and Rhodiola rosea, as well 
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as an intermediate product of chemical synthesis of atenolol (β-receptor blocking agent) and 
puerarin (active component of Lobed Kudzuvine Root). Some previous studies reported that 4-HPA 
controlled the NadA gene expression and could become a potential hypopigmenting agent [23–25]. 
Our results suggested that 4-HPA was a good inhibitor of hypertonicity, hypoxia, or both of the 
two-induced HIF-1α expression. Additionally, 4-HPA, a water-soluble small molecular compound, 
could be a potential agent for the diseases with hypoxia-induced inflammation or edema and some 
carcinomas of which hypoxia-induced HIF-1α promoted the progress [33]. Moreover, HIF-1α played 
important roles in some diseases under hypertonic condition, such as diabetic eye disease [34] and 
some renal diseases [35]. Therefore, 4-HPA might be used in these fields. 
4. Experimental Section 
4.1. Animal Model and Grouping 
Male Sprague–Dawley rats, weighing 180–220 g each, were obtained from the Animal Center 
(Fourth Military Medical University, Xi’an, China). These rats were kept in a temperature-controlled 
house with 12 h light-dark cycles and fed with standard laboratory diet and water ad libitum. All 
experiments approved by the Animal Care and Use Committee of the Fourth Military Medical 
University conformed to the Declaration of the National Institutes of Health Guide for Care and 
Use of Laboratory Animals (Publication No.85–23, revised in 1985). 
Seawater Drowning Animal Model: the rats were anesthetized with 3% sodium pentobarbital  
(1.5 mL/kg, Sigma-Aldrich, St. Louis, MO, USA) intraperitoneally and maintained in the supine 
position during experiments with the head elevated 30°. A catheter was inserted into the right 
jugular artery to obtain blood samples. A 1 mL syringe was gently inserted into the trachea 
approximately 1.5 cm above the carina. Then, 4 mL/kg body weight of seawater was instilled 
within 4 min into both lungs. Seawater (osmolality 1300 mOsm/kgH2O, pH 8.2, temperature 25 °C, 
specific weight (SW) 1.05, NaCl 26.518 g/L, MgSO4 3.305 g/L, MgCl2 2.447 g/L, CaCl2 1.141 
g/L, KCl 0.725 g/L, NaHCO3 0.202 g/L, NaBr 0.083 g/L) was prepared according to the major 
composition of the East China Sea provided by Chinese Ocean Bureau (Beijing, China). 
To assess mortality of rates, drowning rat models were prepared as mentioned before with or 
without different does of 4-HPA (50, 100 or 150 mg/kg body weight, i.p.) (solubility of 4-HPA,  
150 mg/mL, pH 7.4). 4-HPA (Sigma-Aldrich, St. Louis, MO, USA, the chemical structure is 
showed in Figure 10) was administered after seawater instillation for 10 min. The mortality of rats 
were recorded every 2 h after seawater instillation in each group (n = 20). 
Figure 10. The chemical structure of 4-HPA. 
 
Rats were randomly divided into four groups (n = 40), (1) control; (2) 4-HPA (100 mg/kg) only;  
(3) seawater only; and (4) seawater + 4-HPA (100 mg/kg). In the seawater + 4-HPA group, rats 
were treated with 100 mg/kg 4-HPA after seawater instillation for 15 min. Rats were sacrificed at 
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2, 4, or 6 h after seawater instillation. Then, the thorax was opened rapidly and lungs were 
processed for studies in the manner described below. 
4.2. PaO2 and PaCO2 Study 
In each group, blood samples were obtained from a PE-50 catheter which was inserted in the 
right carotid artery at 0, 1, 2, 3, or 4 h after seawater instillation. Then, arterial oxygen tension 
(PaO2) and arterial carbon dioxide tension (PaCO2) of the blood samples was measured with a 
blood gas analyzer (Ymb-3100, Yima Opto-Electrical Technology Co., Ltd., Xi’an, China). 
4.3. ELISA 
The concentrations of TNF-α, IL-1β, and IL-6 were measured by using ELISA kits (R&D 
systems; Minneapolis, MN, USA). Lungs tissue and cells supernatant were processed according to 
the manufacturer’s instructions for ELISA. 
4.4. Bronchoalveolar Lavage Fluid (BALF) White Cell Count  
After seawater instillation for 0, 2, 4, or 6 h, rats were anesthetized with intraperitoneal 
pentobarbital. The lungs were lavaged with 2.5 mL ice-cold phosphate buffered saline five times in 
all groups. The recovery ratio of the fluid was about 90%. The collected bronchoalveolar lavage 
fluid (BALF) was centrifuged at 520× g for 20 min at 4 °C. The cell pellet was then resuspended in 
1 mL of red blood cell-lysis buffer to eliminate red cells. White cells were then re-pelleted by 
centrifugation at 520× g for 20 min at 4 °C. The cell pellet was again resuspended in phosphate 
buffer saline (PBS) and taken for cell counting using a hemocytometer. 
4.5. Assessment of Pulmonary Vascular Leakage  
Pulmonary vascular leakage was assessed as previously described [2] by quantitating 
extravasation of Evans blue into lung parenchyma. In brief, Evans blue dye (20 mg/kg, Sigma-
Aldrich, St. Louis, MO, USA) was given intravenously to the rats 30 min before the animals were 
sacrificed. After the lung was rapidly removed from the thoracic cavity, normal saline was 
immediately injected into the right ventricle till there was effused clear fluid from the left atrium. 
The lung was removed and dried to a constant weight at 60 °C for 72 h. The dried lung was 
weighed and then incubated in formamide (3 mL/100 mg, Sigma-Aldrich, St. Louis, MO, USA) at 
60 °C for 24 h. Then, the supernatant was separated by centrifugation at 5000× g for 30 min. The 
concentration of Evans blue in the supernatant was quantitated by the following formula: A620 
(correction) = A620 − (1.426 × A740 + 0.030). The concentration of Evans blue in the lung tissue 
(ET) was determined from the generated Evans blue standard absorbance curves. At the same time, the 
concentration of Evans blue in blood (EB) was detected by the same method as described above.  




4.6. Wet-to-Dry Weight (W/D) Ratio 
Wet-to-dry weight (W/D) ratio was used to represent the severity of lung edema. After lungs 
were separated from the thoracic cavity at the end of the experiment, the left lungs were weighed 
and then dried to constant weight at 50 °C for 72 h. The ratio of wet-to-dry was finally calculated 
by dividing the wet weight by the dry weight. 
4.7. Histological Study 
At the end of the experiments, the lung tissues were fixed with 4% paraformaldehyde for 24 h 
and embedded in paraffin. After deparaffinisation and dehydration, the lungs were cut into 5 μm 
sections and stained with hematoxylin and eosin. 
4.8. Cell Culture and Treatment 
Cell isolation and preparation of primary AEC (rat alveolar epithelial cells) monolayers: AT2 
(alveolar epithelial type II) cells were isolated from adult male Sprague-Dawley rats (125–150 g) 
by disaggregation with elastate (2.0–2.5 U/mL; Worthington Biochemical, Freehold, NJ, USA), 
followed by differential adherence on IgG-coated bacteriological plates. All animals were treated in 
accordance with the guidelines and approval of the Fourth Military Medical University Institutional 
Animal Care and Use Committee. Freshly isolated AT2 cells were plated in minimal defined 
serum-free medium (MDSF) consisting of Dulbecco’s modified Eagle’s medium and Ham’s F-12 
nutrient mixture in a 1:1 ratio, supplemented with 1.25 mg/mL bovine serum albumin, 10 mM 
HEPES, 0.1 mM nonessential amino acids, 2.0 mM glutamine, 100 U/mL sodium penicillin G, and 
100 μg/mL streptomycin. Cells were seeded onto tissue culture-treated polycarbonate filter cups 
(Nuclepore, Corning-Costar, Corning, NY, USA, 0.4 μm) at a density of 1.0 × 106 cells/cm2 and 
grown to confluence for RNA and protein analyses. Media were changed on the second day after 
plating and every other day thereafter. Cultures were maintained in a humidified 5% CO2 incubator 
at 37 °C. AT2 cell purity (>90%) was assessed by staining freshly isolated cells with tannic acid or 
an antibody (Ab) to a lamellar membrane protein, p180 (Covance Research, Berkeley, CA, USA), 
followed by immunofluorescence visualization. Cell viability (>95%) was measured by trypan blue 
dye exclusion. Day of isolation is designated as day 0; cells were used on day 3 or 4. 
Hypertonicity in vitro: Hypertonicity was induced by 25% seawater (seawater volume/(seawater 
volume + Ham’s F12 medium volume) = 25%), osmolality 538.21 ± 0.99 mOsm/kgH2O, pH 8.2, 
temperature 25 °C. In our preliminary experiment, HIF-1α protein level reached its maximum 
when AEC were stimulated by 25% seawater, compared with 12.5% or 37.5% seawater. 
Hypoxia in vitro: AEC were cultured in a special humidified hypoxic chamber as previously 
described [19]. Use of an antechamber ensured that once cells became hypoxic, they were never  
re-exposed to a normoxic environment. The chamber utilized a positive pressure system and was 
supplied with a gas mixture of 3% O2, 5% CO2, and the balance nitrogen. Culture media and 
seawater (25%) used in the test were allowed to equilibrate to 3% O2 before initiation of the test. 
For effects of 4-HPA on HIF-1α expression induced by hypertonicity, hypoxia, or both of the 
two, primary AEC cells were stimulated with hypertonicity, hypoxia, or both of the two in the 
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presence or absence of 4-HPA (100 μg/mL, Sigma-Aldrich, St. Louis, MO, USA) for 4 h. After 
being stimulated by diverse stimulus, HIF-1α protein, mRNA, HIF-1α related protein translational 
regulators (p70S6K1, S6 ribosomal protein, 4E-BP1, eIF4E), and HIF-prolyl hydroxylase domain 
enzyme isoform-2 (PHD2) protein levels of the cells were detected with Western blotting and RT-
PCR. Additionally, stimulated AEC were incubated with 100 μM cycloheximide (CHX, blocking 
ongoing protein synthesis, obtained from EMD Biosciences, San Diego, CA, USA) from 0–30 min, 
then the cells were harvested at indicated time points for Western blotting. 
4.9. Plasmid Construction and Transfection 
The rat alveolar macrophage cell line NR8383 (endowed by Pharmacology Department, Fourth 
Military Medical University, Xi’an, China) was maintained in Ham’s F12 medium (Sigma-Aldrich,  
St. Louis, MO, USA) supplemented with 10% fetal calf serum (FCS) (Sigma-Aldrich, St. Louis, 
MO, USA), 100 U/mL of penicillin (Sigma-Aldrich, St. Louis, MO, USA) and 100 μg/mL of 
streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 37 °C in a humidified atmosphere 
containing 5% CO2 and 95% air. 
HIF-1α siRNA was used to study the effect of 4-HPA on the production of inflammatory 
cytokines during hypertonic and hypoxic condition. The HIF-1α siRNA and the scramble sequence 
(Invitrogen, Grand Island, NY, USA) were kindly provided by Lili Liu (Department of Oncology, 
Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China), and the siRNA 
expression vector for HIF-1α was constructed as described previously [36]. NR8383 macrophages 
and rat lung microvascular endothelial cell line (RLMVEC) were transfected with HIF-1α siRNA or a 
scramble sequence by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Twenty-four hours after transfection, NR8383 cells with or without 
transfection were stimulated with both of hypertonicity and hypoxia for 4 h and harvested for 
Western blotting to evaluate the changes of HIF-1α expression. Meanwhile, the supernatant was 
collected to detect the contents of TNF-α, IL-1β, and IL-6 by ELISA. In addition, RLMVEC with 
or without transfection were used in permeability assay below. 
4.10. Permeability Assay 
Rat lung microvascular endothelial cells (RLMVEC, VEC Technologies, Rensselaer, NY, USA) 
were cultured in high-glucose DMEM (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 
5% fetal bovine serum (FCS) (Sigma-Aldrich, St. Louis, MO, USA), 50 U/mL of penicillin (Sigma-
Aldrich, St. Louis, MO, USA) and 50 μg/mL of streptomycin (Sigma-Aldrich, St. Louis, MO, USA) 
at 37 °C in a humidified atmosphere containing 5% CO2 and 95% air. RLMVEC were seeded 
(~100,000 cells/insert) on polystyrene filters (No.3470, 6.5-mm diameter, 0.4-μm pore size; Costar 
Transwell, Cambridge, MA, USA). RLMVEC were grown to confluence over 48 h after which the 
cells were treated with (1) standard cell culture conditions; (2) HIF-1α siRNA; (3) 1 μM soluble 
VEGF receptor-1 (sFlt-1, provided by professor Lan Yang, No. 210 Hospital of PLA, Dalian, 
China); (4) 4-HPA (100 μg/mL); (5) hypertonicity + hypoxia; (6) hypertonicity + hypoxia + HIF-1α 
siRNA; (7) hypertonicity + hypoxia + sFlt-1; and (8) hypertonicity + hypoxia + 4-HPA for 4 h, 
respectively. Then, the RLMVEC were washed three times in serum-free medium, and FITC-labeled 
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albumin (50 μM, Sigma-Aldrich, St. Louis, MO, USA) suspended in serum-free medium was added 
to the RLMVEC monolayers (100 μL, VEC Technologies, Rensselaer, NY, USA). The insert was 
placed in a new well of a 24-well plate containing serum-free medium (0.6 mL to ensure that the 
fluid volume on either side of the inserts was equalized to avoid a hydrostatic gradient that might 
alter the rate of albumin flux). Measuring the increase of fluoresceinisothiocyanate (FITC)-albumin 
in the lower well after 1 h assessed the transfer rate of albumin across the monolayer.  
FITC-albumin was quantified in a F4500 fluorimeter (Hitachi, Tokyo, Japan) and compared with a 
standard curve of fluorescence made with various dilutions of the FITC-albumin. The 
measurements of permeability were expressed as the fold of control. 
4.11. Western Blotting 
The lung tissues and cultured cells were prepared to extract proteins with lysis buffer (10 mM 
Tris pH 8.0, 1 mM EDTA, 400 mM NaCl, 10% glycerol, 0.5% NP-40, 5 mM sodium fluoride,  
0.1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol). The lysates were centrifuged at  
12,000 rpm for 30 min at 4 °C, and then supernatants were collected. Equal amounts (50 μg) of protein 
were separated by SDS-PAGE, transferred to nitrocellulose membrane at 100 V for 2.5 h at low 
temperature, and blocked with 5% skim milk for 2 h. Subsequently, anti-HIF-1α antibody (dilution 
1:1000; Millipore, Bedford, MA, USA), anti-p70S6K1 (Mr 70,000 ribosomal protein S6 kinase 1, 
1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-Phospho-p70S6K1 (Phosphorylated  
Thr-421/Ser-424) (1:500; Cell Signaling Technology, Danvers, MA, USA), anti-S6 ribosomal 
protein (1:100; Cell Signaling Technology, Danvers, MA, USA), anti-Phospho-S6 ribosomal 
protein (Ser-234/236) (1:500; Cell Signaling Technology, Danvers, MA, USA), anti-4E-BP1 
(eukaryotic initiation factor 4E (eIF4E)-binding protein 1, 1:500, Cell Signaling Technology, 
Danvers, MA, USA), anti-Phospho-4E-BP1 (Ser-65) (1:500; Cell Signaling Technology, Danvers, 
MA, USA), anti-eIF4E (1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-Phospho-
eIF4E (Ser-209) (1:1000; Cell Signaling Technology), anti-PHD2 (1:1000, Sigma-Aldrich, St. Louis, 
MO, USA), and anti-β-actin (1:2000, Sigma-Aldrich, St. Louis, MO, USA) were respectively 
added and kept with the membranes at 4 °C overnight. After repeated washing, the membranes were 
incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:2000, Sigma-
Aldrich, St. Louis, MO, USA) and bands visualized by using the enhanced chemiluminescence 
(ECL) system (Amersham Pharmacia Biotech, Arlington Heights, IL, USA). The results were 
expressed as the ratio to β-actin level in the same protein samples. 
4.12. Reverse Transcription-PCR  
Total RNA was extracted respectively from lung tissues and cells with Trizol (Invitrogen, Grand 
Island, NY, USA) according to the manufacturer’s instructions. The total RNA concentration was 
determined by spectrometric analysis. HIF-1α mRNA was examined by reverse transcription-PCR 
(RT-PCR) as per the manufacturer’s instructions (Promeaga, Madison, WI, USA). A total of 1 μg 
of RNA was incubated with reverse transcriptase mixture at 50 °C for 30 min, followed by 
amplification with the specific primers (synthesized by Invitrogen). The primers for HIF-1α  
(575 bp) were (forward) 5'-GACACCGCGGGCACCGATT-3', and (reverse) 5'-
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GTTCATCGTCCTCCCCCGGC-3', and for β-actin (240 bp), were (forward) 5'-
TAAAGACCTCTATGCCAACACAGT-3', and (reverse) 5'-
CACGATGGAGGGCCGGACTCATC-3', respectively. Thirty-five amplification cycles consisting of 
30 s of denaturation at 95 °C, 30 s of annealing at 55 °C, and 1 min of extension at 72 °C were 
performed. After amplification, the RT-PCR products were separated on 1% agarose gels (Invitrogen, 
Grand Island, NY, USA), and the bands were visualized by ethidium bromide (Invitrogen, Grand 
Island, NY, USA) staining. Quantitation was obtained by density scanning of the PCR bands using a 
Scion image analysis system (Beta 4.02, Scion Corporation, Colombo, Sri Lanka). The results 
were expressed as the ratio to β-actin mRNA level in the same RNA samples. 
4.13. Statistical Analysis 
Data are expressed as means ± SD Statistically significant differences between groups were 
determined by ANOVA followed by Student’s test. Survival data were presented by the Kaplan 
Meier method [37] and comparisons were made by the log rank test. A statistical difference was 
accepted as significant if p < 0.05. 
5. Conclusions 
4-HPA attenuated inflammation and edema through the suppression of hypertonic and hypoxic 
induction of HIF-1α in seawater aspiration-induced lung injury in rats. It may be considered as a 
potential agent in treatment of seawater aspiration-induced lung injury. 
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Effects of the Novel Compound DK223 ([1E,2E-1,2-Bis(6-
methoxy-2H-chromen-3-yl)methylene]hydrazine) on Migration 
and Proliferation of Human Keratinocytes and Primary 
Dermal Fibroblasts 
Manh Tin Ho, Hyun Sik Kang, Jung Sik Huh, Young Mee Kim, Yoongho Lim 
and Moonjae Cho 
Abstract: Wound healing plays an important role in protecting the human body from external 
infection. Cell migration and proliferation of keratinocytes and dermal fibroblasts are essential for 
proper wound healing. Recently, several studies have demonstrated that secondary compounds 
produced in plants could affect skin cells migration and proliferation. In this study, we identified a 
novel compound DK223 ([1E,2E-1,2-bis(6-methoxy-2H-chromen-3-yl)methylene]hydrazine) that 
concomitantly induced human keratinocyte migration and dermal fibroblast proliferation. We 
evaluated the regulation of epithelial and mesenchymal protein markers, such as E-cadherin and 
Vimentin, in human keratinocytes, as well as extracellular matrix (ECM) secretion and 
metalloproteinase families in dermal fibroblasts. DK223 upregulated keratinocyte migration and 
significantly increased the epithelial marker E-cadherin in a time-dependent manner. We also 
found that reactive oxygen species (ROS) increased significantly in keratinocytes after 2 h of 
DK223 exposure, returning to normal levels after 24 h, which indicated that DK223 had an early 
shock effect on ROS production. DK223 also stimulated fibroblast proliferation, and induced 
significant secretion of ECM proteins, such as collagen I, III, and fibronectin. In dermal fibroblasts, 
DK223 treatment induced TGF-β1, which is involved in a signaling pathway that mediates 
proliferation. In conclusion, DK223 simultaneously induced both keratinocyte migration via ROS 
production and fibroblast proliferation via TGF-β1 induction. 
Reprinted from Int. J. Mol. Sci. Cite as: Ho, M.T.; Kang, H.S.; Huh, J.S.; Kim, Y.M.; Lim, Y.; Cho, 
M. Effects of the Novel Compound DK223 ([1E,2E-1,2-Bis(6-methoxy-2H-chromen-3-
yl)methylene]hydrazine) on Migration and Proliferation of Human Keratinocytes and Primary 
Dermal Fibroblasts. Int. J. Mol. Sci. 2014, 15, 13091-13110. 
1. Introduction 
As the outer sheath of the human body, the skin absorbs initial damage from injuries or wounds. 
Disruption of the normal anatomic structure and loss of organ function lead to the repair process 
known as wound healing. Wound healing integrates different types of dermal cells and immune 
cells, such as keratinocytes and dermal fibroblasts, to mediate hemostasis, coagulation, and 
inflammation [1,2]. Wound healing begins with inflammation and immune cell recruitment to 
protect tissue from foreign invaders, such as bacteria and viruses. The next phase resurfaces the 
skin by stimulating regeneration and repair through proliferation of fibroblasts, re-epithelialization of 
keratinocytes, and other mechanisms. The final phase involves scar formation, which can cause 
concern for some patients when the scar is not aesthetically pleasing. Therefore, several studies 
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have investigated methods to enhance the regeneration process, which is a specific substitution of 
the damaged tissue, and to reduce skin repair, which causes fibrosis and scar formation [1]. 
Herbal plants, such as garlic and curcuma, have been used traditionally for wound healing, and 
it is known that their effects are due to secondary compounds, such as flavonoids, saponins and 
alkaloids [3]. For example, Lopez-Jornet et al. showed that potassium apigenin and other 
flavonoids present in verbena extract possess powerful anti-inflammatory properties [4]. In 
addition, Duarte et al. demonstrated the use of chamomile extract ointment for stimulating oral 
mucosa re-epithelialization and formation of collagen fibers after 10 days of treatment [5]. 
Moreover, these compounds were demonstrated to influence expression of extracellular matrix 
(ECM) proteins in skin, including collagen and elastin, which are markers of skin wrinkle [6]. 
Galicka et al. reported increased collagen synthesis upon exposure to apigenin glycoside  
7-O-glucuronide, a flavonoid glycoside, which also promoted procollagen transformation into 
collagen [7]. 
Furthermore, wound healing was controlled by matrix metalloproteinases (MMPs), enzymes 
that degrade the epidermal layer of the ECM, and are related to the cellular migration, invasion and 
metastasis processes [8]. MMPs, such as MMP1, MMP8, MMP13, play a specific role in mediating 
collagen degradation to reduce scar formation in wound healing. For example, Dang et al.  
reported upregulation of MMP1 expression to double normal levels, resulting in scarless wounds in 
fetal rat skin [9]. The role of MMPs in skin remodeling is well known, they are secreted  
extra-cellularly and regulated ECM protein accumulation in the wound healing process [10]. 
Notably, it has been reported that bioactive compounds regulate the expression and activity of 
MMPs. Catanzaro et al. demonstrated the effects of a sturgeon-based bioactive compound on the 
expression of the tumor necrosis factor-alpha, MMPs, and type-10 collagen genes in human 
chondrocytes [11]. Application of bioactive compounds may offer a potential therapy for 
controlling the wound healing or skin aging process. 
Natural secondary metabolites have been demonstrated to have several potential capabilities in  
gene expression regulation for skin repair. Based on the knowledge of the original structures, drug 
development science can be used to synthesize compounds that are conformationally modified to 
improve their activities [12]. In that way, novel compounds have been synthesized using innovative 
chemical techniques that expand on the original conformation. In this study, we examined the 
hypothesis that the novel compound DK223 ([1E,2E-1,2-bis(6-methoxy-2H-chromen-3-
yl)methylene]hydrazine) could induce keratinocyte migration, fibroblast proliferation, anti-wrinkle 
gene expression, and enhance the regeneration of skin, rather than mediate scar formation. 
2. Results 
2.1. DK223 Promoted the Migration but not the Proliferation of HaCaT Cells 
To investigate the ability of DK223 to induce migration of human keratinocytes, we treated 
HaCaT cells with different concentrations of DK223 in a 48 h scratch wound-healing assay. The 
results showed that DK223 at 2 μM significantly enhanced migration of HaCaT (167%), whereas 
other concentrations did not produce marked effects (Figure 1A). In order to confirm these results, 
we performed the migration assay with the ECIS system using other concentrations of DK223. In 
221 
 
this assay, during cell growth, the current is impeded based on the number of cells covering the 
electrode, which indicates the velocity of cell movement. The results were collected as impedance 
versus time. As expected, 2 μM DK223 significantly enhanced the migration velocity of 
keratinocytes after 24 h compared with the control (Figure 1B). 
We used the MTT assay to assess proliferation of HaCaT cells in response to DK223, and the 
results demonstrated that there was a significant increase in keratinocyte growth with 2 μM DK223 
after 48 h (Figure 1C). Whereas the mRNA and protein expression of p53, p21, p27, cyclin D, and 
cyclin E did not significantly change in 24 h compared with the untreated cells (Figure 1D,E). 
These observations indicate that DK223 could induce cell migration, as well as proliferation of 
human keratinocytes. 
2.2. DK223 Did not Induced Epithelial–Mesenchymal Transition (EMT) in HaCaT Cells 
EMT is critical for wound healing, and tissue regeneration has been shown to induce 
keratinocyte migration [13]. Thus, we examined the mRNA and protein expression of EMT 
markers, such as vimentin, E-cadherin, and Slug after DK223 treatment to investigate whether 
DK223-induced migration affected the EMT process. As shown by Western blot in Figure 2A, two 
mesenchymal markers, vimentin and Slug, were down-regulated in a time-dependent manner, 
whereas the adherents junction protein E-cadherin was increased significantly, peaking 24 h after 
treatment. These results correlated with the changes in mRNA expression measured by RT-PCR 
(Figure 2B). This suggested that DK223 did not induced EMT, processes in HaCaT cells. 
2.3. DK223 Induced NADPH Oxidase Expression and ROS Accumulation 
To gain insight into the mechanism of keratinocyte migration induced by DK223, we assessed 
NADPH oxidase expression and ROS accumulation, as well as the signaling pathways related to 
cell migration. As demonstrated in Figure 3B,C, NADPH oxidase 4 mRNA and protein expression 
increased in a time-dependent manner, peaking 2 h after treatment. This correlated with an up-
regulation in ROS accumulation, which also peaked at 2 h (Figure 3A), as well as with the effects 
on cellular signaling pathways. Phosphorylation of AKT was down-regulated at an early time 
point, while phosphorylation of ERK and JNK increased after 30 min of treatment (Figure 3D–F). 
These findings suggest a relationship between the early increase in ROS accumulation at 2 h and 
concomitant changes in intracellular signaling pathways. 
2.4. DK223 Affected Signaling Pathways and Cell Migration via ROS Accumulation 
To explore the mechanism mediating the effects of DK223 on signaling pathways and ROS 
accumulation, we pretreated cells with the NADPH inhibitor diphenylene iodonium (DPI) or the 
ROS scavenger N-acetylcysteine (NAC) prior to treatment with DK223 for 2 h. As expected, 
NADPH oxidase 4 was inhibited by DPI and NAC pretreatment. NAC also reduced DK223-
induced phosphorylation of JNK and ERK. Interestingly, the activation of AKT, which was down-
regulated by DK223 at 2 h, was also attenuated significantly in the presence of NAC and DPI 
(Figure 3G). These results indicated that DK223 induced the phosphorylation of JNK and ERK at 2 
h via ROS accumulation. Interestingly, DK223-induced migration was inhibited significantly by 
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NAC and DPI (Figure 3H), which indicated that the migration induced by DK223 might be 
regulate by ROS accumulation. 
Figure 1. Effect of DK223 on the migration and proliferation of HaCaT cells. (A) 
Cells were seeded at a density of 3 × 104/mL 24 h before the scratch test. Scratch 
widths were measured 48 h after DK223 treatment. Data represent the mean width 
percentage ± SD for at least three replicates, * p < 0.05; (B) Cells were seeded at a 
density of 3 × 104/mL 24 h before treatment. The impedances were measured and 
analyzed at 24 h after treatment using the ECIS system software. The line data 
indicate the migration velocity of cells treated with different concentrations of 
DK223; (C) Cells were seeded overnight before treatment with varying 
concentrations of DK223 for 48 h. Cells were then incubated with MTT for 4 h at 37 
°C, and the absorbance was measured at 570 nm; (D,E) The expression of cell cycle-
related proteins in HaCaT cells induced by 2 μM DK223 for 24 h. Protein expression 
was examined by Western blot analysis with the specific antibodies indicated, and 
mRNA expression was assessed by RT-PCR with the gene-specific primers indicated. 
A histogram depicting the ImageJ data analysis results is shown. Values represent 
means ± SD of three independent experiments, * p < 0.05 compared with the control in 






Figure 2. Time-dependent expression of EMT-related genes in HaCaT cells after 
treatment with DK223. (A) Protein expression was examined in HaCaT cells treated 
with 2 μM DK223 for different time periods using Western blot analysis with the 
specific antibodies indicated (B) mRNA expression was investigated by RT-PCR with 
the specific primers indicated. 
 
Figure 3. Time-dependent expression of NAPDH oxidase, ROS accumulation and 
signaling pathways in HaCaT cells after treatment with DK223. (A) Time- dependent 
ROS generation was detected in treated HaCaT cells using the DCF-DA assay. Cells 
were treated with 2 μM DK223 at different times and then stained with DCF-DA to 
detect ROS generation, as described previously. H2O2 was used as a positive control; 
(B,C) The expression of NAPDH oxidase 4 was examined by Western blot and  
RT-PCR, as described previously; (D–F) Signaling pathways were examined by 
Western blot with the specific antibodies indicated; (G) Cells were pretreated with 10 
μM DPI or 20 μM NAC for 2 h before 24 h DK223 incubation. Signaling pathways 
were examined by Western blot with the specific antibodies indicated; (H) Cells were 
seeded at a density of 3 × 104/mL 24 h before the scratch test. Scratch widths were 
measured 48 h after DK223 treatment only or co-treatment with 10 μM DPI or 20 μM 
NAC. A histogram shows the results of ImageJ data analysis. Values represent  













Figure 3. Cont. 
 
 
2.5. Migration-Related Proteins Are Down-Regulated by DK223 Treatment in HaCaT Cells 
Because the EMT process did not appear to involve DK223-induced migration, we investigated 
other migration-related proteins, including the MMPs and collagen I and III in serum-free media 
which was concentrated by protein filter centrifugation (serum could block the filter). It has been 
demonstrated recently that these proteins could regulate the migration and proliferation of 
keratinocytes [14,15]. We observed a significant down-regulation in the mRNA and protein 
expression of collagen I and III after 24 h of DK223 treatment (Figure 4A–C), while the levels 
of MMP-1 were increased (Figure 4C) [14]. Thus, high levels of this proteinase might degrade 
collagen I and III upon DK223 treatment. Moreover, another ECM protein, fibronectin, was  
highly expressed (Figure 4A–C) with DK223 treatment, which might be associated with the  
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down-regulation of MMP7 (Figure 4D). MMP7 is also known as a matrilysin, since it can use 
fibronectin as a cleavage substrate [15]. 
Figure 4. Expression of extracellular matrix proteins and migration-related genes in 
HaCaT cells treated with DK223. (A) mRNA expression was examined in HaCaT cells 
treated with 2 μM DK223 for 24 h using RT-PCR with the specific primers indicated; 
(B) Cells were treated with 2 μM DK223 in serum-free media. Conditioned media were 
removed and concentrated using Amicon centrifugation. Proteins in the media were 
analyzed by Western blot for collagen I, III, and fibronectin using the specific 
antibodies indicated; (C) Proteins in the media was analyzed by Western blot for 
MMP1 using the specific antibodies indicated; (D) mRNA expression was examined in 
HaCaT cells treated with 2 μM DK223 for 24 h using RT-PCR with the specific 
primers indicated; (E,F) Zymograph assay of the conditioned media from HaCaT 
cells treated with 2 μM DK223 for 24 h. Conditioned media were removed and 
concentrated using Amicon centrifugation. Proteins in the media were analyzed by a 
gelatin zymograph, as described previously. A histogram shows the results of ImageJ 
data analysis. Data are represented as the mean percentage of distance ± SD from at 















Alternatively, the mRNA expression of two other metalloproteinases, MMP2 and MMP9, also 
increased slightly compared with the control (Figure 4D), which correlated with results from the 
zymography assay for gelatinase activity of MMP2 and MMP9 (Figure 4E,F). These results 
indicate that the effects of DK223 on keratinocyte migration could be mediated by the degradation 
of collagen via a highly expressed collagenase. 
2.6. DK223 Ameliorates Proliferation of Human Dermal Fibroblasts 
Tissue formation, which is the second phase of wound healing, is characterized by migration  
and proliferation of different cell types. After the initiation of keratinocyte migration, fibroblasts 
tend to proliferate [2]. Therefore, we investigated the effects of DK223 on human dermal 
fibroblasts. We initially examined the proliferation of dermal fibroblasts in response to DK223 for 
24 and 48 h using the MTT assay. These results demonstrated that DK223 induced dermal 
fibroblast proliferation in a dose-dependent manner in both 24 and 48 h (Figure 5A). There was no 
significant difference between 2 and 5 μM concentrations of DK223; thus, we used 2 μM in 
subsequent experiments. 
To confirm the enhanced proliferation of fibroblasts treated with DK223, we evaluated the 
mRNA and protein expression of cell cycle-related genes. As shown by Western blot in Figure 5B, 
the protein levels of p21, p27 and p53 were down-regulated significantly after a 24 h exposure to 2 
μM DK223, while cyclin D and cyclin E were increased. These results correlated with changes in 
mRNA expression measured by RT-PCR (Figure 5C) except for p27 expression, which was 
increased after DK223 treatment. These data further indicate that the proliferation of fibroblasts 
increased with 2 μM DK223 after 24 h. 
In addition, the migration results showed that DK223 at 2 and 5 μM significantly enhanced 
migration of fibroblast in both 24 and 48 h, whereas other concentrations did not give high effects 
(Figure 5D). 
2.7. Dermal Fibroblasts Promote DK223-Induced ECM Deposition 
The ECM contains components essential to wound healing, including collagen I, III, and  
fibronectin [16]. Therefore, we examined ECM protein secretion from fibroblasts induced by 
DK223 for 24 h. Western blot analysis revealed high levels of collagen I, III and fibronectin with 
DK223 treatment (Figure 6A), which correlated with mRNA expression (Figure 6B). Another 
mesenchymal marker, vimentin, was augmented significantly compared with the control, indicating 
myofibroblast differentiation and possible migration (Figure 6B). Notably, MMP1, a collagenase 
protein, was inhibited markedly when treated with DK223 (Figure 6B), which could explain the 
high levels of collagen I and III in DK223-treated fibroblasts. However, differential effects were 
seen between MMP2 and MMP9, also known as gelatinase A and gelatinase B. MMP2 was up-
regulated in DK223 treatment, while MMP9 was down-regulated (Figure 6C,D). Thus, correlating 




Figure 5. Proliferation and migration of dermal fibroblasts treated with DK223 and 
expression of cell- cycle-related genes in dermal fibroblasts after incubation with 
DK223. (A) Human dermal fibroblasts were seeded at a density of 3 × 104/mL for 24 
and 48 h before treatment. MTT assay was performed as described previously; (B,C) 
The expressions of cell cycle-related genes, such as p21, p53, p27, cyclin E, cyclin D, 
were examined by Western blot and RT-PCR in 24 h as described previously; (D) 
Cells were seeded at a density of 3 × 104/mL 24 h before the scratch test. Scratch 
widths were measured 48 h after DK223 treatment. A histogram shows the results of 
ImageJ data analysis. Data are represented as the mean distance percentages ± SD 








Figure 6. Expression of extracellular matrix proteins and metalloproteinase genes.  
(A) Dermal fibroblasts were treated with 2 μM DK223 in serum-free media. 
Conditioned media were removed and concentrated using Amicon centrifugation. 
Proteins in the media were analyzed by Western blot for collagen I, III, fibronectin, 
MMP1, and vimentin with the specific antibodies indicated; (B) mRNA expression 
was examined in human dermal fibroblast cells treated with 2 μM DK223 for 24 h 
using RT-PCR and the specific primers indicated; (C,D) Zymograph assay of 
conditioned media from dermal fibroblasts treated with 2 μM DK223 for 24 h. 
Conditioned media were removed and concentrated using Amicon centrifugation. 
Proteins in the media were analyzed by a gelatin zymograph as described previously. A 
histogram shows the results of ImageJ data analysis. Data are represented as the mean 
distance percentages ± SD from at least three replicates, * p < 0.05. 
 
2.8. DK223 Induces TGF-β11 Secretion in Fibroblasts 
Fibroblasts have a key role in wound healing because they secrete growth factors and 
cytokines, such as TGF-β1, connective transforming growth factor (CTGF), IL-6 and IL-8 [17]. 
We investigated the production of TGF-β1 in DK223-treated fibroblasts to determine whether 
proliferation could be correlated with collagen deposition in fibroblasts. We found that DK223 




Figure 7. The effect of DK223 on TGF-β1 expression and on dermal fibroblast 
signaling pathways in response to a TGF-β1 receptor inhibitor. (A) Dermal fibroblasts 
were treated with 2 μM DK223 in serum-free media. TGF-β1 mRNA expression was 
examined in fibroblast cells treated with 2 μM DK223 for 48 h using RT-PCR with 
specific primers; (B,D) Dermal fibroblasts were treated with 2 μM DK223 in  
serum-free medium for different time periods; (C,E) Dermal fibroblasts were pretreated 
with 10 μM TGF-β1 receptor inhibitor (TGFRI)—LY2157299 before incubating with 
DK223 for 6 h. Signaling pathways were examined by Western blot with the specific 
antibodies indicated. A histogram shows the results of ImageJ data analysis. Values 
represent the means ± SD of three independent experiments, * p < 0.05 compared with the 
control in all under experiments. 
 
 
It has been suggested that TGF-β1 might promote fibroblast proliferation [18]. Thus, we 
investigated the correlations between DK223-induced TGF-β1 cellular changes in fibroblasts by 
examining the activation of various signaling pathways. The results demonstrated that the 
phosphorylation of AKT, a potential oncogene, was elevated in a time-dependent manner  
(Figure 7D). In addition, we observed early activation of pSmad2 at 1 h and increased 










(Figure 7D). These events indicate that DK223 activates the JNK/pSmad3L/c-Myc oncogenic 
pathway that mediates increased proliferation of fibroblasts. Interestingly, ERK phosphorylation 
was down-regulated below basal levels after an initial early increase at 1 h (Figure 7D). This  
could be the mechanism underlying the anti-proliferative response of the Ras/Raf/MEK/ERK signaling 
pathway that was previously reported in primary human fibroblasts [19,20]. Taken together, these 
results suggest that TGF-β1 signaling pathways mediate fibroblast proliferation in response  
to DK223. 
To confirm the involvement of TGF-β1, we treated cells with a TGF-β1 receptor inhibitor (TGFRI), 
which significantly inhibited pSmad2, pSmad3, JNK, and Akt phosphorylation (Figure 7C,E). 
Furthermore, TGFRI pretreatment restored ERK phosphorylation to normal levels (Figure 7E). In 
summary, our results indicate that DK223 modified cellular signaling pathways by elevating  
TGF-β1 secretion. 
3. Discussion 
The wound repair process protects the human body from infections and fluid loss; yet, it results 
in scar formation. In this study, we investigated the effects of DK223 on wound healing processes 
with the expectation that DK223 could induce skin regeneration. 
Skin regeneration is characterized by a re-epithelialization process that covers the wound 
surface and stimulates re-angiogenesis [21]. After the wound has been blocked by a blood clot, 
fibroblasts begin secreting ECM proteins, such as collagen III and fibronectin. These proteins 
reorganize the base structure under the blood clot to aid in keratinocyte migration [1]. We have 
studied this phenomenon by treating human keratinocytes with different concentrations of DK223 
in vitro. While DK223 did not promote keratinocyte cell growth, migration was enhanced 
significantly. Mesenchymal markers, such as Vimentin and Slug, were down-regulated in a time-
dependent manner, whereas the epithelial marker E-cadherin was increased markedly. This 
indicates that keratinocytes did not induce the EMT process and that the cells were bound together 
more tightly as migration increased. This phenomenon was compatible with our previous report of 
increased keratinocyte migration and higher levels of junction and adherent proteins, such as  
E-cadherin [22]. This was also reported by Li et al., who showed that a whole sheet of epithelial 
cells could migrate while maintaining tight cell-cell adhesion, a phenomenon they called 
“collective migration” [23]. As shown in Figure 3, DK223 significantly up-regulated E-cadherin, 
which plays an important role in re-epithelialization since adherent junctions prevent the epithelial 
barrier from further damage after wounding [23]. This indicates that DK223 was able to induce 
collective migration to protect the epithelial barrier from wounds. 
In a recent study, Kim et al. demonstrated that HaCaT keratinocyte migration was induced by 
the EGF-like ligand neuregulin, which was activated via Rac1 and Nox-driven ROS  
accumulation [24]. In our study, DK223 also significantly increased HaCaT cell migration via 
intracellular signaling pathways. Our results demonstrated that ROS accumulation peaked at 2 h, 
along with signaling proteins, such as AKT and ERK. In recent studies, AKT2 was shown to induce 
cell migration [25] and ERK/MAPK phosphorylation might be activated by ROS [26,27]. In 
addition, ERK/MAPK phosphorylation ameliorated keratinocyte migration [28]. In light of these 
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results, we propose that DK223 induces keratinocyte migration by modulating intracellular 
signaling pathways via ROS accumulation. 
Dermal fibroblasts are the primary ECM-producing cell type in the skin [29]. Once the wound 
has formed a blood clot via fibrin, dermal fibroblasts proliferate and infiltrate under the  
wound [16]. These cells secrete collagen and fibronectin, which replace the clot fibrin to accelerate 
wound closure [16]. Nevertheless, ECM accumulation in instances of excessive healing may cause 
unaesthetic scars [2]. In this study, DK223 induced keratinocyte migration and promoted the 
fibroblast-to-myofibroblast transition to help the wound heal more rapidly [30], with the evidence 
that vimentin was upregulated in fibroblasts, whereas it modulated ECM production in 
keratinocytes and fibroblasts. Furthermore, DK223 treatment increased fibronectin expression in 
both fibroblasts and keratinocytes. It is well known that fibronectin, which is normally produced in 
the first stage of wound healing, acts as the scaffold for collagen deposition and assists in cell 
migration to promote the wound healing process [31,32]. Collagens I and III are the main products 
of the wound healing process. Production of these collagens is necessary for wound healing; 
however, collagen deposition can promote scar formation. Thus, collagen production must be 
controlled for ideal wound healing. The DK223 effect resulted in increased collagen in fibroblasts, 
whereas a reduction in keratinocytes was seen. Correspondingly, levels of the collagenase MMP1 
were also increased in keratinocytes and reduced in fibroblasts. These observations suggest  
a regulatory role for DK223 in maintaining the balance of ECM production in skin repair. 
Similarly, Xie et al. reported that basic fibroblast growth factor (bFGF) improved wound healing 
by regulating the balance of ECM synthesis and degradation [33]. These simultaneous effects 
balance ECM production in the wound healing process and might prevent keloid scar formation. 
Thus, DK223 differentially modulates MMPs and ECM production in keratinocytes and fibroblasts 
to regulate individual cell functions during wound healing. 
According to our data, DK223 affects both keratinocyte migration and fibroblast proliferation to 
accelerate the wound healing process. It has been previously demonstrated that other novel 
compounds also exhibit similar effects. Lee et al. reported that heat-processed ginseng  
(sun ginseng) protected against UVB-induced damage in keratinocytes and fibroblasts by restoring  
Bcl-2 and Bcl-xL mRNA levels in keratinocytes to reduce UVB-induced apoptosis, and promote 
procollagen production in dermal fibroblasts by inhibiting MMP-1 gene expression [34].  
Werner et al. also reported that the keratinocyte-fibroblast interaction is also important for wound 
healing as keratinocytes modulate fibroblast to myofibroblast differentiation by secreting the 
growth factor-like TGF-β1, which increases production of myofibroblasts in ECM [35]. Moreover, 
Singh et al. suggested an alternative approach for wound healing by focusing on the effects of 
traditional medicines on keratinocytes and fibroblasts. Their bioactive compound increased both 
types of skin cells and reduced free-radical production to support the wound closure process [36]. 
TGF-β1 can participate in the wound healing process by inducing fibroblast migration and 
proliferation [37], activating the MMP family [38] and stimulating re-epithelialization [37]. It has 
been demonstrated that TGF-β1 expression was elevated significantly by excessive wound healing, 
leading to keloid scarring [39,40]. In our study, DK223 slightly increased TGF-β1 expression in 




4. Materials and Methods 
4.1. Reagent 
The DK223 (Figure 1A) compound was synthesized and kindly provided by Youngho Lim in 
the Division of Bioscience and Biotechnology, Konkuk University, Seoul, Korea. K2CO3 (5 mmol, 
692 mg) was dissolved in a solution of 2-hydroxy-5-methoxybenzaldehyde (I, 5 mmol, 760 mg) 
and acrolein (II, 7 mmol, 0.5 mL) in 1,4-dioxane (50 mL) and the reaction mixture was refluxed 
for 6 h. The solvent was evaporated and residue was extracted with diethyl ether (100 mL) and 
water (50 mL). Combined organic layers were dried over MgSO4. Filtration and evaporation 
produced aldehyde (III, 86%, m.p. 48–50 °C), which was used for next step without further 
purification. p-Nitroacylhydrazine (IV, 2 mmol, 334 mg) and 6-methoxy-2H-chromene-3-
carbaldehyde (III, 3 mmol, 570 mg) were dissolved in ethanol (30 mL) and a catalytic volume of 
conc. HCl was added. The resulting mixture was refluxed for 2 h. The reaction formed 
intermediates V and VI, which eventually produced DK233. A similar reaction has been reported 
previously [41]. After cooling to room temperature, the resulting precipitate was filtered and 
washed with ethanol. Recrystallization of crude solid resulted in pure DK223 (355 mg, 50%, m.p. 
246–250 °C; (Figure 8B)). 
Figure 8. (A) Chemical structure of DK223; (B) Method of DK223 synthesis, as 







4.2. Cell Culture 
In this study, we used the spontaneously immortalized keratinocyte cell line (HaCaT) and 
human dermal fibroblasts. HaCaT cells were cultured in RPMI medium (GIBCO, Grand Island, 
NY, USA) supplemented with 10% fetal bovine serum (FBS; GIBCO) and 1% 
penicillin/streptomycin (PAA Laboratories GmBH, Strasse, Austria). Human dermal fibroblast 
cells were cultured in DMEM media supplemented with 10% FBS (GIBCO) and 1% 
penicillin/streptomycin (PAA). Cells were incubated in a humidified atmosphere at 37 °C with  
5% CO2. 
4.3. Scratch Wound Healing Assay 
HaCaT cells were seeded in a 48-well plate before a 24 h wound healing scratch assay [42].  
The scratch wound was made using a sterile 200 μL pipette tip to scratch a line across the  
bottom of the culture dish. Culture media was then removed and replaced with fresh media 
supplemented with DK223 or dimethyl sulfoxide (DMSO) (Amresco, Solon, OH, USA) as a 
control. Photographs were taken at 4× magnification using an OLYMPUS IX70 microscope 
equipped with a digital camera before treatment and 48 h after treatment. The width of the scratch 
was measured by the distance from the both edge of scratch by ImageJ software (National Institutes 
of Health, Bethesda, MD, USA). Each scratch was measured 60 times across the span of wound 
scratch and calculated the average to compare the migration after 24 or 48 h. The experiments were 
repeated 3 dependent times. 
4.4. Migration Assay with the Electric Cell-Substrate Impedance Sensing (ECIS) System 
ECIS® (Electric Cell-substrate Impedance Sensing) is a real-time, label-free, impedance-based 
method of assessing the activities of cells grown in tissue culture. When cells are added to the 
ECIS Arrays and attached to the electrodes, they act as insulators and increase the impedance. As 
cells grow and cover the electrodes, the current is impeded in a manner related to the number of 
cells covering the electrode, the morphology of the cells, and the nature of the cell attachment. 
When cells are stimulated to change their function, the accompanying changes in cell morphology 
alter the impedance. Data are generated as impedance versus time. 
Electrode plates (eight wells, Applied Biophysics, Troy, NY, USA) were induced with an 
electrode-stabilizing solution provided by the manufacturer 10 min prior to seeding with HaCaT 
cells overnight. Cells were then treated with different concentrations of DK223. After 24 h, the 
electrode plates were placed in the ECIS apparatus in the incubator for migration analysis using the 
ECIS system software, according to the manufacturer’s instructions (Applied Biophysics, Troy, 
NY, USA). 
4.5. MTT Assay 
Cells were seeded in a 96-well plate at a density of 3 × 104/mL. HaCaT cells were treated with 
DK223 or DMSO for 24 h, while dermal fibroblasts were treated for 48 h. MTT solution 5 mg/mL 
(Amresco, OH, USA) was added to each well and incubated at 37 °C for 4 h. The medium was 
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then gently removed and replaced with 150 μL DMSO, followed by shaking for 30 min to dissolve 
the precipitate, and the absorbance was measured at 570 nm. 
4.6. Western Blot 
Cells were treated with DK223 or DMSO in a time- and dose-dependent manner. Cells lysate 
proteins were then harvested using a cell scraper and lysed in RIPA buffer. The protein 
concentration was determined using the bicinchoninic (BCA) assay (Thermo Scientific, Rockford, 
IL, USA). The protein in conditioned media (serum free media after treated cell with DK223) was 
concentrated by Amicon (Milipore, Darmstadt, Germany) centrifuge following manufacture 
instruction. The protein in media after centrifugation was determined the concentration using the 
Bardford assay (Bio-Rad, Hercules, CA USA). The proteins were separated by SDS-PAGE, 
followed by Western blot using the appropriate antibodies. 
All antibodies for Western blot were purchased commercially and prepared according to the 
manufacturer’s protocol. p21 (2947), AKT (9272), phosphorylated AKT (9271S), ERK (4695), 
Slug (9585S), and GAPDH (2118) were obtained from Cell Signaling (Danvers, MA, USA).  
E-cadherin (610181) was purchased from BD Science Transduction (San Jose, CA, USA). Cyclin 
E (sc-247), cyclin D1 (sc-246), p53 (sc-126), phosphorylated ERK (sc-7383), collagen I  
(sc-25974), collagen III (sc-28888), and fibronectin (sc-9068) were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, Dallas, TX, USA). MMP1 (444209) was purchased from Calbiochem 
(Hessen, Darmstadt, Germany). We used anti-mouse (PI-2000, Vector Labs Inc., Burlingame, CA, 
USA), anti-rabbit (PI-1000, Vector Labs), and anti-goat (AP-107P, Millipore, Billerica, MA, USA) 
secondary antibodies. Differences were confirmed using ImageJ software to determine the relative 
ratio of changes in the target protein levels to those of the DMSO control. 
4.7. RT-PCR 
Total RNA from treated cells was extracted using TRIzol reagent (Invitrogen, Grand Island, NY, 
USA). Equal amounts of total RNA in each treatment group were used to synthesize cDNA using a 
reverse transcriptase kit (Promega, Seoul, Korea). The resulting cDNA was used for RT-PCR using 
the G-Taq kit (Cosmo Genetech, Seoul, Korea) based on the manufacturer’s protocols. 
RT-PCR was performed using the following gene-specific primers designed using the  
Blast Primer website: GAPDH, forward primer 5'-GAAGGTGAAGGTCGGAGTC-3', reverse 
primer 5'-GAAGATGGTGATGGATTTC-3'; p53, forward primer 5'-
ACACGCTTCCCTGGATTGG-3', reverse primer 5'-CTGGCATTCTGGGAGCTTCA-3'; p21, 
forward primer 5'-GTCAGTTCCTTGAGCCG-3', reverse primer 5'-
GAAGGTAGAGCTTGGGCAGG-3'; and MMP1, forward primer 5'-
AGGGGAGATCATCGGGAC-3', reverse primer 5'-GGCTGGACAGGATTTTGG-3'; MMP2, 
forward primer 5'-AACACCTTCTATGGCTGCCC-3', reverse primer 5'-
ACGAGCAAAGGCATCACCA-3'; MMP7, forward primer 5'-TACAGTGGGAACAGGCTAGG-3', 
reverse primer 5'-GGCACTCCACATCTGGGC-3'. ImageJ software was used to analyze the 




4.8. MMP Zymograph Assay 
An MMP zymograph assay was performed according to the method described by Gogly et al. 
and modified with use of 8% sodium dodecyl sulfate (SDS) gels mixed with gelatin (0.01 mg/mL). 
The SDS in the gels was removed by two 30 min incubations in 200 mL 2.5% Triton X-100 at  
4 °C, and the gel slabs were incubated at 37 °C overnight in incubation buffer. The gels were 
subsequently fixed and stained for 1 h in 0.05% Coomassie Blue R-250. The molecular weight 
protein marker was clearly visible as light blue bands against the blue background. Gelatinase 
activity was detected as clear zones of negative staining against the blue background. The gels 
were scanned as permanent records of the results [43]. 
4.9. ROS Generation Analysis 
Accumulation of ROS was measured based on ROS-dependent oxidation of the oxidation-sensitive 
fluorescent probe 2'7'-dichlorofluorescin diacetate (DCFH-DA) to DCF [44]. Cells were seeded in 
a 96-well plate (3 × 104 cells/mL) for 24 h before flavonoid treatment and then treated with 2 μM 
DK223 for 0, 0.5, 1, 2, 12, and 24 h. H2O2 was used as a positive control. The cells were washed 
with PBS before removing medium, 200 μL of DCFH-DA (100 μM in PBS containing 1% FBS) 
were added, and the cells were incubated for 30 min at 37 °C in the dark. Intracellular ROS 
accumulation was measured using DCFH-DA with a DCF-DA microplate assay. A 
spectrofluorometer (SPECTRAFLUOR, Tecan, Männedorf, Switzerland) was used to assess ROS 
generation by measuring the fluorescence intensities from 10,000 cells/well at an excitation 
wavelength of 485 nm and an emission wavelength of 530 nm. 
4.10. Statistics 
The results were expressed as means ± standard deviation (S.D.). Group comparisons were 
performed using the SPSS v.16.0 software (SPSS Inc., Chicago, IL, USA) with one-way analysis 
(ANOVA) and Student’s t-test. p < 0.05 was considered to indicate statistical significance.  
All experiments were repeated at least in triplicate. 
5. Conclusions 
In conclusion, the novel compound DK223 has potent capabilities in wound healing and skin 
regeneration. It induced keratinocyte migration and fibroblast proliferation, while maintaining 
balance among ECM proteins, such as collagen I, III, and fibronectin. Taken together, DK223 
potentially aids wound healing and attenuates keloid scar development. 
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Development 
 
Prediction of Protein–Protein Interaction with Pairwise 
Kernel Support Vector Machine 
Shao-Wu Zhang, Li-Yang Hao and Ting-He Zhang 
Abstract: Protein–protein interactions (PPIs) play a key role in many cellular processes. 
Unfortunately, the experimental methods currently used to identify PPIs are both time-consuming 
and expensive. These obstacles could be overcome by developing computational approaches to 
predict PPIs. Here, we report two methods of amino acids feature extraction: (i) distance frequency 
with PCA reducing the dimension (DFPCA) and (ii) amino acid index distribution (AAID) 
representing the protein sequences. In order to obtain the most robust and reliable results for PPI 
prediction, pairwise kernel function and support vector machines (SVM) were employed to avoid 
the concatenation order of two feature vectors generated with two proteins. The highest prediction 
accuracies of AAID and DFPCA were 94% and 93.96%, respectively, using the 10 CV test, and the 
results of pairwise radial basis kernel function are considerably improved over those based on 
radial basis kernel function. Overall, the PPI prediction tool, termed PPI-PKSVM, which is freely 
available at http://159.226.118.31/PPI/index.html, promises to become useful in such areas as bio-
analysis and drug development. 
Reprinted from Int. J. Mol. Sci. Cite as: Zhang, S.-W.; Hao, L.-Y.; Zhang, T.-H. Prediction of 
Protein–Protein Interaction with Pairwise Kernel Support Vector Machine. Int. J. Mol. Sci. 2014, 
15, 3220-3233. 
1. Introduction 
Protein–protein interactions (PPIs) play an important role in such biological processes as host 
immune response, the regulation of enzymes, signal transduction and mediating cell adhesion. 
Understanding PPIs will bring more insight to disease etiology at the molecular level and 
potentially simplify the discovery of novel drug targets [1]. Information about protein–protein 
interactions have also been used to address many biological important problems [2–5], such as 
prediction of protein function [2], regulatory pathways [3], signal propagation during colorectal 
cancer progression [4], and identification of colorectal cancer related genes [5]. Experimental 
methods of identifying PPIs can be roughly categorized into low- and high-throughput methods [6]. 
However, PPI data obtained from low-throughput methods only cover a small fraction of the 
complete PPI network, and high-throughput methods often produce a high frequency of false PPI 
information [7]. Moreover, experimental methods are expensive, time-consuming and labor-
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intensive. The development of reliable computational methods to facilitate the identification of 
PPIs could overcome these obstacles. 
Thus far, a number of computational approaches have been developed for the large-scale 
prediction of PPIs based on protein sequence, structure and evolutionary relationship in complete 
genomes. These methods can be roughly categorized into those that are genomic-based [8,9], 
structure-based [10], and sequence-based [11–26]. Genomic- and structure-based methods cannot 
be implemented if prior information about the proteins is not available. Sequence-based methods 
are more universal, but they concatenate the two feature vectors of protein Pa and Pb to represent 
the protein pair Pa–Pb, and the concatenation order of two feature vectors will affect the prediction 
results. For example, if we use feature vectors  to represent protein Pa and Pb, respectively, 
then the Pa–Pb protein pair can be expressed as , or . In general, however, 
 is not equal to . Furthermore, PPIs have a symmetrical character; that is, the 
interaction of protein Pa with protein Pb equals the interaction of protein Pb with protein Pa. Under 
these circumstances, concatenating two feature vectors of protein Pa and Pb to represent the protein 
pair Pa–Pb and then using the traditional kernel  to predict PPIs would not be workable. 
Therefore, in this paper, we introduced two kinds of feature extraction approaches, amino acid 
distance frequency with PCA reducing the dimension (DFPCA) and amino acid index distribution 
(AAID) to represent the protein sequences, followed by the use of pairwise kernel function and 
SVM to predict PPI. 
2. Results and Discussion 
LIBSVM [27], loaded from http://www.csie.ntu.edu.tw/~cjlin, is a library for Support Vector 
Machines (SVMs), and it was used to design the classifier in this paper. The kernel program of the 
software was modified to the pairwise kernel functions, which were formed by the RBF genomic 
kernel function  in all experiments. 
2.1. The Results of DFPCA and AADI with KII Pairwise Kernel Function SVM 
In statistical prediction, the following three cross-validation methods are often used to examine 
a predictor for its effectiveness in practical application: independent dataset test, K-fold crossover 
or subsampling test, and jackknife test [28]. However, of the three test methods, the jackknife test 
is deemed the least arbitrary that can always yield a unique result for a given benchmark dataset as 
demonstrated by Equations (28)–(30) in [29]. Accordingly, the jackknife test has been increasingly 
and widely used by investigators to examine the quality of various predictors (see, e.g., [30–41]). 
However, to reduce the computational time, we adopted the 10-fold cross-validation (10 CV) test 
in this study as done by many investigators with SVM as the prediction engine. 
The four feature vector sets, Hf, Vf, Pf, and Zf, extracted with DFPCA and the five feature 
vector sets, LEWP710101, QIAN880138, NADH010104, NAGK730103 and AURR980116, 
extracted with AAID were employed as the input feature vectors for KII pairwise radial basis kernel 
function (PRBF) SVM. The results of DFPCA and AAID are summarized in Table 1. 
From Table 1, we can see that the performances of the two feature extraction approaches, i.e.,  
amino acid distance frequency with PCA (DFPCA) and amino acid index distribution (AAID), are 
,a bx x
ab a bx x x + ba b ax x x +
a bx x+ b ax x+
1 2( , )k x x
1 2( , )K x x
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nearly equal when using the KII pairwise kernel SVM. The total prediction accuracies are 
93.69%~94%. As previously noted, we used just five amino acid indices, including LEWP710101, 
QIAN880138, NADH010104, NAGK730103 and AURR980116, to produce the feature vector 
sets. When we tested the performance of AAID against the remaining 480 amino acid indices from 
AAindex, we found that the amino acid index does affect predictive results and that the total 
prediction accuracies of those amino acid indices were 79.4%~94%. Among our original five 
indices, as noted above, the performance of AAID was superior in comparison to the results from 
AAindex. To account for the better performance of our five indices, we point to the 
physicochemical and biochemical properties of amino acids. By single-linkage clustering, one of 
agglomerative hierarchical clustering methods, Tomii and Kanehisa [42] divided the minimum 
spanning of these amino acid indices into six regions: α and turn propensities,  
β propensity, amino acid composition, hydrophobicity, physicochemical properties, and other 
properties. The indices of LEWP710101, QIAN880138, NAGK730103 and AURR980116 are 
arranged into the region of α and turn propensities, while NADH010104 is arranged into the 
hydrophobicity region, indicating that the properties of α and turn propensities, and hydrophobicity 
contain more distinguishable information for predicting PPIs. 
Table 1. Results of DFPCA and AAID with PRBF SVM in 10 CV test. 
Feature Set Sn (%) PPV (%) ACC (%) MCC 
Hf 95.94 ± 1.92 91.98 ± 2.88 93.78 ± 1.44 0.8765 
Vf 95.66 ± 2.75 92.52 ± 2.40 93.96 ± 1.86 0.8798 
Pf 95.78 ± 2.23 92.07 ± 1.69 93.76 ± 1.93 0.8760 
Zf 96.06 ± 1.24 91.71 ± 3.13 93.69 ± 1.86 0.8747 
LEWP710101 95.86 ± 2.23 92.08 ± 4.32 93.80 ± 2.42 0.8768 
QIAN880138 96.06 ± 2.83 92.27 ± 1.50 94.00 ± 1.22 0.8808 
NADH010104 95.82 ± 2.98 92.04 ± 2.51 93.76 ± 1.66 0.8760 
NAGK730103 96.06 ± 2.83 92.09 ± 4.02 93.90 ± 3.31 0.8789 
AURR980116 95.94 ± 2.07 92.33 ± 1.42 93.98 ± 1.24 0.8804 
2.2. The Comparison of Pairwise Kernel Function with Traditional Kernel Function 
In order to evaluate the performance of pairwise kernel function, we compared the results of 
pairwise radial basis kernel function (PRBF) and radial basis function kernel (RBF) with the same 
feature vector sets. For RBF, we concatenate the two feature vectors of protein Pa and protein Pb to 
represent the protein pair Pa – Pb; that is, feature vector  was used as the input feature 
vector of RBF. The results of RBF and PRBF with DFPCA in the 10CV test are listed in Table 2. 
  
ab a bx x x +
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Table 2. Results of RBF and PRBF with DFPCA in the 10 CV test. 
Feature Set Kernel Function Sn (%) PPV (%) ACC (%) 
Hf 
RBF 89.96 ± 0.52 89.65 ± 2.17 89.88 ± 1.05 
PRBF 95.94 ± 1.92 91.98 ± 2.88 93.78 ± 1.44 
Vf 
RBF 90.20 ± 1.31 89.33 ± 2.60 89.72 ± 1.72 
PRBF 95.66 ± 2.75 92.52 ± 2.40 93.96 ± 1.86 
Pf 
RBF 89.32 ± 0.86 89.26 ± 2.91 89.28 ± 1.44 
PRBF 95.78 ± 2.23 92.07 ± 1.69 93.76 ± 1.93 
Zf 
RBF 90.84 ± 1.85 88.79 ± 2.50 89.64 ± 1.18 
PRBF 96.06 ± 1.24 91.71 ± 3.13 93.69 ± 1.86 
Table 2 shows that the performance of PRBF is superior to that of RBF for predicting PPI. The 
total prediction accuracies of PRBF are higher at 3.9%~4.48% than those of RBF. 
 
2.3. The Comparison of DF and DFPCA Feature Extraction Approaches 
For the feature extraction approach of distance frequency of amino acids grouped with their 
physicochemical properties, we compared the results of DF and DFPCA with PRBF SVM to test 
the validity of adopting PCA. The reduced feature matrix is set to retain 99.9% information of the 
original feature matrix by PCA. The results of DF and DFPCA with PRBF SVM in the 10CV test are 
listed in Table 3. 
Table 3. Results of DF and DFPCA with PRBF SVM in the 10 CV test. 
Feature Set Feature Extraction Approach Sn (%) PPV (%) ACC (%) MCC 
Hf 
DF 97.37 ± 2.55 66.67 ± 27.8 74.34 ± 24.3 0.5485 
DFPCA 95.94 ± 1.92 91.98 ± 2.88 93.78 ± 1.44 0.8765 
Vf 
DF 97.21 ± 2.39 71.40 ± 23.0 78.17 ± 27.1 0.6093 
DFPCA 95.66 ± 2.75 92.52 ± 2.40 93.96 ± 1.86 0.8798 
Pf 
DF 97.13 ± 4.70 69.48 ± 25.5 77.23 ± 27.2 0.5937 
DFPCA 95.78 ± 2.23 92.07 ± 1.69 93.76 ± 1.93 0.8760 
Zf 
DF 97.65 ± 4.82 62.29 ± 29.5 69.26 ± 23.6 0.4680 
DFPCA 96.06 ± 1.24 91.71 ± 3.13 93.69 ± 1.86 0.8747 
From Table 3, we can see that the performance of DFPCA is superior to that of DF. The total 
prediction accuracies and MCC (see Equation (16) below) of DFPCA are 15.79%~24.43% and 
0.2705~0.4067 higher than those of DF, respectively. Although the sensitivities of DF are a little 
higher (1.43%~1.59%) than those of DFPCA for the Hf, Vf, Pf and Zf feature sets, the positive 
predictive values are much less than that of DFPCA (21%~29%), which means that the DFPCA 
approach can largely reduce the false positives. These results show that the performance of DFPCA 
is superior to that of DF for predicting PPI. It should be noted that feature vectors generated with 
either DF or DFPCA contain statistical information of amino acids in protein sequences, as well as 
information about amino acid position and physicochemical properties. 
2.4. The Performance of the Predictive System Influenced by Randomly Sampling the 
Noninteracting Protein Subchain Pairs 
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To investigate the influence of randomly sampling the noninteracting protein subchain pairs,  
we randomly sampled 2510 noninteracting protein subchain pairs five times to construct five 
negative sets, and we used the DFPCA approach with hydrophobicity property to predict PPI in the 
10CV test. The results, as shown in Table 4, indicate that random sampling of the noninteracting 
protein subchain pairs in order to construct negative sets has little influence on the performance of 
the PPI-PKSVM. 
Table 4. Effect of random sampling of the noninteracting protein subchain pairs on the 
performance of PPI-PKSVM with DFPCA and PRBF SVM in the 10CV test. 
Sampling Time Sn (%) PPV (%) AAC (%) MCC 
1 95.38 ± 3.35 91.20 ± 3.37 93.09 ± 3.45 0.8627 
2 95.42 ± 1.39 91.52 ± 3.24 93.29 ± 1.65 0.8665 
3 95.46 ± 3.03 91.21 ± 1.63 93.13 ± 2.29 0.8635 
4 95.46 ± 3.03 91.49 ± 1.70 93.29 ± 2.13 0.8666 
5 95.94 ± 1.92 91.98 ± 2.88 93.78 ± 1.44 0.8765 
2.5. Comparison of Different Prediction Methods 
To demonstrate the prediction performance of our method, we compared it with other  
methods [25] on a nonredundant dataset constructed by Pan and Shen [25], in which no protein pair 
has sequence identity higher than 25%. The number of positive links, i.e., interacting protein pairs, 
is 3899, which is composed of 2502 proteins, and the number of negative links, i.e., noninteracting 
protein pairs, is 4262, which is composed of 661 proteins. Among the prediction results of different 
methods shown in Table 5, the performance of PPI-PKSVM stands out as the best. When  
compared to Shen’s LDA-RF, the accuracy (see Equation (15) below) and MCC of 
LEWP710101/QIAN880138 and Hf-DFPCA are respectively 1.9%, 2%, 0.038 and 0.039 higher. 
These results indicate that our method is a very promising computational strategy for predicting 
protein–protein interaction based on the protein sequences. 
Table 5. Performance comparison of different PPI methods using Shen’s dataset a in 
the 10 CV test. 
Method Sn (%) Sp (%) ACC (%) MCC 
LEWP710101 97.3 ± 0.04 99.2 ± 0.04 98.3 ± 0.00 0.966 ± 0.0006 
QIAN880138 97.3 ± 0.10 99.1 ± 0.10 98.3 ± 0.10 0.966 ± 0.002 
NADH010104 97.2 ± 0.07 99.2 ± 0.04 98.3 ± 0.05 0.965 ± 0.0007 
NAGK730103 97.2 ± 0.06 99.2 ± 0.04 98.2 ± 0.06 0.965 ± 0.0004 
AURR980116 97.3 ± 0.04 99.1 ± 0.06 98.2 ± 0.06 0.965 ± 0.0006 
Hf-DFPCA 97.6 ± 0.20 99.1 ± 0.10 98.4 ± 0.10 0.967 ± 0.002 
Vf-DFPCA 97.5 ± 0.10 98.9 ± 1.00 98.3 ± 0.80 0.965 ± 0.007 
Pf-DFPCA 96.9 ± 0.10 99.5 ± 0.60 98.2 ± 0.60 0.964 ± 0.004 
Zf-DFPCA 97.9 ± 0.90 96.0 ± 0.20 96.9 ± 1.10 0.939 ± 0.002 
LDA-RF b 94.2 ± 0.40 98.0 ± 0.30 96.4 ± 0.30 0.928 ± 0.006 
LDA-RoF b 93.7± 0.50 97.6 ± 0.60 95.7 ± 0.40 0.918 ± 0.007 
LDA-SVM b 89.7 ± 1.30 91.5 ± 1.10 90.7 ± 0.90 0.813 ± 0.018 
AC-RF b 94.0 ± 0.60 96.6 ± 0.40 95.5 ± 0.30 0.914 ± 0.007 
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AC-RoF b 93.3 ± 0.70 97.1 ± 0.70 95.1 ± 0.60 0.910 ± 0.009 
AC-SVM b 94.0 ± 0.60 84.9 ± 1.70 89.3 ± 0.80 0.792 ± 0.014 
PseAAC-RF b 94.1 ± 0.90 96.9 ± 0.30 95.6 ± 0.40 0.912 ± 0.007 
PseAAC-RoF b 93.6 ± 0.90 96.7 ± 0.40 95.3 ± 0.50 0.907 ± 0.009 
PseAAC-SVM b 89.9 ± 0.70 92.0 ± 0.40 91.2 ± 0.4 0.821 ± 0.006 
a Shen’s dataset contains two subdatasets, C and D, which are available at http://www.csbio.sjtu. 
edu.cn/bioinf/LR_PPI/Data.htm; b These results are taken from Table 4 of the literature [25]. 
3. Experimental Section 
3.1. Dataset 
To construct the PPI dataset, we first obtained the subchain pair name of PPIs from the PRISM 
(Protein Interactions by Structural Matching) server (http://prism.ccbb.ku.edu.tr/prism/), which was 
used to explore protein interfaces, and we downloaded the corresponding sequences of these 
protein subchain pairs from the Protein Data Bank (PDB) database (http://www.rcsb.org/pdb/). 
According to PRISM [43], a subchain pair is defined as an interacting subchain pair if the interface 
residues of two protein subchains exceed 10; otherwise, the subchain pair is defined as a 
noninteracting subchain pair. For example, suppose a protein complex has A, B, C and D 
subchains. If the interface residues of AB, AC, and BD subchain pairs total more than 10, while the 
interface residues of AD, BC and CD subchain pairs total less than 10, then the AB, AC, and BD 
subchain pairs are treated as interacting subchain pairs, while the AD, BC and CD subchain pairs 
are treated as noninteracting subchain pairs. All interacting protein subchain pairs were used in 
preparing the positive dataset, and all noninteracting subchain pairs were used in preparing the 
negative dataset. To reduce the redundancy and homology bias for methodology development, all 
protein subchain pairs were screened according to the following procedures [15]. (i) Protein 
subchain pairs containing a protein subchain with fewer than 50 amino acids were removed; (ii) 
For subchain pairs having ≥40% sequence identity, only one subchain pair was kept. The ≥40% 
determinant may be understood as follows. Suppose protein subchain pair A is formed with protein 
subchains A1 and A2 and protein subchain pair B is formed with protein subchains B1 and B2. If 
sequence identity between protein subchains A1 and B1 and A2 and B2 is ≥40%, or sequence 
identity between protein subchains A1 and B2 and between A2 and B1 is ≥40%, then the two 
protein subchain pairs are defined as having ≥40% sequence identity. In our method, we would 
only retain those subchain pairs having <40% sequence identity. After these screening procedures, 
the resultant positive set was comprised of 2510 interacting protein subchain pairs, while the 
resultant negative set contained many noninteracting protein subchain pairs. To avoid unbalanced 
data between the positive and negative sets, we randomly sampled the 2510 noninteracting protein 
subchain pairs to construct the negative set. Finally, a PPI dataset consisting of 2510 PPI subchain 
pairs and 2510 noninteracting protein subchain pairs was constructed. 
3.2. Distance Frequency of Amino Acids Grouped with Their Physicochemical Properties 
The frequency of the distance between two successive amino acids, or distance frequency, was 
used to predict subcellular location by Matsuda et al., [44] and can be described as follows: For a 
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protein sequence P, the distance set dA between two successive letters (e.g., A) appearing in protein 
sequence P can be represented as: 
 (1) 
where nA is number of letter As appearing in protein sequence P, di is the distance from the ith letter  
A to the (i + 1)th letter A, and di is calculated in a left-to-right fashion. The distance frequency 
vector for letter A can be defined by the following equation: 
 (2) 
where Nj represents the number of times that the jth distance unit appears in the dA set. For 
example, considering the protein sequence AACDAMMADA, the distance sets of letters A, C, D and 
M are shown respectively as 
 
As a result, the corresponding distance frequency vectors are shown respectively as 
. The other 16 basic amino acid 
distance frequency vectors are zero vector, or V = [0,0,0,0,0]. Thus, we can use the feature vector x 
to encode the protein sequence P: 
 
In this work, we used the concept of distance frequency [44] and borrowed Dubchak’s idea of 
representing the amino acid sequence with four physicochemical properties [45] to encode the 
protein subchain sequence. First, according to the amino acid value given by such physicochemical 
properties as hydrophobicity [46], normalized van der Waals volume [47], polarity [48] and 
polarizability [49], the 20 natural amino acids can be divided into three groups [45], as listed in the 
Table 6. For Hydrophobicity, Normalized van der Waals Volume, Polarity and Polarizability, the 
amino acids in Group 1, Group 2 and Group 3 were expressed as H1, H2, H3; V1, V2, V3; P1, P2, P3; 
and Z1, Z2 and Z3, respectively. Second, each protein subchain sequence was then translated into the 
appropriate three-symbol sequence, depending on the particular physicochemical property, be it 
H1−3, V1−3, P1−3, or Z1−3. For example, suppose that the original protein sequence is 
MKEKEFQSKP. Then, by the set of symbols denoted above, in this case, hydrophobicity, this 
sequence can be translated into H3H1H1H1H1H3H1H2H1H2, and the same would be true for V1–3, P1–
3, or Z1–3. Third, the distance frequency of every symbol in the translated sequence was computed. 
In the above example, the H1, H2, H3 distance frequency would be respectively computed for the 
sequence H3H1H1H1H1H3H1H2H1H2. Finally, every protein subchain sequence can be encoded by 
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Table 6. Amino acid groups classified according to their physicochemical value. 
Physicochemical property Group 1 Group 2 Group 3 
Hydrophobicity H1: R,K,E,D,Q,N H2: G,A,S,T,P,H,Y H3: C,V,L,I,M,F,W 
van der Waals volume V1: G,A,S,C,T,P,D V2: N,V,E,Q,I,L V3: M,H,K,F,R,Y,W 
Polarity P1: L,I,F,W,C,M,V,Y P2: P,A,T,G,S P3: H,Q,R,K,N,E,D 
Polarizability Z1: G,A,S,D,T Z2: C,P,N,V,E,Q,I,L Z3: K,M,H,F,R,Y,W 
Conveniently, the feature set based on hydrophobicity, normalized van der Waals volume, 
polarity, and polarizability can be written as Hf, Vf, Pf and Zf, respectively. In general, the 
dimensions of two feature vectors generated separately by two protein subchains are unequal. To 
solve this issue, we enlarge the feature vector dimension of one protein subchain such that it has a 
feature vector dimension equal to that of another subchain. For example, given the following 
protein subchain pair Pa − Pb: 
Subchain Pa amino acid sequence: MKEKEFQSKP 
Subchain Pb amino acid sequence: QNSLALHKVIMVGSG 
If we adopt the property of hydrophobicity, then Pa and Pb amino acid sequences can be 
translated into the following symbol sequence, respectively. 
Subchain Pa: H3H1H1H1H1H3H1H2H1H2 
Subchain Pb: H1H1H2H3H2H3H2H1H3H3H3H3H2H2H2 
Then, the distance sets of subchains Pa and Pb are shown as: 
and the distance 




Hereinafter we will use “DF” to represent the distance frequency method by grouping amino 
acids with their physicochemical properties. 
By our use of DF to represent the protein subchain pair, we can see that the feature vector is 
sparse, while the vector dimension is large, when the subchain sequence is longer. To further 
extract the features, Principal Component Analysis (PCA) was then used to reduce the dimension, 
and amino acid distance frequency combined with PCA reducing the dimension is now  
termed DFPCA. 
3.3. Amino Acid Index Distribution (AAID) 
Let  be the amino acid physicochemical value of the 20 natural amino acids 
 (A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y), respectively, which can be 
accessed through the DBGET/LinkDB system by inputting an amino acid index (e.g., 
1 2 3 1 2 3
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LEWP710101). An amino acid index is a set of 20 numerical values representing any of the 
different physicochemical and biochemical properties of amino acids. We can download these 
indices from the AAindex database (http://www.genome.jp/aaindex/). 
For a given protein sequence P whose length is , we replace each residue in the primary 
sequence by its amino acid physicochemical value, which results in a numerical sequence
, . 
Then, we can define the following feature wi of amino acid to represent the protein sequences: 
 (4) 
where  is the frequency of amino acid that occurs in protein sequecne P,  is the 
physicochemical value of amino acid , and the symbol  indicates the simple product.  and  
are mutually independent. Obviously, wi includes the physicochemical information and statistical 
information of amino acid , but it loses the sequence-order information. Therefore, to let feature 
vectors contain more sequence-order information, we introduced the 2-order center distance  by 
considering the position of amino acid , which is defined as 
 (5) 
where is the total number of amino acid appearing in the protein sequence P, 
 is the position of the amino acid in the sequence, and  is the mean of 
the position of amino acid . 
Now feature di contains the physicochemical information, statistical information and the 
sequence-order information of amino acid , but it still does not distinguish the protein pairs in 
some cases. For example, assume two protein pairs Pa – Pb and Pc – Pd. The sequences of protein 
Pa, Pb, Pc and Pd are respectively shown as: 
Pa: MPPRNKPNRR; Pb: MPNPRNNKPPGRKTR 
Pc: MPRRNPPNRK; Pd: MGTRPPRNNKPNPRK 
Obviously, Pa and Pc, as well as Pb and Pd, have the same wi and di. If we use the orthogonal 
sum vector, we cannot distinguish between the Pa − Pb and Pc − Pd protein pairs. To solve this 
problem, the 3-order center distance ti of amino acid was introduced, which is defined as 
 (6) 
Finally, we can use a combined feature vector to represent protein sequence P by serializing 
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Generally, vector xab is not equal to vector xba. As such, if a query protein pair Pa – Pb is 
represented by xab and xba respectively, the prediction results may be different. In this paper, we 
will choose the pairwise kernel function to solve this dilemma. 
3.4. Pairwise Kernel Function 
Ben-Hur and Noble [13] first introduced a tensor product pairwise kernel function KI to measure 
the similarity between two protein pairs. The comparison between a pair  and another pair 
 for KI is done through the comparison of with  and with , on the one hand, and the 
comparison of  with  and  with , on the other hand, as 
 (10) 
However, the KI kernel does not consider differences between the elements of comparison  
pairs in the feature space; therefore, Vert [50] proposed the following metric learning pairwise 
kernel KII: 
 (11) 
In particular, two protein pairs might be very similar for the KII kernel, even if the patterns of the 
first protein pair are very different from those of the second protein pair, whereas the KI kernel 
could result in a large dissimilarity between the two protein pairs. It is easy to prove that the KII 
kernel satisfies both Mercer’s condition and the pairwise kernel function condition. In this paper, 
we use the KII kernel function to predict PPI. 
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3.5. Assessment of Prediction System 
Sensitivity (Sn), specificity (Sp), positive predictive value (PPV) and total prediction accuracy  






where TP and TN are the number of correctly predicted subchain pairs of interacting proteins and 
noninteracting proteins, respectively, and FP and FN are the number of incorrectly predicted 
subchain pairs of noninteracting proteins and interacting proteins, respectively. 
4. Conclusions 
In this work, we introduced two feature extraction approaches to represent the protein sequence.  
One is amino acid distance frequency with PCA reducing the dimension, termed DFPCA. Another 
is amino acid index distribution based on the physicochemical values of amino acids, termed 
AAID. The pairwise kernel function SVM was employed as the classifier to predict the PPIs. From 
the results, we can conclude that (i) the performance of DFPCA is better than that of DF; (ii) the 
prediction power of PRBF is superior to RBF, suggesting that designing a rational pairwise kernel 
function is important for predicting PPIs; (iii) DFPCA and AAID with pairwise kernel function 
SVM are effective and promising approaches for predicting PPIs and may complement existing 
methods. Since user-friendly and publicly accessible web servers represent the future direction in 
the development of predictors, we have provided a web server for PPI-PKSVM, and it can be 
found at (http://159.226.118.31/PPI/index.html). PPI-PKSVM in its present version can be used to 
evaluate one protein pair. However, we will soon be developing a newer online version able to 
predict large numbers of PPIs. 
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iNR-Drug: Predicting the Interaction of Drugs with Nuclear 
Receptors in Cellular Networking 
Yue-Nong Fan, Xuan Xiao, Jian-Liang Min and Kuo-Chen Chou 
Abstract: Nuclear receptors (NRs) are closely associated with various major diseases such as 
cancer, diabetes, inflammatory disease, and osteoporosis. Therefore, NRs have become a frequent 
target for drug development. During the process of developing drugs against these diseases by 
targeting NRs, we are often facing a problem: Given a NR and chemical compound, can we 
identify whether they are really in interaction with each other in a cell? To address this problem, a 
predictor called “iNR-Drug” was developed. In the predictor, the drug compound concerned was 
formulated by a 256-D (dimensional) vector derived from its molecular fingerprint, and the NR by 
a 500-D vector formed by incorporating its sequential evolution information and physicochemical 
features into the general form of pseudo amino acid composition, and the prediction engine was 
operated by the SVM (support vector machine) algorithm. Compared with the existing prediction 
methods in this area, iNR-Drug not only can yield a higher success rate, but is also featured by a 
user-friendly web-server established at http://www.jci-bioinfo.cn/iNR-Drug/, which is particularly 
useful for most experimental scientists to obtain their desired data in a timely manner. It is 
anticipated that the iNR-Drug server may become a useful high throughput tool for both basic 
research and drug development, and that the current approach may be easily extended to study the 
interactions of drug with other targets as well. 
Reprinted from Int. J. Mol. Sci. Cite as: Fan, Y.-N.; Xiao, X.; Min, J.-L.; Chou, K.-C. iNR-Drug: 
Predicting the Interaction of Drugs with Nuclear Receptors in Cellular Networking. Int. J. Mol. Sci. 
2014, 15, 4915-4937. 
1. Introduction 
With the ability to directly bind to DNA (Figure 1) and regulate the expression of adjacent 
genes, nuclear receptors (NRs) are a class of ligand-inducible transcription factors. They regulate 
various biological processes, such as homeostasis, differentiation, embryonic development, and 
organ physiology [1–3]. The NR superfamily has been classified into seven families: NR0 (knirps 
or DAX like) [4,5]; NR1 (thyroid hormone like), NR2 (HNF4-like), NR3 (estrogen like), NR4 
(nerve growth factor IB-like), NR5 (fushi tarazu-F1 like), and NR6 (germ cell nuclear factor like). 
Since they are involved in almost all aspects of human physiology and are implicated in many 
major diseases such as cancer, diabetes and osteoporosis, nuclear receptors have become major 
drug targets [6,7], along with G protein-coupled receptors (GPCRs) [8–17], ion channels [18–20], 




Figure 1. An illustration to show a nuclear receptor binding to DNA. 
 
Identification of drug-target interactions is one of the most important steps for the new medicine 
development [25,26]. The method usually adopted in this step is molecular docking simulation [27–43]. 
However, to make molecular docking study feasible, a reliable 3D (three dimensional) structure of 
the target protein is the prerequisite condition. Although X-ray crystallography is a powerful tool in 
determining protein 3D structures, it is time-consuming and expensive. Particularly, not all proteins 
can be successfully crystallized. For example, membrane proteins are very difficult to crystallize 
and most of them will not dissolve in normal solvents. Therefore, so far very few membrane 
protein 3D structures have been determined. Although NMR (Nuclear Magnetic Resonance) is 
indeed a very powerful tool in determining the 3D structures of membrane proteins as indicated by 
a series of recent publications (see, e.g., [44–51] and a review article [20]), it is also time-consuming 
and costly. To acquire the 3D structural information in a timely manner, one has to resort to various 
structural bioinformatics tools (see, e.g., [37]), particularly the homologous modeling approach  
as utilized for a series of protein receptors urgently needed during the process of drug  
development [19,52–57]. Unfortunately, the number of dependable templates for developing high 
quality 3D structures by means of homology modeling is very limited [37]. 
To overcome the aforementioned problems, it would be of help to develop a computational 
method for predicting the interactions of drugs with nuclear receptors in cellular networking based 
on the sequences information of the latter. The results thus obtained can be used to pre-exclude the 
compounds identified not in interaction with the nuclear receptors, so as to timely stop wasting 
time and money on those unpromising compounds [58]. 
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Actually, based on the functional groups and biological features, a powerful method was 
developed recently [59] for this purpose. However, further development in this regard is definitely 
needed due to the following reasons. (a) He et al. [59] did not provide a publicly accessible  
web-server for their method, and hence its practical application value is quite limited, particularly 
for the broad experimental scientists; (b) The prediction quality can be further enhanced by 
incorporating some key features into the formulation of NR-drug (nuclear receptor and drug) 
samples via the general form of pseudo amino acid composition [60]. 
The present study was initiated with an attempt to develop a new method for predicting the 
interaction of drugs with nuclear receptors by addressing the two points. 
As demonstrated by a series of recent publications [10,18,61–70] and summarized in a 
comprehensive review [60], to establish a really effective statistical predictor for a biomedical 
system, we need to consider the following steps: (a) select or construct a valid benchmark dataset 
to train and test the predictor; (b) represent the statistical samples with an effective formulation that 
can truly reflect their intrinsic correlation with the object to be predicted; (c) introduce or develop a 
powerful algorithm or engine to operate the prediction; (d) properly perform cross-validation tests 
to objectively evaluate the anticipated accuracy of the predictor; (e) establish a user-friendly  
web-server for the predictor that is accessible to the public. Below, let us elaborate how to deal 
with these steps. 
2. Results and Discussion 
2.1. Benchmark Dataset 
The data used in the current study were collected from KEGG (Kyoto Encyclopedia of Genes 
and Genomes) [71] at http://www.kegg.jp/kegg/. KEGG is a database resource for understanding 
high-level functions and utilities of the biological system, such as the cell, the organism and the 
ecosystem, from molecular-level information, especially large-scale molecular datasets generated 
by genome sequencing and other high-throughput experimental technologies. Here, the benchmark 
dataset  can be formulated as 
 (5) 
where  is the positive subset that consists of the interactive drug-NR pairs only, while  the 
negative subset that contains of the non-interactive drug-NR pairs only, and the symbol  
represents the union in the set theory. The so-called “interactive” pair here means the pair whose 
two counterparts are interacting with each other in the drug-target networks as defined in the 
KEGG database [71]; while the “non-interactive” pair means that its two counterparts are not 
interacting with each other in the drug-target networks. The positive dataset  contains 86  
drug-NR pairs, which were taken from He et al. [59]. The negative dataset  contains 172  
non-interactive drug-NR pairs, which were derived according to the following procedures:  
(a) separating each of the pairs in  into single drug and NR; (b) re-coupling each of the single 
drugs with each of the single NRs into pairs in a way that none of them occurred in ;  
(c) randomly picking the pairs thus formed until reaching the number two times as many as the 
pairs in . The 86 interactive drug-NR pairs and 172 non-interactive drug-NR pairs are given in 
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Supplementary Information S1, from which we can see that the 86 + 172 = 258 pairs in the current 
benchmark dataset  are actually formed by 25 different NRs and 53 different compounds. 
2.2. Sample Representation 
Since each of the samples in the current network system contains a drug (compound) and a NR 
(protein), the following procedures were taken to represent the drug-NR pair sample. 
2.2.1. Use 2D Molecular Fingerprints to Represent Drugs 
First, for the drug part in the current benchmark dataset, we can use a 256-D vector to formulate 
it as given by 





        (6) 
where D represents the vector for a drug compound, and di  its i-th (i =1,2, ,256) component 
that can be derived by following the “2D molecular fingerprint procedure” as elaborated in [10]. The  
53 molecular fingerprint vectors thus obtained for the 53 drugs in  are, respectively, given in 
Supplementary Information S2. 
2.2.2. Use Pseudo Amino Acid Composition to Represent the Nuclear Receptors 
The protein sequences of the 25 different NRs in  are listed in Supplementary Information S3. 
Suppose the sequence of a nuclear receptor protein P with L residues is generally expressed by 
P= R1R2R3R4R5R6R7R8 RL  (7) 
where 1R  represents the 1st residue of the protein sequence P , 2R the 2nd residue, and so  
forth. Now the problem is how to effectively represent the sequence of Equation (3) with a  
non-sequential or discrete model [72]. This is because all the existing operation engines, such as 
covariance discriminant (CD) [17,65,73–79], neural network [80–82], support vector machine 
(SVM) [62–64,83], random forest [84,85], conditional random field [66], nearest neighbor  
(NN) [86,87]; K-nearest neighbor (KNN) [88–90], OET-KNN [91–94], and Fuzzy K-nearest 
neighbor [10,12,18,69,95], can only handle vector but not sequence samples. However, a vector 
defined in a discrete model may completely lose all the sequence-order information and hence limit 
the quality of prediction. Facing such a dilemma, can we find an approach to partially incorporate 
the sequence-order effects? 
Actually, one of the most challenging problems in computational biology is how to formulate  
a biological sequence with a discrete model or a vector, yet still keep considerable sequence  
order information. To avoid completely losing the sequence-order information for proteins, the 
pseudo amino acid composition [96,97] or Chou’s PseAAC [98] was proposed. Ever since the  
concept of PseAAC was proposed in 2001 [96], it has penetrated into almost all the areas of 
computational proteomics, such as predicting anticancer peptides [99], predicting protein subcellular 
location [100–106], predicting membrane protein types [107,108], predicting protein submitochondria 
locations [109–112], predicting GABA(A) receptor proteins [113], predicting enzyme subfamily 
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classes [114], predicting antibacterial peptides [115], predicting supersecondary structure [116], 
predicting bacterial virulent proteins [117], predicting protein structural class [118], predicting the 
cofactors of oxidoreductases [119], predicting metalloproteinase family [120], identifying cysteine 
S-nitrosylation sites in proteins [66], identifying bacterial secreted proteins [121], identifying 
antibacterial peptides [115], identifying allergenic proteins [122], identifying protein quaternary 
structural attributes [123,124], identifying risk type of human papillomaviruses [125], identifying 
cyclin proteins [126], identifying GPCRs and their types [15,16], discriminating outer membrane 
proteins [127], classifying amino acids [128], detecting remote homologous proteins [129], among 
many others (see a long list of papers cited in the References section of [60]). Moreover, the concept 
of PseAAC was further extended to represent the feature vectors of nucleotides [65], as well as other 
biological samples (see, e.g., [130–132]). Because it has been widely and increasingly used, recently 
two powerful soft-wares, called “PseAAC-Builder” [133] and “propy” [134], were established for 
generating various special Chou’s pseudo-amino acid compositions, in addition to the web-server 
“PseAAC” [135] built in 2008. 
According to a comprehensive review [60], the general form of PseAAC for a protein sequence 
P is formulated by 






where the subscript   is an integer, and its value as well as the components  u  (u=1,2, , ) will 
depend on how to extract the desired information from the amino acid sequence of P (cf. Equation (3)). 
Below, let us describe how to extract useful information to define the components of PseAAC for 
the NR samples concerned. 
First, many earlier studies (see, e.g., [136–141]) have indicated that the amino acid composition 
(AAC) of a protein plays an important role in determining its attributes. The AAC contains  
20 components with each representing the occurrence frequency of one of the 20 native amino 
acids in the protein concerned. Thus, such 20 AAC components were used here to define the first 
20 elements in Equation (4); i.e., 
 i = fi
(1)      (i =1,2,  ,  20) (9) 
where fi
(1) is the normalized occurrence frequency of the i-th type native amino acid in the nuclear 
receptor concerned. Since AAC did not contain any sequence order information, the following 
steps were taken to make up this shortcoming. 
To avoid completely losing the local or short-range sequence order information, we considered 
the approach of dipeptide composition. It contained 20 × 20 = 400 components [142]. Such  
400 components were used to define the next 400 elements in Equation (4); i.e., 
 j+20 = f j
(2)      ( j =1,2,  , 400) (10) 
where f j
(2)
is the normalized occurrence frequency of the j-th  dipeptides in the nuclear  
receptor concerned. 
To incorporate the global or long-range sequence order information, let us consider the following 
approach. According to molecular evolution, all biological sequences have developed starting out 
from a very limited number of ancestral samples. Driven by various evolutionary forces such as 
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mutation, recombination, gene conversion, genetic drift, and selection, they have undergone many 
changes including changes of single residues, insertions and deletions of several residues [143], 
gene doubling, and gene fusion. With the accumulation of these changes over a long period of time, 
many original similarities between initial and resultant amino acid sequences are gradually faded 
out, but the corresponding proteins may still share many common attributes [37], such as having 
basically the same biological function and residing at a same subcellular location [144,145]. To 
extract the sequential evolution information and use it to define the components of Equation (4), 
the PSSM (Position Specific Scoring Matrix) was used as described below. 
According to Schaffer [146], the sequence evolution information of a nuclear receptor protein P 
































0  represents the original score of the i-th amino acid residue (i = 1, 2,…, L) in the nuclear 
receptor sequence changed to amino acid type j (j = 1, 2,…, 20) in the process of evolution. Here, the 
numerical codes 1, 2,…, 20 are used to respectively represent A, C, D, E, F, G, H, I, K, L, M, N, P, 
Q, R, S, T, V, W, the 20 single-letter codes for the 20 native amino acids. The L × 20 scores in 
Equation (7) were generated by using PSI-BLAST [147] to search the UniProtKB/Swiss-Prot 
database (The Universal Protein Resource (UniProt); http://www.uniprot.org/) through three 
iterations with 0.001 as the E-value cutoff for multiple sequence alignment against the sequence of 
the nuclear receptor concerned. In order to make every element in Equation (7) be scaled from their 
original score ranges into the region of [0, 1], we performed a conversion through the standard 




































0      (1 i  L,   1 j  20) (13) 
Now we extract the useful information from Equation (8) to define the next 20 components of 
Equation (4) via the following equation 








L ( j =1,2,  ,  20) (15) 
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Moreover, we used the grey system model approach as elaborated in [68] to further define the 
next 60 components of Equation (4); i.e., 
 j+440 = j      ( j =1,  2,  ,  60) (16) 
where  
3 j2 = w1 f j
(1)a1
j
3 j1 = w1 f j
(1)a2
j








     ( j =1, 2,  ,  20) (17) 
In the above equation, w1, w2 , and w3  are weight factors, which were all set to 1 in the current 
study; f j
(1) has the same meaning as in Equation (5); a1
j , a2
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Combining Equations (5), (6), (10) and (12), we found that the total number of the components 
obtained via the current approach for the PseAAC of Equation (4) is 
 = 20+ 400+ 20+ 60 = 500 (21) 






(1) if 1 u 20
fu
(2) if 21 u 420
u if 421 u 440










2.2.3. Formulate the Pair of Drugs with Nuclear Receptor 
Since the elements in Equations (2) and (4) are well defined, we can now formulate the drug-NR 
pair by combining the two equations as given by 




where G represents the drug-NR pair, +  the orthogonal sum, and the 256 + 500 = 756 components 
are defined by Equations (2) and (18). 
For the sake of convenience, let us use xi  (i =1,  2,  ,  756) to represent the 756 components in 
Equation (19); i.e., 






To optimize the prediction quality with a time-saving approach, similar to the  
treatment [148–150], let us convert Equation (20) to 











where the symbol  means taking the average of the quantity therein, and SD means the 
corresponding standard derivation. 
2.2.4. Operation Engine or Algorithm 
In this study, the SVM (support vector machine) was used as the operation engine. SVM has 
been widely used in the realm of bioinformatics (see, e.g., [62–64,151–154]). The basic idea of 
SVM is to transform the data into a high dimensional feature space, and then determine the optimal 
separating hyperplane using a kernel function. For a brief formulation of SVM and how it works, 
see the papers [155,156]; for more details about SVM, see a monograph [157]. 
In this study, the LIBSVM package [158] was used as an implementation of SVM, which can be 
downloaded from http://www.csie.ntu.edu.tw/~cjlin/libsvm/, the popular radial basis function 
(RBF) was taken as the kernel function. For the current SVM classifier, there were two uncertain 
parameters: penalty parameter C and kernel parameter  . The method of how to determine the two 
parameters will be given later. 
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The predictor obtained via the aforementioned procedure is called iNR-Drug, where “i” means 
identify, and “NR-Drug” means the interaction between nuclear receptor and drug compound. To 
provide an intuitive overall picture, a flowchart is provided in Figure 2 to show the process of how 
the predictor works in identifying the interactions between nuclear receptors and drug compounds. 
Figure 2. A flowchart to show the operation process of the iNR-Drug predictor. 
 
3. Experimental Section 
3.1. Metrics for Measuring Prediction Quality 
To provide a more intuitive and easier-to-understand method to measure the prediction quality, 
the following set of metrics based on the formulation used by Chou [159–161] in predicting signal 
peptides was adopted. According to Chou’s formulation, the sensitivity, specificity, overall 
accuracy, and Matthew’s correlation coefficient can be respectively expressed as [62,65–67] 
Input a query 
protein sequence and 
a drug code 
500-D Chou’s PseAAC  256-D drug vector  
Combination!!






































































where N  is the total number of the interactive NR-drug pairs investigated while N
+  the number of 
the interactive NR-drug pairs incorrectly predicted as the non-interactive NR-drug pairs; N  the 
total number of the non-interactive NR-drug pairs investigated while N   the number of the non-
interactive NR-drug pairs incorrectly predicted as the interactive NR-drug pairs. 
According to Equation (23) we can easily see the following. When N
+ = 0 meaning none of the 
interactive NR-drug pairs was mispredicted to be a non-interactive NR-drug pair, we have the 
sensitivity Sn =1 ; while N+ = N+  meaning that all the interactive NR-drug pairs were 
mispredicted to be the non-interactive NR-drug pairs, we have the sensitivity Sn = 0. Likewise, 
when N+
 = 0 meaning none of the non-interactive NR-drug pairs was mispredicted, we have the 
specificity Sp =1; while N+ = N meaning all the non-interactive NR-drug pairs were incorrectly 
predicted as interactive NR-drug pairs, we have the specificity Sp = 0 . When N+ = N+ = 0  
meaning that none of the interactive NR-drug pairs in the dataset and none of the non-
interactive NR-drug pairs in  was incorrectly predicted, we have the overall accuracy Acc =1; 
while N
+ = N+ and N+
 = N meaning that all the interactive NR-drug pairs in the dataset and 
all the non-interactive NR-drug pairs in  were mispredicted, we have the overall accuracy 
Acc = 0. The Matthews correlation coefficient MCC is usually used for measuring the quality  
of binary (two-class) classifications. When N
+ = N+
 = 0  meaning that none of the interactive  
NR-drug pairs in the dataset and none of the non-interactive NR-drug pairs in  was 
mispredicted, we have MCC =1; when N+ = N+ / 2 and N+ = N / 2 we have MCC = 0  meaning 
no better than random prediction; when N
+ = N+ and N+
 = Nwe have MCC = 0  meaning total 
disagreement between prediction and observation. As we can see from the above discussion, it is 
much more intuitive and easier to understand when using Equation (23) to examine a predictor for 
its four metrics, particularly for its Mathew’s correlation coefficient. It is instructive to point out 
that the metrics as defined in Equation (23) are valid for single label systems; for multi-label 
systems, a set of more complicated metrics should be used as given in [162]. 
3.2. Jackknife Test Approach 
How to properly test a predictor for its anticipated success rates is very important for its 
development as well as its potential application value. Generally speaking, the following three  
cross-validation methods are often used to examine the quality of a predictor and its effectiveness  
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in practical application: independent dataset test, subsampling or K-fold (such as five-fold,  
seven-fold, or 10-fold) crossover test and jackknife test [163]. However, as elaborated by a 
penetrating analysis in [164], considerable arbitrariness exists in the independent dataset test. Also, 
as demonstrated in [165], the subsampling (or K-fold crossover validation) test cannot avoid 
arbitrariness either. Only the jackknife test is the least arbitrary that can always yield a unique 
result for a given benchmark dataset [73,74,156,166–168]. Therefore, the jackknife test has been 
widely recognized and increasingly utilized by investigators to examine the quality of various 
predictors (see, e.g., [14,15,68,99,106,107,124,169,170]). Accordingly, in this study the jackknife 
test was also adopted to evaluate the accuracy of the current predictor. 
As mentioned above, the SVM operation engine contains two uncertain parameters C and . To 
find their optimal values, a 2-D grid search was conducted by the jackknife test on the benchmark 
dataset . The results thus obtained are shown in Figure 3, from which it can be seen that the  
iNR-Drug predictor reaches its optimal status when C = 23 and = 29 . The corresponding rates 
for the four metrics (cf. Equation (23)) are given in Table 1, where for facilitating comparison, the 
overall accuracy Acc reported by He et al. [59] on the same benchmark dataset is also given 
although no results were reported by them for Sn, Sp and MCC. It can be observed from the table 
that the overall accuracy obtained by iNR-Drug is remarkably higher that of He et al. [59], and that 
the rates achieved by iNR-Drug for the other three metrics are also quite higher. These facts 
indicate that the current predictor not only can yield higher overall prediction accuracy but also is 
quite stable with low false prediction rates. 
Figure 3. A 3-D graph showing how to optimize the two parameters  and C in SVM 





Table 1. The jackknife success rates obtained iNR-Drug in identifying the interactive  
NR-drug pairs and non-interactive NR-drug pairs for the benchmark dataset   
(cf. Supplementary Information S1). 
Metrics Used for Measuring Prediction 
Quality (cf. Equation (23)) 
iNR-Drug 
a












  85.66% 
MCC 75.19% N/A 
a The parameters used: 32C   and = 29  for the SVM operation engine; b See [59]. 
3.3. Independent Dataset Test 
As mentioned above (Section 3.2), the jackknife test is the most objective method for examining 
the quality of a predictor. However, as a demonstration to show how to practically use the current 
predictor, we took 41 NR-drug pairs from the study by Yamanishi et al. [171] that had been 
confirmed by experiments as interactive pairs. For such an independent dataset, 34 were correctly 
identified by iNR-Drug as interactive pairs, i.e., Sn = 34 / 41= 82.92%, which is quite consistent 
with the rate of 79.07% achieved by the predictor on the benchmark dataset  via the jackknife test 
as reported in Table 1. 
4. Conclusions 
It is anticipated that the iNR-Drug predictor developed in this paper may become a useful high 
throughput tool for both basic research and drug development, and that the current approach may 
be easily extended to study the interactions of drug with other targets as well. Since user-friendly 
and publicly accessible web-servers represent the future direction for developing practically more 
useful predictors [98,172], a publicly accessible web-server for iNR-Drug was established. 
For the convenience of the vast majority of biologists and pharmaceutical scientists, here let us 
provide a step-by-step guide to show how the users can easily get the desired result by using iNR-
Drug web-server without the need to follow the complicated mathematical equations presented in 
this paper for the process of developing the predictor and its integrity. 
Step 1. Open the web server at the site http://www.jci-bioinfo.cn/iNR-Drug/ and you will see the 
top page of the predictor on your computer screen, as shown in Figure 4. Click on the Read Me 
button to see a brief introduction about iNR-Drug predictor and the caveat when using it. 
Step 2. Either type or copy/paste the query NR-drug pairs into the input box at the center of  
Figure 4. Each query pair consists of two parts: one is for the nuclear receptor sequence, and the 
other for the drug. The NR sequence should be in FASTA format, while the drug in the KEGG 
code beginning with the symbol #. Examples for the query pairs input and the corresponding output 
can be seen by clicking on the Example button right above the input box. 
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Figure 4. A semi-screenshot to show the top page of the iNR-Drug web-server. Its 
website address is at http://www.jci-bioinfo.cn/iNR-Drug. 
 
Step 3. Click on the Submit button to see the predicted result. For example, if you use the three 
query pairs in the Example window as the input, after clicking the Submit button, you will see on 
your screen that the “hsa:2099” NR and the “D00066” drug are an interactive pair, and that the 
“hsa:2908” NR and the “D00088” drug are also an interactive pair, but that the “hsa:5468” NR and 
the “D00279” drug are not an interactive pair. All these results are fully consistent with the 
experimental observations. It takes about 3 minutes before each of these results is shown on the 
screen; of course, the more query pairs there is, the more time that is usually needed. 
Step 4. Click on the Citation button to find the relevant paper that documents the detailed 
development and algorithm of iNR-Durg. 
Step 5. Click on the Data button to download the benchmark dataset used to train and test the  
iNR-Durg predictor. 
Step 6. The program code is also available by clicking the button download on the lower panel  
of Figure 4. 
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Qualitative Analysis of the Helical Electronic Energy of  
Inherently Chiral Calix[4]arenes: An Approach to  
Effectively Assign Their Absolute Configuration 
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Shao-Yong Li, Wei Qiao and Jun-Min Liu 
Abstract: For all microhelices on aromatic rings of inherently chiral calix[4]arene,  
an expression was derived from one approximation and one hypothesis on the basis of  
the electron-on-a-helix model of Tinoco and Woody as follows: 21 ( )H K
E
/   0 , where 1/   for 
the right-handed microhelix and 1/    for the left-handed microhelix; and H and K are constant 
and greater than zero. The expression correlates microhelical electronic energy (E) with the atom 
polarizability difference ( 0 ) on both microhelix ends, which intuitively and clearly shows the 
impact of helical substituent polarizability on helical electronic energy. The case analysis almost 
entirely proves that the qualitative analysis of the helical electronic energy of inherently chiral 
calix[4]arenes with the expression is scientific and can be used to effectively assign their  
absolute configuration. 
Reprinted from Int. J. Mol. Sci. Cite as: Zheng, S.; Chang, M.-L.; Zhou, J.; Fu, J.-W.; Zhang, Q.-W.; 
Li, S.-Y.; Qiao, W.; Liu, J.-M. Qualitative Analysis of the Helical Electronic Energy of Inherently 
Chiral Calix[4]arenes: An Approach to Effectively Assign Their Absolute Configuration. Int. J. 
Mol. Sci. 2014, 15, 9844-9858. 
1. Introduction 
Inherently chiral calixarenes, whose chiralities result from the dissymmetric substitution of 
achiral residues on calixarene skeletons, are a type of attractive chiral molecule, because of their 
potential applications in chiral recognition and asymmetrical catalysis [1–6]. Although the first 
example of inherently chiral calixarene [7] appeared in 1982 and all varieties of them have been 
reported by now [1–3,6], only a few of them have been characterized by absolute configuration 
assignment, which seriously impedes their application in chiral recognition [8–14] and asymmetrical 
catalysis [10,11,15–20]. Therefore, the development of effective approaches for the absolute 
configuration assignment of inherently chiral calixarenes is of great importance. 
A few approaches have been used to assign the absolute configuration of inherently chiral 
calixarenes, including chemical interconversions [19,21–25], X-ray crystallography [23], circular 
dichroism (CD) analysis [25] and density functional theory (DFT) calculation [26]. However, 
chemical interconversion requires an inherently chiral calixarene, whose absolute configuration has 
been assigned. A crystal is not always readily available for crystal structure determination. CD 
analysis is limited in inherently chiral calixarene, whose different phenoxyl orientations are 
confirmatory. The newer DFT calculation seems applicable, but commonly very time-consuming 
for the too large basis set of inherently chiral calixarenes. The relationship between the absolute 
configuration of a chiral molecule and its specific optical rotation has long been a very important 
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and well-known research area in stereochemistry. Many empirical and semi-empirical methods and 
rules, especial those developed by Brewster and Wang [27–31], have been devoted to it. As a part of 
electron helix theory [29], a variety of approaches have been exhaustively presented by Wang to 
establish the relationship between absolute configurations of chiral molecules and their helical 
characters. Their practicability and effectivity are also proven by many simple chiral molecules. 
However, the helical characters of inherently chiral calixarenes are so complex that their analysis 
cannot be fully achieved with general approaches in electron helix theory and used to assign their 
absolute configurations. Although the dilemma exists, we still believe that they are one of the best 
empirical solutions for the absolute configuration assignment of chiral molecules. Keeping this in 
mind, we now try to bring forward some approximations and hypothesis in the framework of 
electron helix theory to achieve the helical electronic energy analysis and absolute configuration 
assignment of inherently chiral calix[4]arene. 
2. Results and Discussion 
By keeping the calixarene skeleton integrated, the common dissymmetrical substitutions to 
create inherent chirality are O-alkylation or acylation on the OH group and meta- or para-
substitution on the aromatic ring, although their synthesis can be achieved from either fragment 
condensation or dissymmetrical derivation of the macrocylic skeleton. Conformational inversion 
combined with functionalization at different positions can produce a variety of inherently chiral 
calixarenes [1–3,6]. It is known that there are two types of helices: the physical helix originated from 
asymmetric orbital twisting; and the geometrical helix originated from purely geometrical twisting, in 
many chiral molecules [29]. Theoretically, these two helices should also exist in inherently chiral 
calix[4]arenes. 
As illustrated in Figure 1, three types of helices, the macrocyclic skeleton helix comprised of  
four phenyls and four bridging carbons (Figure 1b), the bridging carbon helix originated from 
asymmetrically substituted bridging carbon C1 (Figure 1c) and the phenyl ring helix originated 
from the asymmetrically substituted phenyl ring A1 (Figure 1d), can be abstracted from the 
inherently chiral calix[4]arene model (Figure 1a). 
The nature of the sp2 hybrid orbital of phenyl carbon can theoretically impel each phenyl and its 
substituents to be almost located on one plane and their six pairs of exterior angles to be almost 
120°, although their substituents can slightly destroy the tendency. For example, in a representative  
meta-substituted inherently chiral calix[4]arene (−)-1 [21], the dihedral angles and six pairs of 
exterior angles on phenyl ring A1 from its crystal data are shown in Table 1. Since a very large 
substituent (Br) exists on phenyl ring A1, these dihedral angles are indeed small and can be omitted, 




Figure 1. Structural analysis of inherently chiral calix[4]arene and representative 
inherently chiral calix[4]arene (−)-1. inherently chiral calix[4]arene model (a); 
macrocyclic skeleton helix (b); bridging carbon helix (c); phenyl ring helix (d); 
geometrical helix model of inherently chiral calix[4]arene model (e) and geometrical 
helix model of (−)-1 (f). 
 
Table 1. The dihedral angles and six pairs of exterior angles on phenyl ring A1 of (−)-1. 
Dihedral Angle (°) 
1 f aC C C Br
1
    = 4.2828 a bBr C C N
1
    = 2.8760 b cN C C H
1
    = −0.1161 
4c dH C C C
1
    = −6.3989 4 d eC C C O
1
    = 6.7100 1e fO C C C
1
    = −7.0711 
Exterior Angle (°) 
a bBrC C2  = 118.450 b aNC C2  = 122.317 c bHC C2  = 119.125
a fBrC C2  = 119.182 b cNC C2  = 119.757 c dHC C2  = 119.096 
4 d cC C C2  = 121.734 e dOC C2  = 118.688 1 f eC C C2  = 118.703
4 d eC C C2  = 120.026 e fOC C2  = 118.095 1 f aC C C2  = 124.316 
In a macrocyclic skeleton helix, four dummy atoms (D1, D2, D3 and D4) on four phenyl centers 
are used to replace four phenyls, respectively. Then, one geometrical helix model (Figure 1e) can 
be abstracted from the macrocyclic skeleton helix after successively connecting four dummy atoms 
and four bridging carbons. When the above-stated slight destruction of their substituents is ignored, 
the geometrical helix model should be equivalent to the macrocyclic skeleton helix. The 
geometrical helix model can be split into two parts along the dotted line of D1D3. Since the 
substitution pattern of all bridging carbons are same, the distances between each dummy atom and 
bridging carbon should normally be equal. When the relation of the angles exists as 
1 1 2 1 4 4D C D D C D2 2 , 1 2 2 4 4 3C D C C D C2 2  and 2 2 3 4 3 3D C D D C D2 2 , the geometrical 
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helices on the two parts will be canceled. For example, in (−)-1, the distances between dummy 
atoms and bridging carbons and three pairs of angles in the geometrical helix model (Figure 1f) 
based on its crystal data are shown in Table 2. It is obvious that these distances are indeed 
approximately equal, and these slight differences between three pairs of angles can indeed be 
ignored. Therefore, the geometrical helices on its two parts can be canceled, and the whole 
macrocyclic skeleton helix in (−)-1 can be omitted. 
Table 2. The distances between dummy atoms and bridging carbons and three pairs of 
angles in the geometrical helix model of (−)-1. 
Distance (Å) 
1 1C D
d  = 2.9240 4 1C Dd  = 2.9161 1 2C Dd  = 2.9212 4 4C Dd  = 2.9209 
2 2C D
d  = 2.9308 3 4C Dd  = 2.9385 2 3C Dd  = 2.9094 3 3C Dd  = 2.9144 
Angle (°) 
1 1 2D C D2  = 104.257 1 2 2C D C2  = 121.606 2 2 3D C D2  = 102.747 
1 4 4D C D2  = 108.995 4 4 3C D C2  = 121.172  4 3 3D C D2  = 102.767 
Four substituents (one equatorial hydrogen (He), one axial hydrogen (Ha) and aromatic rings A1 and 
A2) exist on bridging carbon C1. He and Ha differentiate each other due to their outer electronic 
shielding effect from two adjacent aromatic rings. In all kinds of inherently chiral calix[4]arenes, 
the length difference between bond C1–He and C1–Ha, the angle difference between
1 1
eH C A2  and 
1 1
aH C A2  and the angle difference between 
1 2
eH C A2  and 
1 2
aH C A2  are commonly slight and  
can almost be ignored. For example, in (−)-1, the corresponding bond length and angle from  
its crystal data are as follows: 1
eC H
b  = 0.9904 Å, 1
aC H
b  = 0.9909 Å, 1 feH C C2  = 109.7822°,  
1 f
aH C C2  = 109.8750°, 1 geH C C2  = 109.8749° and 1 gaH C C2  = 109.8069°. These slight 
differences of bond length and angle about He and Ha can indeed be ignored. Moreover, until now, 
the hydrogen polarizability difference originated from different outer electronic environments is 
still not experimentally or theoretically determined. Here, to simplify the calculation, the above 
differences of He and Ha were tentatively ignored. Then, bridging carbon C1 (Figure 1a) can be 
treated as an achiral one. The geometrical helix and physical helix on bridging carbon C1 can  
be omitted. 
In the phenyl ring helix in Figure 1d, when the above-stated slight destruction of their 
substituents is ignored, phenyl ring A1 and its six substituents can be almost treated as coplanar. 
Then, the geometrical helix on phenyl ring A1 can be omitted, and only its physical helix needs be 
considered. Therefore, after the omission of the macrocyclic skeleton helix, bridging carbon helices 
and geometrical helices on four phenyl rings, only physical helices on four phenyl rings need be 
considered for the helical character analysis of inherently chiral calix[4]arenes. 
Since all aromatic rings are asymmetric and the architectures on two sides of each aromatic ring 
plane are different, then inherently chiral calix[4]arenes can theoretically be regarded as a type of 
complex planar chiral molecule (Figure 2b). Referring to the helical character analysis for planar 
chirality [29], the helices of representative aromatic ring A1 in Figure 2b (the dashed line denotes 
the remainder of calix[4]arene) can be resolved into six microhelices, X–a–b–Y, Y–b–c–Z, Z–c–d–
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C4, C4–d–e–O, O–e–f–C1 and C1–f–a–X, respectively. Here, the microhelical electronic energy of 
microhelix X–a–b–Y was representatively analyzed. 
Figure 2. Helical character analysis of microhelix X–a–b–Y in inherently  
chiral calix[4]arene. inherently chiral calix[4]arene model (a); complex planar chiral 
model of aromatic ring A1 (b); helical character analysis of aromatic ring A1 (c); 
different electron movement of bond Xa, ab and bY (d); electron movement of bond bY 
relative to xy plane when αX < αY (e); electron movement of bond bY relative to xy plane 
when αX > αY (f); right-handed cylindrical microhelix model when αX < αY (g) and  
left-handed cylindrical microhelix model when αX > αY (h). 
 
2.1. Microhelical Model 
The calix[4]arene cavity is comprised of four aromatic rings and has a high electronic density. 
Each aromatic ring has a tendency to move away from the cavity to weaken their electrostatic 
repulsion. As a result, each aromatic ring is essentially equal to being placed in a dissymmetrical 
electric field. Therefore, the electrons on bonds Xa, ab and bY of microhelix X–a–b–Y should move 
away from their atomic nuclei, and the corresponding induced dipoles would come into being in a 
dissymmetrical electric field. 
Now, a Cartesian coordinate was introduced to analyze the electron movement of bond bY, in 
which the coordinate axis parallel to bond bY is set as the x-axis, the plane of aromatic ring A1 is set 
as the xy plane and the coordinate axis perpendicular to the xy plane is set as the z-axis (Figure 2c). 
In the orientation parallel to the x-axis, since the permanent bonding force between b and Y is 
known to be far greater than the normal induced dipole force, the electron movement of bond bY 
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parallel to the x-axis can be omitted [32]. Moreover, in the orientation parallel to the y-axis, since 
there is two permanent electrostatic repulsions from atom X and Z, the electron movement of bond 
bY parallel to the y-axis can also be omitted. Therefore, only the electron movement of bond bY 
parallel to the z-axis needs to be considered. Analogously, only the electron movement of bond Xa 
and ab parallel to the z-axis need to be considered. 
According to the polarizability difference of atom X, a, b and Y, the electron movement of bond 
Xa, ab and bY can be illustrated in Figure 2d, in which electron movement distance is proportional 
to the length of the arrowed line. If the electron-distorted bonds can be approximately considered 
as linear and the plane composed of bond Xa and ab (red bold line) is selected as the x'y' plane, the 
electron movement of bond bY (blue plain line) relative to the x'y' plane can be illustrated in  
Figure 2e,f. When the polarizability sequence is αX < αY, a right-handed cylindrical microhelix 
model [28,33] can be abstracted in Figure 2g. When the polarizability sequence is αX > αY, a  
left-handed cylindrical one can be abstracted in Figure 2h. 
2.2. Microhelical Radius 
If the directly connected substituents on all aromatic rings of inherently chiral calix[4]arene are 
different, the length of all aromatic bonds and their directly connected bonds should be different.  
In order to facilitate the calculation of the microhelix radius, one approximation was tentatively 
made that the length of all aromatic bonds and their directly connected bonds is equal to the 
average length of all aromatic bonds. 
In Figure 2e,f, segment bU is the projection of bond bY in the x'y' plane, the point, o, is the 
intersection point of the extension lines of Xa and bU. Then, based on the approximation, the 
relative relations of bond length on microhelix X–a–b–Y in Figure 2e,f can be drawn as: 
Xa ab bY oa ob B      (28) 
here, B is a constant, denoting the average length of all aromatic bonds. 
The nature of the sp2 hybrid orbital of phenyl carbon can theoretically impel each phenyl and its 
substituents to be almost located on one plane and their six pairs of exterior angles to be almost 
120°, which has been proven by a representative meta-substituted inherently chiral calix[4]arene 
(−)-1. Then, the relative relations of angle on microhelix X–a–b–Y can be drawn as: 
o60oab abo aob XoU2 2 2 2   (2) 
Moreover, in order to facilitate the calculation of the height difference (h) between atom X and Y 
on the cylindrical microhelix, one hypothesis was artificially brought forward that the electric 
fields parallel to the z-axis (DZ) acting on all aromatic rings and their directly connected 
substituents are equal when the conformation of inherently chiral calix[4]arene becomes stable. 
Then, the distance (d) from the negative charge to the positive charge in the induced dipole 
moment (P) can be calculated as: 
ZP = αD qd ; 
zDd α
q




where α is atomic polarizability and q is the induced charge. Normally, the bonds between all 
aromatic rings and their directly connected substituents are the σ bond, in which there are two 
bonding electrons, one from a substituent and the other from an aromatic carbon. So q can be 
treated as a constant for all microhelices on aromatic rings. 
Then, the height difference (h) between atom X and Y on microhelix X–a–b–Y can be derived as: 
z
X Y X Y
Dh = d d =
q
    (4) 
The length of segment bU and XU can be derived as: 
3 4




DbU bY h B h B
q
          
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(5) 
From Expressions (1), (2) and (5), the length of segment XU can be calculated as: 
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2.3. Microhelical Electronic Energy 
The states and eigenvalues of an electron constrained to move on a helix were successfully 
solved on the basis of the electron-on-a-helix model by Tinoco and Woody [34]. The calculation 
formula of helical electronic energy (E) of a microhelix with an electron of mass m constrained on 
a k-turn helix with a radius, r, and a pitch, 2πw, was deduced as follows: 
2 2




  (9) 
where ħ is the reduced Planck constant and n is the quantum number of the transition [31,34]. 
Apparently, the helical electronic energy (E) of microhelix X–a–b–Y can theoretically be calculated 
with the formula. 
Since microhelix X–a–b–Y is essentially a physical helix and bond Xa, ab and bY are σ bonds, it 
can be deduced that its pitch should be far less than its radius. Then, for this microhelix, the above 
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Then, the reciprocal of electronic energy (E) of microhelix X–a–b–Y can be deduced from 
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Since the interior structure and exterior environment of all microhelices on aromatic rings of 
inherently chiral calix[4]arene are similar, the variable k, n, m and q should be the same to them. 
Moreover, based on the above approximation and hypothesis, the variables, B and DZ are also the 














 ; X Y  0    (12) 
where H and K are constant and greater than zero for all microhelices on aromatic rings of 
inherently chiral calix[4]arene. Then, Expression (8) can be transformed into: 
21 H K
E
  0  (13) 
Essentially, the electronic energy of the electron in a helix is the same whether the helix is right- 
or left-handed. However, similar to other energy concepts, such as potential energy, the sign of the 
electronic energy can be artificially stipulated based on a selected reference point. Therefore, in 
order to distinguish left-handed and right-handed microhelices, we stipulate that Expression (13) 
is only suitable for a right-handed microhelix and should be changed into Expression (14) when 
the microhelix is left-handed, as follows: 
21 H K
E
   0  (14) 
Actually, the above two expressions can be united into: 
3 421 H KE /   0  (15) 
where 1/   for the right-handed microhelix and 1/    for the left-handed microhelix. 
By the way, two concepts, “helical character” and “helical electronic energy”, should be 
tentatively discussed. Wang noted that “in the context of this helix theory, the terms, that is, the 
helical character and the local energy of electrons of a helix, are equivalent” [30]. From  
Expression (15) and the illustration in Figure 2, it is obvious that our comprehensive “helical 
character” comprises helical radius, pitch and orientation, the mass and quantity of electrons 
constrained on the helix, “helical electronic energy”, exterior electric field acting on the helix, and 
so on. Therefore, here, the “helical electronic energy” is a connotation of “helical character”, which 
is slightly different from those proposed by Wang. 
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There are two rules presented by Wang that “a molecular helix’s helical character (local 
electronic energy) increases as its length, which usually correlates to its ring size, decreases  
(Rule I); and, at a fixed helix length, increases as its radius, which correlates to the relevant groups’ 
polarizability distinctions that result in the bonds’ helical deformations, decreases (Rule II)” [30]. 
Expression (15) intuitively and clearly shows the impact of helical substituent polarizability 
distinction on helical electronic energy in inherently chiral calix[4]arenes, which is actually 
accordant with Rule II. 
Since the above deduction is suitable for all microhelices on aromatic rings of inherently chiral 
calix[4]arene, Expression (15) can be universally used to qualitatively calculate their microhelical 
electronic energy. Therefore, if the sum of the reciprocal of the helical electronic energy of 
inherently chiral calix[4]arene is less than zero, it can be assigned as a right-handed helix and 
dextrorotatory, and vice versa [35,36]. Based on Expression (15), we can effectively deduce the 
signs of the helical electronic energy of inherently chiral calix[4]arenes and assign their absolute 
configurations with the limited polarizability data and sequences of atoms directly attached to  
their microhelices. 
Although a variety of inherently chiral calix[4]arenes were synthesized until now, there are only 
enumerable entities whose absolute configurations and optical rotation signs have been ascertained. 
Here, the scientificity of the qualitative calculation of helical electronic energy based on  
Expression (15) can be verified with inherently chiral calix[4]arene (−)-1 [21], (−)-2 [21], (−)-3 [22], 
(+)-4 [26], (+)-5 [23], (−)-6 [12], (+)-7a and (+)-7b [24] and (+)-8 [25] (Figure 3). Prior to the 
qualitative calculation of their helical electronic energy, the polarizability of their bridging carbons 
should be differentiated. Each bridging carbon is connected with one equatorial hydrogen (He), one 
axial hydrogen (Ha) and two different aromatic rings. The difference of He and Ha can be also ignored 
as stated above. Then, the bridging carbon polarizability should be decided by the electrification of the 
two remaining aromatic rings. 
In (−)-1, its atom polarizability sequence on the meta-substituted aromatic ring is 
1 2 2in NHBr N HC C
    6 5 6 6  and 3 4 3 41 2in NH(3.013) (0.387) (1.061) (0.964)Br H NC    6 
[37]. Then, without consideration of microhelices canceled by each other, the reciprocal of its 
helical electronic energy can be deduced from microhelices C1–Br, Br–N, N–H and C2–H (here, the 
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Figure 3. Inherently chiral calix[4]arenes, whose absolute configuration and optical 
rotation sign have been ascertained. 
 
In (+)-2, its atom polarizability sequence on the meta-substituted aromatic ring is 
1 22 2in NO in NHN N HC C
    6 5 6 6  and 3 4 3 412 2in NO in NH(1.090) (0.387) (1.061) (0.964)N H NC       
[37]. Then, without consideration of microhelices canceled by each other, the reciprocal of its 
helical electronic energy can be deduced from microhelices C1–N1, N1–N2, N2–H and C2–H as: 
2
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 (17) 
Therefore, it should be a right-handed helix and dextrorotatory. 
In (−)-3, its atom polarizability sequence on the meta-substituted aromatic ring is  
1 2in N=CN HC C
   6 5 6  [37]. Then, without consideration of microhelices canceled by each other, 










1 [( ) ( ) ( ) ]
[( ) ( ) ( ) ]
2 ( )( ) 0
N in N C N in N C H HC C
N in N C N in N C H HC C





     
     




      
5      
    6
 (18) 
Therefore, it should be a left-handed helix and levorotatory. 
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In (+)-4, its atom polarizability sequence on the meta-substituted aromatic ring  
is 1 2 3in Ar in CMeC C HC C    6 5 7 6  (here, Ar denotes 2,4,6-trihydroxyphenyl) and 
3 4 3 41 3in Ar in CMe(1.352) (0.387) (1.061) (1.061)C H CC       [37]. Then, without consideration of 
microhelices canceled by each other, the reciprocal of its helical electronic energy can be deduced 
from microhelices C1–C4, C4–C3, C3–H and C2–H as: 
4 1 4 3 3 2
1 13 3
1 13 3
2 2 2 2
2 2 2 2
in CMe in CMe
in CMe in CMe
1 [( ) ( ) ( ) ( ) ]
[( ) ( ) ( ) ( ) ]
2 ( )( ) 0
H HC C C C C C
C in Ar C in Ar C C H HC C





       
       
     
        
5        
      
 (19) 
Therefore, it should be a right-handed helix and dextrorotatory. 
In (+)-5, since the electron-withdrawing capability is Br H6  and 3 2( ) OHOCH CH 6 , the  
phenyl polarizability should be 4 3 2 1A A A A   666 5  and the bridging carbon polarizability should 
be 3 2 4 1C C C C   666 5 (because the polarizability is electron-rich groups > electron-poor 
analogues) [29]. Moreover, since the bond polarizability is O – H O C–6  [37], the oxygen 
polarizability should be 1 2 4 3>O O O O   5 5 . Then, besides those symmetrical microhelices, 
microhelices C2–O2 and C4–O1 and microhelices C1–O2 and C1–O1 can also be canceled by each 
other. Without consideration of microhelices canceled by each other, the reciprocal of its helical 
electronic energy can be deduced from microhelices C3–O3, C2–O3, C3–O4 and C4–O4 as: 
3 3 2 3 3 4 4 4
3 3 2 3 3 4 2 4
3 2 4 3
2 2 2 2
2 2 2 2
1 [( ) ( ) ( ) ( ) ]
[( ) ( ) ( ) ( ) ]
2 ( )( ) 0
C O C O C O C O
C O C O C O C O





       
      
   
       
5        
   
 (20) 
Therefore, it should be a right-handed helix and dextrorotatory. 
In (−)-6, since the electron-withdrawing capability is Br H66  and 
4 2 3 1
2O Pr O CH COOH O H O H5 6 5 , the phenyl polarizability should be 3 4 2 1A A A A   666 5  and 
the bridging carbon polarizability should be 3 2 4 1C CC C    665 5 . Moreover, since the 
polarizability sequences are O – H O C–6  and carbonyl carbon alkyl carbon 6  [37], the oxygen polarizability 
is 3 1 2 4O O O O   5 6 6 . Then, besides those symmetrical microhelices, microhelices C
1–O1 and 
C4–O1 and microhelices C2–O3 and C3–O3 can also be canceled by each other. Without 
consideration of microhelices canceled by each other, the reciprocal of its helical electronic energy 
can be deduced from microhelices C2–O2, C1–O2, C4–O4 and C3–O4 as: 
2 2 1 2 4 4 3 4
3 2 1 2 1 4 3 4
1 3 2 4
2 2 2 2
2 2 2 2
1 [( ) ( ) ( ) ( ) ]
[( ) ( ) ( ) ( ) ]
2 ( )( ) 0
C O C O C O C O
C O C O C O C O





       
       
   
       
5        
   6
 (21) 
Therefore, it should be a left-handed helix and levorotatory. 
In (+)-7a and (+)-7b, since the electron-withdrawing capability is 
4 2 1 3
2O CH COOH O Pr O Pr O H7 5 6  (for (+)-7a) and 4 2 1 32 3O CH COOCH O Pr O Pr O H7 5 6  (for  
(+)-7b), their phenyl polarizability should be 3 2 1 4A A A A   6 5 7  and the bridging carbon 
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polarizability should be 3 2 1 4C CC C   7 6 7 . Moreover, since the polarizability sequences are 
O – H O C–6  and carbonyl carbon alkyl carbon 6  [37], the oxygen polarizability is 3 4 2 1O O O O   6 6 5 . 
Then, besides those symmetrical microhelices, microhelices C1–O2 and C1–O1 can also be canceled 
by each other. Without consideration of microhelices canceled by each other, the reciprocal of their 
helical electronic energy can all be deduced from microhelices C2–O3, C2–O2, C3–O4, C3–O3, C4–
O1 and C4–O4 as: 
2 2 3 3 4 4 2 3 3 4 4 1
2 1 2 2 3 3 4 4 2 3 3 4 4 1
2 2 2 2 2 2
2 2
1 [( ) ( ) ( ) ( ) ( ) ( ) ]
( 2 2 2 2 2 2 )
C O C O C O C O C O C O




           
             
           
        
 (22) 
Since 3 2C C 7  and 2 1O O 5 , then: 
2 2 4 4 2 4 4 2 2 4 4 2
1 ( 2 2 2 2 ) 2 ( )( ) 0
C O C O C O C O C C O O
K K
E
           5            (23) 
Therefore, they should be right-handed helices and dextrorotatory. 
In (+)-8, since the electron-withdrawing capability is 1 2 3 42 2O CH Ph O CH Ph O H O H5 6 5  
[29], the phenyl polarizability should be 3 4 1 2A A A A   5 6 5  and the bridging carbon 
polarizability should be 3 2 4 1C C C C   6 5 6 . Moreover, since the group polarizabilities are 
O – H O C–6 , the oxygen polarizability should be 3 4 1 2O O O O   5 6 5 . Then, besides those 
symmetrical microhelices, microhelices C3–O3 and C3–O4, microhelices C2–O3 and C4–O4 and 
microhelices  
C2–H (on aromatic ring A3) and C4–H (on aromatic ring A4) can also be canceled by each other. 
Without consideration of microhelices canceled by each other, the reciprocal of its helical 
electronic energy can be deduced from microhelices C2–H, C2–O2, C1–O2 and C1–H on aromatic 
ring A2 and C1–H, C1–O1, C4–O1 and C4–H on aromatic ring A1 as: 
2 2 2 1 2 1 1 1 4 4 1 4
2 2 2 1 2 1
2 1 2
2 2 2 2 2 2 2 2
2 2 2 2
1 [ ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ]
2 [ ( ) ( ) ( ) ( ) ]
4 ( )( ) 0
H H H HC C O C O C C C O C O C






               
       
   
                 
5        
    6
 (24) 
Therefore, it should be a left-handed helix and levorotatory. 
It should be mentioned that geometrical helices, resulting from an intermolecular or 
intramolecular non-bonded interaction in a high concentration and polar solvents, are not taken into 
consideration in the above analysis and calculation from Expression (15). Therefore, the calculated 
results only can be compared with those measured in low concentration and non-polar solvents. It 
is very surprising and satisfying that all of optical rotations from the above analysis are consistent 
with the actual facts, except (+)-8. Therefore, from the above case analysis, the qualitative analysis 
of the helical electronic energy of inherently chiral calix[4]arenes with Expression (15) is almost 
entirely proven as scientific and can be used to effectively assign their absolute configurations. 
Due to structural similarity, Expression (15) can be popularized to assign the absolute 
configurations of other inherently chiral calix[n]arenes (n = 5, 6, 8) and other inherently chiral 
concave molecules. However, it must be admitted that this expression is only a qualitative analysis 
tool for the helical electronic energy of inherently chiral calix[4]arenes. The above approximation 
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and hypothesis in its deduction need to be further verified, and the variables, m, q and DZ, need to 
be quantified with theoretic deduction and experimental data. Moreover, the exception from (+)-8 
may be satisfactorily interpreted in an upcoming quantificational expression. Therefore, the 
relevant verification and variable quantification will be explored in our subsequent works. 
3. Conclusions 
In summary, inherently chiral calix[4]arenes can be theoretically regarded as a type of complex 
planar chiral molecule when bridging carbons are treated as achiral and each phenyl ring and its six 
substituents are treated as coplanar. Based on one approximation and one hypothesis, we derive 
Expression (15) to qualitatively analyze microhelical electronic energy. Its scientificity and 
effectivity in absolute configuration assignments of inherently chiral calix[4]arenes were almost 
entirely confirmed with all of the entities, whose absolute configurations and optical rotation signs 
have been ascertained. 
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Elucidating Polypharmacological Mechanisms of Polyphenols 
by Gene Module Profile Analysis 
Bin Li, Min Xiong and Hong-Yu Zhang 
Abstract: Due to the diverse medicinal effects, polyphenols are among the most intensively 
studied natural products. However, it is a great challenge to elucidate the polypharmacological 
mechanisms of polyphenols. To address this challenge, we establish a method for identifying 
multiple targets of chemical agents through analyzing the module profiles of gene expression upon 
chemical treatments. By using FABIA algorithm, we have performed a biclustering analysis of 
gene expression profiles derived from Connectivity Map (cMap), and clustered the profiles into  
49 gene modules. This allowed us to define a 49 dimensional binary vector to characterize the gene 
module profiles, by which we can compare the expression profiles for each pair of chemical agents 
with Tanimoto coefficient. For the agent pairs with similar gene expression profiles, we can predict 
the target of one agent from the other. Drug target enrichment analysis indicated that this method is 
efficient to predict the multiple targets of chemical agents. By using this method, we identify 148 
targets for 20 polyphenols derived from cMap. A large part of the targets are validated by 
experimental observations. The results show that the medicinal effects of polyphenols are far 
beyond their well-known antioxidant activities. This method is also applicable to dissect the 
polypharmacology of other natural products. 
Reprinted from Int. J. Mol. Sci. Cite as: Li, B.; Xiong, M.; Zhang, H.-Y. Elucidating 
Polypharmacological Mechanisms of Polyphenols by Gene Module Profile Analysis. Int. J.  
Mol. Sci. 2014, 15, 11245-11254. 
1. Introduction 
Since reactive oxygen species (ROS), e.g., superoxide radical, hydrogen peroxide, and hydroxyl 
radical, are involved in the pathogenesis of many diseases, such as cancer, neurodegenerative 
diseases and atherosclerosis [1], antioxidants in particular polyphenolic antioxidants, have been 
widely expected to exert prophylactic or therapeutic effects on these diseases [2–5]. However, a 
large number of researches indicated that the strong in vitro antioxidant activities of polyphenols 
can not be translated into in vivo therapeutic effects [5–9]. This antioxidant paradox was primarily 
explained by the poor bioavailability of exogenous polyphenols [10]. Our analysis about the 
biological roles of polyphenols revealed that they were evolved for filtering UV light rather than 
scavenging intense ROS, which provided an evolutionary explanation to the weak in vivo radical-
scavenging potential of polyphenols [11]. The evolutionary consideration also suggested that 
natural polyphenols have evolved an excellent scaffold with well-balanced rigidity and flexibility 
to adapt to different structures of enzymes in the biosynthetic pipeline, which enables the 
compounds to bind various proteins [12]. This finding implies that natural polyphenols have 
inherent potential to exert polypharmacological effects other than redox modulation [13]. However, 
how to elucidate the polypharmacological mechanisms of natural polyphenols is a great challenge, 
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because the conventional methods to dissect drug mode of action (MoA) are laborious and low 
throughput [14]. 
Recently, gene expression-based analysis showed great potential in identifying drug  
targets [15–17]. But the existent methods for gene expression profile analysis normally use limited 
signature genes (usually corresponding to ~500 probes out of 22,000+), which lose valuable 
information. In addition, these methods are efficient to reveal a single MoA or target for a certain 
drug, rather than its polypharmacological mechanisms [16]. Since gene expression signatures 
related to different biological activities cluster into different modules [18], we speculate that the 
polypharmacological mechanisms of polyphenols may be better dissected in terms of module 
profiles of gene expression. 
In a previous analysis about connectivity map (cMap), which contains 7056 expression  
profiles of 5 different human cell lines treated with 1309 agents (including 20 polyphenols), we 
generated 49 gene modules by using biclustering approach FABIA (factor analysis for bicluster 
acquisition) [19]. Through analyzing the biological functions of the modules, we revealed that 
some polyphenols exert polypharmacological effects through activating transcription factors, such 
as estrogen receptors, nuclear factor (erythroid-derived 2)-like 2, and peroxisome  
proliferator-activated receptor gamma. In this study, we first establish a gene module-based target 
identification method and then use this method to further elucidate the polypharmacological 
mechanisms for the 20 polyphenols. 
2. Results and Discussion 
In a prior research, the cMap-derived 1309 agents and expression profiles have been grouped 
into 49 gene modules by FABIA algorithm [19], which consist of 5921 probes, much greater than 
those used in the conventional microarray analysis [15,16]. Thus, each chemical agent in cMap has 
a gene module profile, which is defined by a 49 dimensional binary vector, with 1 or 0 representing 
the presence or not of the module (Table S1). This allows us to calculate Tanimoto coefficient for 
each pair of the compounds to characterize the similarity of their gene expression profiles. The 
bigger the Tanimoto coefficient is, the more similar biological effects of the compound pairs are 
expected. For the compound pairs with similar gene module profiles, if one has the MoA and/or 
target information, we can predict the medicinal behaviors of the other. A total of 856,086 pairwise 
Tanimoto coefficients were calculated for the 1309 compounds in the cMap dataset (Table S2). The 
top 1% and 5% coefficients are higher than 0.45 and 0.33, respectively (Figure 1). 




To evaluate the effectiveness of this parameter in target identification, we performed a target 
enrichment test. First, by searching DrugBank [20] and Therapeutic Target Database (TTD) [21], 
we retrieved 573 approved drugs from 1309 agents, which hit 536 targets. Then, we found that 209 
targets were shared by at least two drugs. These targets and corresponding 476 drugs can be used to 
assess the target enrichment significance. Although the drug targets collected by DrugBank and 
TTD may be incomplete and may be indirect targets, these information have been successfully used 
by previous studies to evaluate the target enrichment efficiency [16]. 113,050 pairwise Tanimoto 
coefficients were calculated for the 476 drugs. The drug pairs with Tanimoto coefficients of higher 
than 0.33 were used to estimate the probability of target sharing by hypergeometric test. The results 
showed that 78 targets of 128 drugs can be enriched (q < 0.05) (Table S3). It is noteworthy that 96 
of 128 drugs have multiple targets (≥2), for which the average ratio of target enrichment reaches 
68.75% (66/96) (Table S3). In particular, the 7 targets of chlorpromazine, 8 targets of maprotiline, 
and 14 targets of imipramine were completely enriched (Table S3). Thus, the present method has 
great potential to predict MoA and targets of chemical agents, especially to dissect the 
polypharmacological mechanisms of natural products. 
The cMap-derived 1309 agents involve four kinds of polyphenols, i.e., flavonoids (16 agents), 
monolignols (2 agents) and stilbenoids (1 agent), phenylpropanoids (1 agent). The gene module 
profiles of these polyphenols show that they are involved in more gene modules than other agents 
(14.85 ± 4.80 vs. 11.85 ± 5.42, p < 0.01, t-test), suggesting that polyphenols indeed have more 
complex biological functions than others. The most common modules covered by the 20 polyphenols 
include module 11 (with occurrence of 14), module 18 (with occurrence of 13), module 25 (with 
occurrence of 13), module 7 (with occurrence of 12), and module 3 (with occurrence of 12). 
According to the previously enriched biological functions of 49 gene modules [19], the major 
functions associated with these modules are protein transport, protein location, cytoskeleton 
organization, cell motion, purine and pyrimidine metabolism, oxidative phosphorylation, cell cycle, 
RNA processing, ubiquitin-dependent protein catabolic process and translational elongation. By 
searching in GeneDecks [22], it was found that four of the five common modules (modules 3, 11, 
18 and 25) are tightly linked to cancer and tumors (p < 0.0001). 
There are 93 drugs that are similar to the 20 polyphenols in terms of gene expression module 
profile (with Tanimoto coefficients > 0.45), which correspond to 148 targets and provide 
meaningful clues to clarifying the polypharmacology for these polyphenols (Table S4). In the 
predicted medicinal effects, anti-neoplastic is most popular (with occurrence of 17 in 93 drugs), in 
good agreement with the above finding that cancer is linked to most common gene modules. 
Tables 1–4 list the predicted targets of four most intensively studied polyphenols, including 
genistein (a representative component of soybean), quercetin (one of most widely distributed 
flavonoids), resveratrol (a representative component of red wine), and (−)-catechin (a 
representative component of green tea). It can be seen that antineoplastic and antihypertensive are 
the most common predicted activities of the four polyphenols, which agree well with the health 
benefits of their dietary sources. For instance, accumulating evidence indicated that high soybean 
intake and regular green tea drinking are associated with low incidence rates of human cancers and 
hypertension [23–28]. In addition, a large part (50%) of the predicted targets of these polyphenols 
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are validated by experiments, most (92.3%) of which are direct targets (Tables 1–4). These results 
strongly warrant the experimental evaluation of other predicted targets. 
It is intriguing to note that phosphodiesterase enzymes (PDEs) and estrogen receptor are 
predicted targets for three of four polyphenols. This finding agrees well with the opinion that plant 
polyphenols collectively behave as phytoestrogens and can inhibit several isoforms of PDEs [29–31]. 
A major progress in recent natural medicine research was the identification of PDEs as the target of 
resveratrol [32]. The present analysis highlights the similar pharmacological mechanisms underlying 
genistein and quercetin. 
Table 1. Predicted similar drugs and associated targets of genistein. 
Drugs Therapeutic Uses Targets References 
Imatinib Antineoplastic Agents 
Platelet-derived growth factor receptor a [33] 
Proto-oncogene tyrosine-protein  
kinase ABL1 a [34] 
Mast/stem cell growth factor receptor a [35] 
Raloxifene Antihypocalcemic Agents Estrogen receptor 
a [36] 
Iloprost Antihypertensive Agents 
Prostaglandin E2 receptor, EP2 subtype b [37] 
cAMP-specific 3',5'-cyclic 
phosphodiesterase a [38] 
Prostacyclin receptor c [37] 
Cisapride 
Anti-Ulcer Agents 
5-Hydroxytryptamine 4 receptor - Gastrointestinal Agents 
Prokinetic Agents 
Fluticasone Anti-inflammatory Agents Glucocorticoid receptor 
a [39] 
Diethylstilbestrol Antineoplastic Agents Estrogen receptor a [36] 
Finasteride Anti-baldness Agents Steroid-5-alpha reductase a [40] Antihyperplasia Agents 
Sulindac sulfide Rheumatoid arthritis - - 
Prednisone 
Anti-inflammatory 




Estrogen receptor a [36] Anticholesteremic 
Agents 
Dydrogesterone Progesterones Progesterone receptor  
a as direct targets of genistein; b as indirect target of genistein which increases prostaglandin release;  




Table 2. Predicted similar drugs and associated targets of quercetin. 
Drugs Therapeutic Uses Targets References 
Tolazoline 
Adrenergic alpha-Antagonists 




Estrogen receptor a [41] 
Bone Density Conservation Agents 
Finasteride 
Anti-baldness Agents 
Steroid-5-alpha reductase - Antihyperplasia Agents 
Skin and Mucous Membrane Agents 
Sulindac sulfide Rheumatoid arthritis - - 
Iloprost Antihypertensive Agents 
Prostaglandin E2 receptor, EP2 subtype - 
cAMP-specific 3',5'-cyclic phosphodiesterase a [42] 
Prostacyclin receptor - 
Raloxifene 
Antihypocalcemic Agents 
Estrogen receptor a [41] 
Bone Density Conservation Agents 
Apomorphine Antiparkinson Agents 
Dopamine receptor a [43] 
Adrenergic receptors - 
5-Hydroxytryptamine receptor a [43] 
Fluticasone Anti-inflammatory Agents Glucocorticoid receptor - 
Tocainide Anti-Arrhythmia Agents Sodium channel protein type 5 subunit alpha a [44] 
a as direct targets of quercetin. 
Table 3. Predicted similar drugs and associated targets of resveratrol. 





Synaptic vesicular amine transporter - 
Antipsychotic Agents 
Mercaptopurine 




Niclosamide Antiparasitic Agents - - 
Daunorubicin Antineoplastic Agents DNA topoisomerase  - 
Terfenadine 
Anti-Allergic Agents Histamine H1 receptor  - 
Antiarrhythmic Agents  
Potassium voltage-gated channel subfamily H 
member 2 a 
[45] 
Muscarinic acetylcholine receptor M3 - 
Fluphenazine Antipsychotic Agents Dopamine receptor  - 
Dipyridamole Vasodilator Agents 
Adenosine deaminase - 
cGMP-specific 3',5'-cyclic phosphodiesterase a [46] 
Rescinnamine Antihypertensive Agents Angiotensin-converting enzyme a [47] 
Trifluoperazine Antipsychotic Agents Dopamine receptor  - 
Metixene Antiparkinson Agents Muscarinic acetylcholine receptor - 




Table 4. Predicted similar drugs and associated targets of (−)-catechin. 
Drugs Therapeutic Uses Targets References 
Letrozole Antineoplastic Agents Cytochrome P450 19A1 a [48] 
Triprolidine Anti-Allergic Agents Histamine H1 receptor  
Pindolol 
Antihypertensive Agents Adrenergic receptor - 
Vasodilator Agents 5-hydroxytryptamine receptor - 
Norfloxacin Anti-Bacterial Agents DNA topoisomerase 2-alpha a [48] 
Prilocaine Anesthetics Sodium channel protein type 5 subunit alpha - 
Estradiol 
Anti-menopausal Agents 
Estrogen receptor a [49] 
Anticholesteremic Agents 
Doxycycline Anti-Bacterial Agents 30S ribosomal protein  - 
Bendroflumethiazide Antihypertensive Agents 
Solute carrier family 12 member 3 - 
Calcium-activated potassium channel  
subunit alpha 1 
- 
Carbonic anhydrase - 
Theophylline 
Bronchodilator Agents Adenosine A1 receptor - 
Vasodilator Agents cGMP-specific 3',5'-cyclic phosphodiesterase a [29] 
Naltrexone Anti-craving Agents Opioid receptor a [50] 
a as direct targets of (−)-catechin. 
3. Experimental 
3.1. Tanimoto Coefficient Calculation  
Tanimoto coefficient (TC) was calculated with a perl program to compare the gene module 




where NA and NB are the number of bits set for gene module profiles of compounds A and B, 
respectively, and NAB is the set bits that A and B have in common. If TC = 1, the compound pair 
have the same module profiles; if TC = 0, the pair have totally different module profiles. 
3.2. Drug Target Enrichment 
Hypergeometric test was used to assess the drug target enrichment significance. The  





where N is the number of total approved drugs for target enrichment (i.e., 476), M is the number of 
drugs involving the similar module profiles (with Tanimoto coefficient > 0.33), i is the number of 
drugs sharing the same target in N, K is the number of drugs sharing the same target in M. Thus, 
we can calculate the probability by chance, at least x occurrences of a target among those 
associated with the M drugs. The p-values were further adjusted by False Discovery Rate 
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calculation (with R function ‘p.adjust()’ using Benjamini-Hochberg method [51]). The enriched 
targets were ranked by p-value from most significant to least significant. Then, for each target the  




where Count is the total number of enriched targets. The enriched targets were then selected using a q-
value threshold of 0.05. 
4. Conclusions 
Natural products (NPs) have made important contributions to safe guarding human health. Not 
only ancient humans depended on NPs to cure various diseases, modern pharmaceutical industry 
also benefit from NPs to find hits, leads and drugs [12]. Therefore, it is of great significance to 
elucidate the therapeutic mechanisms of NPs. However, this is a big challenge, because NPs 
usually hit multiple targets with relatively weak affinity and the conventional target identification 
methods are laborious and low throughput [14]. 
In this study, we established a gene module-based target identification method. Because gene 
modules cover more gene probes, this method is more efficient than conventional microarray 
analysis methods in information extraction. Therefore, this method enables the discovery of richer 
information about the medicinal effects of chemical agents, which is very helpful to clarify the 
polypharmacological mechanisms of polyphenols and other NPs. Moreover, this method may  
be used to predict targets for NPs beyond those contained in cMap, so it is expected to find  
more and more applications in the omics era, because the NP-related microarray data are  
rapidly accumulated. 
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Prediction of Multi-Target Networks of Neuroprotective 
Compounds with Entropy Indices and Synthesis, Assay,  
and Theoretical Study of New Asymmetric  
1,2-Rasagiline Carbamates 
Francisco J. Romero Durán, Nerea Alonso, Olga Caamaño, Xerardo García-Mera, 
Matilde Yañez, Francisco J. Prado-Prado and Humberto González-Díaz 
Abstract: In a multi-target complex network, the links (Lij) represent the interactions between the 
drug (di) and the target (tj), characterized by different experimental measures (Ki, Km, IC50, etc.) 
obtained in pharmacological assays under diverse boundary conditions (cj). In this work, we handle 
Shannon entropy measures for developing a model encompassing a multi-target network of 
neuroprotective/neurotoxic compounds reported in the CHEMBL database. The model predicts 
correctly >8300 experimental outcomes with Accuracy, Specificity, and Sensitivity above  
80%–90% on training and external validation series. Indeed, the model can calculate different 
outcomes for >30 experimental measures in >400 different experimental protocolsin relation  
with >150 molecular and cellular targets on 11 different organisms (including human). Hereafter, 
we reported by the first time the synthesis, characterization, and experimental assays of a new 
series of chiral 1,2-rasagiline carbamate derivatives not reported in previous works. The 
experimental tests included: (1) assay in absence of neurotoxic agents; (2) in the presence of 
glutamate; and (3) in the presence of H2O2. Lastly, we used the new Assessing Links with Moving 
Averages (ALMA)-entropy model to predict possible outcomes for the new compounds in a high 
number of pharmacological tests not carried out experimentally. 
Reprinted from Int. J. Mol. Sci. Cite as: Durán, F.J.R.; Alonso, N.; Caamaño, O.; García-Mera, X.; 
Yañez, M.; Prado-Prado, F.J.; González-Díaz, H. Prediction of Multi-Target Networks of 
Neuroprotective Compounds with Entropy Indices and Synthesis, Assay, and Theoretical Study of 
New Asymmetric 1,2-Rasagiline Carbamates. Int. J. Mol. Sci. 2014, 15, 17035-17064. 
1. Introduction 
Entropy measures are universal parameters useful to codify biologically relevant information in 
many systems. In the 1970’s Bonchev and Trinajstic et al. published works about the use of 
Shannon’s entropy to calculate a structural information parameter [1–4]. Kier published another 
seminar works on the use of Shannon’s entropy to encoding molecular structure in 
Cheminformatics studies in 1980 [4]. Many other authors used Shannon’s entropy parameters for 
the same purpose on small molecule structure [5–10]. Graham et al. [11–16] used entropy 
measures to study the information properties of organic molecules. Entropy information measures 
were used to describe proteins [17,18], DNA sequences [19], protein networks [20], and magnetic 
resonance outcomes [21]. The software MARCH-INSIDE (MI) uses the theory of Markov chains 
to calculate the parameters θk(G). These values are the Shannon entropies of order kth of a graph G. 
The θk(G) values are useful quantify information about the structure of molecular systems [22]. 
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The graph G represents a complex molecular system as a network of nodes interconnected by links 
(Lij = 1) or not connected (Lij = 0). MI algorithm associates a Markov matrix to the graph G in 
order to define the probabilities of interactions (ties or relationships) between nodes. These entropy 
parameters θk(G) can be calculated for many types of systems (molecular or otherwise). We have 
studied small molecules, RNA secondary structures, protein sequences, viral surfaces, cerebral 
cortex networks, metabolic networks, host-parasite networks, world trading networks, social 
networks, etc. In molecules, we know the information about links Lij (covalent bonds, hydrogen 
bonds, spatial contacts, etc.) beyond any reasonable doubt. However, we can use the information 
(θk(G) values)of the system to predict interactions with other systems in a network of a  
higher-structural level. For instance, we use the θk(G) values of drugs and targets structure to 
predict drug–target interactions (links) in drug–target network. In other cases, linking patterns 
change, are not known, or we find contradictory information. This is the case of the existence of 
different relationships between nodes in biological webs or social networks. In these cases, we  
can use the θk(G) values of known networks to find models useful to predict links in new  
networks [23–25]. 
On the other hand, the discovery of new drugs for the treatment of neurodegenerative diseases 
such as Alzheimer’s, Parkison’s, and Huntington’s disease, Friedreich ataxia and others, is an 
important goal of medicinal chemistry [26–29]. The genes causing hereditary forms of some of 
these diseases have been identified but the molecular mechanisms of the neuronal degeneration 
have not been totally understood yet [30]. This picture, and some disappointing results in clinical 
trials, makes interesting the prediction of drug candidates with computational techniques [31,32]. 
In order to design these computational models we need to process chemical information from 
public databases. These databases have accumulated immense datasets of experimental results of 
pharmacological trials for many compounds. For instance, CHEMBL [33,34] is one of the biggest 
with more than 11,420,000 activity data for >1,295,500 compounds, and 9844 targets. This huge 
amount of information offers a fertile field for the application of computational techniques [34,35]. 
The analysis of all this data is very complex due to the presence of multi-target, multi-output, 
and multi-scale information. Multi-target complication emerges due to the existence of compounds 
with multiple targets [36–38]. This led to the formation of complex networks of drug–target 
interactions. We can represent drug–target networks as a graph with two types of nodes drugs (di) 
and targets (tj) interconnected by links (Lij). Barabasi et al. [39], constructed a drug–target network 
based on Food and Drug Administration (FDA) drugs and proteins linked by drug–target binary 
associations. Csermely et al. [40], reviewed the use of networks, including drug–target networks, for 
drug discovery. 
Multi-output feature refers to the necessity of prediction of different experimental parameters 
(IC50, Ki, Km, etc.) to decided whether two nodes (drug and target) interact (Lij = 1) or not (Lij = 0). 
Multi-scaling refers to the different structural levels of the organization of matter. In this case, the 
input variables quantify molecular information (drugs structure) and macromolecular information 
(targets). They have to quantify also cellular (cellular targets) and organism information (specie 
that express the target). In these models we have a high number of assays carried out in very 
different conditions (cq) like time, concentrations, temperature, cellular targets, tissues, organisms, 
etc. In a recent work, we combined the θk(G) values calculated with MI and the idea of Moving 
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Average (MA) operators with a similar purpose [41]. In time series analysis the MA operators are 
average values of characteristic of the system for different seasons. In fact, MA models became 
popular after the initial works of Box and Jenkins [42]. In time series analysis, MA models may 
combine other operators I = Integrated, AR = Autoregressive, N = Non-linear operators, or X = 
Exogenous effects. In this sense, others models have emerged combining different operators: 
ARMA, ARIMA, VARIMA, ARIMAX, NARMA, etc. In multi-output modeling, we calculate the 
MA operators as the average of the property of the system (molecular descriptors or others) for all 
drugs or targets with a specific response in one assay carry out under a sub-set of conditions (cj). 
Consequently, our MA operator is not acting over a time domain but over a sub-set of conditions of 
the pharmacological assays. The idea of application of MA operators to other domains different 
from time is gaining adepts due to its advantages. For instance, Botella-Rocamora et al. [43] 
developed a model for disease mapping using spatial Box–Jenkins operators with the form of MAs, 
to define dependence of the risk of a disease to occur. In our models, we use MA in relation with 
properties of nodes of networks (drugs, proteins, reactions, laws, neurons, etc.); which form links 
Lij(cq) in specific sub-set of conditions (cq). For this reason, we decided to call this strategy as 
ALMA (Assessing Links with Moving Averages) models. Speck-Planche and Cordeiro reported 
different multi-target or multi-output models using the same type of ALMA models [44–46]. 
In the specific area of neurodegenerative diseases, almost all these datasets includes also large  
sub-sets of assays involving potential neuroprotective drugs, targets, as well as drug-target and/or 
target–target interactions. The database NeuroDNet has interactive tools to create interaction 
networks for twelve neurodegenerative diseases. According to Vasaikar et al. [47], it is the first of 
its kind, which enables the construction and analysis of neurodegenerative diseases through protein 
interaction networks, regulatory networks and Boolean networks. In the case of neuroprotective 
compounds, some authors have reported multi-target ALMA models. García et al. used topological 
descriptors for a large series of 3370 active/non-active compounds to fit a classification function 
that can predict links Lij (interactions) of heterogeneous series of GSK inhibitors compounds with 
different neurological targets relevant to Alzheimer’s disease and parasite species. Speck-Planche et 
al. [48], developed a multi-target model using a large and heterogeneous database of inhibitors 
against five proteins associated with Alzheimer’s disease. The model correctly classified more than 
90% of active and inactive compounds in the treatment of Alzheimer’s disease on both, training 
and prediction series. Several guidelines are offered in other paper to show how the use of 
fragment-based descriptors can be determinant for the design of multi-target inhibitors of proteins 
associated with Alzheimer’s disease [49]. 
In a recent work, we used the method TOPS-MODE (TM) [50] to calculate the structural 
parameters of drugs. The model correctly classified 4393 out of 4915 total cases with Specificity 
(Sp), Accuracy (Ac), and Sensitivity (Sn), of 80%–98%. We also used the method TM to develop 
one ALMA [51] model useful for the prediction of neuroprotective drugs. This dataset includes 
Multi-output assay endpoints of 2217 compounds for at least one out of 338 assays, with  
148 molecular or cellular targets, and 35 types of activity measures in 11 model organisms 
(including human). In a third work [52], we introduced another ALMA model for 
neurotoxicity/neuroprotective effects of drugs based on the method MI. First, we used MI to 
calculate molecular descriptors of the type of stochastic spectral moments of all compounds. Next, 
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we found a model that classified correctly 2955/3548 total cases on training and validation series 
with Ac, Sn, and Sp > 80%. Each data point (>8000) contains the values of 37 possible measures of 
activity, 493 assays, 169 molecular or cellular targets, and 11 different organisms (including 
human) for a given compound. The model has shown excellent results also in computational 
simulations of high-throughput screening experiments, with Ac = 90.6% for 4671 positive cases. 
Both models are able to predict the links Lij(cq) between ith drugs and jth targets according to the 
assay aq. However, we do not carried out a formal construction and a comparison of the drug-target 
networks for the CHEMBL data in previous papers. In any case, despite the high versatility of 
entropy measures to codify structural information, there is no report of a multi-target model for 
drug–target interactions for compounds with neuroprotective/neurotoxic effect. In this work, we 
report the first multi-target, multi-output, and multi-scale ALMA model for CHEMBL data of 
neuroprotective/neurotoxic effect of drugs. Then, we construct and compare for the first time three 
Multi-output assay complex networks for these CHEMBL dataset using the two previous models  
and the model reported in this work. From there, we reported by the first time the synthesis, 
characterization, and experimental assays of a new series of rasagiline carbamate derivatives not 
reported in previous works. We carried out three different experimental tests: assay (1) in absence 
of neurotoxic agents; (2) in the presence of glutamate; and (3) in the presence of H2O2. Finally, we 
used the new entropy model to predict possible outcomes for these compounds in a high number of 
pharmacological tests not carried out experimentally. The results presented here show the high 
potential of entropy parameters of chemical information for the design of neuroprotective drugs, 
the construction of complex bio-molecular networks, and the potential of ALMA models for multi-
target, multi-output, and multi-scale modeling. 
2. Results and Discussion 
2.1. Development of New Model for Prediction of Drug–Target Networks 
2.1.1. Model Training and Validation 
We report a model to predicting when the ith compound may present a high (Lij(cq) = 1) or not 
(Lij(cq) = 0) value of the experimental parameter used to characterize interaction with a molecular 
or cellular target involved in a neuroprotective/neurodegenerative process. The output Sij(cq) of our  
multi-output model depend on both chemical structure of the ith drug di and the set of conditions 
selected to perform the biological assay (cq) including the jth target, of course. In consonance, the 
ALMA model should predict different probabilities if we change the organisms (c1), the biological 
assays (c2), the molecular/cellular target (c3), or the standard experimental parameter measured (c4), 
for the same compound [53].The best ALMA-entropy model found in this work was: 
3 4 3 4 3 4



























The statistical parameters for the above equation in training are: Number of cases used to train 
the model (N), Canonical Regression Coefficient (Rc), Chi-square (χ2), and p-level [54]. The 
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probability cut-off for this Linear Discriminant Analysis (LDA) model is ip1(cq) > 0.5 ≥ Lij(cq) = 1. 
It means that the drug di predicted by the model, with probability p > 0.5, is expected to give a 
positive outcome in the qth assays carry out under the given set of conditions cq. This  
ALMA-entropy model presents excellent performance in both training and external validation 
series with Sn, Sp, and Ac > 80% (see Table 1). Values higher than 75% are acceptable for  
LDA-QSAR models, according to previous reports [55–59]. 
The first term in the equation, quantify both the quality of the input data p(cl) and the  
information θi5 about the structure of the drug (see material and methods and previous works [51]). 
We can expand the Box–Jenkins MA terms in the ALMA equation in order to clearly depict all the 
parameters involved: 
3 4 3 4
3 4 3 4 3 4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After inspection of this equation, we can see that the ALMA model can predict for the same 
compound different scores for different experimental parameters, targets, assays, or even different 
organisms. In Table 2 we illustrate the values of probability of drug–target interaction pij(cq) 
predicted with the previous model, for several examples of known drugs or new promising 
compounds. These are the probabilities with which the ith compound interact with the jth drug  
under the assay conditions cq. This is equivalent to pij(cq) > 0.5 ≥ Lij(cq)pred = 1. However, online 
supplementary material files contain a complete list with many examples of positive and  
control cases. 
The Table 2 shows predictions of the same drug in different sets of conditions of assay cq, 
including different targets, organisms, or assays. Therefore, we only have to substitute in the 
equation the value of θi5 of the compound and the respective values p1(cq)·<θi5(cq)> for the MA 
operators of each condition. In the Table 3 we depict many examples of values of MA operators 
p1(cq)·<θi5(cq)> for different conditions. 
Table 1. Results of Assessing Links with Moving Averages (ALMA) models for 
entropy measures vs. different spectral moments. 
Descriptor Sub-Set Stat. a % Groups Ci(mj)pred = 1 Ci(mj)pred = 0 Reference 
MI-Entropy 
Train 
Sp 79.0 Lij(Cq)obs = 1 1092 290 
This work 
Sn 91.5 Lij(Cq)obs = 0 412 4438 
Ac 88.7 Total 
CV 
Sp 81.3 Lij(Cq)obs = 1 379 87 
Sn 92.6 Lij(Cq)obs = 0 119 1492 




Table 1. Cont. 




Sp 84.6 Lij(Cq)obs = 1 1172 214 
[52] 
Sn 82.4 Lij(Cq)obs = 0 224 1051 
Ac 83.5 Total 
CV 
Sp 83.3 Lij(Cq)obs = 1 385 77 
Sn 81.6 Lij(Cq)obs = 0 78 347 




Sp 81.3 Lij(Cq)obs = 1 1533 352 
[51] 
Sn 98.0 Lij(Cq)obs = 0 36 1762 
Ac 89.5 Total 
CV 
Sp 81.0 Lij(Cq)obs = 1 513 120 
Sn 97.7 Lij(Cq)obs = 0 14 585 
Ac 89.1 Total 
MI, MARCH-INSIDE; a Sensitivity = Sn = Positive Correct/Positive Total; Specificity = Sp = Negative 
Correct/Negative Total; Accuracy = Ac = Total Correct/Total; TM, TOPS-MODE. 
Table 2. Examples predicted with the model. 
Compound (i) pij(cq) Assay ID Measure (Units) Organism Target Protein 
Arecoline 0.94 796814 Efficiency (%) rno Muscarinic  
acetylcholine receptor 
Bipinnatin-A 1.00 751272 Inhibition (%) mmu Acetylcholine receptor  
protein β chain 
Carachol 0.99 796814 Efficiency (%) rno Muscarinic  
acetylcholine receptor 
Caulophylline 0.96 838016 EC50 (nM) hsa 
Neuronal acetylcholine 
receptor; α4/β2 
Citalopram 0.99 740208 Ki (nM) mmu Dopamine transporter 
Condelphine 1.00 748943 −Log(IC50) (nM) rno 
Neuronal acetylcholine 
receptor protein α-7 subunit 
Delcorine 1.00 748943 −Log(IC50) (nM) rno 
Neuronal acetylcholine 
receptor protein α-7 subunit 
Delsoline 1.00 748943 −Log(IC50) (nM) rno 
Neuronal acetylcholine 
receptor protein α-7 subunit 
Desipramine 0.99 797692 −Log(IC50) (nM) rno Norepinephrine transporter 
Elatine 1.00 748943 −Log(IC50) (nM) rno 
Neuronal acetylcholine 
receptor protein α-7 subunit 
Emopamil 1.00 817225 −Log(IC50) (nM) rno 
Voltage-gated R-type 
calcium channel α-1E 
subunit 
Epibatidine 0.94 838016 EC50 (nM) hsa 
Neuronal acetylcholine 
receptor; α4/β2 
Epibatidine 0.19 825420 Efficacy (%) hsa 
Neuronal acetylcholine 
receptor; α4/β2 




Table 2. Cont. 
Compound (i) pij(cq) Assay ID Measure (Units) Organism Target Protein 
Femoxetine 0.99 740207 Ki (nM) mmu Norepinephrine transporter 
Femoxetine 0.99 740208 Ki (nM) mmu Dopamine transporter 
Fisetin 0.05 1027709 %max (%) mmu HT22 cells 
Fluoxetine 0.99 740207 Ki (nM) mmu Norepinephrine transporter 
Fluoxetine 0.99 740208 Ki (nM) mmu Dopamine transporter 
Imipramine 0.99 740206 Ki (nM) mmu Dopamine transporter 
Imipramine 0.99 740207 Ki (nM) mmu Norepinephrine transporter 
Imipramine 0.99 740208 Ki (nM) mmu Dopamine transporter 
Inuline 1.00 748943 −Log(IC50) (nM) rno 
Neuronal acetylcholine 
receptor protein α-7 subunit 
Karacoline 1.00 748943 −Log(IC50) (nM) rno 
Neuronal acetylcholine 
receptor protein α-7 subunit 
L-Arginine 0.99 755144 Activity (nM) hsa Nitric-oxide synthase, brain 
L-NIL 0.59 752266 −Log(IC50) (nM) hsa Nitric-oxide synthase, brain 
L-NMMA 0.99 876477 −Log(IC50) (nM) hsa Nitric-oxide synthase, brain 
L-NNA 0.98 752385 −Log(IC50) (nM) hsa Nitric-oxide synthase, brain 
L-NNA 0.86 752276 Ki (nM) hsa Nitric-oxide synthase, brain 
LY-379268 0.99 714803 Activity (nM) hsa 
Metabotropic  
glutamate receptor 4 
LY-379268 0.99 877752 Activity (nM) hsa 
Metabotropic  
glutamate receptor 2 
LY-379268 0.99 718128 Activity (nM) hsa 
Metabotropic  
glutamate receptor 6 
LY-389795 0.99 718128 Activity (nM) hsa 
Metabotropic  
glutamate receptor 6 
LY-389795 0.98 715721 Activity (nM) hsa 
Metabotropic  
glutamate receptor 5 
LY-389795 0.97 714446 Activity (nM) hsa 
Metabotropic  
glutamate receptor 3 
Lycoctonine 1.00 748943 −Log(IC50) (nM) rno 
Neuronal acetylcholine 
receptor protein α-7 subunit 
M826 1.00 841780 Ki (nM) hsa Caspase-3 
M827 1.00 841780 Ki (nM) hsa Caspase-3 
Methyllycaconitine 1.00 750084 Ki (nM) rno 
Neuronal acetylcholine 
receptor protein α-10 subunit 
NBQX 0.99 641893 −Log(IC50) (nM) rno 
Glutamate receptor  
ionotropic, AMPA 2 
NBQX 0.99 641893 −Log(IC50) (nM) rno 
Glutamate receptor  
ionotropic, AMPA 4 
NBQX 0.99 641893 −Log(IC50) (nM) rno 
Glutamate receptor  




Table 2. Cont. 
Compound (i) pij(cq) Assay ID Measure (Units) Organism Target Protein 




Glutamate receptor  
ionotropic, AMPA 1 
Nipecotic acid 0.28 785010 
−Log(IC50) 
(nM) 
rno GABA transporter 1 
Nipecotic acid 0.28 785010 
−Log(IC50) 
(nM) 
rno GABA transporter 2 
Nipecotic acid 0.28 785010 
−Log(IC50) 
(nM) 
rno GABA transporter 3 
Nipecotic acid 0.28 785010 
−Log(IC50) 
(nM) 
rno Betaine transporter 
NOHA 0.04 755137 
NO  
formation (%) 
rno Nitric-oxide synthase, brain 










receptor protein α-7 subunit 
Omega  
nitro-arginine 
0.99 752258 Ki (nM) hsa Nitric-oxide synthase, brain 
Oxotremorine 0.84 798083 pD2 rno 
Muscarinic acetylcholine 
receptor M1 
Paroxetine 1.00 740206 Ki (nM) mmu Dopamine transporter 
RedAm-Ethyl 0.33 840782 Selectivity hsa 
Nitric-oxide  
synthase, endothelial 
RedAm-Ethyl 0.28 840782 Selectivity hsa Nitric-oxide synthase, brain 
Resveratrol 0.99 1613870 EC50 (nM) hsa 
Nuclear factor NF-κB  
p105 subunit 
Resveratrol 0.99 1613870 EC50 (nM) hsa 
Nuclear factor NF-κB  
p65 subunit 
Stemofoline 1.00 936299 EC50 (nM) hvi 
Nicotinic acetylcholine 
receptor α1 subunit 
Thiocytisine 0.51 857972 Log Ki rno 
Neuronal acetylcholine 
receptor; α4/β2 
rno, Rattus norvegicus (Rat); mmu, Mus musculus (Mouse); hsa, Homo sapiens (Human); and hvi, Heliothis virescens. 
2.1.2. Comparison with Other ALMA Models 
An interesting exercise is the comparison of the present model and the network predicted with 
outcomes obtained with other methods. Until the best of our knowledge, there are only two similar 
models. Both models make use of the spectral moments of a molecular matrix as input variables 
(Di) to quantify the molecular structure of drugs. The first model [51] applies spectral moments μk 
of order kth of the bond adjacency matrix (1B) calculated with the TM approach. The equation of 
this model is the following: 
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The second model [52] employs as input the πik values of the Markov matrix (1Π) of atom–atom 
electron delocalization calculated with the software MI. In the TM method, we weighted the edges 
of the molecular graph with standard distances of chemical bonds whereas the MI algorithm 
employs atom standard electronegativities to weighting the nodes of molecular graph. The equation 
of the second model is: 
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In both cases, as well as in the present ALMA-entropy model, we used MA terms to quantify 
the deviations of the structure of one compound from sub-sets of compounds with a positive 
outcome in different conditions cq. The three methods showed excellent values of Ac, Sp, and Sn 
on both training and validation series (see Table 1). Apparently, the TM model shows better values 
of these parameters but we have to take into consideration the differences in the complexity of the 
data sets used to train and validate these models. The TM-spectral moment model is able to classify 
correctly 83%–82% of 4915 cases in total (on training and validation series respectively). The MI-
spectral moment model is able to classify correctly 89%–92% of 3598 cases. Notably, the MI-
entropy model is able to classify correctly 89%–92% of 8309 cases. Consequently, the statistics for 
the present model refer to a dataset with more than twice the number of data points present in 
previous models. 
2.1.3. Construction of Drug–Target Networks with ALMA Models 
ALMA models may be useful both (1) for computational or virtual High-Throughput Screening 
(HTS) screening of large databases like CHEMBL and/or (2) for construction of drug–target 
networks. All the results, discussed in previous section, indicate that many compounds may act as 
multi-target drugs with non-linear or indirect effect (orthosteric and/or allosteric) over different 
targets in different pathways. In a recent special issue edited by Csermely, Nussinov, and  
Szilágyi [60], different research groups discussed about this topic and related concepts such as  
allo-networks. In one of these papers, Mueller et al. [61] have developed a computational model 
for the HTS of drugs with action over mGluR5; which represent a promising strategy for the 
treatment of schizophrenia. Considering the relevance of allotropy for these and other receptors for 
our study, and all previous comments about allo-network drugs, we decided to use our model to 
construct a drug-target network. The interest in doing so is that this type of network-based tools 











Considering these points, we constructed here by the first time a drug–target network with 
CHEMBL experimental outcomes of multiplex assays of neuroprotective effects of drugs with the 
same dataset used in the previous section. This is probably the first drug–target network 
representation of the interaction of neuroprotective compounds with cellular or protein targets; 
many of them susceptible to allosteric modulators. In this directed network, we used three classes 
of nodes, drugs (di), targets (tj), and pharmacological assays (aq). They are connected by only three 
classes of arcs (directed links) drug ≥ (di ≥ tj), drug ≥ assay (di ≥ aq), and target-assay (tj ≥ aq). 
Other types of relationships were not considered. The observed drug–target network was 
constructed with the input dependent variable Lij(cq). In consequence, if CHEMBL reports the case 
of drug di that causes an strong biological response (Lij(cq) = 1) in one biological experiment carry 
out under the conditions cq = (tj, aq), we have to draw in the network the path di ≥ tj ≥ aq. We 
omitted here the representation of nodes for the type of experimental measure and the organism 
that express the target. This avoids very highly connected nodes that may cause a strong distortion 
in network topology and mask or hidden the relevance of important drugs or targets. 
The observed network constructed with the dataset published in the previous work has 968 
nodes = 721 drugs + 72 targets + 175 pharmacological assays for neuroprotective effects. We 
apply, also, the software MI to quantify the structural information of the drug–target networks. In 
so doing, we calculated the Shannon entropy (Sh), as well as δ = node degrees for the nodes (drugs, 
targets, and assays) in the network, see Table 4. Please note that the Sh entropy values for the 
nodes in the drug–target network (supra-molecular structural level) are different from the θk 
entropy values use to quantify the information about the structure of the drug (molecular structural 
level). Actually, we do not use a classic Shannon entropy (H) but a first-order Markov–Shannon 
entropy [25]. 
After a first inspection, we can observe that the degree of a node (δ) in the network has average 
values of δ = 4.8 ≈ 5 for all nodes, δ = 4.8 ≈ 5 for drugs, and δ = 4.3 ≈ 4 for assays. It means that, 
on average, each drug interacts with five targets and we can measure this interaction with 
approximately four assays. It is easy to realize that the higher δ for targets may be determined in 
part by their position in the network. For each link of drug or assay node, we have two interactions 
for the target di ≥ tj and tj ≥ aq). As a result, we can decompose the δ into δ = δin + δout = node  
degree = in-degree + out-degree [63]. For this reason, we carried out all calculations eliminating the 
direction of arcs. In so doing, we considered them as symmetric links to avoid this “over-booking” 
of target nodes. Consequently, the average is δ = 6.1 ≈ 6 for targets, a value still higher, but closer 
to 5 than to 8–10, the double is expected. 
In a second stage, we use our model to reconstructing/predicting the same network, based on the 
probability p(mj) outputs of the model. Two nodes are connected when the probability predicted by 
the model is p(cq) > 0.5, it means that p(di, tj), or p(di, aq), or p(tj, aq) are >0.5, for different pairs of 
links. We can perceive that the values of the drug–target network predicted by the model are very 
similar to those of the observed network. Consequently, we can conclude that the model is efficient 
not only in the overall prediction of links in the network (high Ac, Sp, and Sn, see Table 1) but in the  
reconstruction of topological patterns. For instance, from information theory we can deduce that the  
uncertainty of links is similar in both networks because Shannon entropy calculated for all links is 
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Shobs = 0.005 − 0.007 ≈ Shpred = 0.004 − 0.006. In Figure 1, we represented the Observed (A) vs. 
Predicted (B) complex networks. 
Table 4. Topological properties of CHEMBL complex networks predicted with  
ALMA-entropy models. 
Network Node Type n Sh1 a δ δin δout 
Observed 
Total 2450 0.00428 7 3 3 
Compounds 2103 0.00413 6 3 3 
Assays 211 0.00575 6 3 3 
Rat proteins 54 0.00291 7 4 3 
Human proteins 70 0.00568 21 18 3 
1 
Total 2508 0.00438 7 3 3 
Compounds 2208 0.00446 6 3 3 
Assays 183 0.00468 15 11 4 
Rat proteins 40 0.00279 6 3 3 
Human proteins 67 0.00210 5 1 3 
2 
Total 2511 0.00428 7 3 3 
Compounds 2209 0.00445 6 3 3 
Assays 184 0.00464 15 11 4 
Rat proteins 40 0.00266 6 3 3 
Human proteins 68 0.00209 4 1 3 
3 
Total 2511 0.0044 7 3 3 
Compounds 2209 0.00445 6 3 3 
Assays 184 0.00464 15 11 4 
Rat proteins 40 0.00266 6 3 3 
Human proteins 68 0.00209 4 1 3 
4 
Total 2491 0.0046 7 3 3 
Compounds 2209 0.00471 6 3 3 
Assays 184 0.00449 14 11 4 
Rat proteins 40 0.00251 6 2 3 
Human proteins 68 0.00209 4 1 3 
5 
Total 2491 0.0046 7 3 3 
Compounds 2209 0.00471 6 3 3 
Assays 184 0.00449 14 11 4 
Rat proteins 40 0.00251 6 2 3 
Human proteins 68 0.00209 4 1 3 





Figure 1. Multitarget, Multiscale, and Multi-output networks, of CHEMBL sub-set of 
neuroprotection related drugs (yellow), targets (red), and pharmacological assays 
(green) Observed (A) vs. Predicted (B). 
 
2.2. Experimental and Theoretical Study of New Compounds 
2.2.1. Synthesis and Experimental Assay of New 1,2-Rasagiline Derivatives 
The compounds 2, 3, 4, 5, 6, 7, 8, and 9 were synthesized according to the strategy given in  
Figure 2. As shown in this scheme, they were synthesized from the aminoalcohol 1 [(1R,2S)-(+)-1-
amino-2-indanol], a commercial product. The alkylation of 1 with propargyl bromide and 
potassium carbonate in hot acetonitrile provided, in a global yield of 92%, a mixture of the 
corresponding mono- and dipropargylated derivatives (2 and 3), which were separated by flash 
column chromatography using hexane/EtOAc (3:1) as eluent. Compound 3 was converted to the 
corresponding acetate (4) and benzoate (5) by treatment with acetic anhydride or benzoyl chloride, 
Et3N and catalytic amounts of 4-dimethylaminopyridine (DMAP) in MeCN. The carbamate 
derivatives (6, 7, 8, and 9) were synthesized, from the hidroxy mono- or dipropargylaminoindans 
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(2 and 3), by reaction with the corresponding dialkylcarbamyl chloride in NaH and acetonitrile 
following the procedure described in the literature [64]. 
Figure 2. Synthesis of compounds 2–9. 
 
The new compounds synthesized in this work (2, 3, 4, 5, 6, 7, 8, and 9) were subjected to an 
initial study to determinate its neuroprotective ability in both the presence and the absence of 
neurotoxic agents (ANA). The method of reduction of the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was used to ascertain the cell viability, given by the number 
of cells present in the culture. The ability of cells to reduce MTT is an indicator of the integrity of 
mitochondria, and its functional activity is interpreted as a measure of cell viability [65]. Three 
assays were conducted in a culture of motor cortex neurons of 19-day-old Sprague–Dawley rat 
embryos. All results are expressed as the mean ± S.E.M. [51,52] of at least three independent 
experiments (Table 5). 
Firstly, we studied the ability to induce a neuroprotective effect in the absence of any neurotoxic 
stimulation. Secondly, we studied the neuroprotective effect in the presence of glutamate, a 
compound that causes a pathological process, in which neurons are damaged leading to apoptosis 
when its receptors, such as the NMDA and AMPA, are over-activated. Lastly, the ability of the 
compounds synthesized to protect from damage by H2O2, that causes neuronal death by oxidative 
stress, was analyzed. The results obtained allow to deduce the existence of a moderate 
neuroprotective effect in the absence of any toxic stimulus, presenting the best results type 6 and 9 
carbamate derivatives, with values of 11.5% and 8.4%, respectively, followed by the compound 3, 




















































0.0 2.8 0.0 6.5 −2.8 1.2 
3 
 
4.7 6.0 −0.2 1.6 −12.3 2.1 
4 
 
4.2 6.5 −8.1 4.9 −14.2 2.1 
5 
 
1.2 5.0 3.8 5.0 2.9 1.0 
6 
 
11.5 8.8 −4.0 5.5 −9.1 2.4 
7 
 
4.0 4.5 2.6 3.9 -6.1 1.1 
8 
 
−1.7 6.9 −5.2 5.9 −8.9 1.9 
9 
 
8.4 10.7 −5.2 2.3 −14.0 2.0 
a % protection (comp 5 μM), in the Absence of Neurotoxic Agents (ANA); b % protection (comp 5 μM) 
against Glutamate 100 μM; c % protection (comp 5 μM) against H2O2 100 μM. 




2.2.2. Using ALMA-Entropy Model to Predicting New Drugs in Other Assays 
We used the ALMA-entropy model to predicting the more probable results for all the new 
rasagiline derivatives synthesized in this work, in >500 assays not carried out experimentally. 
When the molecular descriptors (entropy indices) of the new rasagiline derivatives were introduced 
in our model, we obtained the probable interaction with different targets. The model predicts that 
most of them could interact with the subunits A and B of the 5-hidroxy-tryptamine type 3 receptors 
(5-HT3Rs), see Table 6. These results seem to be consistent with the literature, since the antagonists 
of 5-HT3Rs have been related to neuroprotective properties in vitro and in vivo [66]. In fact, this 
could be a potential mechanism of neuroprotection added to several described mechanisms for 
rasagiline derivatives [67,68]. Rasagiline is also known for promoting serotoninergic activity by 
other ways, which is a clinically relevant fact in certain circumstances [69]. All in one highlights 
the intricate relationships of these drugs with the 5-hidroxy-tryptamine (serotonine) system. 
Table 6. Some predictive results for interaction between compound 6 with 5HT3Rs and 
other targets. 
Si(cj) Meassure Assay ID Target ID Target a Neurotoxic Agent 
2.097 pA2 617971 1899 5HT3aR ANA 
2.097 pA2 617969 1899 5HT3aR ANA 
2.097 pA2 617971 3895 5HT3bR ANA 
2.097 pA2 617969 3895 5HT3bR ANA 
1.78 Selectivity 848737 3568 bNOS H2O2 
1.78 Selectivity 840777 3568 bNOS H2O2 
1.78 Selectivity 755901 3568 bNOS H2O2 
1.17 Activity (%) 866501 2586 nAChRβ-3 H2O2 
0.42 pIC50 (nM) 710048 3772 mGluR1 Glu 
a nAChRβ-3 = neuronal acethyl-choline receptor β3, mGluR1 = metabotropic glutamate receptor type 1. 
In any case, we need to analyze these results with caution. In our previous works [51,52], we 
predicted with new models and confirmed experimentally that some rasagiline derivatives (similar 
to the derivatives studied in this work) presented activity over glutamate receptors (GluRs) 
pathway. In the first of these works [51], we study experimental measures of neuroprotective 
capacity of new 1,3-rasagiline derivatives. All the compounds, except one of them, had a high 
protective activity against damage mediated by H2O2. The best one of all, a monopropargyl trans 
derivative, showed also a high neuroprotective action in all three type of assays. Our first model 
predicted for this compound high probability of activity in relationship with acetylcholine and 
GABA, in addition to GluRs. In coincidence, acetylcholine receptors (AChRs) have been 
associated with neuroprotective proprieties in several recent experimental works, and there are  
also reports of association of GABA and GluRs with neuroprotective ability [70,71].  
Nuritova et al. [72], discussed a neuroprotective strategy involving retrograde release of glutamate. 
In our second work [52], we studied two types of substituent groups (propargyl groups attached 
to the nitrogen and a carbamate or esther group instead of hydroxyl). The compounds also 
presented two different chirality patterns but with 1,3 substitutions pattern. The compounds of this 
second series were active experimentally in the absence and presence of neurotoxic agents. The 
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best compound of this second series, a dipropargyl derivative, was predicted to have brain nitric 
oxide synthase (bNOS) as the most probable target and certain probability of multi-target ligand. 
Again, bNOS was associated experimentally with neuroprotective action in several works [73,74]. 
The compounds studied this third work present similar substituent groups and stereochemistry 
but one 1,2 substitution pattern. Based on the previous results, we should expect a similar 
experimental activity and predictions. However, in the previous section we shown experimentally 
that the present set of compounds seems not to be very active over GluRs and the model predicts 
the higher scores of activity over 5-HT3Rs instead of the expected receptors. As we stated in the 
previous paragraph, 5-HT3Rs have been related to neuroprotective properties in vitro and  
in vivo [66]. A plausible hypothesis (pendent of further experimental confirmation) is the variation 
in receptor affinity (from GluRs to 5-HT3Rs pathway) due to the change from 1,3 to 1,2 
substitution pattern. From our point of view, these correspondences between targets that our 
equations predict, and the references cited from the literature could indicate biological plausibility 
of our models. 
3. Materials and Methods 
3.1. Computational Methods 
3.1.1. ALMA-Entropy Models 
ALMA models may be classified as a general type of model to assessing the links in different 
systems. They are adaptable to all molecular descriptors and/or graphs invariants or descriptors for 
complex networks. In general, we refer to a descriptor Dik of type kth of the ith system (compound 
or drug di in this case) represented by a matrix M. In fact, in this work we are going to compare the 
model based on entropy values θik of a Markov matrix 1Π with other ALMA models based on other 
invariants of the same matrix 1Π, or invariants of the bond adjacency matrix 1B. Consequently, we 
describe first the general equations of the model using a generic descriptor, or graph theoretical 
invariant Dik, and later we give the specific equation for the entropy model based on θik values. The 
aim of this model is to link the scores Sij(cq) with the molecular descriptors Dik of a  
given compound di and the Box–Jenkins MA operators written in the form of deviation terms  
ΔDik(cq) = Dik – <Dik(cq)>. The model has the following general form: 
3 4
3 4




















































































The output dependent variable is Sij(cq) = Sij(cl, c2, c3, c4, c5) = Sij(cl, aq, ot, tj, sx). The variable 
Sij(cq) is a numerical score of the biological activity of the ith drug (di) vs. the jth target measured in 
one assay carried out under the set of qth conditions cq. Our hypothesis is H0: we can calculate the 
output Si(cq) as a linear combination of scores. We have two types of scores. The first type are the 
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scores 'Sik = 'ak·p(cl)·iDk that account for the quality of data p(cl) and for contributions of the kth 
molecular descriptors to the final activity score Sij(cq). In fact, we used the probability p(c1) = 1.0; 
0.75; or 0.5 for data curated in CHEMBL database at levels of expert, intermediate, or  
auto-curation level, respectively. The second type are scores ''Sijk(cq>1) = ''ak·ΔDik(cj) for the 
contributions of deviations ΔDik(cq) = (Dik − <Dik(cq)>) of the descriptors of di from the average of 
those of active molecules Lij(cq) = 1 for different cq. In general, cj refers to different Multi-output 
assay conditions, e.g., targets, assays, cellular lines, organisms, organs, etc. In this sense, c0 = is the 
accuracy of the data for this assay, c1 = au is the assay per se, c2 = ot is the organism that express 
the target, c3 = tj is the jth cellular or molecular target, and c5 = sx is standard experimental measure 
of activity. Then, the parameter Dik and ΔDik(cq) are the input independent variables and Lij(cq) = 1 
is the input dependent variable. Here, <Dik(cq)> is the average of the kth descriptors Dik of all ith 
compounds considered as active (Lij(cq) = 1) in an assay carry out under the set of conditions cq. 
The parameters ΔDik(cq) are similar to the MA used in time series analysis for Bob–Jenkins 
ARIMA models and others [42]. This type of MA model has been used before to solve different 
problems in Cheminformatics before. It means that, firstly, we sum the values of Dik for all the nj 
drugs with Lij(cq) = 1 in the assay carry out in the conditions cj. Next, we divide this sum by the 
number of compounds nj with this condition. 
















In this model, we used only one molecular descriptor θi5. This is the Shannon entropy of order  
k = 5 calculated with MI. We do not use low-order entropies k = 0, 1, 2, 3, and 4. Accordingly, the 
general equation is: 
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This type of moving average or deviation-like models was coined by us as the ALMA models, 
and has been used before to solve different problems [54,75–77]. In order to seek the model we 
used the technique Linear Discriminant Analysis (LDA) implemented in the software package 
STASTICA 6.0 [78]. The statistical parameters used to corroborate the model were: Number of 
cases in training (N), and overall values of Sp, Sn, and Ac [54]. 
3.1.2. CHEMBL Dataset 
We downloaded from the public database CHEMBL a general data set composed of >8000  
Multi-output assay endpoints (results of multiple assays) [33,34]. We assigned a value of the 
observed (obs) class variable Lij(cq)obs = 1 (active compound) or Lij(cq)obs = 0 (non-active 
compounds) to every ith drug biologically assayed in different conditions cj. The dataset used to 
train and validate the model includes N = 3548 statistical cases, formed by Nd = 3091 unique drugs 
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which have been assayed each one in at least one out of 37 possible standard type measures 
determined in, at least, one out of 493 assays. Each assay involves, in turn, at least one out of 169 
molecular or cellular targets expressed in the tissues of at least one out of 11 different organisms 
(including human). 
3.2. Experimental Methods: Chemistry 
3.2.1. Synthesis of 1,2-Rasagiline Derivatives 
Melting points are uncorrected and were determined in Reichert Kofler Thermopan (Reichert, 
Vienna, Austria) or in capillary tubes on a Büchi 510 apparatus (BÜCHI Labortechnik AG, Flawil, 
Switzerland). Infrared spectra were recorded on a JASCO FT/IR-4100 spectrophotometer (JASCO 
Analytical Instruments, Easton, PA, USA). The 1H-NMR spectra (300 MHz) and 13C-NMR spectra  
(75 MHz) were recorded in a Bruker AMX spectrometer (Bruker BioSpin Corporation, Fremont, 
CA, USA), using TMS as internal reference (chemical shifts in δ values, J. in Hz). EI Mass spectra 
were recorded on a HEWLETT-PACKARD 5988A spectrometer (Hewlett-Packard Company, Palo 
Alto, CA, USA). FABMS were obtained using MICROMASS AUTOSPEC mass spectrometer 
(WATERS, Milford, MA, USA) and ESIMS were determined on a BRUKER AMAZON ETD 
spectrometer (Bruker BioSpin Corporation). We performed microanalyses in a Perkin-Elmer 240B 
elemental analyzer (PerkinElmer, Waltham, MA, USA) by the Microanalysis Service of the 
University of Santiago de Compostela. The specific rotation was measured with a PERKIN-
ELMER 241 polarimeter (PerkinElmer), and it is expressed in (°) (dm−1) (g−1) (mL). Most of the 
reactions were monitored by TLC on pre-coated silica gel plates (Merck 60 F254, 0.25 mm, Merck 
KGaA, Darmstadt, Germany). Synthesized products were purified by flash column chromatography 
on silica gel (Merck 60, 230–240 mesh, Merck KGaA) and crystallized if necessary. Solvents were 
dried by distillation prior use. 
Compound (3): (1S,2R)-(+)-cis-1-(N-Propargylamino)-2-indanol (2) and (1S,2R)-(+)-cis-1-(N,N-
dipropargylamino)-2-indanol. A mixture of 1 (0.20 g, 1.34 mmol), K2CO3 (0.18 g, 1.34 mmol) and 
MeCN (7 mL) was stirred at room temperature under argon for 5 min. A solution of propargyl 
bromide (0.3 mL, 2.7 mmol) dissolved in MeCN (2 mL) was added dropwise with stirring. After 
being stirred for 24 h, the solvent was evaporated and the residue was dissolved in EtOAc (10 mL). 
The organic layer was washed with NaOH 2N (3 × 10 mL) and dried (Na2SO4). The removal of 
excess of solvent to give a white solid, that was purified by flash column chromatography using 
hexane/EtOAc (3:1) as eluent to give, in first place 3 (170 mg, yield 56%) as a white solid and in 
second place 2 (90 mg, yield 36%) as a white solid. 
(+)-cis-2. M.p. 106–108 °C.  = +38° (25 °C, 0.25, CHCl3). IR ν = 3277, 2906, 1421, 
1339, 1140, 1051, 731 cm−1. 1H NMR (300 MHz, CDCl3) δ = 7.32–7.22 (m, 4H, Harom), 4.51–4.47 
(m, 1H, 2-H), 4.31–4.29 (m, 1H, 1-H), 3.69–3.52 (AB system , 1H, J = 17.2 Hz, CH2), 3.68–3.51 
(AB system, 1H, J. = 17.2 Hz, CH2), 3.11–2.96 (m, 2H, 3α-H, 3β-H), 2.67 (br. s., 1H, D2O exch., 
OH), 2.31 (t, 1H, J. = 2.2 Hz, CH). 13C RMN (75 MHz, CDCl3) δ = 141.85 (C-3a), 141.05 (C-7a), 
128.17, 126.79, 125.58 and 123.94 (CHarom), 82.27 (C≡CH), 71.90 (C-2), 70.87 (C≡CH),  
64.78 (C-1), 39.59 (CH2), 37.16 (C-3). MS (EI): m/z (%): 186 (2) [M−1]+, 168 (5) [M+–H2O], 148 
325 
 
(100) [M+–propargyl], 130 (21), 115 (10), 103 (31), 77 (11). Anal. calcd. for C12H13NO (187.24):  
C 76.98, H 7.00, N 7.48; found C 76.63, H 7.12, N 7.36. 
(+)-cis-3. M.p. 106–109 °C.  = +72° (25 °C, 0.25, CHCl3). IR ν = 3279, 2894, 1339, 
1244, 1137 cm−1. 1H NMR (300 MHz, CDCl3) δ = 7.52–7.50 (m, 1H, 7-H), 7.29–7.18 (m, 3H, 4-H, 
5-H, 6-H), 4.52 (dd, 1H, J. = 13.2, 6.9 Hz, 2-H), 4.42–4.40 (m, 1H, 1-H), 3.74 (br. s., 1H, D2O 
exch., OH), 3.65–3.39 (AB system, 2H, J. = 17.1 Hz, CH2), 3.64–3.38 (AB system, 2H, J. = 17.1 
Hz, CH2), 3.24–2.79 (part AB of an ABM system, 2H, JAB = 16.4 Hz, JAM =7.2 Hz, JBM = 6.1 Hz, 
3α-H, 3β-H), 2.29 (t, 2H, J. = 2.3 Hz, 2 × CH). 13C RMN (75 MHz, CDCl3) δ = 141.47 (C-3a), 
138.15 (C-7a), 128.68, 127.04, 126.65 and 125.46 (CHarom), 80.37 (2 × C≡CH), 72.87 (C-2), 71.39 
(2 × C≡CH), 68.37 (C-1), 41.04 (2 × CH2), 40.31 (C-3). MS (EI): m/z (%): 226 (2) [M+1]+, 225 (5) 
[M+], 224 (4) [M−1]+, 208 (2) [M+–H2O], 186 (100) [(M−1)+–propargyl], 133 (32), 116 (35), 77 (29). 
Anal. calcd. for C15H15NO (225.29): C 79.97, H 6.71, N 6.22; found C 79.81, H 6.92, N 6.29. 
Compound (4): (1S,2R)-(−)-cis-1-(N,N-Dipropargylamino)-2-indanyl acetate. A mixture of 3  
(0.08 g, 0.36 mmol), acetic anhydride (66 μL, 0.72 mmol), Et3N (100 μL, 0.72 mmol), DMAP  
(a catalytic amount) in MeCN (5 mL), under argon, was stirred at room temperature for 3 h. The 
solvent was removed and the residue was partitioned between EtOAc (10 mL) and H2O (10 mL), 
and the organic layer was washed with a saturated solution of NaCl (3 × 10 mL), dried (Na2SO4) 
and evaporated, to give 4 (as a white solid (76 mg, yield 80%). M.p. 52–53 °C. º  = −70.6° 
(25 °C, 0.25, CHCl3). IR ν = 3239, 2890, 1729, 1210, 1035 cm−1. 1H NMR (300 MHz, CDCl3)  
δ = 7.49–7.46 (m, 1H, 7-H), 7.31–7.21 (m, 3H, 4-H, 5-H, 6-H), 5.68 (dt, 1H, J. = 5.4, 2.4 Hz, 2-H), 
4.61 (d, 1H, J. = 5.4 Hz, 1-H), 3.77–3.63 (AB system, 2H, J. = 17.5 Hz, CH2), 3.76–3.62 (AB 
system, 2H, J. = 17.3 Hz, CH2), 3.17–2.93 (part AB of an ABM system, 2H, JAB = 17.2 Hz,  
JAM = 5.7 Hz, JBM = 2.5 Hz, 3α-H, 3β-H), 2.21 (t, 2H, J. = 2.4 Hz, 2 × CH), 2.02 (s, 3H, CH3).  
13C NMR (75 MHz, CDCl3) δ = 170.40 (COCH3), 140.01 (C-3a), 139.48 (C-7a), 128.07, 126.97, 
125.24 and 125.13 (CHarom), 81.21 (2 × C≡CH), 77.04 (C-2), 71.74 (2 × C≡CH), 68.94 (C-1), 39.99 
(2 × CH2), 37.68 (C-3), 21.70 (CH3). MS (FAB): m/z (%): 269 (6) [M+2]+, 268 (26) [M+1]+,  
225 (2) [M+–acetyl], 197 (18), 169 (12), 154 (88), 137 (100). Anal. calcd. for C17H17NO2 (267.32): 
C 76.38, H 6.41, N 5.24; found C 76.12, H 6.68, N 5.36. 
Compound (5): (1S,2R)-(−)-cis-1-(N,N-Dipropargylamino)-2-indanyl benzoate. To a solution of 
of 3 (0.08 g, 0.36 mmol), DMAP (a catalytic amount) in MeCN (5 mL), at 0 °C and under argon, 
was added dropwise a solution of benzoyl chloride (82 μL, 0.72 mmol) and Et3N (100 μL,  
0.72 mmol). The mixture was stirred at room temperature for 2 h. the solvent was evaporated and 
the residue was dissolved in CH2Cl2 (10 mL). The layer organic was washed with a saturated 
solution of NaCl (3 × 10 mL), dried (Na2SO4) and evaporated, to give a yellow oil that was purified 
by flash column chromatography using hexane–EtOAc (6:1) as eluent to give 5 (73 mg, yield 73%) 
as a yellow oil. º  = −85.6° (25 °C, 0.25, CHCl3). IR ν = 3289, 2842, 1714, 1267, 1108, 1069 
cm−1. 1H NMR (300 MHz, CDCl3) δ = 7.95–7.92 (m, 2H, 2'-H, 6'-H), 7.56–7.50 (m, 7H, 3'-H, 4'-H, 
5'-H, 4 × Harom), 6.00 (dt, 1H, J. = 5.6, 2.6 Hz, 2-H), 4.74 (d, 1H, J. = 5.3 Hz, 1-H), 3.75 (d, 4H,  
J. = 2.3 Hz, 2 × CH2), 3.29–3.06 (part AB of an ABM system, 2H, JAB = 17.0 Hz, JAM = 5.7 Hz, 
JBM = 2.7 Hz, 3α-H, 3β-H), 2.15 (t, 2H, J. = 2.1 Hz, 2 × CH). 13C NMR (75 MHz, CDCl3)  
δ = 166.36 (CO), 140.30 (C-3a), 139.81 (C-7a), 133.16 (C'-4), 130.72 (C'-1), 129.83, 128.61, 
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128.39, 127.28, 125.49 and 125.43 (4 × CHarom, 4 × C'-H), 81.30 (2 × C≡CH), 77.75 (C-2), 72.20 
(2 × C≡CH), 69.17 (C-1), 40.40 (2 × CH2), 38.13 (C-3). MS (FAB): m/z (%): 331 (11) [M+2]+, 330 
(40) [M+1]+, 231 (68), 186 (3), 154 (95), 137 (100), 105 (25). Anal. calcd. for C22H19NO2 (329.39): 
C 80.22, H 5.81, N 4.25; found C 80.05, H 6.01, N 4.34. 
3.2.2. Reaction of Carbamylation 
To a stirred and ice-cooled solution of 2 or 3 (0.43 mmol) in acetonitrile (5 mL) was added the  
N,N-dialkylcarbamyl chloride (0.73 mmol), followed by a dropwise addition of NaH (60% in oil,  
0.56 mmol). The reaction mixture was stirred for 24 h at room temperature under argon. After 
evaporation of the solvent in vacuo, water (10 mL) was added and extracted with ether (3 × 10 
mL). The organic phase was washed with dilute KOH (pH 10–11), dried and evaporated to dryness  
in vacuo. Purification by column chromatography (Hexane:EtOAc 4:1) afforded: 
Compound (6): (1S,2R)-(−)-cis-1-(N-Propargylamino)-2-indanyl dimethylcarbamate. This 
compound was obtained as a yellow solid (100 mg, yield 73%). M.p. 119–122 °C. º  = −50.4° 
(23 °C, 0.25, CHCl3). IR ν = 3264, 2923, 1693, 1388, 1184, 1047 cm−1. 1H NMR (300 MHz, 
CDCl3) δ = 7.40–7.39 (m, 1H, 7-H), 7.28–7.13 (m, 3H, 4-H, 5-H, 6-H), 5.52–5.48 (m, 1H, 2-H), 
4.38 (d, 1H, J = 5.0 Hz, 1-H), 3.61–3.46 (AB system, 1H, J. = 16.8 Hz, CH2), 3.60–3.45 (AB 
system, 1H, J. = 16.8 Hz, CH2), 3.19–3.04 (AB system, 1H, J = 16.5 Hz, 3α-H), 3.17–3.03 (AB 
system, 1H, J. = 16.5 Hz, 3β-H), 2.90–2.80 (m, 6H, 2 × CH3), 2.62 (t, 1H, J. = 2.5 Hz, CH), 2.25 
(br. s., 1H, D2O exch., NH). 13C NMR (75 MHz, CDCl3) δ = 155.97 (CO), 142.09 (C-3a), 139.75 
(C-7a), 127.97, 126.69, 124.93 and 124.66 (CHarom), 82.17 (C≡CH), 76.00 (C-2), 71.64 (C≡CH), 
63.28 (C-1), 37.46 (CH2), 36.35 (C-3), 29.94 and 29.67 (2 × CH3). MS (FAB): m/z (%): 258 (1) 
[M]+, 257 (6) [M−1]+, 168 (100), 116 (80), 72 (80). Anal. calcd. for C15H18N2O2 (258.32): C 69.74, 
H 7.02, N 10.84; found C 69.65, H 7.13, N 10.93. 
Compound (7): (1S,2R)-(−)-cis-1-(N-Propargylamino)-2-indanyl diethylcarbamate. Isa yellow 
solid (98 mg, yield 66%). M.p. 68–69 °C. º  = −37.6° (23 °C, 0.25, CHCl3). IR ν = 3242, 
2972, 1677, 1425, 1270, 1173, 1066 cm−1. 1H NMR (300 MHz, CDCl3) δ = 7.42–7.39 (m, 1H,  
7-H), 7.29–7.21 (m, 3H, 4-H, 5-H, 6-H), 5.54 (dt, 1H, J. = 5.3, 3.6 Hz, 2-H), 4.41–4.39 (m, 1H, 1-
H), 3.63–3.49 (AB system, 1H, J. = 16.8 Hz, CH2), 3.62–3.48 (AB system, 1H, J. = 16.8 Hz, CH2),  
3.29–3.09 (m, 6H, 3α-H, 3β-H, 2 × CH2CH3), 2.25 (t, 1H, J. = 2.4 Hz, CH), 1.93 (br. s., 1H, D2O 
exch., NH), 1.28–1.01 (m, 6H, 2 × CH2CH3). 13C NMR (75 MHz, CDCl3) δ = 155.18 (CO), 142.24  
(C-3a), 139.80 (C-7a), 127.91, 126.65, 124.88 and 124.61 (CHarom), 82.19 (C≡CH), 75.64 (C-2), 
71.54 (C≡CH), 63.52 (C-1), 41.92 and 41.30 (2 × CH2CH3), 37.45 (CH2), 36.50 (C-3), 13.99 and 
13.51 (2 × CH2CH3). MS (FAB): m/z (%): 288 (18) [M+2]+, 287 (100) [M+1]+, 286 (8) [M]+, 285 
(6) [M−1]+, 231 (21), 154 (27), 137 (26). Anal. calcd. for C17H22N2O2 (286.37): C 71.30, H 7.74, N 
9.78; found 71.12, H 7.99, N 9.92. 
Compound (8): (1S,2R)-(−)-cis-1-(N,N-Dipropargylamino)-2-indanyl dimethylcarbamate. Was 
obtained as a white solid (76 mg, yield 58%). M.p. 109–112 °C. º  = −38° (25 °C, 0.25, 
CHCl3). IR ν = 3292, 2922, 1685, 1397, 1272, 1186, 1050 cm−1. 1H NMR (300 MHz, CDCl3)  
δ = 7.48 (t, 1H, J = 3.9 Hz, 7-H), 7.27–7.22 (m, 3H, 4-H, 5-H, 6-H), 5.61 (dt, 1H, J. = 5.6, 3.3 Hz, 
2-H), 4.63–4.61 (m, 1H, 1-H), 3.67–3.66 (m, 4H, 2 × CH2), 3.16–2.97 (AB system, 1H,  
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J. = 16.8 Hz, 3α-H), 3.14–2.96 (AB system, 1H, J. = 16.8 Hz, 3β-H), 2.91–2.81 (m. 6H, 2 × CH3), 
2.21 (t, 1H, J. = 2.2 Hz, 2 × CH) 13C NMR (75 MHz, CDCl3) δ = 155.98 (CO), 140.05 (C-3a), 
139.82 (C-7a), 127.96, 126.76, 125.39 and 125.10 (CHarom), 81.10 (2 × C≡CH), 77.36 (C-2), 71.91 
(2 × C≡CH), 68.31 (C-1), 40.24 (2 × CH2), 37.94 (C-3), 36.49 and 36.14 (2 × CH3). MS (FAB): m/z 
(%): 298 (19) [M+2]+, 297 (100) [M+1]+, 296 (4) [M]+, 295 (9) [M−1]+, 231 (30), 204 (21), 154 
(31), 137 (39). Anal. calcd. for C18H20N2O2 (296.36): C 72.95, H 6.80, N 9.45; found 72.78, H 
7.01, N 9.53. 
Compound (9): (1S,2R)-(−)-cis-1-(N,N-Dipropargylamino)-2-indanyl diethylcarbamate. This 
compound was obtained as an oil (70 mg, yield 49%). º  = −18.6° (25 °C, 0.25, CHCl3).  
IR ν = 3292, 2928, 1688, 1425, 1270, 1167, 1062 cm−1. 1H NMR (300 MHz, CDCl3)  
δ = 7.49 (t, 1H, J = 4.2 Hz, 7-H), 7.28–7.23 (m, 3H, 4-H, 5-H, 6-H), 5.59 (dt, 1H, J. = 5.8, 3.9 Hz, 
2-H), 4.62 (d, 1H, J. = 5.8 Hz, 1-H), 3.71–3.57 (m, 4H, 2 × CH2), 3.35–3.23 (m, 4H, 2 × CH2CH3), 
3.17–2.98 (AB system, 1H, J. = 16.8 Hz, 3α-H), 3.15–2.97 (AB system, 1H, J = 16.8 Hz, 3β-H),  
2.21 (t, 2H, J. = 2.2 Hz, 2 × CH), 1.12–1.01 (m, 6H, 2 × CH2CH3). 13C NMR (75 MHz, CDCl3)  
δ = 155.21 (CO), 139.98 (C-3a), 139.86 (C-7a), 128.00, 126.74, 125.55 and 125.01 (CHarom), 81.06 
(2 × C≡CH), 76.58 (C-2), 71.97 (2 × C≡CH), 67.99 (C-1), 41.65 and 41.12 (2 × CH2CH3),  
40.14 (2 × CH2), 37.81 (C-3), 13.97 and 13.47 (2 × CH2CH3). MS (FAB): m/z (%): 326 (20) [M+2]+, 
325 (92) [M+1]+, 324 (2) [M]+, 323 (8) [M−1]+, 288 (89), 230 (51), 154 (71), 137 (100). Anal. calcd. 
for C20H24N2O2 (324.42): C 74.04, H 7.46, N 8.64; found 73.89, H 7.61, N 8.75. 
3.3. Experimental Methods: Biology 
3.3.1. Culture of Rat Cortical Neurons 
Embryos were selected from 19 to 20 days pregnant rats by caesarean section. Meninges were 
removed and cortex was isolated after the dissection of the brain. The fragments obtained from 
several embryos were subjected to mechanic digestion. We re-suspended the cells in a Neurobasal 
medium with 2% B-27. We seeded in 48-well plates at a density of 100,000 cells/mL. Neuronal 
cultures were allowed to grow for 8–10 days. Incubations with different CSF were done when the 
microscope showed the existence of a dense neuronal network. Embryos were selected from 19 to 
20 days pregnant rats, which were decapitated and embryos were extracted from the womb by 
caesarean section. Meninges were removed and a portion of motor cortex was isolated after the 
dissection of the brain. Fragments obtained from several embryos were subjected to mechanic 
digestion and cells were re-suspended in Neurobasal medium with 2% B-27 and seeded in 48-well 
plates at a density of 100,000 cells/mL. Neuronal cultures were allowed to grow for 8–10 days and 
when the microscope showed the existence of a dense neuronal network, incubations with different 
CSF were done [79]. 
3.3.2. Measurement of Neuronal Viability 
We used the MTT reduction assay following the procedure previously described [65]. After  
the appropriate incubations with the compounds alone, or co-incubated with 100 μM H2O2 or 
glutamate, 0.5 mg/mL MTT were added to each well and incubation was performed at 37 °C for 2 h. 
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Formazan salt formed was dissolved in DMSO, and colorimetric determination were performed at  
540 nm. Control cells without compounds or toxic stimulus were considered 100% viability. 
Neuronal viability after exposure to compounds or different treatments was expressed as% of 
control within each individual experiment. Graph Pad Prism Software (GraphPad Software,  
San Diego, CA, USA) was used to perform statistical analyses and graphical presentation. 
Experiments were reproduced at least three times. Data were expressed as mean ± S.E.M. values. 
Groups were compared by ANOVA/Dunnett’s test. A p-value ≤0.05 was accepted as the limit of 
statistical significance. 
4. Conclusions 
We can use Shannon entropy measures to developing predictive models for multi-target networks 
of neuroprotective/neurotoxic compounds. In doing so, we can use Box–Jenkins operators of 
molecular descriptors to obtain multi-target, multi-scale, and multi-output models able to predict 
different outcomes for multiple combinations of output experimental measures, experimental 
protocols, organisms, and molecular and cellular targets. One of these models has been 
demonstrated here to be useful as a complementary tool in the organic synthesis and evaluation  
of the multi-target biological activity of new compounds with potential neuroprotective activity. 
The model is also a very useful tool to predict complex networks of drug-target interactions  
with possible applications to the study of non-linear effects in the biological activity of 
neuroprotective drugs. 
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